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SUMMARY 
 
PROJECT TITLE: ROLE OF GLUCOSE, ACETATE AND PLASMA IN THE 
MAINTENANCE OF MITOCHONDRIAL FUNCTION, ENERGY METABOLISM AND 
CELL INTEGRITY DURING PLATELET STORAGE IN ADDITIVE SOLUTIONS 
 
A potential benefit of the use of artificial media for the suspension of platelets as 
concentrates is a reduction of the morphological, functional and metabolic changes 
observed in platelets during storage and collectively referred to as the platelet storage 
lesion (PSL). A better understanding of the nature of the PSL may suggest strategies for 
manipulation of the storage environment to improve platelet viability and efficacy post-
transfusion. In this context, two principal considerations formed the basis for the study: 
 
• The hypothesis that apoptosis is a central mechanism responsible for the changes 
observed in the PSL. 
• The investigation of this hypothesis within the applied setting of improving the 
storage environment of platelet concentrates. 
The study investigated the role on the PSL of plasma protein (in the form of albumin), 
acetate and glucose in leucoreduced platelet concentrates suspended in a medium with 
minimal plasma. A 14-day storage study on platelet concentrates in either plasma or a 
70:30 ratio of a commercial additive solution (SSP+) and plasma provided an 
overview of platelet in vitro characteristics under standard storage conditions. The work 
led to targeted investigations into the nature of the cell death mechanism in platelet 
concentrates. 
 
Results suggested that in storage media with adequate energy stores, a Bcl-2 protein-
mediated mechanism of cell death was viable, though possibly storage-time dependent 
and limited by pre-existing levels of anti-apoptotic Bcl-2 proteins in the platelets.  
Further studies would be required to determine if this mechanism is akin to caspase-
dependent apoptosis. In media lacking glucose, a mechanism more reminiscent of 
necrosis was observed, associated with decreased ATP levels, accelerated mitochondrial 
dysfunction, elevated intracellular free calcium and culminating in platelet disruption.  
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1. INTRODUCTION 
 
Platelets are the smallest of the cellular elements in the circulation. Their role in the 
maintenance of haemostasis has been recognised since the late 19th century (Coller, 
2007). More recently, their involvement in inflammation and white cell recruitment has 
been identified (for recent reviews see Morrell et al., 2007, Li et al., 2011, Semple et al., 
2011). To place the thesis in context, this introduction begins by providing an abridged 
description of platelet structure, formation and function in the normal individual. The 
role of platelets in transfusion medicine forms the second section of the introduction; 
including current methods of platelet concentrate (PC) preparation and the challenges 
faced by transfusion centres in ensuring adequate stocks of this component are 
maintained. The interest in the use of additive solutions for platelet storage will be 
introduced at this stage, in concert with the changes undergone by platelets during 
storage – collectively referred to as the platelet storage lesion (PSL). An overview of the 
apoptotic process is included to provide a foundation for subsequent discussion on the 
central hypothesis of the thesis, which states that apoptosis has a principal role in the 
development of the progressive changes observed in platelets during storage. 
 
STRUCTURE OF THE RESTING PLATELET 
Platelets are anucleate, discoid cells with a diameter ranging between 2 to 5 µm and a 
mean cell volume between 6 - 10 fL (White, 2007). The cytoskeleton of the platelet is 
comprised of tubulin polymers as well as spectrin tetramers interconnected by long 
actin filaments. Spectrin molecules form a dense membrane skeleton adjacent to the 
cytoplasmic side of the plasma membrane (Fox et al., 1988) (figure 1.1). Spectrin self-
assembles into twisted strands 200 nm in length that form heterodimers of αβ subunits 
that associate in a head to tail alignment to form tetramers interconnected at their 
termini by the barbed ends of actin filaments capped by adducing proteins (Barkalow et 
al., 2003). 
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 Figure 1.1: Membrane skeleton of the resting platelet with holes to the open 
canalicular system also evident (see text) (Hartwig, 2006) (Reproduced with 
permission, © Elsevier Inc) 
  
Actin comprises the most abundant protein in platelets, with 30 – 40% of the 
approximately 2 million copies in the platelet forming linear polymers (F-actin) cross-
linked by other proteins, such as filamin and α-actinin, to form a stable, supporting 
structure (Fox, 1993). Actin filaments extend from the space-filling network in the 
centre of the platelet towards the periphery, where their orientation changes to allow the 
filaments to run parallel to the membrane and bind to the spectrin membrane skeleton 
via adducin links (Hartwig and DeSisto, 1991, Hartwig, 2006). Of particular interest is 
the binding of filamin to the cytoplasmic tail of the GP1bα subunit of the von 
Willebrand factor receptor (vWFR) on the platelet surface, a linkage that emerges 
between the dense meshwork of spectrin strands and helps to constrain movement in the 
latter (Hartwig, 2007). The high concentration of vWFR on the platelet surface (25000 
copies per platelet) also aids the stability of the surface skeleton with respect to the 
underlying actin framework (Hartwig et al., 1999). Patients with Bernard-Soulier 
syndrome lack this filamin-GPIbα linkage and present with abnormally large and fragile 
platelets (Nurden, 2007). The discoid shape of the resting platelet is principally 
maintained by a coiled microtubule positioned adjacent to the plasma membrane. 
Observations suggest it is a single contiguous structure approximately 100 µm in length 
and formed into 8 to 12 coils to fit within the circumference of the platelet (figure 1.2).  
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Figure 1.2: Microtubule ring of resting platelet (scale bar equals 0.1µm) (Hartwig, 
2006)(Reproduced with permission, © Elsevier Inc) 
 
The platelet exterior is demarcated by a relatively thick glycocalyx comprising 
glycoproteins intimately involved in platelet adhesion, activation and aggregation. The 
surface appearance of platelets under scanning electron microscopy appears fairly 
convoluted, with openings to the open canalicular system (OCS) appearing as small 
pits. The latter is morphologically similar to the plasma membrane and forms an 
internal continuation of this membrane. The actin filaments not associated with the 
cytoskeletal framework described above form a cytoplasmic skeleton which provides a 
scaffold for the suspension of intracellular organelles.  
 
Platelets contain two main types of secretory organelles, termed α-granules and dense 
granules. Approximately 40 to 80 α-granules with an approximate diameter of 500 nm 
are present in normal platelets, containing a variety of proteins including vonWillebrand 
factor (vWF), CD62P (P-selectin), coagulation factors V and VIII, fibrinogen, integrins 
αIIbβ3 and α5β3, and various chemokines such as β-thromboglobulin (β-TG), RANTES 
and platelet factor 4 (PF4) (Reed, 2007, Blair and Flaumenhaft, 2009). Normally 
separate from each other, the fusion of α-granules in a proportion of the platelet 
population may be one of the earliest morphological indications of a storage lesion 
(White and Clawson, 1980). Dense granules are smaller and fewer in number, with only 
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4 to 8 normally present per platelet. They are known to contain high concentrations of 
adenine nucleotides (including ATP and ADP), serotonin, pyrophosphate, calcium and 
magnesium (McNicol and Israels, 1999). In addition, platelets contain a minimal 
number of lysosomes, though their function in platelets is not yet clear. Numerous 
particles of glycogen are also present in the platelet cytoplasm, often in dense 
concentrations, though again their function in the platelet remains to be fully determined 
(White, 2007). Mitochondria in platelets are relatively few in number, but are important 
in maintaining the energy requirements of the cell as well as having an increasingly 
recognised role in the cell’s “decision” to proceed to clearance through a mechanism of 
programmed cell death.  
 
Platelets contain a complex and characteristic network of internal membranes comprised 
of two distinct systems not found in other blood cells. The OCS is derived from 
invaginations of the plasma membrane and greatly enhances the surface area exposed to 
the external environment (Escolar et al., 1989). It can serve as a major conduit for the 
uptake of compounds from the external environment as well as the rapid expulsion of 
substances from secretory organelles following platelet activation. The OCS also 
provides a source of conveniently accessed membrane required during the formation of 
structures such as pseudopodia following platelet adhesion to an injured area (White, 
2007). The dense tubular system (DTS) is comprised of residual smooth endoplasmic 
reticulum (ER) originating from rough ER in the megakaryocyte. It is involved in the 
synthesis of prostaglandins and thromboxane A2 and is believed to comprise the 
principal store of intracellular calcium in the platelet (Ebbeling et al., 1992). 
 
PLATELET FORMATION 
Platelets originate from megakaryocyte precursor cells, which are in turn derived from 
myeloid progenitor cells. Uniquely among haemopoietic precursor cells, 
megakaryocytes undergo successive cycles of DNA replication without dividing; a 
process referred to as endomitosis and constituting cycles of interrupted mitosis. Up to 
six cycles of DNA replication have been observed, though a final diploid number of 
16N is more common (Italiano and Hartwig, 2007). Following endomitosis, the 
megakaryocyte undergoes a process of maturation in the bone marrow which includes 
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the formation of the secretory granules and the development of the complex 
demarcation membrane system (DMS) characteristic of the mature megakaryocyte 
(Schulze et al., 2006). Both α-granules and dense granules mature within the 
megakaryocyte, possibly via multivesicular bodies which form an intermediate stage 
and may serve to sequester the characteristic proteins and compounds into their 
appropriate secretory body. Some of the proteins associated with α-granules are 
synthesised endogenously, including β-thromboglobulin and vonWillebrand factor. 
Others, such as fibrinogen, are subsequently obtained from the megakaryocyte 
environment via receptor-mediated endocytosis (Handagama et al., 1987). Additional 
proteins important for platelet function are also enclosed within granules at this stage. 
The DMS is an extensive network that dominates the cytoplasm of the mature 
megakaryocyte. Its most likely role is thought to be the provision of membrane during 
the platelet production process (Mahaut-Smith et al., 2003, Italiano and Hartwig, 2007). 
Approximately 1011 platelets are produced daily, based on each megakaryocyte able to 
generate 103 platelets and a rate of megakaryocyte generation of 108 per day (Hartwig, 
2003). 
There have been a number of models posited to explain platelet formation. The 
currently favoured model involves the formation of proplatelets – long, cytoplasmic 
extensions of the megakaryocyte characterised by terminal swellings approximately the 
same size of mature platelets (Becker and De Bruyn, 1976, Radley and Haller, 1982). 
The formation of proplatelets involves the initial spreading of the megakaryocyte 
followed by the dissociation of the cortical cytoplasm at one end of the cell. The 
breakdown of the megakaryocyte proceeds from this point, with the cytoplasmic 
material increasingly condensed into pseudopodia which further develop into thin 
cytoplasmic connections only 2 to 4 nm in diameter, tipped with the swollen 
proplatelets. The process ends approximately 10 hours after initiation with a rapid 
“retraction” of the cytoplasmic connections that frees the proplatelets and discards the 
remnants of the megakaryocyte nucleus (Italiano et al., 1999, Bluteau et al., 2009) 
(figure 1.3). Techniques allowing proplatelet formation in mice to be studied as a 
dynamic process in vivo suggest that megakaryocytes remain in close contact with bone 
marrow sinusoids, with extensions protruding into microvessels from which fragments 
resembling proplatelets are released into the vasculature and mature to produce 
platelets. The authors additionally suggest that the process is likely to be aided by blood 
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flow-induced shear stress (Junt et al., 2007). In vitro evidence on isolated proplatelets 
has provided initial confirmatory evidence that platelet formation is potentiated by shear 
and may proceed through intermediate stages termed “preplatelets” that may help in 
regulating platelet size (Thon et al., 2010). 
 
   
Figure 1.3: Megakaryocyte (murine) forming proplatelets in vitro (Italiano et al., 1999) 
(Reproduction permitted with accreditation, © The Rockefeller University Press) 
 
The tubulin and actin polymers involved in shape maintenance in the mature discoid 
platelet also play a vital role in the transformation of megakaryocytes into proplatelets 
(Patel et al., 2005b). Microtubules composed of dimers of αβ-tubulin initially extend 
from the centre of the immature megakaryocyte to the periphery. With the development 
of pseudopodia, the microtubules consolidate into bundles below the plasma membrane 
of these structures and progressively thin within the cytoplasmic connections to form 
coils composed of 5 to 10 microtubules around the terminal proplatelets, consistent with 
the microtubule coil noted in mature platelets. Microtubules are also involved in the 
migration of organelles and granules from the cell body of the megakaryocyte to the 
proplatelet (Richardson et al., 2005, Italiano and Hartwig, 2007). Figure 1.4 provides a 
summary of platelet formation based on this favoured model. 
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Figure 1.4: Summary of platelet biogenesis from megakaryocytes by the formation of 
proplatelets (Patel et al., 2005a)(Reproduced with permission, © American Society for 
Clinical Investigation) 
 
 
The dissociation of megakaryocytes into proplatelets displays morphological 
similarities to apoptosis, including disruption of cytoskeletal proteins, DNA 
fragmentation, condensation of nuclear and plasma membranes, blebbing, cell shrinkage 
and the formation of fragmentary bodies (Kaluzhny et al., 2002). The comparison is 
supported by the presence in mature megakaryocytes of caspases – proteases known to 
be central players in the execution of apoptosis - and the absence of anti-apoptotic 
members of the Bcl-2 family of proteins; as well as the inhibition of proplatelet 
formation by the addition of the pan-caspase inhibitor z-VAD-fmk (De Botton et al., 
2002, Clarke et al., 2003). Mature platelets reside in the circulation for approximately 
ten days. In view of this limited lifespan, it is interesting to speculate whether 
programmed cell death plays a role in the clearance of platelets from the circulation, and 
whether such a concept can be extended to explain the limited time platelets can 
currently be stored as concentrates.  
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APOPTOSIS 
Apoptosis was first invoked to describe a morphologically distinct form of cell death 
originally characterised by chromatin and nuclear condensation followed by 
fragmentation of the cell into membrane-bound apoptotic bodies able to be removed by 
phagocytes in a controlled process (Kerr et al., 1972). This was contrasted with the 
cellular disruption seen with necrosis, leading to the release of intracellular contents into 
the general environment and the onset of inflammation (Perrotta et al., 2003). Further, 
apoptosis is generally considered to be an energy-dependent process, with marked 
reduction in ATP levels having been described as a “switch” promoting the onset of a 
necrotic cell death (Leist et al., 1997, Eguchi et al., 1997, Nicotera and Melino, 2004). 
Morphological changes reminiscent to those described in apoptotic cells were noted in 
platelets exposed to various agonists as well as in platelets stored in culture or as 
platelet concentrates (reviewed by Leytin and Freedman, 2003). As nuclear involvement 
was found not to be a requirement for apoptosis to occur, the idea that a similar 
mechanism may be at least partially responsible for the adverse changes observed in 
platelets stored as concentrates was suggested (Mignotte and Vayssiere, 1998, Brown et 
al., 2000, Li et al., 2000).  
 
Central to the description of many of the processes linked to apoptosis is the role of a 
family of proteases called caspases that are able to specifically cleave proteins after 
aspartic acid residues, with specificity conferred by the four amino acids on the NH2-
terminal side of the cleavage site (Thornberry and Lazebnik, 1998). Initiator caspases 
such as caspase-8 and -9 act as mediators and control the activation of effector caspases 
such as caspase-3, which actually execute the demise of the cell by disrupting cellular 
structures and inactivating proteins that inhibit apoptosis (Snyder and Kuter, 2000, 
Taylor et al., 2008). Two principal pathways are currently invoked to describe the 
progression of apoptosis: the extrinsic pathway (also referred to as the death receptor 
pathway) and the intrinsic (or mitochondrial) pathway (figure 1.5). 
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Figure 1.5: Principal components of the extrinsic and intrinsic pathways of apoptosis 
(see text for details) (Hengartner, 2000) (Reproduced with permission, © Nature 
Publishing Group) 
 
 
The extrinsic pathway is initiated by the activation of various death receptors by their 
associated ligands, including CD95. Activation of these receptors leads to the assembly 
of the death-inducing signalling complex (DISC) which recruits multiple copies of 
procaspase-8 to the complex via the Fas-associated death domain protein (FADD). The 
proximity of the procaspase-8 molecules results in their activation which subsequently 
leads to the activation of the effector caspases (Green, 2011, Kroemer et al., 2007, 
Hengartner, 2000, Walczak and Sprick, 2001). Evidence for the involvement of this 
pathway in platelet death has not been conclusively established (Leytin, 2012). 
 
As the alternative name of the intrinsic pathway implies, mitochondria play a central 
role, with various intracellular signals converging on the mitochondria and promoting 
permeabilisation of the mitochondrial membrane. This results in the release of pro-
apoptotic factors from the mitochondrial intermembrane space (IMS), including 
cytochrome c. This constitutes the principal pathway in vertebrates (Green and 
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Kroemer, 2004) and is the mechanism of apoptosis alluded to and investigated in this 
thesis by virtue of the selection of assays adopted.  
 
Intrinsic (Mitochondrial) Pathway of Apoptosis 
Cytochrome c is a principal component of the mitochondrial respiratory chain and 
considered a key factor in many models of apoptosis. It is primarily found in association 
with the phospholipid cardiolipin in the space between the inner and outer 
mitochondrial membrane, either in a loosely bound conformation mediated by 
electrostatic interactions or as a tightly bound form. Only the soluble form of 
cytochrome c is released into the cytosol, requiring first the disassociation of the protein 
from cardiolipin followed by release into the cytosol (Ott et al., 2002). Once in the 
cytosol, cytochrome c binds to apoptotic protease activating factor-1 (Apaf-1), 
promoting its binding to dATP/ATP which in turn leads to the formation of a 
multimeric complex referred to as the apoptosome (Bao and Shi, 2006) (figure 1.6). 
Apaf-1 also incorporates a caspase-recruitment domain (CARD) which is exposed 
following oligomerisation, recruiting procaspase-9 and assisting its autoactivation to 
caspase-9 (Bratton and Salvesen, 2010). This effector caspase is subsequently able to 
cleave and activate the zymogen of the executioner caspase, caspase-3 (Zou et al., 1999, 
Wang, 2001). Concomitant with the release of cytochrome c is the release of 
compounds such as Smac/DIABLO which interfere with the action of inhibitors of 
apoptosis (IAPs) – a family of proteins able to inhibit active caspases (Du et al., 2000, 
Verhagen et al., 2000, Bratton and Salvesen, 2010). 
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Figure1.6: Activation of caspase-3 by the apoptosome following release of cytochrome 
c into the cytosolic space (Wang, 2001) (Reproduced with permission, © Cold Spring 
Harbor Laboratory Press) 
 
 
Permeabilisation of the outer mitochondrial membrane would seem to be a pre-
requirement for the release of pro-apoptotic factors normally residing within these 
organelles. One suggested control mechanism involves the Bcl-2 family of proteins, 
which contains both pro- and anti-apoptotic members (Green and Kroemer, 2004). 
Mitochondrial outer membrane permeabilisation (MOMP) regulated by the pro-
apoptotic members Bak or Bax has even been suggested to be a “point of no return” 
(Dewson and Kluck, 2009). Bak is found in association with the mitochondrial outer 
membrane in normal cells, whereas Bax translocates to the membrane from the cytosol 
following activation. Pro-apoptotic Bak or Bax may disrupt the membrane via 
mitochondrial pores formed by the oligomerisation of the proteins or via disruption of 
the phospholipid layers (Finkel, 2001, Dewson and Kluck, 2009). Alternatively, it has 
been suggested that Bax interacts with components of the permeability transition pore 
(PTP) – a complex of proteins linking the inner and outer mitochondrial membranes. 
Questions remain over the importance of this structure in apoptosis, though the 
pseudopathological conditions that promote pore opening such as elevated cytosolic 
calcium levels, low ATP concentrations and oxidative stress, may point to a role in 
other forms of cell death (Kroemer and Reed, 2000, Orrenius et al., 2003, Halestrap, 
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2006, Crompton, 1999, Duchen, 1999). The anti-apoptotic members Bcl-2 and Bcl-XL 
block the oligomerisation of Bax and Bak, thus preventing the release of compounds 
such as cytochrome c. In addition, they may influence mitochondrial physiology more 
directly by maintaining the ∆Ψm and the exchange of adenine nucleotides (Desagher 
and Martinou, 2000). A third class of BCl-2 family proteins is termed the BH3-only 
proteins and appear to control the activity of previously mentioned members of the 
family.  
 
PLATELET FUNCTION 
Platelets play a vital role in the formation of a haemostatic plug at sites of vascular 
injury, thus helping to arrest bleeding and promote wound healing. Two principal 
processes enable this function; the initial adhesion of platelets to the damaged 
subendothelium and the subsequent aggregation of platelets to one another to form the 
primary haemostatic plug (Wei et al., 2009). In addition, activated platelets provide a 
catalytic surface for the activity of the coagulation factors (Galan et al., 2000), leading 
to the stabilisation of the primary plug with fibrin. 
 
Platelet Adhesion to the Vessel Wall 
The initial interaction of platelets with an injured vessel wall is mediated via platelet 
receptors to the newly exposed subendothelium. The glycoproteins GPIbα and GPVI 
have been identified as playing an important role in the initial tethering of the platelet to 
the injured area. A more stable contact is subsequently accomplished following the 
activation of the integrins α2β1 and αIIbβ3 (Brass et al., 2007).  
 
GPIbα and its associated subunit, GPIbβ, form a noncovalent complex with GPIX and 
GPV, with approximately 25 000 to 50 000 copies of the complex expressed on the 
surface of the platelet (Kroll et al., 1996). Although GPIbα has been shown to bind to 
various ligands, its association with the A1 domain of vWF is the best codified in terms 
of the platelet’s role in haemostasis (Wei et al., 2009). vWF is an adhesive, multimeric 
glycoprotein found in the α-granules of platelets as well as the Weibel-Palade bodies of 
endothelial cells (Sadler, 2009). The majority of vWF from the endothelial cells is 
secreted into the extravascular space and binds to collagen exposed on the breached 
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vessel wall (Ruggeri, 2003, Furie and Furie, 2008). On initial release from the Weibel-
Palade bodies, vWF is composed of very large prothrombotic multimers of up to 20000 
kDa (Andrews et al., 2007). On release, these ultra-large multimers are cleaved into 
smaller and less adhesive units by the metalloproteinase ADAMTS-13 (Padilla et al., 
2004). vWF is also found in plasma at concentrations of approximately 2 × 10-8 mol/L 
(Goto et al., 1998), but inappropriate binding of this soluble fraction to the 
GPIbα expressed on the platelet surface is avoided by the requirement of a stimulus to 
confer either vWF or its receptor to an active conformation (Andrews et al., 2007, 
Lenting et al., 2010). The conditions of high shear experienced within arterioles, with 
shear rates between 1000 to 10000 per second, may provide such a trigger (Jackson et 
al., 2009). At these high shear rates, the capture of platelets to the vessel wall appears to 
principally involve the binding of GPIbα to vWF. This initial contact occurs quickly but 
also has a high dissociation rate and is insufficient by itself to secure the platelets to the 
site of injury. Instead, the effect is to slow the platelets and promote contact with the 
vessel wall, with the discoid shape of the platelet resulting in a hesitant sliding action 
which increases the surface area in contact with the vessel wall (Jackson, 2007). The 
recent discovery of membrane tethers – long strands of lipid membrane extruded from 
platelets under high flow conditions - may aid this process by reducing the strain on the 
primary adhesive bonds (Dopheide et al., 2002) (figure 1.7). 
 
 
Figure 1.7: Scanning electron micrographs showing the formation of platelet tethers on 
a surface of immobilized vWF (Scale bar equals 1 µm) (Dopheide et al., 2002) 
(Reproduced with permission, © The American Society of Hematology) 
  
GP1b/IX/V is also able to bind to collagen indirectly via the A3 domain of vWF. 
However, there is increasing evidence that the principal platelet receptor for collagen is 
GPVI and the initial translocation phase may aid in promoting the binding of GPVI 
receptors on the platelet surface to exposed fibrillar collagen on the damaged 
endothelium. Although the affinity of this interaction is again relatively weak, it serves 
to activate and re-configure the integrins α2β1 and αIIbβ3 to a high-affinity state, with 
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GPIb/IX/V and GPVI possibly functioning synergistically in this regard (Nieswandt and 
Watson, 2003, Andrews et al., 2007). The integrin α2β1 (also referred to as GPIa/IIa) 
was the first collagen receptor identified (Santoro, 1986) and is currently ascribed a 
supporting role in platelet adhesion by reinforcing various “outside-in” signalling events 
(Varga-Szabo et al., 2008).  
 
Platelet Aggregation 
The release of soluble agonists from initially activated platelets following adhesion to 
the exposed endothelium serves to amplify the activation response through the binding 
of ADP, thromboxane A2 and thrombin to their respective G-protein coupled receptors, 
serving to maintain αIIbβ3 in a high-affinity configuration (Wei et al., 2009). Associated 
with the binding of platelet receptors to their respective ligands on the subendothelium 
are transient increases in the concentration of cytoplasmic calcium; a potent second 
messenger in a variety of platelet interactions. Binding of GPIbα to VWF results in 
transient elevations of calcium unrelated to extracellular levels of the ion (Nesbitt et al., 
2002) and enhanced by the binding of ADP to its P2Y1 receptor, leading to platelet 
shape change and activation of the integrin αΙΙββ3 (Jin et al., 1998). Binding of ADP to 
its second P2-type receptor – P2Y12 – is also believed to contribute to αΙΙββ3 activation 
(Leon et al., 2004). The more stable binding associated with integrin αIIbβ3 to vWF and 
consequent thrombus formation results in more prolonged increases in intracellular free 
calcium levels (Savage and Ruggeri, 2007).  
 
The integrin αIIbβ3 (also known as GPIIb/IIIa) is critically involved in the formation of 
platelet-platelet aggregation and clot formation. It is the most abundant glycoprotein on 
the platelet surface, with approximately 60 000 to 80 000 copies per platelet (Wagner et 
al., 1996). In addition, there is an intracellular pool of the integrin located in the α-
granules available to enhance surface expression following activation (Shattil et al., 
1998, Wagner et al., 1996). The high-affinity conformation of αIIbβ3 is able to bind to 
various ligands. Binding to fibrinogen and vWF directly promote platelet aggregation, 
whilst binding to fibrin, fibronectin, thrombospondin and vitronectin may help to 
mediate platelet adhesion and aggregation (Plow et al., 2007). The interaction between 
the integrin αIIbβ3 and fibrinogen has been found to be the dominant mechanism for 
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platelet aggregation at lower shear rates below 1000 s-1, characteristic of veins and the 
larger vessels of the arterial circulation. Free-flowing platelets are able to bind directly 
to fibrinogen on the surface of damaged vessels under these conditions with the 
previously described binding of GPIbα to VWF playing a lesser role (Jackson, 2007). 
Binding of activated platelets to one another via fibrinogen and its receptors forms 
stable contacts that promote thrombus growth (Goto et al., 1998) (figure 1.8).  
 
 
Figure 1.8: Receptor-ligand interactions between platelets and the endothelial surface 
under conditions of high shear, leading to initial tethering and translocation of the 
platelets prior to platelet-platelet interactions and stabilisation of the platelet plug 
(Jackson, 2007) (Reproduced with permission, © The American Society of Hematology) 
 
Although the binding of GPIbα to vWF and of integrin αIIbβ3 to fibrinogen have been 
found to dominate at different conditions of shear flow in perfusion experiments, the 
formation of a thrombus in vivo will likely result in microenvironments that will require 
the various mechanisms that promote platelet adhesion and aggregation to operate 
synergistically to create a stable haemostatic plug. This is supported by experiments on 
knockout mice which have shown that both vWF and fibrinogen are required for stable 
thrombus growth (Ni et al., 2000). 
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Platelet Involvement in the Coagulation Response 
The creation of a haemostatic plug serves to localise the subsequent coagulation 
response at the site of injury. Spatial confinement of the reactions involved in 
coagulation would aid the activity of the various enzymes and enhance the formation of 
a stable fibrin clot. Anionic phospholipids, principally phosphatidylserine (PS), on the 
platelet surface are believed to serve this purpose (Bevers et al., 1982, Krailadsiri et al., 
2001). PS serves to anchor coagulation proteins containing domains rich in γ-
carboxyglutamic acid (Gla) residues formed by carboxylation of glutamic acids in a 
vitamin K-dependent manner (Vermeer, 1990, Lemmon, 2008). The Gla domain is 
present in prothrombin as well as factors VII, IX and X (Zwaal et al., 1998). Binding to 
membrane-bound PS requires Ca2+ ions which are thought to coordinate the required 
structural modification of the Gla domain as well as anchoring the protein to the bound 
lipid (Huang et al., 2003, Ohkubo and Tajkhorshid, 2008). 
  
The distribution of phospholipids on the platelet membrane of the resting platelet is 
asymmetric, with cholinephospholipids (phosphatidylcholine and sphingomyelin) 
preferentially expressed on the outer leaflet of the plasma membrane and 
aminiphospholipids, principally phosphatidylserine and phosphatidylethanolamine (PE), 
mostly confined to the inner leaflet (Vance, 2008). The maintenance of this asymmetry 
is thought to be dependent on the activity of two ATP-dependent processes. The 
dominant of the two processes involves the transport of PS and PE from the outer to the 
inner leaflet by a translocase specific to the transport of aminophospholipids, with one 
molecule of ATP estimated to be hydrolysed per phospholipid transported (Beleznay et 
al., 1993). A less-specific ‘floppase’ transports both choline- and aminophospholipids 
from the inner to the outer leaflet. As the half-times for floppase activity are on the 
order of 1.5 hours compared with approximately 5 – 10 minutes for the 
aminophospholipid translocase, the cumulative result is an asymmetric distribution of 
PS and PE (Connor et al., 1992). ATP depletion or the inactivation of the 
aminophospholipid translocase is not sufficient to substantially disrupt lipid asymmetry 
in isolation due to the slow transbilayer movement of lipids (Bevers and Williamson, 
2010). Rapid loss of asymmetry occurs through the activity of a bi-directional lipid 
scramblase, which requires sustained micromolar concentrations of intracellular calcium 
evident as a result of platelet activation or programmed cell death (Bevers et al., 1995). 
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Unlike the translocase and floppase, the function of the scramblase is not energy-
dependent, though prolonged ATP depletion may decrease its activity (Martin et al., 
1995). Interestingly, the increase in intracellular calcium also inhibits the activity of the 
aminophospholipid translocase, thus ensuring that the loss of asymmetry is not 
corrected (Bevers et al., 1999) (figure 1.9). 
 
 
Figure 1.9: Model of mechanisms involved in membrane phospholipid asymmetry. Also 
alluded to is the importance of PS in promoting coagulation and clearance of apoptotic 
cells by phagocytes. (Zwaal and Schroit, 1997) (Reproduced with permission, © The 
American Society of Hematology) 
 
Briefly, current understanding posits that the coagulation response is initiated when 
injury to the vessel wall exposes subendothelial tissue factor (TF) (Weiss et al., 1989). 
Circulating factor VIIa binds to the exposed TF forming a complex that proceeds to 
activate factors IX and X to their active forms (Mackman, 2009). The factor Xa formed 
by this process combines with factor Va on the exposed endothelium to generate a 
limited quantity of thrombin. It serves to activate factor VIII by dissociating it from 
circulating vWF and allowing it to form a complex with FIXa on the surface of 
activated platelets. This tenase complex further recruits factor Xa and promotes its 
association with factor Va to form a prothrombinase complex that stimulates a burst of 
thrombin formation from its prothrombinase precursor (Monroe and Hoffman, 2006, 
Gale, 2011) (figure 1.10).  
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Figure 1.10: Schematic of tenase and prothrombinase complexes in association with 
membrane phospholipids (Zwaal et al., 2004) (Reproduced with permission, © Elsevier 
B.V.) 
 
Thrombin is a potent platelet agonist which promotes further platelet activation via G-
protein-coupled protease-activated receptors (PARs) on the platelet surface (Jardin et 
al., 2007, Jackson et al., 2003). PAR-1 and PAR-4 are both specifically cleaved by 
thrombin, with the suggestion that PAR-1 mediates platelet activation by low amounts 
of thrombin while more sustained activation involves PAR-4 and requires higher 
concentrations of thrombin (Kahn et al., 1999). Agonist-stimulated platelet activation is 
initiated by hydrolysis of phosphatidylinositiol 4,5-bisphosphate (PIP2) by 
phospholipase C into the second messengers inositol 1,4,5-trisphosphate (IP3) and 
diacylglycerol (DAG). As well as accelerating platelet activation, thrombin is 
responsible for stabilising the haemostatic plug by converting fibrinogen to fibrin (Furie 
and Furie, 2008, Mann et al., 2003). IP3 binds to its receptor on the DTS, promoting the 
release of Ca2+ from intracellular stores. The decrease in Ca2+ releases the DTS-located 
transmembrane protein stromal interaction molecule 1 (STIM1), allowing it to 
translocate to the platelet surface and regulate the opening of the calcium channel Orai1, 
resulting in an influx of extracellular calcium in a mechanism referred to as store-
operated calcium entry (SOCE) (Varga-Szabo et al., 2009). Increased concentrations of 
Ca2+ and DAG activate “Ca2+ and diacylglycerol regulated guanine nucleotide exchange 
factor 1” (CalDAG-GEFI) (Crittenden et al., 2004, Bergmeier and Stefanini, 2009), 
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which leads to the interaction of Rap1b, Rap1-interacting adaptor molecule (RIAM) and 
talin 1. The interaction leads to the exposure on talin of an integrin binding site which 
disrupts the connection between the α and β subunits of the integrin αIIbβ3, altering the 
configuration and allowing for the subsequent binding to fibrinogen and vWF (Petrich 
et al., 2007) (figure 1.11).  
 
 
Figure 1.11: Interaction of the principal platelet receptors with the various effectors 
associated with platelet adhesion and aggregation (for details see text) (Broos et al., 
2012) (Reproduced with permission, © Elsevier B.V.) 
 
The TF/VIIa complex is able to assemble and function adequately in the absence of 
anionic phospholipids (Bach et al., 1986). However, the assembly and activity of the 
tenase and prothrombinase complexes is highly dependent on the surface exposure of 
PS – a fact illustrated in the rare congenital bleeding disorder known as Scott syndrome 
in which the inability to express PS on platelet activation leads to a failure to bind 
factors Va and VIIIa to the platelet surface, with consequent failure to effectively 
generate thrombin (Nurden and Nurden, 2007). First recognised in lymphocytes, surface 
expression of PS is also associated with cells entering apoptosis and is believed to act as 
a recognition signal for cell clearance by phagocytes (Fadok et al., 1992, Bevers and 
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Williamson, 2010). A study on B lymphocytes from a Scott patient detected normal PS 
exposure in cells stimulated to undergo apoptosis but failed to detect a similar change in 
cells exposed to a calcium ionophore, suggesting that two distinct pathways of PS 
exposure may be operating in haemopoietic cells (Williamson et al., 2001, Zwaal et al., 
2004). A recent study investigated this concept in platelets using mice with variable 
expression of the pro-apoptotic Bcl-2 family members Bak and Bax. Bak-/-Bax-/- 
platelets exposed to the apoptosis-inducing BH3 mimetic ABT737 failed to express PS 
on the surface, whereas exposure to either a calcium ionophore or CRP/thrombin 
resulted in normal levels of PS exposure. These results confirmed the hypothesis that 
expression of PS on the platelet surface follows two distinct pathways depending on 
whether the platelets are subjected to a physiologic agonist or an apoptotic process 
(Schoenwaelder et al., 2009, Bevers and Williamson, 2010). Finally, in addition to its 
procoagulant function, PS also serves to contain the extent of thrombin formation by 
directing the action of the protein C pathway, which degrades the FVIIIa and FVa 
associated to the PS-expressing lipid surface (Zwaal and Schroit, 1997). 
  
Although the haemostatic role of platelets has been considered their primary function, 
there is an increasing appreciation of their contribution to inflammation through their 
recruitment of leucocytes to sites of vascular injury and the release or expression of 
various mediators associated with inflammatory conditions (McNicol and Israels, 2008, 
Zarbock et al., 2007). 
 
PLATELETS IN CLINICAL PRACTICE 
Platelet concentrates are generally administered to treat thrombocytopenia, which 
constitutes a common complication of critical illness (Arnold et al., 2006, Tinmouth and 
Freedman, 2003). Platelet transfusion constitutes the principal replacement therapy to 
combat active bleeding exacerbated by a low platelet count in conditions such as sepsis 
and other causes of disseminated intravascular coagulation, disease-induced and 
iatrogenic bone marrow failure and gynaecological emergencies such as preeclampsia 
Increasingly, platelet concentrates have been used prophylactically to maintain platelet 
counts, particularly in cancer patients undergoing chemotherapy and in recipients of 
stem cell or bone marrow transplants (Perrotta and Snyder, 2007, Levi et al., 2009, 
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British Committee for Standards in and Blood Transfusion Task Force, 2003). A 
platelet concentration of 10 × 109/L is often recommended as a transfusion trigger in 
these stable patients, with the aim of raising the platelet count by at least 20 × 109/L per 
single adult dose (Williamson, 2004). 
 
PLATELET CONCENTRATES 
Techniques for the separation of platelets from whole blood and their administration as 
a concentrate in order to increase the platelet number without increasing the fluid load 
to the recipient have been described since the 1950s (Minor and Burnett, 1952). The 
development of gas-permeable plastic containers greatly facilitated the production of PC 
and promoted their routine use (Perrotta and Snyder, 2007).  
 
Storage Packs 
A critical development stemmed from the recognition that platelets require an 
environment that allows adequate exchange of oxygen and carbon dioxide. First-
generation plastic containers were composed of polyvinyl chloride (PVC) rendered 
pliable by use of the plasticizer di-2-ethylhexyl phthalate (DEHP) (Murphy et al., 1982). 
The lifetime of platelets in PVC containers was limited to 3 days and even within this 
short period, pH levels in many of the units had decreased below 6.0 by end of storage; 
a condition known to be harmful and lead to loss of viability (Murphy et al., 1970). 
Additionally, there were concerns about possible harmful effects caused by the leaching 
of plasticizer into the component (Jaeger and Rubin, 1972) which led to the 
development of containers comprised of polyethylene instead of PVC. In vitro studies 
with these packs found that pH was better maintained, with results correlating with a 
reduced rate of lactate production. Polyethylene is approximately twice as permeable to 
oxygen as standard PVC and it was suggested that this increased rate of oxygen  
availability was responsible for the improved pH levels (Murphy and Gardner, 1975). 
Studies under anoxic conditions had previously shown that an inability to maintain 
oxidative metabolism will increase the cell’s dependency on anaerobic metabolism in an 
attempt to preserve energy levels, leading to an increase in the rate of lactate production 
– a process referred to as the Pasteur effect (Guppy et al., 1995). 
 
22 
 
The polyethylene storage packs were found to be too fragile for practical component 
manufacture. However, the accepted requirement to maintain appropriate gas exchange 
led to the development of second generation containers using plastics such as polyolefin 
that were sufficiently robust for routine use and retained the required permeability to 
maintain adequate gas exchange (Murphy et al., 1982). Further work suggested that 
other physical characteristics of the storage pack, including the thickness of the plastic 
film and the size of the pack, also played a role in maintaining platelet viability. 
Together, these parameters serve to define the oxygen diffusion capacity of the 
container – a more useful measure of the pack’s ability to maintain platelet viability 
than oxygen permeability alone (Wallvik and Akerblom, 1990). Thus, thinner plastics 
can help to compensate for lower oxygen permeability (Murphy and Gardner, 1975) and 
a modest increase in pack size can aid gaseous exchange by maximising the surface area 
for diffusion (Kakaiya and Katz, 1984, de Wildt-Eggen et al., 1998). Since platelets 
have a fixed demand for oxygen at a set temperature, the measure of oxygen diffusion 
capacity can also aid in defining the maximum platelet yield that a storage pack can 
support (Wallvik and Akerblom, 1990). Associated with the ability to allow oxygen into 
the packs is the ability for carbon dioxide to diffuse to the outside, since a build-up of 
CO2 would lead to the formation of carbonic acid and contribute to a decrease in pH 
over time. 
 
Sterilisation 
Bacterial contamination of the platelet component is a complication of PC storage with 
potentially fatal consequences. Estimates of the prevalence of bacterial contamination in 
platelet components range from 1 in 2000 to 1 in 3000 units, with the risk of a severe 
transfusion reaction of approximately 1 in 50000, significantly exceeding the risk of 
receiving a unit contaminated with one of the viruses routinely screened for by 
transfusion services in the UK (Blajchman et al., 2004). Numerous procedures have 
been introduced to reduce the risk of bacteraemia in PC; including rigorous arm 
cleaning before venupuncture, the diversion of the first 20-30 mL of blood to prevent 
the skin plug removed by the needle from entering the main pack, and monitoring of 
units for bacterial activity over the storage period or before transfusion of the 
component (Pietersz, 2009). A vital component of these efforts is the provision by pack 
manufacturers of a closed collection and storage system with guaranteed sterility. Three 
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principal methods of sterilisation have been adopted: steam sterilisation, γ-irradiation 
and use of ethylene oxide. Some authors have suggested that the method of sterilisation 
can affect the characteristics of platelets under storage, with steam sterilisation resulting 
in higher levels of platelet activation and lactate production compared with ethylene 
oxide (van der Meer and Pietersz, 2007). 
 
Agitation 
Studies have shown that storing platelets under static conditions results in a relatively 
rapid decrease in pH, lower aggregation responses and increased platelet activation; as 
measured by supernatant levels of secretory granule contents such as platelet factor 4 
and β-thromboglobulin (Mitchell et al., 1994, Snyder et al., 1983). Since such studies 
have been performed using storage packs with adequate permeability for oxygen, it is 
the lack of mixing that is generally attributed to be responsible for the relatively poor 
storage characteristics (Wallvik and Akerblom, 1990). The mode of agitation has also 
been found to impact on platelet viability, with horizontal flat-bed agitators widely 
adopted over rotational mixers (Holme et al., 1978). Periods of interrupted agitation are 
likely to occur as PCs are transported to hospitals or temporarily stored in small 
facilities with limited resources. Studies have determined that storage under static 
conditions for up to 24 hours at any time point during the storage period does not lead to 
significant platelet damage as measured by various in vitro assays (Van Der Meer et al., 
2007, Hunter et al., 2001). Interruption of agitation for longer periods had a more 
significant effect on pH levels, with longer static periods and higher platelet 
concentrations resulting in lower pH values (Dumont et al., 2007).  
 
Temperature 
Current guidelines for the storage of PC require the units to be stored at 22°C ± 2°C. 
The risk of a PC developing a clinically relevant dose of bacteria over the storage period 
would be decreased if PC could be stored at temperatures of 2 – 6°C typical of red cell 
components. Bacterial contamination in platelet components is estimated to be 50 times 
more prevalent than in red cells (Kuehnert et al., 2001), with the higher storage 
temperature a significant factor of this increased risk. Experiments investigating storage 
of platelets at 4°C using metabolically suppressed platelets - in which energy stores for 
the platelets were depleted by initial storage at 37°C in a glucose-free, antimycin A-
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containing buffer - suggest that cold storage at 4°C seems to stabilise metabolic activity 
and does not lead to increased expression of markers associated with platelet activation, 
such as CD62P and CD63. In addition, response in functional assays such as TRAP-
induced aggregation was improved compared with platelets stored at ambient 
temperatures (Badlou et al., 2005, Cauwenberghs et al., 2007). Morphological changes 
do occur during cold storage that are similar to the changes following platelet activation 
and have been termed cold-induced activation. Such changes appear to be the result of 
F-actin fragmentation and microtubule depolymerisation. Changes in the viscosity of 
the platelet membrane have also been noted in animal studies. The effect is the loss of 
the normal discoid shape and the appearance of platelets with a spherocytic 
morphology. It is unclear whether such a change in shape would by itself pose a 
problem for the transfusion of these platelets, as animal studies have suggested 
spherocytic platelets are not preferentially cleared from the circulation (Hoffmeister et 
al., 2003a). However, early studies showed that platelets stored at 4°C were rapidly 
cleared from the circulation following transfusion (Josefsson, 2007). More recent 
investigations have measured a down-regulation in the expression of CD42b, which 
may be related to the mechanism for clearance of chilled platelets (Sandgren et al., 
2007). Chilling irreversibly clusters the GPIb/IX/V complex on the platelet surface. 
Hepatic macrophages expressing the integrin αΜβ2 are capable of detecting the 
clustered GPIbα through binding of the lectin domain of the integrin to the β-GlcNAc 
residues of the glycoprotein’s N-linked glycans. Recognition leads to the phagocytosis 
of the chilled platelets and removal from the circulation, with approximately two thirds 
of platelets chilled before infusion estimated to be quickly cleared by this mechanism 
(Hoffmeister et al., 2003a). Initally encouraging results suggested masking of the 
GlcNAc residues by enzymatic galactosylation may preclude the premature clearing of 
chilled platelets (Hoffmeister et al., 2003b, Babic et al., 2007). However, the results 
from the in vitro studies did not translate to better retention of chilled platelets in a 
phase 1 clinical trial (Wandall et al., 2008), and rapid clearance from the circulation 
remains the most intractable problem in adopting cold storage for platelet concentrates.  
 
On the opposite side of the temperature scale, storing platelets at physiological 
temperatures of 37°C is not contemplated, as the in vitro characteristics of platelet 
ageing are accelerated. These include an increased rate of ATP utilisation and a 
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doubling of oxygen consumption compared to platelets stored at 22°C, suggesting an 
increase in metabolism (Holme and Heaton, 1995). A recent study by Bertino et. al. 
(2003) also demonstrated accelerated decreases in pH and platelet concentration along 
with increases in lactate dehydrogenase levels. This last study also suggested that 
programmed cell death may be promoted by storage at 37°C (Bertino et al., 2003). 
 
Current Methods of PC Preparation 
Current methodologies for the preparation of platelet concentrates are based on three 
approaches (Tynngard, 2009): 
− Single donor PCs collected by apheresis technology; an automated process by which 
platelets are separated from whole blood by centrifugation or elution, with the red 
cells returned to the donor. Depending on the donor, between one and three adult 
dose PCs may be collected during the approximately 90 minute procedure, with 4 to 
5 litres of whole blood being processed (Perrotta and Snyder, 2007). 
− Platelet concentrates prepared from platelet rich plasma (PRP-PC), in which PRP is 
separated from whole blood by a gentle centrifugation step. The PRP is separated 
from the red cells into a satellite pack which is then subjected to a “hard” 
centrifugation step. The excess plasma is extracted into a separate pack and the 
resulting platelet pellet gently re-suspended in the remaining 50 – 70 mL of plasma 
to generate a concentrate. Four to six of these units may be pooled to provide a 
single adult dose. Pooling traditionally occurred shortly before transfusion due to 
concerns that storage of pooled concentrates may increase the risk of bacterial 
growth and degrade the quality of the component (Sweeney et al., 2004). Recent 
studies, however, have provided robust evidence that pooling does not adversely 
affect the platelets. Preparation of PRP-PC remains the preferred method for PC 
production in the United States. 
− Platelet concentrates prepared from a pool of 4-6 whole blood-derived buffy coats 
(BC-PC). An initial hard centrifugation step separates the buffy coat, containing the 
white cells and platelets, from the bulk of the red cells and plasma. The buffy coats 
may be stored overnight without agitation at 22 ± 2°C before being pooled (though 
some organisations prefer to store the whole blood overnight, using butanediol 
plates to cool and maintain the whole blood at approximately 22°C for up to 24 
hours) (Murphy, 2005, Pietersz, 2011, Dijkstra-Tiekstra et al., 2011). Between four 
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to six buffy coats are aseptically pooled using an autologous unit of plasma (or an 
artificial suspending medium). Gentle centrifugation of the buffy coat pool separates 
the platelets as a concentrate from the red cells and a significant fraction of the 
white cells, with removal of the remaining white cells achieved through an integral 
filter leading to the PC storage pack. This is the method currently adopted in Europe 
and Canada (figure 1.12). A detailed description of the preparation of PC from 
pooled buffy coats is provided in chapter 2 (Methods). 
  
 
Figure1.12: Schematic of whole blood-derived platelet concentrates (a) from platelet-
rich plasma (b) from pooled buffy coats (Vassallo and Murphy, 2006) (Reprinted with 
permission, © Lippincott Williams & Wilkins) 
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Improvements in the preparation and storage of PCs have allowed the extension of the 
storage period from an initial limit of three days to five days. The ability to store PCs 
for longer periods has long been desired, as it would ease the logistical pressures on 
transfusion services to maintain the supply, especially as mandatory blood grouping and 
virology testing requirements significantly impinge on a shelf life limited to five days. 
In the 1980s, the US Food and Drug Administration was sufficiently confident in the 
ability of storage packs to retain adequate platelet viability over seven days that they 
approved the adoption of this extended storage period. Concerns over an increase in 
cases of bacterial contamination forced regulatory authorities to reverse the decision 
(Braine et al., 1986, Heal et al., 1986, Slichter, 2004). However, the introduction of 
approved measures to monitor the sterility of platelet concentrates has allowed the 
limited re-introduction of 7-day storage periods. An associated development is the 
introduction of pathogen inactivation technology. In PC, currently CE marked pathogen 
inactivation methods rely on the targeting of nucleic acids with compounds which 
subsequently photoactivate on exposure to ultraviolet wavelenghts, causing irreversible 
damage to the molecules and preventing the proliferation of viruses, bacteria and white 
cells (Prowse, 2012).  
 
A further consideration is the impact of an extended storage period on in vitro platelet 
characteristics as well as platelet function and recovery following transfusion. Changes 
in platelet morphology, functional responses, metabolic parameters and markers of 
senescence have been noted in relation to the processing and storage of PC. 
Collectively, these changes have been termed the platelet storage lesion (PSL). 
Numerous studies have suggested that prolonging the storage period is related to the 
increased expression of the PSL, leading to the requirement of a better understanding of 
this phenomenon if further improvements in the provision of PCs to hospitals are to be 
forthcoming (for recent reviews see Maurer-Spurej and Chipperfield, 2007, Shrivastava, 
2009, Ohto et al., 2009, Thon et al., 2008). The following section describes the nature of 
the storage lesion in association with some of the assays adopted for its investigation. 
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PLATELET STORAGE LESION 
Platelet Morphology 
Platelet activation results in a transformation from the normal discoid morphology of 
the resting platelet to a more spherical form with spiny projections (Maurer-Spurej and 
Chipperfield, 2007). Similar morphological changes have been observed in platelets 
stored as concentrates and have been linked to reduced platelet recoveries in early 
studies, leading to the suggestion that the maintenance of a discoid form is a 
prerequisite for platelet survival (see Goodrich et al. for references Goodrich et al., 
2006). A scoring system was developed to provide a semi-quantitative measure of 
platelet morphology as viewed under oil-phase microscopy (1000× magnification), with 
platelets categorised as discs, spheres, dendritic forms or ballooned forms. Each form is 
given a score from 4 to 0 and the percentage of each type multiplied by the score 
(Kunicki et al., 1975, Murphy et al., 1994). Recovery and survival of platelets in 
radiolabelled re-infusion studies were found to correlate with the morphology score in 
these early studies. Reviews of subsequent studies have shown a 20-45% decrease in the 
morphology score between fresh and 5-day old platelets (Murphy et al., 1994, Cardigan 
and Williamson, 2003). A change in morphology with storage has also been suggested 
from monitoring the “swirling” of platelets in a storage pack. A population of discoid 
platelets will scatter incident light in numerous directions due to the varying orientation 
of the platelets in relation to the light as the unit is gently rocked. The appearance is that 
of a turbulent fog when the unit is held up to a light source. Spherical platelets have a 
uniform shape and will not produce this effect (Brecher and Hay, 2004, Bertolini et al., 
2000). However, murine studies have shown that discoid platelets may also be removed 
rapidly from the circulation and both murine and primate platelets activated in vitro 
with thrombin and displaying a non-discoid morphology are able to circulate normally. 
Such work has led some to suggest that shape change is not related to platelet clearance 
in the circulation (Hoffmeister et al., 2003a, Italiano et al., 2003). In addition, evidence 
from a study using a rabbit model suggested that the morphological score is not related 
to the haemostatic efficiency of transfused platelets (Rothwell et al., 2000).  
 
Associated with the measure of platelet morphology is the measure of platelet size, 
generally described by the mean platelet volume (MPV). MPV in vivo appears to be 
maintained independent of platelet age. An increase in MPV is evident in 
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thrombocytopenic patients, possibly related to a compensatory thrombopoiesis, with the 
suggestion that younger platelets are larger and functionally more responsive 
(Thompson et al., 1984, Albanyan et al., 2009). During storage, an increase in MPV is 
often evident, arguably related to swelling of the platelet population and a disc-to-
sphere transformation. Some authors have suggested caution in the interpretation of 
MPV results, as platelet lysis or the formation of microparticles may lead to a relative 
decrease in this measure (Fijnheer et al., 1989). Indeed, studies often report a decrease 
in platelet concentration with duration of storage, the most likely explanation being the 
breakdown of relatively fragile, possibly older, platelets (Hornsey et al., 2008). Studies 
have also noted that the processing methodology can have a relative impact on MPV. A 
lower MPV has been noted in apheresis-derived platelet concentrates compared with 
BC-PC, possibly due to preferential collection of smaller platelets by the apheresis 
technology (Albanyan et al., 2009).  
 
Platelet Activation 
The monitoring of platelet activation as a component of the PSL has included the 
measurement of markers associated with secretory granule release, the formation of 
microparticles and conformational changes in membrane glycoproteins such as the 
integrin αΙΙββ3, as well as the morphological changes already described (Heijnen et al., 
1999, Kulkarni et al., 2000). Assays may be performed on non-stimulated platelets from 
PCs to determine the spontaneous activation caused by processing and storage, as well 
as agonist-stimulated platelets to determine the residual capacity for platelets to respond 
to physiological agonists (Vetlesen et al., 2007). As a marker of α-granule release, 
surface expression of CD62P has generally been found to increase with storage, with 
the concentration of thrombin required to achieve an equivalent level of expression also 
increasing with longer storage periods (Leytin et al., 2008). The latter observation 
suggests a depletion of the α-granule contents with storage, though alternative 
explanations may involve shedding of the PAR-1 receptor or disruption of the signalling 
process (Reiter et al., 2003, Jilma-Stohlawetz et al., 2008). CD62P binds to the P-
selectin glycoprotein ligand-1 (PSGL-1) receptor principally found on the myeloid 
lineage of leucocytes, leading to the suggestion that an increased expression of CD62P 
in activated platelets could be responsible for their accelerated clearance from the 
circulation following transfusion (Perseghin et al., 2004, Gutensohn et al., 2002). 
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However, studies investigating the relationship between surface CD62P and platelet 
recovery post-transfusion have yielded inconsistent results (Holme et al., 1997, Dumont 
et al., 2002, Rinder and Smith, 2003), possibly reflecting the lack of standardisation in 
methodology which may vary with respect to sample preparation as well as flow 
cytometric settings. A 1992 study by Triulzi et al concluded that there was no 
correlation between CD62P expression and corrected count increments (r2=0.34) 
(Triulzi et al., 1992). Proteolytic cleavage of CD62P from the platelet surface has been 
found to yield a 100 kDa soluble fragment which has been suggested by some authors to 
constitute a better indicator of platelet activation during storage than surface expression 
of the protein (Michelson et al., 1996, Berger et al., 1998). Expression of CD62P has 
been reported to correlate well with other markers of degranulation such as β-
thromboglobulin, RANTES and platelet factor 4 - all constituents of α-granules and all 
reported as increasing significantly with storage (Shanwell et al., 2003, Cardigan et al., 
2003). As with CD62P expression, correlation of these markers with platelet recovery 
has been poor (Murphy et al., 1994, Snyder, 1992). Dense granule release has been 
investigated via the expression of CD63 (Sandgren et al., 2008). The use of this marker 
alongside CD62P in studies of cerebral ischaemia have found continued expression of 
CD63 with none of the degradation evident with CD62P (Marquardt et al., 2002), 
leading to the suggestion that it may form a better marker of in vitro platelet activation 
than CD62P (Sandgren et al., 2007). 
 
Flow cytometric assays have also been employed to investigate changes to membrane 
glycoproteins during storage. Surface expression of CD42b (the GPIbα component of 
the GPIb-IX-V complex) has been found to decrease moderately with storage, though 
levels remain at approximately 90% of starting levels (Diedrich et al., 2008, Cardigan et 
al., 2008). The decrease may be related to redistribution of the glycoprotein into the 
open canalicular system and although a possible consequence would be a decrease in 
adhesive function, no such effect has been measured under flow conditions (Turner et 
al., 2005, Sandgren et al., 2008).  
 
Platelet-derived microparticles are small (40 nm – 1 µm) fragments expressing platelet-
specific antigens that have been found to increase in number with storage of PC 
(Niewland and Sturk, 2007). The increased formation of microparticles is associated 
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with platelet activation, with increased formation noted after stimulation with 
physiological agonists as well as the calcium ionophore A23187, exposure to high shear 
and in clinical situations associated with platelet activation (Heijnen et al., 1999). There 
is some hesitation in employing microparticle formation as a marker for monitoring the 
PSL, as their small size is at the limit of the resolution possible by flow cytometry 
(Maurer-Spurej and Chipperfield, 2007). Indeed, transmission electron microscopy 
studies have implied that there are two distinct populations of microparticles with 
apparent diameters of 0.4 – 0.6 µm and 0.08 – 0.2 µm (Sandberg et al., 1985). The latter 
population would likely be lost in the background “noise” of the instrument (Bode et al., 
1991).  
 
Platelet Metabolism 
Platelets under standard storage conditions employ both aerobic and anaerobic 
metabolism to maintain their energy stores. Extracellular pH of PCs is employed by 
transfusion services as an ubiquitous measure of the effectiveness of processing and 
storage methods to maintain the metabolic activity of platelets, as levels below 6.2 have 
been associated with poor performance in other in vitro parameters (Murphy et al., 
1994, Rinder and Smith, 2003). The decrease in pH traditionally reported in PC 
suspended in plasma is attributed to the accumulation of lactic acid due to continued 
glycolysis, even in the presence of adequate oxygen (Murphy and Gardner, 1975), with 
a pH of 6.0 associated with a lactate concentration of approximately 30 mmol/L 
(Gulliksson, 2003). The concentration of hydrogen ions will be buffered by the presence 
of bicarbonate in the plasma, which in PC suspended in 100% plasma is sufficient to 
buffer lactate levels up to approximately 20 - 25 mmol/L (Murphy, 2002, Kilkson et al., 
1984). This has led to the suggestion that lactate concentration would be a better 
predictor of in vivo recovery than pH (Goodrich et al., 2006). Rates of lactate 
production and glucose consumption have also been adopted to monitor the PSL. 
Aerobic metabolism has been indirectly monitored in PC through the measurement of 
partial pressures of oxygen and carbon dioxide, with increases in pO2 and concurrent 
decreases in pCO2 interpreted as a decline in oxidative metabolism (Holme et al., 1987). 
Conversely, lower pO2 levels are indicative of increased oxygen consumption (Picker et 
al., 2009). Some care is required in the interpretation of these parameters with current 
gas-permeable storage packs, as the pressures also relate to the equilibration of O2 and 
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pCO2 in the pack relative to atmospheric pressures (Zhang et al., 2008a). An additional 
parameter that may be useful in this context is a calculated rate of oxygen consumption 
that includes the gas permeability of the plastic as well as PC and atmospheric partial 
pressures of oxygen (Kilkson et al., 1984). 
 
Losses of ATP and ADP associated with PC storage have been reported in the literature 
(Rao et al., 1993), though levels of ATP are most often presented in publications. 
Starting levels of ATP in PC are somewhat variable depending on the methodology 
used to perform the measurements (Girotti et al., 1989) but there seems to be a growing 
consensus that ATP levels below 4.0 µmol/1011 platelets (or approximately 70% of day 
1 values) are related to reduced in vivo recoveries below 50% (Cardigan et al., 2005). 
Early studies also noted that ATP levels were only observed to decrease after glucose 
concentrations decreased below 50% of starting levels (Savage, 1982). A further 
measure to assess the energy potential of platelets in PCs is the adenylate energy charge 
(AEC), regarded as indicative of the overall energy status of the cell. It requires the 
measurement of ATP, ADP and AMP levels, and is calculated as follows: AEC = 
(2ATP + ADP)/2(ATP + ADP + AMP) (Rao et al., 1981, Verhoeven et al., 1985). 
 
Platelet Function and Viability 
One of the few in vitro assays adopted to monitor the PSL that has been found to 
correlate with platelet recovery post-transfusion is the extent of shape change (ESC) 
(r=0.71), with levels below 15% (or less than 60% of day 1 values) correlating with less 
than 50% recovery (Holme et al., 1998, Diedrich et al., 2008). The assay is a measure of 
the change in light transmission of a platelet sample in response to the addition of ADP 
(VandenBroeke et al., 2004). Significant correlation also exists between the ESC assay 
and morphology scores (r=0.93) (Holme et al., 1998) and this may have led to the 
common interpretation of this assay as an indicator of platelet shape change in response 
to the addition of a weak agonist. This explanation has been recently challenged, with 
the suggestion that the decrease in light transmission in Born-type aggregometers is 
caused by the formation of microaggregates rather than a disc to sphere transformation. 
Two lines of evidence have been used to support this interpretation: i) the observation 
that platelets at 37°C appeared as smooth discs when at rest, with no change in 
morphology when exposed to stirring at 1000 rpm even though light transmission under 
33 
 
these conditions increased abruptly, ii) platelets that had already been observed to have 
undergone a change in shape proceeded to show a decrease in light transmission on the 
addition of 0.5 iu/mL thrombin (Maurer-Spurej and Devine, 2001). In addition, the 
authors suggest that microaggregation is distinct from normal aggregation, since 
platelets from patients with Glanzmann’s thrombasthenia, which lack the integrin αIIbβ3 
required for complete platelet aggregation, continue to show the initial decrease in light 
transmission. 
 
An assay often performed in conjunction with the ESC is the hypotonic shock response 
(HSR), which measures the relative recovery of platelets to a hypotonic insult. The 
addition of water results in swelling of the platelets with gradual extrusion of the water 
by viable platelets, probably via an ATP-dependent expulsion of K+ and Cl- ions (Okada 
et al., 2001). This change can be photometrically measured, since the refractive index of 
the platelets decreases with the uptake of water, leading to an increase in light 
transmission which gradually declines again as the water is extruded (Holme, 1998). 
The HSR has shown reasonable correlation with in vivo platelet recovery (r=0.57) 
(Holme et al., 1998), with recovery levels below 50% associated with HSR values 
below 70-75% (Cardigan et al., 2005) or less than 60% (Diedrich et al., 2008) for PC 
suspended in 100% plasma. 
 
Determining the ability of platelets stored as PC to function normally after transfusion is 
a major goal of the various assays employed to study the PSL, and the capacity of stored 
platelets to form aggregates in vitro in response to various physiological agonists would 
seem a logical approach to accomplish this. Traditional platelet aggregometers measure 
light transmission through a platelet sample. Aggregation would be expected to result in 
an increase in light transmission as the formation of large particles enhanced the 
unimpeded transmission of light (Born, 1962). The rate of aggregate formation and the 
maximum response are the parameters generally quoted (Tynngard, 2009). Platelets 
stored for 5 days under standard conditions have been shown to have a poor aggregation 
response to single agonists such as ADP, epinephrine and collagen (Murphy et al., 
1994), with confirmatory results from studies which found a reduced aggregation 
response in platelets stored as PC compared to platelets retained as whole blood 
(Shapira et al., 2000, Jansen et al., 2004). The response to stronger agonists such as 
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thrombin or paired weaker agonists has been reported as better maintained (Murphy et 
al., 1994). The latter may be a better indicator of performance in vivo since activation by 
single weak agonists does not reflect conditions in the circulation (Cardigan and 
Williamson, 2003). Another factor to consider in the interpretation of aggregation 
response is the observation that a reduced response can recover after transfusion (Miyaji 
et al., 2004). In addition, studies with platelets stored at 4°C have concluded that 
platelet aggregation response does not correlate with in vivo platelet recovery and 
survival, as the chilled platelets have an improved aggregation response but are rapidly 
cleared from the circulation (Kattlove et al., 1972). Interestingly, work with PCs 
suspended in additive solutions or washed platelets have resulted in a decreased or 
absent aggregation response on addition of ADP (Schoenfeld et al., 2004). A decrease 
in ADP receptor responsiveness due to the lack of a permissive factor present in plasma 
has been suggested as a possible explanation (Keuren et al., 2006). Platelet adhesion to 
glass slides coated with collagen has also been observed to decrease substantially with 
increased platelet storage; though, in contrast to the previous observation, the presence 
of plasma did not seem to impact on the results (Brown et al., 2000). As an assay for the 
determination of platelet function after transfusion, standard aggregometry suffers from 
the disadvantage that reactions are restricted to a low shear environment which does not 
reflect conditions in vivo. A variety of techniques and instruments have been introduced 
to address this limitation. One approach is to measure the adhesion and/or aggregation 
of platelets to a subendothelial surface/matrix or an agonist-coated membrane under 
controlled shear conditions (Morrison et al., 2007, Tanaka, 2006, Rand et al., 2003). A 
second approach measures the elastic properties of a forming blood clot. Application of 
these techniques to the study of the storage lesion appears to be limited, though studies 
measuring the strength of clot retraction have discerned little or no change after five 
days of storage (Tynngard et al., 2008, Reid et al., 1998). 
 
Mechanisms of Cell Death 
Associated with the maintenance of ATP levels in storage may be the functional 
capacity of the platelets’ mitochondria to maintain the electron transport chain across 
the inner mitochondrial membrane (Newmeyer and Ferguson-Miller, 2003). The 
deliberate uncoupling of oxidative phosphorylation in platelets through the addition of 
the protonophore carbonyl cyanide m-chlorophenylhydrazone (CCCP) has been 
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reported to result in a marked reduction in platelet recovery post-transfusion in a mouse 
model (Kile, 2009). The experimental approach has been proposed as a model for the 
PSL, since the disruption of oxidative phosphorylation has been associated with platelet 
shape change, disruption of membrane phospholipid asymmetry, microparticle 
formation, surface expression of CD62P and loss of membrane GPIbα (Bergmeier et al., 
2003). The impact on the mitochondrial inner membrane can be discerned by 
measurements of the mitochondrial membrane potential, commonly performed by 
measuring the uptake of cationic dyes into the mitochondria. Published data on the 
behaviour of the mitochondrial membrane potential in PC over the storage period vary, 
with some studies suggesting there is little or no change whilst others report significant 
decreases (Perrotta et al., 2003, Li et al., 2005b). This discrepancy extends to the 
response of this parameter to the addition of calcium ionophore (Perrotta et al., 2003, 
Albanyan et al., 2009). Alternative approaches to the measurement of inner 
mitochondrial membrane permeabilisation, such as loading of the platelets with calcein 
which does not normally cross this barrier, may help to resolve some of these questions 
(Kroemer and Reed, 2000). Although the physiological role of mitochondria has 
traditionally been confined to the generation of ATP, an increasing body of work has 
linked mitochondria with events leading to programmed cell death (Jackson and 
Schoenwaelder, 2010). A fall in mitochondrial membrane potential has been described 
as an early event during apoptosis, with a collapse of the potential associated with 
irreversible cell death (Hortelano et al., 1999). Investigation of apoptosis in relation to 
the PSL is not as well established as the aforementioned parameters. However, changes 
to the expression of anionic phospholipids on the platelet surface over the storage 
period, as measured by the binding of fluorescently-labelled annexin V, have been 
reported in multiple studies. Increased binding is often interpreted as increased 
expression of phosphatidylserine and thus as a marker of platelet activation and 
procoagulant activity (Brown et al., 2000); with progressive exposure indicative of 
apoptosis (Perez-Pujol et al., 2005). PS on the cell surface is also considered to be a 
marker for the phagocytic removal of cells (Fadok et al., 1992), though it is unclear if 
this forms a substantive mechanism for the clearance of platelets after transfusion 
(Bergmeier et al., 2003). 
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With increasing interest on the possible role of apoptosis in the PSL, investigators are 
adopting a wider range of assays targeting specific aspects of the process. These include 
methods for measuring caspase activity (Bertino et al., 2003, Perrotta et al., 2003), the 
release of intermembrane space proteins such as cytochrome c  and the role of Bcl-2 
family members (Leytin et al., 2006); with approaches that manipulate the platelet 
environment with the use of inhibitors further contributing to the understanding of the 
mechanisms involved in the PSL (Dasgupta et al., 2010, Lopez et al., 2007). 
 
Platelet Recovery and Survival 
In vivo measures to assess the efficacy of transfusing platelet components generally 
involve platelet recovery and survival studies - in which autologous platelets 
radiolabelled with chromium-51 or indium-111 are re-infused into healthy volunteers - 
or calculations of the platelet increment following a transfusion. Recent scrutiny of 
recovery and survival methods has led to the publication of guidelines and protocols for 
the sample preparation and analysis of results from the Biomedical Excellence for Safer 
Transfusion to aid in standardisation of techniques (The Biomedical Excellence for 
Safer Transfusion, 2006). Limits of 66% and 50% as a proportion of values from fresh 
units have been suggested as acceptable for recovery and survival measures, 
respectively (Murphy, 2004), and appear to be generally accepted (AuBuchon and 
Snyder, 2006). Significant variability in some of the required factors remains, such as 
estimates of blood volume and differences in the uptake of transfused platelets by the 
recipient’s spleen (Holme, 2008, Aster, 1966). Additionally, the response by 
thrombocytopenic patients is likely to differ from that in healthy volunteers, with an 
apparent shortening in mean platelet lifespan observed in patients with platelet counts 
below 90 × 109/L (Hanson and Slichter, 1985, de Wildt-Eggen and Gulliksson, 2003).  
Corrected count increment (CCI) is the standard by which transfusion efficacy is 
clinically assessed, though parameters such as post-transfusion count and presence or 
absence of bleeding are often used (Arnold et al., 2006). Assuming all transfused 
platelets are viable, the expected increment should be 20 × 109/L (Holme, 2008). In 
practice, increments between 10 – 15 × 109/L are more commonly seen, with increments 
decreasing by 35 – 50% in day 7 platelet concentrates compared with fresh units 
(Murphy, 2002). Levels below 7.5 × 109/L have been regarded as constituting a failed 
transfusion (Norfolk et al., 1998). In addition, the relationship between recovery and 
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survival studies and the CCI remains to be established (van der Meer et al., 2010). The 
above investigations also provide little information on the ability of transfused platelets 
to perform their haemostatic function; a factor which may be related to the lack of 
correlation between in vivo studies and many of the assays used to assess the PSL. 
Nevertheless, with these limitations in mind, the in vitro characterisation of platelets 
stored as concentrates remains an important aspect in the determination of PC quality, 
not least because of the range of in vitro assays able to be applied to the study of the 
increasingly complex physiological role of platelets. 
ADDITIVE SOLUTIONS 
Reports on the use of artificial media for the suspension of platelets as concentrates 
have been evident in the literature since the 1980s (Rock et al., 1985). Interest has 
continued due to a number of actual and purported benefits, including: 
− Increasing the volume of plasma available for fractionation. This provided the 
initial impetus for the development of additive solutions, and though not currently 
a consideration in the UK it remains a practical goal in many countries.  
− Reducing the occurrence of non-haemolytic transfusion reactions (NHTRs). The 
frequency of reactions has been reported as between 20-30%, though moderate to 
severe reactions were only noted in 2.2% of PC transfusion episodes in a 
relatively recent study (Schoenfeld et al., 2004, Enright et al., 2003). 
Leucoreduction has reduced the incidence of NHTRs caused by the release of 
white cell-associated cytokines such as interleukin-6 and tumour necrosis factor α 
(Muylle and Peetermans, 1994). Plasma proteins have generally been implicated 
in allergic reactions. The washing of platelets with saline or Plasmalyte-A has 
been reported to reduce the incidence of reactions, as has the removal of the 
majority of the plasma component (Vo et al., 2001, Heddle et al., 1999, Azuma et 
al., 2009). Studies comparing the incidence of allergic reactions after transfusion 
of PCs stored in additive solution compared to plasma have also observed a 
reduction (de Wildt-Eggen et al., 2000). Finally, removing the plasma would 
facilitate the transfusion of ABO incompatible PC transfusions (Ringwald et al., 
2006). 
− A consideration is the requirement for low plasma concentrations in some 
pathogen inactivation treatments (Williamson, 2004). 
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− Of particular relevance to this study is the possibility that optimising the storage 
media may reduce the adverse consequences of the PSL, leading to a more 
standardised component with an extended shelf life (Holme, 1998, Sandgren et 
al., 2010).  
 
There are presently four additive solutions CE marked and approved for use in Europe 
(Cardigan, 2008). These are PAS-II, Composol and PAS-IIIM; marketed as T-Sol 
(Fenwal; Mont Saint Guibert, Belgium), Composol®PS (Fresenius Kabi; Bad Homburg, 
Germany) and SSP+ (MacoPharma; Mouvaux, France), respectively. In addition, 
PAS-III (marketed as Intersol; Baxter Healthcare, IL) is approved for use with a 
pathogen reduction system (Knutson et al., 2000) and is the only solution licensed for 
use in the USA (Alhumaidan and Sweeney, 2012). The composition of the four 
solutions is provided in table 1.1. 
 
Table 1.1: Composition of CE marked platelet additive solutions 
Composition (mmol/L) 
 
T-Sol(1) Intersol(3)(4) Composol®PS(2) SSP+(2) 
Sodium chloride  115.5 77.3 90.0 69.0 
Sodium acetate  30.0 32.5 27.0 32.5 
Trisodium citrate  10.0 10.8 10.9 10.8 
Potassium chloride  -  5.0 5.0 
Magnesium 
chloride.6H2O  -  1.5 1.5 
Sodium gluconate  -  23.0 - 
Sodium dihydrogen 
phosphate  - 6.3 - 6.7 
Disodium hydrogen 
phosphate - 21.5 - 21.5 
pH 7.2 7.2 7.0 7.2 
1: (Hornsey et al., 2006). 2: (Zhang et al., 2008a). 3:(Sandgren et al., 2010). 4:(Knutson et al., 2000) 
 
Components of Additive Solutions 
Gulliksson has proposed that four elements are requisite for a platelet storage media, 
referred to as “cornerstones”: citrate, acetate, phosphate and glucose (Gulliksson, 2000). 
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Indeed, some of the early studies considering the prospects of developing synthetic 
media for platelet storage were based on red cell anticoagulants such as CPD (citrate 
phosphate dextrose). Reports suggested adequate 5-day storage of BC-PC with 
suspensions of 40% CPD plasma and 60% saline (Gulliksson et al., 1992). 
 
Citrate 
Citrate concentrations below 8 mmol/L have been associated with clotting due to 
activation of coagulation mechanisms and the formation of fibrin (Prowse et al., 1987). 
Conversely, citrate concentrations between 14-26 mmol/L were associated with 
increased generation of lactate compared with the lower concentration (Gulliksson, 
1993), suggesting low concentrations of citrate should be adopted to limit lactate 
production and the concomitant drop in pH. Such studies led to the compromise value 
of approximately 10 mmol/L employed in most additive solutions (Murphy, 1999).   
 
Phosphate 
Phosphate has been postulated to have two seemingly contradictory effects during 
platelet storage, acting as a buffer whilst also promoting glycolysis and the production 
of lactate (Ringwald et al., 2006). The stimulation of glycolysis is likely due to the 
requirement for phosphate in the conversion of glyceraldehydes-3-phosphate to 3-
phosphoglycerate in the second stage of the process (Gulliksson et al., 2000). A study 
by Gullikson et al compared PC collected in acid citrate dextrose (ACD) anticoagulant 
with PAS-II against PC collected in CPD with PAS-II and observed significantly lower 
lactate production in the former (Gulliksson et al., 1997). Further studies comparing PC 
in PAS-II with PC in PAS-III (PAS-II with added phosphate) (Hornsey et al., 2006) 
confirmed the reduction in glycolysis was most likely to be due to the presence of 
phosphate (Gulliksson et al., 2000). Despite the increased glycolysis, a phosphate 
concentration of 10 mmol/L has been found to stabilise pH in storage media with 
minimal plasma carry-over (Shimizu and Murphy, 1993). The effect of phosphate on 
pH may not be a simple linear relation, since no difference in pH was found by 
increasing the phosphate concentration from 26 to 40 mmol/L (Dekkers et al., 2007). As 
an intricate component of adenine nucleotides, the presence of phosphate in the storage 
media may be expected to impact on the concentrations of ATP and ADP. Lower levels 
of adenine nucleotides have indeed been observed with PC suspended in media lacking 
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phosphate (Gulliksson et al., 1997, Gulliksson et al., 2000). This may be a particular 
consideration for media used in conjunction with ACD anticoagulant, which unlike 
CPD lacks phosphate, and continues to be the preferred anticoagulant for apheresis-
collected PCs due to the ease of platelet re-suspension (Flatow and Freireich, 1966). 
Composol®PS contains gluconate instead of phosphate, with the aim of retaining the 
buffering capacity of the medium without the increase in lactate production. 
 
In phosphate-containing media such as SSP+, the inclusion of magnesium and 
potassium has been shown to reduce glycolysis as well as platelet activation, with better 
maintenance of pH and HSR (de Wildt-Eggen et al., 2002). Gullikson et al have also 
suggested that the presence of K+ and Mg2+ may allow the reduction of the residual 
plasma volume in AS-containing storage media from the current requirement of 30% to 
20% (Gulliksson et al., 2002). The mechanism responsible for the suppression of 
glycolysis is unclear and may be indirect (Zhang et al., 2008b). Reduced activation has 
been demonstrated by lower CD62P expression and lower levels of secretory granule 
contents such as RANTES, PF4 and β-TG (Shanwell et al., 2003). As well as reduced 
CD62P expression, increased concentrations of Mg2+ decreased ADP-induced 
aggregation as well as the binding of fibrinogen to ADP-activated platelets (Gulliksson 
et al., 2003). It is possible that Mg2+ may inhibit aggregation by altering membrane 
fluidity or by influencing the formation of cAMP (Sheu et al., 2002). Potassium also 
plays a role in maintaining the platelet membrane potential (Ishikawa and Sasakawa, 
1987); in addition, a decrease in cytosolic concentrations has been suggested to play a 
role in apoptosis by stimulating cytochrome c release and thus promoting the formation 
of the apoptosome (Gogvadze et al., 2004).  
Acetate 
Acetate has been included in synthetic media to act as an oxidisable fuel and its 
presence has been observed to decrease anaerobic metabolism and increase oxygen 
consumption (Holme, 1992). In human plasma, acetate is present at very low levels, 
with concentrations between 0.05 – 0.25 mmol/L (Skutches et al., 1979). It is 
metabolised via the tricarboxylic acid (TCA) cycle from where it undergoes further 
oxidation to CO2 and H2O (figure 1.13). When added exogenously to PCs it is rapidly 
taken up by platelets, with reports that almost 50% is converted to CO2 within ten 
minutes (Holme, 1992). Studies with 14CO2-labelled acetate confirmed this rapid 
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turnover, with consumption rates calculated as 0.5 mmol/day/1010plts and 90% of the 
metabolised acetate converted to CO2. Acetate also appeared to be used preferentially 
by aerobic metabolism, with all the oxygen consumed able to be accounted for by the 
metabolism of acetate (Guppy et al., 1990). The ease with which acetate is metabolised 
to acetyl CoA may actually inhibit the oxidation of other potential fuels such as fatty 
acids, since acetyl CoA suppresses the β-oxidation of free fatty acids (Murphy, 1999). A 
further benefit of incorporating acetate in the storage media is the removal of a H+ ion, 
given that acetate is metabolised in its acid form. This results in a buffering action 
against the decrease in pH produced by glycolysis. 
 
Figure 1.13: Simplified schematic of metabolic pathways. (A) – glycolysis (B) – 
tricarboxylic acid (TCA) cycle (Tynngard, 2009) (Reproduced with permission, © 
Elsevier Ltd) 
 
The presence of acetate may also have a more direct action against the generation of 
lactate since acetyl CoA combines with oxaloacetate to form citrate, which then 
proceeds through to the TCA cycle. Citrate and ATP both inhibit phosphofructokinase, 
one of the rate-limiting enzymes of the glycolytic cycle, thus reducing lactate formation 
(Murphy, 1999). It has been postulated that, theoretically, the presence of acetate could 
provide unlimited buffering capacity for PC, as the rate of acetate consumption matches 
the rate of lactate production at 22°C (Murphy, 2002). In practice, studies have 
measured reductions in bicarbonate consumption of nearly 60% in PRP-PC suspended 
in plasma with exogenously added acetate compared with controls (Murphy, 1995). 
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However, despite its apparent role as an oxidative fuel, storage studies suggest that the 
addition of acetate does not aid in the maintenance of ATP levels during storage 
(Holme, 1992). 
Glucose 
The final component of Gullikson’s required quartet is glucose. Metabolism of glucose 
is able to proceed via either glycolysis or through the TCA cycle to complete oxidation. 
A study by Kilkson et al investigated the relationship between glucose consumption, 
lactate production and oxygen consumption in platelet concentrates and concluded that 
if glucose was the sole source of oxidisable fuel, the ratio of glucose consumption to 
lactate production should be 0.66. The measured value was 0.52 - very close to that 
expected from the stoichiometry of glucose consumption by glycolysis. The results thus 
suggested that a fuel source other than glucose was primarily responsible for oxidative 
metabolism (Kilkson et al., 1984). The study also concluded that approximately 85% of 
energy generation in PC is obtained from aerobic metabolism and only 15% from 
glycolysis. Measurements of 14CO2 originating from radiolabelled glucose concluded 
that only 1.4% of the glucose was entering the TCA cycle, corroborating Kilkson’s 
earlier work (Guppy et al., 1990). These studies led to the question of whether glucose 
could be omitted from the storage media, thus negating the pH drop caused by 
glycolytic lactate production (Murphy et al., 1991). There were also practical 
advantages in that heat sterilisation methods caused the caramelisation of glucose at the 
neutral or alkaline pH suitable for PC storage (Ringwald et al., 2006). However, studies 
omitting glucose have resulted in lower in vivo recoveries and poorer in vitro 
characteristics, including lower ATP levels during storage and accelerated platelet lysis; 
leading various authors to conclude that glucose may be necessary throughout the 
storage period (Gulliksson, 2001, Li et al., 2005a, Zhang et al., 2008a). As seen in table 
1.1, residual plasma provides the only source of glucose in currently accepted 
formulations.  
 
Requirement for Plasma 
Guidelines for the use of additive solutions for PC storage currently require the 
incorporation of approximately 30% of autologous plasma in the suspension media. The 
requirement is based on results from various storage studies that have concluded 
residual plasma is needed to maintain platelet quality in vitro (Klinger et al., 1996, 
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Keuren et al., 2006), though the proportion of plasma may depend on the particular 
additive solution used (Cardigan and Williamson, 2003). A 30% carryover of plasma 
will provide approximately 7.5 mmol/L of glucose to an adult dose PC with an 
approximate rate of consumption of 1.0 mmol/L per day (Murphy, 1999). Thus, there 
should be sufficient glucose to maintain stores for the nominal 5-day storage period and 
possibly 7 days. A further consideration is the buffering capacity provided by the 
bicarbonate in the plasma, which converts the free H+ ion produced by glycolysis into 
CO2 and H2O. The former is subsequently able to diffuse through the gas-permeable 
storage packs, thus stabilising the extracellular pH (Tynngard, 2009). Plasma may also 
provide a further source of fuel for aerobic metabolism in the form of free fatty acids 
(FFA) (Holmsen, 1981, Cesar et al., 1987). The concentration of FFA increases in 
plasma with storage due to the hydrolysis of plasma triglycerides, though there remains 
some ambiguity as to whether plasma carryover would supply a sufficient concentration 
to constitute the primary fuel source (Kilkson et al., 1984, Gulliksson, 2000, Ringwald 
et al., 2006). Studies with minimal plasma carryover (<2%) have reported decreased 
HSR and discoid shape which could not be attributed to metabolic changes and may 
instead point to plasma factors that aid in the maintenance of membrane integrity 
(Holme, 1992, Gulliksson, 2001).  
 
AIMS OF THE THESIS 
Two principal considerations formed the basis of this study: 
• The hypothesis that apoptosis is a central mechanism responsible for the changes 
collectively referred to as the platelet storage lesion  
• The investigation of this hypothesis within the applied setting of improving the 
storage environment of platelet concentrates to enhance the efficacy of platelets 
following transfusion. 
In this context, the thesis aimed to investigate the occurrence of an apoptosis-like 
process during PC storage in relation to more familiar parameters of the storage lesion 
and the effect of different storage conditions. To simplify the environment in which the 
platelets were stored, leucoreduced BC-PC suspended in a synthetic medium with 
minimal plasma carryover were selected as the system for study. This allowed for the 
controlled manipulation of the storage medium whilst minimising the possible impact 
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on results of white cell metabolism and the complex composition of plasma. The role of 
plasma proteins (in the form of albumin), acetate and glucose were selected for 
investigation. The rationale for selecting these constituents for investigation was: 
• Albumin: The requirement for 30% plasma carryover to reduce the expression of 
the storage lesion may be related to the presence of plasma survival factors, with a 
putative role in maintaining membrane integrity and reducing apoptosis-related 
measures such as caspase 3 activation and changes in membrane permeability 
(Brown et al., 2000, Perrotta et al., 2003). The addition of albumin from a 
commercially available human source was thus hypothesized to delay the onset of 
markers associated with cell death and platelet disruption. 
• Acetate: The buffering capacity of acetate may be the principal reason for its 
consideration as one of the essential constituents of additive solutions. However, its  
role as an oxidisable fuel may be more ambiguous, with studies reporting an 
increase in oxygen consumption but an inability to maintain ATP levels. Since 
apoptosis is classically described as an ATP-dependent process, the presence of 
acetate in the storage medium may be expected to promote expression of the 
markers of cell death, despite a decrease in lactate formation and associated fall in 
pH. 
• Glucose: The impact, if any, of glucose on the apoptosis markers selected for the 
study may aid in determining whether the requirement for glucose throughout the 
storage period apparent in various studies is related to inhibition of an apoptosis-
like process (Li et al., 2005a).  
An initial extended storage study on BC-PC suspended in either plasma or a 70:30 ratio 
of SSP+ and plasma provided an overview of the in vitro characteristics of platelets 
stored as concentrates under standard conditions. 
 
Subsequent to this series of experiments, the opportunity to collaborate with colleagues 
at the School of Medicine, University Hospital of Wales, allowed for further 
investigations aimed at exploring the central hypothesis more directly. These studies 
were based on the ability of platelets from Scott Syndrome patients to express PS on 
their surface in response to a pro-apoptotic BH3 mimetic (ABT-737). An increasing 
expression of aminophospholipids on the surface of Scott platelets during storage, 
comparable to the response from normal platelets, would suggest that a mechanism akin 
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to apoptosis plays a role in the PSL. The investigations were subsequently extended to 
study the expression of aminophospholipids during storage in relation to thrombin 
generation.  Finally, the possibility that a Bcl-2 protein-mediated mechanism of cell 
death may be viable in stored platelets was investigated. An acknowledged weakness of 
the thesis is the lack of platelet functional assays among the suite of methods adopted, 
and the option remains to undertake future studies to further investigate the results in 
relation to platelet function. 
  
There is an increasing appreciation that the PSL involves most if not all physiological 
platelet functions (Cauwenberghs et al., 2007). In particular, the concept that platelets 
may undergo an apoptosis-like process during storage may contribute significantly to 
the understanding of the PSL and suggest strategies for possible manipulation of the 
platelet storage environment to further improve platelet viability and efficacy post-
transfusion. 
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2. METHODS 
 
EXPERIMENTAL DESIGN 
Storage characteristics of platelets stored as concentrates over an extended 
storage period: comparison of PC suspended in 100% autologous plasma 
versus PC suspended in a 70:30 SSP+/plasma medium 
A minimum of 10 units from each of the two processes were required for the study, with 
sample size being derived from the current UK guidelines for performing an initial  
evaluation of a novel blood component (James, 2005). A non-paired design was adopted 
to reflect the standard method of processing. Units were stored for 14 days, with 
samples aseptically removed for testing on days 1, 2, 3, 6, 8, 10 and 14 - day 1 being the 
day of PC preparation. The range of assays undertaken aimed to investigate aspects of 
platelet metabolism, viability, morphology, activation and apoptosis-like activity. 
Details of unit preparation and assay methodology are provided in the following 
sections. For ease of reference, the assays are listed below:  
Unit characteristics 
Unit volume 
Platelet concentration 
Platelet yield  
End of storage sterility and leucodepletion 
Platelet Metabolism 
 pH (22°C or 37°C; dependent on storage medium)  
 pO2 (37°C) 
 pCO2 (37°C) 
Bicarbonate levels (37°C) 
 Glucose levels and rate of consumption 
 Lactate levels and rate of production 
Oxygen consumption rate (22°C) 
ATP and ADP levels 
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Viability and morphology measures 
 Mean platelet volume 
 Swirling 
 Extent of shape change 
 Hypotonic shock response 
Platelet activation 
Surface expression of CD62P (% positive and median fluorescence intensity) 
 Soluble CD62P concentration 
Apoptosis-like activity 
Annexin V binding to platelet surface 
 Mitochondrial membrane potential 
 
Storage characteristics of platelets suspended in standard additive solution: 
Investigation of the impact of albumin, glucose and acetate on the platelet 
storage lesion 
The standard additive solution (SAS) provided the necessary electrolytes and formed 
the basis of the storage medium. The impact on the platelet storage lesion of the 
addition of albumin, glucose and acetate to the additive solution was investigated in 
three separate studies, termed simply Albumin Study, Glucose Study and Acetate Study. 
Each experiment within a study required the preparation of four buffy coat-derived PCs 
suspended in SAS. The influence of donor variability on platelet storage characteristics 
was minimised by pooling the four platelet concentrates and re-splitting them into four 
now identical units. “Optimal” concentrations of the two reagents not being investigated 
were also added to the medium (though as a result of results obtained in the albumin 
study, albumin was not added to units in the glucose and acetate studies). Four different 
concentrations of the reagent of interest were added to each of the four units. Samples 
were removed aseptically for testing on days 2, 3, 6, 8 and 10; day 1 being the day of 
PC preparation and day 0 the day of whole blood collection.  
 
In addition to the tests listed above, two more assays designed to determine if an 
apoptosis-like mechanism was associated with the PSL were adopted for this series of 
studies. These were: 
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 Intracellular calcium levels 
Identification and quantitation of phospholipids on the platelet surface (in 
collaboration with the University Hospital of Wales) 
 
Finally, an additional experiment was performed to determine the impact on platelet 
storage characteristics of the processing method employed to create the units for the 
additive study. In this experiment, three platelet concentrates were prepared by the same 
method but re-suspended in autologous plasma instead of additive solution.  
 
STATISTICAL ANALYSIS 
Comparison of PC suspended in 100% autologous plasma versus PC suspended in a 
70:30 SSP+/plasma medium 
Normality was not met by some of the data groups (using the Kolmogorov-Smirnov test 
for normality), therefore summary statistics are presented as the median and range in the 
tables and median and interquartile range (25th and 75th percentiles) in the graphs. 
Differences between groups were analysed by the Mann-Whitney Rank Sum test, with a 
p value <0.05 regarded as statistically significant. 
 
Investigation of the impact of albumin, glucose and acetate on the platelet storage 
lesion 
Due to the small number of replicate experiments (n=3) in the albumin study, statistical 
comparisons between the test groups were not undertaken and the results from all three 
replicates are provided in the text. Graphical representations of the results are restricted 
to displaying the mean of the three results only. 
 
For the glucose and acetate studies, all results are presented as mean ± standard 
deviation, with statistical comparisons undertaken by a one way ANOVA. A p-value 
below 0.01 was considered statistically significant. Subsequent multiple comparisons 
were performed by the Holm-Sidak method, with an overall significance level of 0.05. 
All graphs and statistical analysis were generated with SigmaPlot version 10.0 (Systat 
Software Inc., Chicago, IL). 
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ETHICAL CONSIDERATIONS 
Whole blood collections were obtained from volunteer donors in the South Wales 
region by established blood collection teams of the Welsh Blood Service. The buffy 
coats were surplus to the requirements of the blood service and were destined to be 
discarded; thus, there was no impact on the service provided to local hospitals. Buffy 
coats were initially identified simply by a donation number, with no donor information 
appended to the units. The platelet concentrates processed from the buffy coats were 
assigned a test number unrelated to the donation number. Donor anonymity was thus 
ensured throughout the studies. All components were discarded following testing 
according to standard operating procedures in place at the Welsh Blood Service. The 
study was reviewed and approved by the Welsh Blood Service management. The South 
East Wales Research Ethics Committee was approached and stated that the proposed 
study raised no ethical issues and did not require an ethics submission (March 2006 – 
Appendix 1).  
 
PREPARATION OF PLATELET CONCENTRATE UNITS  
PLATELET CONCENTRATES IN 100% AUTOLOGOUS PLASMA 
Background 
Platelet concentrates were prepared using the method employed at the Welsh Blood 
Service for the routine processing of buffy coat-derived platelet concentrates. The buffy 
coats were derived from the processing of whole blood donations collected into bottom 
and top packs (RCB436CU2; Pall Medical, Ascoli, Italy). The whole blood was 
separated into its components within 8 hours of collection, with the buffy coats stored 
overnight at 22 ± 2°C without agitation. Four buffy coats are required for the 
preparation of one adult dose platelet concentrate.  
 
Method 
 Connect four ABO-specific buffy coats by means of a TSCD II sterile tubing welder 
(Terumo Corporation, Tokyo, Japan). Sterile connect an ELX storage pack (Pall 
Medical, Portsmouth, UK) to the last buffy coat and a plasma unit from one of the 
four whole blood collections to the first buffy coat. 
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 Pool the buffy coats together into the last pack, using the plasma to “flush” any 
remaining material from the buffy coat packs. 
 Centrifuge the pooled buffy coat at 900 g (based on a 210 mm average radius of 
rotation) for an accumulated centrifugal effect (ACE) of 1.27 × 107 at 22°C (Sorvall 
RC12BP; Thermo Fisher Scientific, Loughborough, UK). 
 Express the platelet concentrate through the integral Autostop white cell reduction 
filter (Pall Medical, Portsmouth, UK) using an Optipress II blood processor (Fenwal 
Europe, Mont-Saint-Guibert, Belgium). 
 
PLATELET CONCENTRATES IN 70% SSP+ and 30% PLASMA 
Background 
Commercially available additive solutions licensed in Europe for the production of 
platelet concentrates require approximately 30% of autologous plasma to be retained in 
the unit (Sandgren et al., 2010). The commercial additive solution selected was SSP+ 
(MacoPharma UK Ltd, Twickenham, UK). The selection was based on in vitro studies 
that suggest platelets are adequately maintained  in a SSP+/plasma suspending 
medium for at least 7 days, with results comparing favourably with those from other 
commercial additive solutions (Ringwald et al., 2006, Gulliksson et al., 2002, Hornsey 
et al., 2006). 
 
Development of Method 
A previous study performed at the Welsh Blood Service determined the optimal 
centrifugation settings for the preparation of platelet concentrates suspended in a 
medium of approximately 70% plasma and 30% additive solution (Owen H., BSc 
project). The study added 280 mL of additive solution (T-Sol; Baxter Healthcare Corp., 
Deerfield, IL) to four pooled buffy coats. To confirm that this would be a suitable 
volume of SSP+ to use, data from a study performed at the Welsh Blood Service in 
2003 that measured the volume and haematocrit of the dry buffy coats used for the 
preparation of PCs was reviewed. The mean volume of the buffy coats was 56.3 mL and 
the mean haematocrit was 0.448 (n=68). The calculated mean volume for plasma in the 
buffy coats would thus be 31.1 mL. For platelet concentrates comprised of four buffy 
coats, the total volume of plasma would be 124.3 mL. For 70% of the unit to be 
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composed of additive solution, 291.2 mL of SSP+ would need to be added to the 
pooled buffy coats. The addition of 280 mL of SSP+ would thus result in a SSP+ to 
plasma ratio of approximately 69% to 31%. This was judged acceptable and allowed for 
the use of the pre-established centrifugation settings. 
 
Method 
The method outlined above for the preparation of PCs in 100% plasma was adopted for 
the preparation of units in 70% additive solution, with the exception that 280 mL of 
SSP+ was used to pool the buffy coats. SSP+ was purchased from MacoPharma in 
300 mL packs and the correct volume to be added determined by weight. In addition, 
due to the lower specific gravity of the suspending medium, the centrifugation setting 
used for the processing of the pooled buffy coat was a gentler 550 g for 4 minutes 30 
seconds at 22°C. Leucodepletion of the packs was performed as for the units suspended 
in 100% plasma. 
 
All units were stored at 22 ± 2°C on a flatbed agitator (Helmer, Noblesville, IN) under 
constant agitation. 
 
PLATELET CONCENTRATES SUSPENDED IN 100% ADDITIVE SOLUTION 
Background 
The series of experiments investigating the characteristics of platelets stored solely in 
additive solution aimed to control the suspending medium in order to determine the 
impact of various reagents on platelet survival and function in vitro. Two principles thus 
guided the preparation of units; first, the removal of as much plasma as possible and 
secondly, the successful leucodepletion of the units. As a suspending medium, plasma 
provides a complex environment for the platelets. Similarly, as white cells degrade 
during storage they release substances such as cytokines into the extracellular 
environment which are known to adversely affect platelet survival (Bordin et al., 1994). 
The presence of either plasma or white cells would introduce a significant variable and 
would make it more difficult to attribute any changes in platelet characteristics during 
storage to the presence or absence of the reagent under investigation. 
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The formulation of the standard additive solution used as the basis of the suspending 
media was provided by Pall Medical’s R&D Group in Covina, California. Its 
constituents are as follows: 
Sodium chloride     110 mmol/L 
Potassium chloride         5 mmol/L 
Magnesium chloride hexahydrate       3 mmol/L 
Citric acid          2.5 mmol/L 
Tribasic sodium citrate dihydrate       7.5 mmol/L 
Sodium dihydrogen phosphate monohydrate     4 mmol/L 
   Total volume: 400 mL 
 
 
Development of Procedure 
Standard Additive Solution 
The preparation of the standard additive solution was outsourced to Stockport 
Pharmaceuticals (Stockport, UK). The company provided the required formulation as a 
single batch with a long shelf life, thus negating another potential source of variability 
in the results. The solution was transferred from the glass bottles in which it had been 
supplied to the plastic packs using a transfer needle to directly connect the glass bottle 
to a spare plasma storage pack. 
  
The procedure was performed in a Biological Safety Cabinet Class II (Bioquell, 
Andover, UK). A port on the empty plasma pack was opened and a sampling site 
coupler with a needle injection site (Baxter Healthcare Ltd, Newbury, UK) was inserted. 
The bottle was supported upside down by a retort stand and the plasma pack secured 
below it with a second clamp. A sterile 16G transfer needle (Baxa Ltd, Bracknell, UK) 
was used to pierce the sampling site coupler and the pack manoeuvred to allow the other 
end of the needle to pierce the cap on the bottle. A sterile venting pin (Baxa Ltd, 
Bracknell, UK) was inserted into the same cap to allow air displacement to push the 
solution into the plasma pack (figure 2.1). The surfaces of the sample site coupler and 
the bottle cap were cleaned with pre-injection swabs (SSL International PLC, Durham, 
UK), whilst clamps and the operator’s hands were sprayed with a chlorhexidone/ethanol 
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spray (Hydrex Hard Surface Spray, Adams Heathcare, Leeds, UK). Preliminary trials of 
the method confirmed that the solution remained sterile during the transfer. 
 
 
Figure 2.1: Procedure for transferring SAS from manufacturer’s bottle to labile plasma 
pack 
 
The pH of the standard additive solution was 4.9, which would be too acidic even 
during the processing stage of platelet concentrate production. The pH of the solution 
was raised by the addition of sodium phosphate dibasic (Na2HPO4), with the aim of 
achieving a pH of 7.2 (as is the case in the commercial solution SSP+). Subsequent 
trials suggested a concentration of 55 mmol/L of Na2HPO4 would be required to raise 
the pH of the SAS to approximately 7.2. To confirm whether concerns about the low pH 
of the additive solution would translate to low pH levels in actual components, four 
platelet components were individually prepared. Two units were suspended in unaltered 
SAS and the remaining two in SAS with 55 mmol/L Na2HPO4 to compensate for the 
low pH. The pH22oC levels for the former two units were 6.0 and 6.1, whilst for the 
compensated units levels were 6.7 and 7.1. As pH levels below 6.2 have been associated 
with loss of platelet viability (Murphy et al., 1994, Gulliksson, 2001), it was decided to 
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modify the composition of the SAS at the time of platelet preparation with the addition 
of Na2HPO4. 
 
Processing of Platelet Concentrates Suspended in Additive Solution 
Preparation of reagents 
Albumin 
Zenalb®20 (Bio Product Laboratory, Elstree, UK) is a 20% (w/v) solution routinely 
issued by UK transfusion centres to hospitals and was selected as a cost effective source 
of human albumin. The normal concentration of albumin in the circulation is 3.3 – 5.2 
g/dL (Boldt, 2010). Adopting 4.0 g/dL as the optimal concentration; a unit volume of 
300 mL would require the addition of 12 g of albumin, equating to a volume of 60 mL 
of Zenalb®20. For the albumin study, one of the four replicate packs would thus contain 
60 mL albumin, one unit would contain half this concentration (30 mL) and a third unit 
would contain twice this concentration (120 mL). The fourth unit would be suspended 
in SAS only. (All four units would also contain defined concentrations of acetate, 
glucose and sodium bicarbonate – see below). A method for aseptically replacing the 
correct volume of SAS with the required volume of albumin was developed: 
  
 Transfer the contents of three 100 mL Zenalb®20 bottles into a single empty plasma 
storage pack, using the same procedure described above for the transfer of SAS 
from glass bottles to a plastic storage pack. 
 Sterile connect a waste pack to three of the packs containing 400 mL of SAS. 
Remove the volume of SAS to be replaced by albumin, estimating the volume by 
weight. 
 Sterile connect the pack containing albumin to each of the three packs in turn and 
transfer the required volume of albumin.  
The contents of the modified SAS packs are now ready to re-suspend the platelets 
following their hard centrifugation. 
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Unit identification: 
The four units in each experiment were identified by a test number as follows: 
ALB-000-nn (no albumin added) 
ALB-030-nn (30 mL albumin added; equivalent to 2 g/dL) 
ALB-060-nn (60 mL albumin added; equivalent to 4 g/dL) 
ALB-120-nn (120 mL albumin added: equivalent to 8 g/dL) 
(In each case, nn refers to a unique test number) 
 
Glucose 
Glucose was purchased as dextrose monohydrate (Sigma-Aldrich, Dorset, UK: code 
D9559, molecular weight = 198.17). The initial study establishing the storage 
characteristics of platelet concentrates suspended in 100% autologous plasma (study 1; 
chapter 3) found the mean concentration of glucose in these units to be 15.2 mmol/L at 
the beginning of storage. The “optimal” concentration in SAS-suspended units was thus 
chosen to be 15 mmol/L. This concentration was also expected to last for the entire 
storage period, as studies have shown that glucose utilisation rarely exceeds 1 mmol/L 
per day (Murphy, 1999). Aiming for a final unit volume of 315 mL and the addition of 
glucose in a 5 mL volume: 
CiVi = CfVf 
Ci × 0.005 = 15 × 10-3 × 0.315 
Ci = 0.945 mmol/L 
Therefore, 0.9364 g of dextrose monohydrate was dissolved in 5 mL of distilled water 
to yield the optimal concentration. 
 
Unit identification: 
The four units in each experiment were identified by as follows: 
GLU-000-nn (no glucose added) 
GLU-075-nn (final concentration of 7.5 mmol/L) 
GLU-150-nn (final concentration of 15 mmol/L) 
GLU-300-nn (final concentration of 30 mmol/L) 
(In each case, nn refers to a unique test number) 
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Acetate 
Acetate was sourced as sodium acetate trihydrate (Sigma-Aldrich, Dorset, UK: code 
S1304, molecular weight = 136.08). Exogenously added acetate has been reported to be 
metabolised at approximately 0.5 mmol/L per day per 1012 platelets (Murphy, 1995). In 
a later publication, the same author recommended that the optimal concentration of 
acetate should be at least 2 mmol/L for each day of projected storage (Murphy, 1999). 
As the maximum storage period originally envisaged for this series of experiments was 
14 days, this would require a concentration of 28 mmol/L acetate to be added to the 
storage media, corresponding well with the concentration of 32.5 mmol/L acetate 
present in the commercial additive solution, SSP+. Aiming for a final unit volume of 
315 mL and the addition of acetate in a 5 mL volume: 
CiVi = CfVf 
Ci × 0.005 = 28 × 10-3 × 0.315 
Ci = 1.764 mmol/L 
Therefore, 1.2002 g of sodium acetate trihydrate was dissolved in 5 mL of distilled 
water to yield the “optimal” concentration. 
 
Unit identification: 
The four units in each experiment were identified by as follows: 
ACE-000-nn (no acetate added) 
ACE-014-nn (final concentration of 14 mmol/L) 
ACE-028-nn (final concentration of 28 mmo/L) 
ACE-056-nn (final concentration of 56 mmol/L) 
(In each case, nn refers to a unique test number) 
 
Sodium bicarbonate 
All units were provided with the same concentration of sodium bicarbonate (Sigma-
Aldrich; Dorset, UK: code S1554, molecular weight = 84.01) for increased buffering 
capacity. The concentration was derived from a variety of sources. First, the normal 
concentration of bicarbonate in adult humans is approximately 25 mmol/L (Kumar and 
Clark, 2009). In addition, a number of studies evaluating the storage characteristics of 
platelet concentrates suspended in plasma have measured mean bicarbonate levels at the 
start of storage between 15 – 19 mmol/L (Gulliksson, 2000, Sweeney et al., 2006, 
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Wagner et al., 2008, Hornsey et al., 2008). Finally, Pall Medical’s R&D Group 
recommended the final concentration of sodium bicarbonate should be 20 mmol/L (S. 
Holme, personal communication) and this value was adopted for all additive solution 
studies. Aiming for a final unit volume of 315 mL and the addition of acetate in a 7.5 
mL volume, the final concentration of acetate required was: 
CiVi = CfVf 
Ci × 0.0075 = 20 × 10-3 × 0.315 
Ci = 0.840 mmol/L 
Therefore, 0.5293 g of sodium bicarbonate was dissolved in 7.5 mL of distilled water to 
yield the optimal concentration. (The slightly higher volume of distilled water compared 
to glucose and acetate was necessary to fully dissolve the sodium bicarbonate).  
 
Preparation of Units 
Blood services occasionally receive requests to provide platelet concentrates with 
minimal plasma levels for individual patients. The protocol developed by the Welsh 
Blood Service for such an eventuality was modified for the processing of platelet 
concentrates in SAS and is described in detail below. This method was not initially 
preferred because it requires that the platelets experience a hard centrifugation step 
without the expected cushioning provided by the other cellular components, likely 
resulting in higher initial levels of platelet activation. However, the requirement for 
leucodepleted units dictated the adoption of this harsher processing methodology.  
 
 Four ABO-specific platelet concentrates were prepared from buffy coats held 
overnight without agitation at 22 ± 2°C by the method previously described in 
connection with the preparation of PC in 100% plasma.  
 The four platelet concentrates were sterile connected to a 2 litre transfer pack 
(Terumo Europe, Leuven, Belgium) and the contents gently mixed.  
 The pooled concentrates were split by weight into the four ELX packs, resulting in 
four identical units. A waste pack was sterile connected to each of the four PCs. 
 The four PCs were centrifuged at 2400 g for 10 minutes at 22°C to pellet the 
platelets (calculated from an average radius of rotation for the rotor of 210 mm). 
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 The majority of the plasma was removed into the waste pack by gravity, with care 
exercised to minimise the loss of platelets. 
 Packs containing SAS were sterile connected to the ELX packs and the platelets re-
suspended in 300 mL of SAS as soon as possible by gentle manual mixing. 
 The required concentrations of glucose, sodium bicarbonate and acetate were added 
to the units aseptically in a Class II biological safety cabinet using sterile syringes 
and 0.2 µm syringe filters (Pall Life Sciences, Farlington, UK). 
 Units were stored on a flatbed agitator (Helmer, Noblesville, IN) at 22 ± 2°C under 
constant agitation. 
Figure 2.2 provides a diagrammatic summary of the processing method. 
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Figure 2.2: PROCESSING OF PLATELET CONCENTRATES SUSPENDED IN ADDITIVE SOLUTION 
 
 
 4 ABO-specific PC processed in 
plasma, including leucodepletion 
4 PC pooled into 2 L transfer 
pack 
Pooled PC re-split into four 
identical units 
Centrifuge at 2400 g for 10 minutes at 22°C to pellet platelets  
Removal of waste plasma by gravity 
Re-suspension of platelets in SAS 
by gentle manual mixing. 
(Albumin is added to required units 
at this stage) 
 
Addition of required 
concentrations of glucose, 
acetate and sodium 
bicarbonate injected into units 
via 0.2 µm syringe filter. 
Storage of units at 22°C with 
constant agitation 
60 
 
Determination of Residual Plasma 
The residual plasma after PC preparation was calculated by volume in seven units from 
the glucose study as follows: 
• Calculate the volume of the PC pool before centrifugation. 
• Calculate the volume of the PC pool after centrifugation and after removal of the 
majority of the plasma. 
• Calculate the volume of the platelets (based on the MPV) and subtract from the 
above values. 
• Calculate the percentage of plasma retained. 
A mean percentage of 4.46 ± 1.11% of plasma was retained by the method adopted. 
 
SAMPLING FROM UNITS 
The units were gently mixed and the tail stripped three times to obtain a representative 
sample without unduly damaging the platelets through excessive stripping. A sampling 
pouch (MacoPharma, Mouvaux, France) was aseptically connected to the tail on the 
platelet concentrate by means of a TSCD II sterile tubing welder (Terumo Corporation, 
Tokyo, Japan) and approximately 15 mL transferred from the unit. The sample was 
subsequently dispensed into a 30 mL plastic universal container (Sterilin Ltd, 
Caerphilly, UK) from which all further samples for testing on the day were obtained.  
 
DESCRIPTIVE PARAMETERS 
UNIT VOLUME 
Unit volume was calculated by subtracting the tare weight of the ELX storage pack 
(36.6 g) from the gross weight and dividing the result by the specific gravity of the 
suspending medium. The specific gravities for the various suspending media were as 
follows: 
 100% plasma    1.03 (Dumont, 2003) 
 70% plasma/30% SSP+  1.01 (Sandgren, 2008) 
 100% SAS    1.00 (as water) 
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PLATELET CONCENTRATION AND MEAN PLATELET VOLUME 
A sample of approximately 500 – 1000 µL was transferred into a vacutainer containing 
K2EDTA as an anticoagulant (Greiner Bio-One GmbH, Kremsmünster, Austria) and the 
vial allowed to mix for at least 30 minutes before analysis. Platelet concentration 
(×109/L) and mean platelet volume (MPV) were obtained with a Pentra 80 haematology 
analyser (HoribaABX Diagnostics, Montpellier, France). The platelet yield was 
calculated by multiplying the platelet concentration by the unit volume in litres. 
 
RESIDUAL WHITE CELL COUNTING 
Confirmation that the units had been successfully leucodepleted was obtained via a flow 
cytometric assay used routinely at the Welsh Blood Service for the quality monitoring 
of the white cell reduction processes. The method employs a kit (DNA-Prep; Beckman 
Coulter, Milton Keynes, UK) that includes propidium iodide (PI) as a nuclear stain. 
Fluorospheres with a known concentration allows absolute counting to calculate the 
white cell concentration per µL. Each sample was acquired for three minutes at high 
flow rate on an FC500 flow cytometer (Beckman Coulter, Miami, FL). Previous 
validation of the assay determined a limit of quantitation of 0.2 WBC/unit.  
 
CONFIRMATION OF END OF STORAGE STERILITY 
At the end of storage period, approximately 20 mL from the unit was transferred to an 
aseptically connected sampling pouch (MacoPharma, Mouvaux, France). The sample 
was equally divided between an aerobic and anaerobic culture bottle (Biomérieux Inc, 
Durham, NC) in a Class II biological safety cabinet (Bioquell, Andover, UK). The 
bottles were incubated at 36°C for 7 days in a bacterial monitoring system (BacTAlert 
3D, Organon Teknika Corp., Durham, NC). The units were retained throughout the 
incubation period in order to allow for the confirmation of any positive results. As most 
of the assays would be adversely affected by the presence of bacteria, results from any 
units confirmed to be contaminated would be rendered void.  
 
62 
 
MEASUREMENT OF pH AND METABOLITES 
Background 
Levels of metabolites were measured with an ABL705 biochemistry analyser 
(Radiometer Ltd, Copenhagen, Denmark). The instrument is regularly calibrated, with 
performance monitored by quality control material. Measurements are performed by the 
instrument at 37°C. 
 
The oxygen consumption rate (OCR) is a measure of oxygen utilisation that takes into 
account the platelet concentration and the permeability characteristics of the storage 
pack (Kilkson et al., 1984), and was adopted as a complementary measure to the 
extracellular partial pressure of oxygen. 
 
Practical Considerations 
Extracellular pH was reported at 22°C for the extended storage study with PCs 
suspended in plasma or SSP+ to reflect the storage temperature and the temperature 
recommended for the reporting of quality monitoring in the UK Guidelines (James, 
2005). The temperature correction provided by the instrument was adopted for the pH 
measurements (Severinghaus, 1966), though there is some uncertainty regarding the 
accuracy of this conversion factor when applied to PCs suspended in a medium other 
than plasma (Cardigan et al., 2008). Due to the minimal volumes of plasma in PC stored 
in SAS, pH was reported at 37°C for these studies (Ringwald et al., 2012).  Blood gases 
were reported at 37°C to conform to most of the existing literature. By contrast, the 
OCR was calculated using partial pressures of oxygen at 22 °C – the targeted storage 
temperature of the components. The temperature correction calculation for pO2 
provided by the biochemistry analyser was regarded as unsuitable for this application 
since it contained a factor for a measured or assumed value of oxyhaemoglobin, 
assuming the use of a whole blood sample. Thus, the correction factor provided by 
Kilkson et al was adopted, requiring the multiplication of the measured pO2 at 37°C by 
a factor of 0.856 (Kilkson et al., 1984).  
 
Due to the labile nature of blood gases, in particular pO2,  measurements were acquired 
as soon as possible after sampling and in all cases within two minutes of sampling, with 
syringes capped during transfer to the instrument. 
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Calculation of oxygen consumption rate 
Based on the following calculation: 
2(OC ) × 760)(10
2
29
POOKcontentplatelet ∆×=
 
(Kilkson et al., 1984) 
where: 
 C(O2) is the oxygen consumption rate (nmol/min/109 plts) 
 K(O2) is the capacity for O2 transport by the container  
∆PO2 is the partial pressure of oxygen in the atmosphere minus the partial 
pressure of oxygen in the concentrate 
 
The O2 transmission rate for the ELX storage pack is 2201 mL m-2 day-1 (Pall Medical, 
Covina, CA; personal correspondence). Rearranging the above equation and using kPa 
as the unit for pressure: 
)10(
325.101/2201)( 922 ionconcentratPlt
POOC ∆×=  
where: 
 101.325 = atmospheric pressure (kPa) (Barry and Chorley, 2003) 
 21.3 = partial pressure of O2 in the atmosphere (kPa) (21%) - used to calculate 
∆PO2 
 
Calculation of Bicarbonate Levels 
Bicarbonate levels were calculated based on the relationship between pH, [CO2] and 
[HCO3-] described by the Henderson-Hasselbalch equation: 
][
][log
2
3
CO
HCOpKpH
−
+=  
The first dissociation constant for carbonic acid (Ka1) in plasma at 37°C was employed, 
with a pKa value of 6.1 (Wooten, 2003). A value for the Henry constant of 0.034 
(Sander) was used to relate the concentration of CO2 to its measured partial pressure. 
The concentration of bicarbonate was thus calculated as:  
034.010][ )1.6(23 ××= −− pHpCOHCO  
 (with the partial pressure of oxygen converted from kPa to mmHg by multiplying the 
former by the conversion factor of 7.500638 (ABL705 Reference Manual)). 
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MEASUREMENT OF ATP AND ADP 
Background 
The assay was developed by the Coagulation Laboratory at the University Hospital of 
Wales (UHW), Cardiff and modified for use with a Lucy 1 microplate luminometer 
(Anthos, Salzburg, Austria). The principle behind the assay is the ATP-dependent 
oxidation of luciferin (D-LH2): 
 
D-LH2 + ATP + O2      AMP + PP + D-L + CO2 + LIGHT 
(Holme and Peck, 1998) 
 
The firefly luciferase-catalysed reaction generates light in the visible range (540-600 
nm), the intensity of which can be related to the concentration of ATP by means of a 
standard line. Levels of ADP in the sample are measured indirectly in a separate step by 
first converting ADP to ATP. This utilises the final reaction of the glycolytic pathway in 
which phosphoenolpyruvate (PEP) is converted to pyruvate, irreversibly transferring a 
phosphoryl group from PEP to ADP in the process: 
 
 
Phosphoenolpyruvate      Pyruvate 
 
 
(Courtesy of University Hospital of Wales, Cardiff) 
 
The “native” level of ATP measured in the first step of the assay is subtracted from the 
“total” ATP level obtained in the PEP conversion to pyruvate to yield the concentration 
of ADP.  
 
Development of the Assay 
Platelet concentrate samples from the buffy coat-derived process have a platelet 
concentration approximately three times as high as the concentration in whole blood 
from a normal individual. As the ATP extraction method used is based on the latter, the 
PC samples were diluted 1 in 3 with double-centrifuged autologous plasma, resulting in 
Luciferase 
Pyruvate kinase 
ADP ATP 
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concentrations of approximately 250 to 300 × 109/L. Following the extraction of ATP 
by ethanol, the samples were stored below -70°C before analysis. 
 
Samples were initially prepared in 12 x 75 mm plastic test tubes and pre-diluted 1 in 10 
in a Tris-EDTA assay buffer. The ATP standard incorporated in the kit was similarly 
diluted. The same volume of sample and ATP standard was used in order to simplify the 
calculation.  
 
Method 
Microplates 
Chromalux HB high binding, high reflectivity white polystyrene microplates suitable 
for luminescence applications were purchased from Dynex Technologies (Jencons 
Scientific Ltd, Leighton Buzzard, UK) 
 
Reagents 
ATP Kit SL (Biothema Luminescent Assays, Handen Sweden. Distributor: Labtech 
International, Ringmer, UK: code LAB-144-041). 
 
Kit comprises: 
ATP SL reagent (containing D-luciferin, luciferase, Mg2+, inorganic 
pyrophosphate and bovine serum albumin) 
ATP standard at a concentration of 10-5 mol/L ATP 
Tris-EDTA buffer 
Phosphoenolpyruvate (PEP) (Sigma-Aldrich, Dorset, UK: code P7002) 
Pyruvate kinase from rabbit muscle, Type VII (Sigma-Aldrich, Dorset, UK: code 
P7768). 
Bovine serum albumin (BSA) (Sigma-Aldrich, Dorset, UK: code A7030). 
Magnesium acetate tetrahydrate (Merck, Darmstadt, Germany: code A712419 628) 
Potassium acetate (Sigma-Aldrich, Dorset, UK: code 236497) 
Tris (hydroxymethyl) amine (VWR International, Poole, UK: code 103154M) 
Acetic acid, glacial (Fisher Scientific, Loughborough, UK: code A/0406/PB08) 
Ethylenediamintetraacetic acid (EDTA) disodium salt (VWR International, Poole, UK: 
code 100933T) 
Triton X-100 (Sigma-Aldrich, Dorset, UK: code T9284) 
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Ethanol, absolute (Sigma-Aldrich, Dorset, UK: code 02880) 
 
Preparation of Reagents 
Disodium EDTA: 0.1 mol/L solution in 0.9% NaCl. 
Triton X-100: 10% (v:v) in 0.9% NaCl (Viscous fluid: pipette slowly and allow to 
dissolve overnight at ambient temperature). 
Magnesium acetate: 0.1 mol/L solution in distilled water. 
Potassium acetate: 0.1 mol/L solution in distilled water. 
Assay buffer (Tris-EDTA buffer)  
 Dissolve 1.2114 g of Tris (0.1 mol/L) and 0.0744 g of EDTA (0.002 mol/L) in 100 
mL of distilled water 
 Adjust pH to 7.75 with glacial acetic acid.  
 Prepare on the day of assay and discard any excess. 
BSA buffer 
 To 10 mL of assay buffer add 0.01 g of BSA 
 Prepare on the day of assay and discard any excess. 
PEP stock solution; 100 µM 
 Add 0.0117 g to 500 µL of distilled water. 
 Prepare on the day of assay and discard any excess 
PEP working solution 
 Prepare just before use as follows: 
100 µM PEP stock solution  50 µL 
Magnesium acetate, 0.1 M  1.250 mL 
Potassium acetate, 0.1 M  0.750 mL 
Pyruvate kinase 
 Prepare a 1 in 10 dilution using BSA buffer (10 µL required per sample). 
ATP-SL reagent 
 Add the entire contents of the diluent vial to the lyophilised reagent. Protect from 
light. (On the advice of colleagues from UHW, the reconstituted reagent was stored 
for a maximum of three days at 2 – 8°C). 
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ATP Standard 
 Prepare a 1 in 10 dilution in Tris-EDTA buffer to a total volume of 10 mL. Protect 
from light. Discard excess. 
ATP Extraction 
 Prepare a 1 in 3 dilution of the platelet concentrate in double-centrifuged autologous 
plasma to yield an approximate platelet concentration of 300 × 109/L. 
 Pipette 500 µL of diluted sample into two labelled cryovials (one vial to be retained 
as a spare). 
 Add 50 µL of 0.1 mmol/L EDTA and 50 µL of 10% Triton X-100. 
 Vortex for a few seconds and add 500 µL of absolute ethanol. 
 Vortex for a few seconds. Incubate the vials for 15 to 30 minutes at 2 – 8°C before 
storing below -70°C. 
Assay 
 Thaw samples at 37°C in a waterbath. 
 Centrifuge at 2000 g for 15 minutes at 4°C. Decant the supernatant into a labelled 
tube. 
 Prepare 1 in 10 dilution of the supernatant, using assay buffer as the diluent. 
 Prepare two tubes per sample and a pair of blanks as follows: 
 
 Tube A Tube B Blank Blank + PK 
Pre-diluted 
sample 
10 µL 10 µL ⁄ ⁄ 
Assay buffer 400 µL 400 µL 410 µL 410 µL 
PEP working 
solution 
40 µL 40 µL 40 µL 40 µL 
Pyruvate kinase ⁄ 10 µL ⁄ 10 µL 
 
 Incubate for 30 minutes at ambient temperature in the dark. 
 Dispense 230 µL of “Blank” in position A1 of a microplate and 230 µL of “Blank + 
PK” in position A2. 
68 
 
 Dispense 230 µL of “tube A” for the first sample into B1 and 230 µL of the 
corresponding “tube B” in position B2. 
 Follow the pattern with any remaining samples. Load the plate into the luminometer. 
 
General Operation of the Luminometer 
Set the operating temperature of the instrument to 25°C. The input line from dispenser 1 
is secured in the ATP-SL reagent whilst the input line from dispenser 2 is secured in the 
ATP standard. Prime the Hamilton dispenser three times and insert the output lines from 
both dispensers into their corresponding apertures in the luminometer. Dispenser 1 is 
programmed to dispense 25 µL of ATP-SL reagent on an initial measurement run, with 
dispenser 2 dispensing 5 µL of ATP standard on the following run. Sixty points are 
measured over a one minute period, with the peak intensity of light emitted comprising 
the reportable value. Four peak measurements are obtained per sample: 
A1: No pyruvate kinase added 
 A2: No pyruvate kinase added; ATP standard added 
 B1: Pyruvate kinase added 
 B2: Pyruvate kinase added; ATP standard added 
 
Calculation: 
ATP standard is provided in the kit at a concentration of 10-5 mol/L of ATP. The final 
volume dispensed into the microplate following sample preparation is 255 µL + 5 µL of 
ATP standard. Therefore, the concentration of standard in the microplate well is: 
 
255/5 = 51 
10-5/51 = 1.96 × 10-7 mol/L 
Calculation of the blank: 
Blank = 96.1)12(
1
×
− BlankBlank
Blank
 
 
 ATP concentration (×10-7): 
Blank
AA
A
−





×
−
96.1)12(
1
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ATP (µmol/1011platelets): 
ATP × 10-7 × 10 = ATP × 10-6 ≡ ATP µmol/L 
Convert platelet concentration from 109/L to 1011/L 
Divide ATP concentration (µmol/L) by platelet concentration (x 1011 platelets) 
 
Total ATP concentration as measured by the addition of pyruvate kinase in tube B is 
obtained as above using the appropriate peak measurements from tube B and the blank 
containing pyruvate kinase. 
ADP concentration (µmol/1011platelets): 
Total ATP – ATP 
 
HYPOTONIC SHOCK RESPONSE 
Background 
The hypotonic shock response (HSR) assesses the ability of platelets to recover from the 
addition of a hypotonic solution to the suspending medium. Metabolically viable 
platelets with intact membranes are able to extrude the excess water, in conjunction with 
K+ and Cl- ions, in an ATP dependent process (VandenBroeke et al., 2004, Okada et al., 
2001). The osmotic swelling caused by the uptake of water by the platelets results in a 
lowering of the refractive index of the platelets and a related increase in light 
transmission. The effect is reversed as healthy platelets resume their normal volume. 
This change in light transmission can be measured with a platelet aggregometer. The 
initial decrease in transmission following the addition of a volume of distilled water is 
measured. After a four minute incubation at 37°C with constant stirring the light 
transmission is measured again and the percentage recovery to the hypotonic shock is 
calculated as follows (see figure 2.3): 
PBSY
Y
eryreHSR
−
×′
=
100(%)cov  
(modified from Holme, 1998) 
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Figure 2.3: Diagram illustrating the expected chart output for the hypotonic shock 
response (Holme et al., 1998) (Reproduced with permission, © John Wiley and Sons)  
 
where, 
Y =  Initial decrease in light transmission 
Y’ =  Light transmission after 4 minutes (Light transmission after 1 minute not used) 
PBS =  Light transmission through sample containing PBS instead of water (to 
compensate for the effect of diluting the sample) 
 
 
Development of the Assay 
The HSR assay in use at the Pall Medical Blood Processing R&D Group in the United 
States was adopted for this study following a visit to that laboratory in 2006. The 
method used an SPA-2000 aggregometer (Chrono-Log, Havertown, PA) which 
performs the calculations automatically; however, a chart recorder is also needed to 
provide a visual record of the reaction and allow the operator to determine if the kinetics 
of the response are acceptable. 
 
Some points to note include: 
 The assay was performed in duplicate, and if the HSR recoveries varied by more 
than 10%, the assay was repeated to provide a third result. The mean of the two 
closest values was reported as the percentage recovery. 
 Autologous platelet-poor plasma was used as the sample diluent, following 
published recommendations for its use in preference to AB plasma or additive 
solution (VandenBroeke et al., 2004).  
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Method 
Reagents 
Phosphate buffered saline (PBS), pH 7.4 (Sigma-Aldrich, Dorset, UK: code P-4417) 
HEPES (VWR International Ltd, Lutterworth, UK: code 441485H) 
Distilled water  
 
Preparation of reagents 
Phosphate buffered saline: 
Dissolve 1 tablet of PBS in 200 mL of distilled water. Store at 2 – 8°C for up to 6 
months – discard if there are visible signs of contamination. 
HEPES buffer (1 mol/L): 
Dissolve 2.383 g of HEPES in 10 mL of distilled water. Store at 2 – 8°C for up to 6 
months – discard if there are visible signs of contamination. 
 
Preparation of platelet sample and platelet- poor plasma (PPP) 
HEPES buffered platelet poor plasma (PPP): 
Double centrifuge approximately 12 mL of autologous plasma at 2000 g for 10 minutes 
at 22°C. Dispense 10 mL into a universal and add 150 µL of HEPES buffer (final 
concentration 15 mmol/L). 
Platelet concentrate sample: 
Require 7 mL of sample with a platelet concentration of 300 × 109/L; therefore, in 7 
mL, aiming to contain 2100 × 106 platelets. Example: 
PC with a concentration of 1264 × 106/mL platelets 
2100/1264 = 1.661 mL of PC sample required in 
7.000 – 1.661 = 5.339 mL of HEPES-buffered PPP 
 
Assay 
 Switch on SPA-2000 aggregometer. Ensure temperature is 37 ± 1°C before use. 
Place toggle switch on HSR. 
 Warm distilled water and PBS in a 37°C waterbath. 
 Pipette 500 µL of HEPES-buffered PPP into a microcuvette containing a stir bar and 
place in the well marked “PPP”. 
 Pipette 500 µL of pre-warmed, diluted platelet concentrate sample into each of four 
microcuvettes containing stir bars. Place in the 37°C incubation wells. 
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 Press STEP and insert one of the samples into the “PRP” well following the 
instrument’s directions. Press STEP again. 
 When the instrument prompts for the addition of PBS, firmly inject 250 µL of pre-
warmed PBS into the sample and press STEP once immediately. 
 When the instrument prompts for a new sample, remove the PBS-diluted sample and 
insert a second PC sample into the “PRP” test well and press STEP once. 
 When the instrument prompts for the addition of water, firmly inject 250 µL of pre-
warmed distilled water into the sample microcuvette and press STEP once. 
 The aggregometer will automatically calculate and print the %HSR after a four 
minute recovery period. 
 Repeat the procedure to obtain a duplicate result. Ensure the results are within 10% 
of each other. If not, repeat the assay.  
 Report the mean of the replicate results. 
 
EXTENT OF SHAPE CHANGE 
Background 
Addition of ADP to a suspension of platelets unable to aggregate due to the presence of 
EDTA results in a decrease in light transmission through the sample which can be 
measured with a platelet aggregometer. This photometric effect is generally attributed to 
a disc to sphere transformation by healthy platelets in response to the weak agonist. 
Platelets that have already changed to a spherical form as a result of insult, including 
prolonged storage, cannot undergo further shape change (VandenBroeke et al., 2004). 
The percentage decrease in light transmission is thus related to the proportion of 
platelets with a normal discoid morphology in the original sample and provides a more 
objective measure of platelet morphology than light microscopy (Murphy et al., 1994). 
The derivation of the calculation for the extent of shape change is as follows (Holme et 
al., 1998): 
where, 
73 
 
X = % transmission of platelet poor plasma (PPP) 
Y = % transmission of platelet rich plasma (PRP) 
A = maximum decrease following shape change  
 
Conversion of the percentage of transmission to extinction is provided by  
E = -log(T%/100) 
Therefore, 
EPPP = -log(X/100) 
EPRP = -log(Y/100) 
Eshape change = -log[(Y-A(X-Y))/100] 
ESC = (Eshape change – EPRP)100%/(EPRP – EPPP) 
 
Development of the Assay 
The extent of shape change (ESC) assay used the ChronoLog SPA-2000 aggregometer. 
The %ESC was calculated automatically by the instrument, with a chart recorder also 
providing a graphical representation of the reaction. 
 
Method 
Reagents 
Phosphate buffered saline (PBS), pH 7.4 (Sigma-Aldrich, Dorset, UK: code P-4417) 
Adenosine diphosphate (ADP) (Sigma-Aldrich, Dorset, UK: code 01905) 
Ethylenediaminetetraacetic acid (EDTA) disodium salt (VWR International Ltd, 
Lutterworth, UK: code 443882G) 
HEPES (VWR International Ltd, Lutterworth, UK: code 441485H) 
 
Preparation of reagents 
Phosphate buffered saline: 
Dissolve 1 tablet of PBS in 200 mL of distilled water. Store at 2 – 8°C for up to 6 
months – discard if there are visible signs of contamination. 
 
ADP (1 mmol/L): 
Dissolve 0.0043 g ADP in 10 mL of PBS. Pipette 200 µl aliquots into labelled cryovials 
and store below -60°C for up to 6 months 
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EDTA (0.1 mol/L): 
Dissolve 3.722 g of EDTA in 100 mL of distilled water. Store at 2 – 8°C for up to 6 
months – discard if there are visible signs of contamination. 
HEPES buffer (1 mol/L): 
Dissolve 2.383 g of HEPES in 10 mL of distilled water. Store at 2 – 8°C for up to 6 
months – discard if there are visible signs of contamination. 
 
Preparation of platelet sample and platelet- poor plasma (as for HSR assay) 
The same sample prepared for the HSR assay can be used for the ESC assay. 
 
Assay 
 Switch on SPA-2000 aggregometer. Ensure temperature is 37 ± 1°C before use. 
Place toggle switch on ESC. 
 Pipette 500 µL of HEPES-buffered PPP into a microcuvette containing a stir bar and 
place in the well marked “PPP”. 
 Pipette 500 µL of pre-warmed, diluted platelet concentrate sample into each of two 
microcuvettes containing stir bars. Place in the 37°C incubation wells. 
 Press STEP and insert one of the samples into the “PRP” well following the 
instrument’s directions. Press STEP again. 
 When the instrument prompts for the addition of EDTA, firmly inject 10 µL of 
EDTA into the sample and press STEP once immediately. 
 When the instrument prompts for the addition of ADP, firmly inject 10 µL of ADP 
into the sample microcuvette and press STEP once immediately. 
 The aggregometer will automatically calculate and print the %ESC. 
 Repeat the procedure to obtain a duplicate result. Ensure the results are within 5% of 
each other. If not, repeat the assay and report the mean of the two closest results. 
 
SURFACE CD62P EXPRESSION AND ANNEXIN V BINDING 
Background 
CD62P is an adhesion molecule stored in the α-granules of platelets and expressed on 
the platelet surface following activation (Berger et al., 1998). An anti-CD62P 
monoclonal antibody conjugated to a fluorescent dye allows for the identification and 
quantitation by flow cytometry. 
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Annexin V is a glycoprotein with a high binding affinity for negatively charged 
phospholipids in the presence of calcium ions (Picker et al., 2009). These lipids include 
phosphatidylserine (PS) and phosphatidylethanolamine (PE) which are normally 
preferentially found on the inner leaflet of the platelet membrane. Failure of the calcium 
and ATP-dependent processes that maintain this asymmetric distribution results in 
translocation of the phospholipids to the outer leaflet. Addition of exogenous annexin V 
conjugated to a fluorescent dye is able to bind to the negatively charged phospholipids 
on the platelet surface and allow for the monitoring of this phenomenon throughout 
storage (Dachary-Prigent et al., 1993).  
 
Development of the Assay 
The assay combines the measurement of the surface expression of CD62P and annexin 
V binding and was initially developed by the Welsh Blood Service in collaboration with 
Beckman Coulter as part of an MSc project investigating the effect of bacterial 
contamination on platelet activation (Pearce N, MSc project). The assay uses annexin V 
bound to fluorescein isothiocyanate (FITC) provided as a kit that also includes a 
concentrated buffer solution incorporating Ca2+ ions. Anti-CD62P bound to 
phycoerythrin (PE) was purchased separately. Fluorescence was detected on the FL1 
and FL2 detectors, respectively, of an FC500 flow cytometer (Beckman Coulter, Miami, 
FL). Platelets were identified on their scatter characteristics using the automatic gating 
function provided by the FC500 to avoid operator variability. Although the option to 
use the largest gate was selected (excluding 0.11% of the population), it is 
acknowledged that by using this approach, platelet fragments and platelets with 
abnormal morphology which could express surface CD62P and/or aminophospholipids, 
and may thus be of biological importance, could be excluded from the analysis. Though 
this limitation was expected to be more evident in samples from older units, the 
software proved flexible enough to deal with the change in morphology occurring in the 
majority of the population, as illustrated in figure 2.4.  
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Figure 2.4: Scatter characteristics of events from glucose study. Example taken from 
unit with no added glucose and comparing the scatter characteristics on day 2 
compared to day 10. Discriminator is set at 2 on forward scatter 
 
A separate tube using anti-CD61 conjugated to PC7 was used to verify that the 
population identified on scatter comprised predominantly of platelets. (A separate tube 
was employed as a verifier as it was suspected that the CD61 antibody was interfering 
with the binding of the anti-CD62P and resulting in a lower estimation of surface 
CD62P. A similar approach was recently described by Albanyan et. al (Albanyan et al., 
2009). In addition to determining the percentage of platelets expressing CD62P and 
binding to annexin V, the assay provides a measure of the degree of surface expression 
per platelet by means of the mean or median fluorescence intensity. The mean 
fluorescence intensity was used for the binding of annexin V as there was a clear 
separation between negative and positive events. By contrast, the expression of surface 
CD62P was not clearly defined and thus the median fluorescence intensity was 
preferred (figure 2.5). The regions used to identify positive events were positioned for 
each individual assay by means of isotypic controls, with the region set to include 1% of 
negative events. 
 
DAY 10 DAY 2 
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Figure 2.5: Comparison of single parameter histograms illustrating surface expression 
of CD62P and annexin V binding on day 10 platelets (glucose study) 
 
During the initial development phase, the final volts and gains chosen for the assay were 
transferred to a separate protocol. Fluorospheres (Flow-Set; Beckman Coulter, Milton 
Keynes, UK) acquired through this protocol were used to set targets identifying where 
the Flow-Set fluorospheres were expected to fall with subsequent applications of the 
protocol. Performing the Flow-Set protocol prior to the assay thus allowed confirmation 
that events will fall within the expected regions. The samples were not fixed; therefore, 
the assay was performed as quickly as possible to minimise any extraneous activation of 
the platelets.  
 
Assay 
Reagents 
Annexin V-FITC kit (Beckman Coulter, Milton Keynes, UK: code IM3546)  
Annexin V buffer (10x) (Becton Dickinson, Oxford, UK: code 556454) 
CD61-PC7 (Beckman Coulter, Milton Keynes, UK: code IM3716) 
IgG1-PC7 (Beckman Coulter, Milton Keynes, UK: code 737662) 
CD62P-PE (Beckman Coulter, Milton Keynes, UK: code IM1759U) 
IgG1 (Mouse)-PE (Beckman Coulter, Milton Keynes, UK: code A07796) 
IgG1 (Mouse)-FITC (Beckman Coulter, Milton Keynes, UK: code A07795) 
Flow-Set fluorospheres (Beckman Coulter, Milton Keynes, UK: code 6607007) 
PC7 Setup kit (Beckman Coulter, Milton Keynes, UK: code 737664) 
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Preparation of Reagents 
Annexin V Buffer (1x): 
Dilute 1 volume of 10x annexin V buffer with 9 volumes of distilled water. (In the 
procedure this is simply referred to as AV buffer.) 
 
Preparation of Samples 
The final platelet concentration required for the assay is approximately 5 × 106 platelets. 
The sample volumes required are listed in Table 2.1: 
 
Table 2.1: Required volumes to provide a platelet concentration of 5×106 platelets 
Platelet concentration 
(×109/L) 
Volume of platelet concentrate required 
(µL) 
1000 5.00 
900 5.55 
800 6.25 
700 7.14 
 
Samples with a platelet concentration greater than 1000 × 109/L would require a 
preliminary dilution. 
 
Procedure 
 Seven test tubes are required:  
1 – Dilution of sample for verifier tube 
2 – Controls preparation 
3 – Verifier preparation 
4 – Test preparation 
5 – Controls 
6 – Verifier 
7 - Test 
 Pipette the required volume of platelet concentrate to the bottom of tubes 1, 2 and 4. 
 Make up the volume of tube 1 to 25 µL with AV buffer and transfer 5 µL to the 
bottom of tube 3. 
 Pipette 20 µL of IgG1-FITC, 20 µL of IgG1-PE and 10 µL of IgG1-PC7 to the 
bottom of tube 2. 
 Pipette 10 µL of CD61-PC7 to the bottom of tube 3. 
 Pipette 20 µL of CD62P-PE to the bottom of tube 4. 
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 Gently mix all three preparation tubes and incubate in the dark for 15 minutes at 
ambient temperature. 
 Dispense sufficient AV buffer to increase the volume of tube 4 to 100 µL. Transfer 
10 µL to the bottom of tube 7 (test). Add 90 µL of AV buffer followed by 1 µL of 
annexin V-FITC. Incubate in the dark for 15 minutes at ambient temperature. 
 Dispense sufficient AV buffer to increase the volume of tube 2 to 100 µL. Mix and 
transfer 10 µL to the bottom of tube 5 (controls) and add 491 µL of AV buffer. 
 Pipette 5 µL of AV buffer to tube 3. Mix and transfer 10 µL to the bottom of tube 6 
(verifier) followed by 491 µL of AV buffer. 
Tubes 5 and 6 can remain with tube 7 until the last has finished incubating. 
 After the second incubation, add 400 µL of AV buffer to tube 7. 
 Acquire immediately on the flow cytometer. 
 
SOLUBLE CD62P LEVELS 
Background 
A solid phase enzyme-linked immunosorbent assay (ELISA) was selected for the 
measurement of soluble CD62P (sCD62P) in the supernatant of platelet concentrates. 
The 96-well plates are pre-coated with a monoclonal antibody specific for sCD62P. The 
intensity of the colour reaction is proportional to the level of sCD62P in the sample, 
with levels quantified against a line generated by a series of standard provided in the kit 
by the manufacturer.  
 
Development of the Assay 
The kit was used according to manufacturer’s instructions. The sensitivity of the assay 
is quoted by the manufacturer as typically less than 0.5 ng/mL. 
 
Assay 
Reagents 
Human soluble P-selectin/CD62P immunoassay (R&D Systems Europe; Abingdon, 
UK; code BBE6)  
[includes sCS62P 96 well microplate, sCD62P standards, sCD62P control, sCD62P 
conjugate, conjugate diluent, sample diluent, wash buffer concentrate, substrate and stop 
solution] 
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Preparation of Standards/Samples 
Standards and Control: 
Reconstitute all standards with 1 mL of distilled water – no further dilution required.  
Reconstitute the control with 500 µL of distilled water. Subsequently, dilute the 
reconstituted control 1 in 20 with sample diluent.  
Samples: 
Thaw frozen samples in 37°C waterbath and prepare 1 in 20 dilutions with sample 
diluent. 
 
Procedure 
[All standards, samples and controls are assayed in duplicate and the mean of the two 
results reported] 
 Add 100 µL of standards, samples and control to each well on the microplate 
 Add 100 µL of conjugate to each well. Cover and incubate the plate for one hour at 
ambient temperature. 
 Aspirate and wash the plate three times with diluted wash buffer. Blot the plate dry 
after the final wash to remove any excess fluid. 
 Add 100 µL of substrate to each well. Incubate the plate for 15 minutes at ambient 
temperature. 
 Stop the colour reaction with 100 µL of acid stop solution. 
 Measure the optical density of each well on a Spectra II microplate reader (Tecan 
UK Ltd, Reading, UK), using 450 nm as the primary wavelength with a correction 
filter set to 620 nm.  
The software automatically calculates the concentration of soluble CD62P based on the 
standard line.  
 
 
COMPOSITION OF EXTERNALISED PHOSPHOLIPIDS ON THE PLATELET 
MEMBRANE AS MEASURED BY MASS SPECTROMETRY 
Background 
The School of Medicine at Cardiff University has developed a method for detecting and 
quantifying specific aminophospholipids externalised on the platelet membrane using 
mass spectrometry (MS). The procedure involves labelling of the externally expressed 
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phospholipids with a cell-impermeable biotinylation reagent - sulfo-NHS-biotin – with 
L-lysine used to quench any excess biotin. Lipids are extracted using a solvent mixture 
of acetic acid, isopropanol and hexane, with the lipids suspended in the hexane layers. 
The hexane layers are dried under nitrogen flow and analysed for PE- or PS-esterified 
12S-hydroxyeicosatetraenoic acids (12S-HETEs) on MS/MS spectra (Thomas et al., 
2010, Zhang et al., 2002) at the apex of peaks obtained during liquid chromatography 
separation. 12-HETE is an eicosanoid derived from arachidonic acid by the action of 
12-lipoxygenase, with the esterified form of 12S-HETE generally retained on the cell 
membrane. Four 12S-HETE-PE structures and one 12S-HETE-PS were identified based 
on the mass/charge ratio of characteristic daughter ions (figures 2.6 and 2.7). Internal 
standards, in the form of 10 ng of 12(S)-HETE-d8 and 10 ng of di-14:0-
phosphatidylethanolamine (DMPE), were included in 1 mL of sample containing 2 × 
108 platelets per mL to allow for the quantitation of phospholipids on the platelet 
surface. 
 
Figure 2.6: Structures of four 12-HETE-PE present in platelets (courtesy of C Thomas; 
School of Medicine, Cardiff University) 
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Figure 2.7: Example of fragmentation pattern for 12-HETE-PE (courtesy of C Thomas; 
School of Medicine, Cardiff University) 
 
Development of the Assay 
Total lipid extraction and separation of the hexane layers was performed at the Welsh 
Blood Service following the method provided by the School of Medicine. The drying of 
the hexane layers under nitrogen flow was performed at the School of Medicine, 
University Hospital of Wales. Sample preparation and storage was undertaken in 10 mL 
borosilicate glass tubes (Fisher Scientific UK Ltd, Loughborough, UK). 
 
Assay 
Reagents 
Acetic acid (HPLC grade) (Fisher Scientific, Loughborough, UK: code A/0406/PB08) 
Propan-2-ol (HPLC grade) (Fisher Scientific, Loughborough, UK: code P/7508/17 
Hexane (HPLC grade) (Fisher Scientific, Loughborough, UK: code H/0406/17) 
Sodium chloride (VWR International Ltd, Lutterworth, UK: code 102414J) 
Sodium bicarbonate (Sigma-Aldrich, Dorset, UK: code S1554) 
Potassium chloride (Sigma-Aldrich, Dorset, UK: code P3911) 
Disodium hydrogen phosphate (Sigma-Aldrich, Dorset, UK: code 56814) 
Magnesium chloride (Sigma-Aldrich, Dorset, UK: code M2670) 
HEPES (VWR International Ltd, Lutterworth, UK: code 441485H) 
D+-Glucose (Sigma-Aldrich, Dorset, UK: code G8270) 
12(S)-HETE-d8 (Cayman Chemical, Ann Arbor, MI : code 334570) 
DMPE (Axxora UK Ltd, Nottingham, UK : code ALX-300-037) 
Tin (II) chloride (Sigma-Aldrich, Dorset, UK: code 204722-10G) 
L-lysine (Sigma-Aldrich, Dorset, UK: code L5501-5G) 
EZ-Link Sulfo-NHS-Biotin (Fisher Scientific, Loughborough, UK: code 21217) 
Chloroform (Sigma-Aldrich, Dorset, UK: code C2432) 
Methanol (HPLC grade) (Fisher Scientific, Loughborough, UK: code M/4056/15)  
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Reagent Preparation 
TYRODE’S BUFFER (in 200 mL distilled water) 
Sodium chloride (NaCl)     134 mmol/L  1.5662 g 
Sodium bicarbonate (NaHCO3)      12 mmol/L  0.2016 g 
Potassium chloride (KCl)      2.9 mmol/L  0.0432 g 
Disodium hydrogen phosphate (Na2HPO4)   0.34 mmol/L  0.0097 g 
Magnesium chloride (MgCl2)          1 mmol/L  0.0407 g 
HEPES          10 mmol/L  0.4766 g 
Glucose           5 mmol/L  0.1802 g 
Final pH: 7.4 (adjust with 2.5 mol/L NaOH). 
STORAGE: Store at 2 – 8°C for 1 month 
 
ACID-CITRATE-DEXTROSE (ACD) (in 50 mL distilled water) 
Trisodium citrate        85 mmol/L  1.2499 g 
Citric acid         65 mmol/L  0.6243 g 
Glucose       100 mmol/L  0.9008 g 
STORAGE: Store at 2 – 8°C for 1 month 
 
TYRODE’S + ACD 
Combine Tyrode’s buffer and ACD in a 9:1 (v:v) ratio prior to use. 
 
SOLVENT MIXTURE 
[1M acetic acid/prpan-2-ol/hexane at 2:20:30, v/v/v) 
Acetic acid 1M      4 mL 
Propan-2-ol       40 mL 
Hexane       60 mL 
STORAGE: Store at ambient temperature for 3 months. 
 
TIN II CHLORIDE (SnCl2), 100 mmol/L 
Dissolve 0.0190 g of SnCl2 in 1 mL absolute ethanol. 
STORAGE: Store at 2 – 8°C for 3 months. 
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DMPE (10 µL required per sample - Purchased as 50 mg white powder) 
Dissolve 1 mg (0.0010 g) in 1 mL chloroform to yield stock concentration of 1 × 103 
ng/µL. Dispense approximately 20 µL into glass microvials and store below -70°C. 
When required, thaw a vial of the stock solution and dilute 1 µL with 600 µL 
chloroform and 400 µL methanol to yield concentration of 1 ng/µL. 
[Final dilution is a chloroform:methanol ratio of 4:1 (v:v)] 
STORAGE: Store vials of stock solution below -70°C for 6 months. Do not re-freeze 
thawed vials. 
 
12(S)-HETE-d8 (Purchased as 25 µg in 250 µL acetonitrile) 
Dilute 5 µL of 12(S)-HETE-d8 in 395 µL of chloroform plus 100 µL of methanol to 
yield a final concentration of 1 ng/µL. 
STORAGE:  Reagent as bought – 2 years at -20°C. Working solution – discard on day 
of the assay 
 
L-LYSINE (50 mmol/L) 
Dissolve 0.0366 g in 5 mL of distilled water. 
STORAGE: Store at 2 – 8°C for 3 months.       
 
Lipid Extraction 
 Centrifuge 1 mL of platelet concentrate at 900 g for 10 minutes at 22°C. 
 Discard the supernatant and re-suspend the pellet in approximately 2 mL of 
Tyrode’s/ACD buffer. (Re-suspension may require gentle mixing with a disposable 
pipette). 
 Centrifuge the re-suspended platelets at 800 g for 10 minutes at 22°C. Discard the 
supernatant and re-suspend the pellet in Tyrode’s/ACD buffer to a platelet 
concentration of 2 × 108 platelets per mL. 
 Pipette 1 mL of the platelet suspension into a labelled 10 mL glass vial and add 
0.0015 g of sulfo-NHS-biotin. Incubate for 10 minutes at ambient temperature. 
 Quench any excess biotin by adding 10 µL of 50 mmol/L L-lysine and incubate for 
10 minutes at ambient temperature. 
 Add 10 µL of 100 mmol/L tin (II) chloride to reduce the hydroperoxide to their 
corresponding stable alcohols and incubate for 10 minutes at ambient temperature. 
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 Add 2.5 mL of solvent mixture to extract the lipids. 
 Add 10 µL of 12-HETE-d8 followed by 10 µL of DMPE as standards. Vortex and 
add 2.5 mL of hexane. 
 Vortex and centrifuge at 360 g for 5 minutes at 4°C. 
 Recover the hexane (upper) layer containing the extracted lipids into a labelled 10 
mL borosilicate glass vial. 
 Add an equal volume of hexane to the remaining aqueous solution, vortex and re-
centrifuge at 360 g for 5 minutes at 4°C. 
 Combine the hexane layers and store below -70°C until transport in dry ice can be 
arranged to the School of Medicine. 
 
MITOCHONDRIAL MEMBRANE POTENTIAL 
Background 
Changes in mitochondrial membrane potential (∆Ψm) were detected flow 
cytometrically using the fluorescent cationic dye JC-1 (5,5’,6,6’-tetrachloro-1,1’,3,3’-
tetraethyl-benzimidazolylcarbocyanine iodide). JC-1 exists as a monomer at low 
concentrations, with an emission maximum of 529 nm. At higher concentrations it 
forms red-fluorescing J-aggregates with an emission maximum of 590 nm. 
 
The membrane potential determines the concentration of JC-1 in the mitochondrial 
matrix, with passage of the dye through the inner mitochondrial membrane eased with 
higher (more negative) potentials. The resulting accumulation of JC-1 promotes the 
formation of J-aggregates. Depolarisation of the membrane results in a decrease in the 
concentration of JC-1 in the matrix, favouring the retention of the green-fluorescing 
monomeric configuration. A loss of membrane potential during platelet storage will 
thus be evident as a decrease in the red-green fluorescence ratio (Verhoeven et al., 2005, 
Li et al., 2005b).  
 
Development of Assay 
The adoption of a platelet concentration of 30 × 109/L and an incubation of 20 minutes 
at 37°C stemmed from the optimal conditions suggested by Verhoeven et.al (Verhoeven 
et al., 2005). T-Sol platelet additive solution (116 mmol/L sodium chloride, 10 
mmol/L sodium citrate, 30 mmol/L sodium acetate, pH 7.2) was used as the sample 
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diluent. Precedent for the use of an additive solution in this context was set by 
Verhoeven et.al with the use of Composol-PS (Fresenius Kabi, Bad Homburg, 
Germany). JC-1 was purchased in powder form (5 mg). After consultation with the 
manufacturer, it was decided to prepare 5 mmol/L stock solutions of the dye in 
anhydrous dimethyl sulphoxide (DMSO) and store the aliquots below -30°C until 
required. 
 
Repeatability of the assay was determined using ten individually prepared samples from 
a six-day old apheresis platelet concentrate, yielding a coefficient of variation of 2.41%. 
Baseline levels for the assay obtained from 27 one-day old apheresis platelet 
concentrates resulted in a range for the red/green fluorescence ratio of 4.49 – 6.32. 
Investigations into the robustness of the assay concentrated on the impact of a delay in 
the preparation of the samples, as this would determine the timing of the assay 
alongside the other planned tests. It was determined that the fluorescence ratio remained 
stable for at least 40 minutes after sampling from the unit, allowing potentially more 
labile assays to be prepared first. 
  
Carbonyl cyanide 3-chlorophenylhydrazone (CCCP) is a protonophore that acts as a 
mitochondrial membrane disruptor and uncoupler of oxidative phosphorylation. The 
addition of CCCP was thus expected to act as a positive process control (Hortelano et 
al., 1999)(Hortelano, 1999, 28). CCCP was added at a concentration of 5 µmol/L. 
Platelet populations were identified based on scatter characteristics, with a stop on 
50000 events. Green fluorescence was detected on FL1, with the FL2 detector used to 
identify the red-fluorescing J-aggregates.  
 
Method 
Reagents 
CCCP (Sigma-Aldrich, Dorset, UK: code C2759) 
JC-1 (Invitrogen, Paisley, UK: code: T3168) 
DMSO, anhydrous (Sigma-Aldrich, Dorset, UK: code D8418) 
T-Sol platelet additive solution (Baxter, Norfolk, UK: code RDB7846)   
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Preparation of Reagents 
0.1M CCCP stock solution: 
 Prepare a 0.1 M stock solution (0.0205 g of CCCP to 997 µL of DMSO) 
 Dispense into labelled cryovials as 20 µL aliquots and store below -30°C 
5 mM CCCP (working solution): 
 Add 380 µL of DMSO to thawed vial of CCCP stock solution 
5 mM JC-1 stock solution: 
 Dispense 1.534 mL of DMSO into the 5 mg vial of JC-1. 
 Once dissolved, dispense into labelled cryovials in 25 µL aliquots 
100 µM JC-1 (working solution): 
 Add 1.225 mL of DMSO to thawed vial of JC-1 stock solution 
 
Procedure 
 Obtain a platelet count from the unit sample 
 Dilute with T-Sol to a concentration of 30 × 109/L (at least 2 mL required per assay) 
Two plastic test tubes are required per assay, one serving as the test and a second 
serving as a control 
 Dispense 5 µL of 100 µM JC-1 to the bottom of both test tubes 
 Dispense 1 µL of 5 mM CCCP to the bottom of the control tube 
 Dispense 995 µL of the diluted sample to both tubes 
 Cap tubes and incubate in a 37°C waterbath for 20 minutes (protect from light) 
 Acquire on the flow cytometer.  
 
INTRACELLULAR FREE CALCIUM 
Background 
A flow cytometric assay using two fluorescence indicators was developed for the 
measurement of intracellular free calcium. Fluo-4 is a derivative of fluo-3 in which two 
chlorine atoms are substituted by fluorine, resulting in improved excitation from the 
standard 488 nm argon laser used in the FC500 flow cytometer. Emission maximum is 
516 nm, with binding of calcium ions resulting in increased fluorescence. In contrast, 
Fura Red exhibits decreased fluorescence on binding to calcium, with an emission 
maximum of approximately 675 nm. The separation in emission maxima, coupled with 
the differing response of the dyes to varying calcium concentration, allows for the 
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adoption of a ratiometric analysis, with both dyes combined in a single assay. Obtaining 
a ratio from two separate dyes minimises the effect of various artefacts unrelated to 
changes in calcium concentration. These include the impact of cell size and shape as 
well as variations in the loading and subsequent leakage of fluoresecent indicators 
(Dustin, 2000). 
 
The common fluorescent indicators for Ca2+ are polycarboxylate anions that cannot 
cross the lipid bilayer of the plasma membrane. The uptake and retention of the dyes is 
facilitated by the use of the acetoxymethyl (AM) ester of each dye. The AM group 
masks the negative charge of the carboxyl groups allowing the ester form to pass 
through the cell membrane. Once inside the cell, nonspecific esterases cleave the 
masking groups, allowing the carboxyl groups to bind to calcium ions and resulting in a 
charged form of the dye that is more easily retained inside the cell (Takahashi et al., 
1999). A complication of the use of AM esters is their low solubilities. This can be 
improved with the addition of a mild, non-ionic surfactant such as Pluronic® F-127 
(Kao, 1994). 
 
Development of the Assay 
A modified Tyrode’s buffer (137 mmol/L NaCl, 2.8 mmol/L KCl, 1 mmol/L MgCl2, 12 
mmol/L NaHCO3, 0.4 mmol/L Na2HPO4, 10 mmol/L HEPES, 5.5 mmol/L glucose, 
0.35% BSA (w/v)) was used as the sample diluent (do Ceu Monteiro et al., 1999). 
Bovine serum albumin was added to the medium on the basis that serum proteins such 
as BSA can improve the loading efficiency (Kao, 1994). The net effect was to 
accentuate the difference between the two emission fluorescences. 
 
Dyes were purchased in 50 µg volumes and reconstituted in anhydrous DMSO to a 
concentration of 1 mmol/L to provide a stock solution. A working solution was prepared 
on the day of the assay by adding equal volumes of Pluronic® F-127. Any remaining 
stock solution was stored below -30°C. Any remaining working solution was discarded 
at the end of the day, since Pluronic® F-127 can decrease the stability of AM esters. 
(The manufacturer recommended that AM esters be used at a final concentration 
between 1 – 10 µmol/L). Little difference in fluorescence intensity was evident within 
this range and a final concentration of 5 µmol/L was adopted for both dyes. 
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Incubation times of fifteen and thirty minutes were evaluated. The impact on Fluo-4 
was minimal, but a marked increase in fluorescence intensity was noted for Fura Red 
with the longer incubation period. As fluorescence is expected to decrease upon calcium 
binding with Fura Red, a higher starting point would be advantageous and an incubation 
period of thirty minutes was adopted for the assay. Compartmentalisation refers to the 
uptake of dye by organelles within the cell, some of which may contain high levels of 
calcium and thus potentially contribute to the fluorescence signal. As some operators 
have reported increased compartmentalisation with incubation temperatures of 37°C 
compared to ambient temperature, the latter was adopted (Takahashi et al., 1999, 
Dustin, 2000). 
 
Cytosettings were initially established using individual dyes and subsequently optimised 
using a combined protocol. Final settings were: 
 FL1 (Fluo-4 detector): 550 volts 
 FL4 (Fura Red detector): 675 volts 
 Compensation: FL4-FL1 = 1.8   FL1-FL4 = 5.0 
 
The calcium ionophore A23187 was employed as a positive control, with a final 
concentration of 20 µmol/L. A final concentration of 5 x 106 platelets was initially 
adopted based on the concentration used for the CD62P/Annexin V-binding assay and 
found to yield acceptable results. Platelets were identified based on their scatter 
characteristics, with a stop on 10000 platelet events. 
 
Method 
Reagents 
Fura Red (Invitrogen, Paisley, UK: code F-0321) 
Fluo-4 (Invitrogen, Paisley, UK: code F-14201) 
A23187 free acid calcium ionophore (Invitrogen, Paisley, UK: code A-1493)  
DMSO, anhydrous (Sigma-Aldrich, Dorset, UK: code D8418) 
Pluronic® F-127 (20%) in DMSO (Invitrogen, Paisley, UK: code P3000MP) 
 
Preparation of Reagents 
Modified Tyrode’s buffer (200 mL): 
 Sodium chloride   137 mmol/L  1.6013 g 
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 Potassium chloride    2.8 mmol/L  0.0418 g 
 Magnesium chloride          1 mmol/L  0.0407 g 
 Sodium hydrogen carbonate      12 mmol/L  0.2016 g 
 Disodium hydrogen phosphate  0.4 mmol/L  0.0114 g 
 HEPES      10 mmol/L  0.4766 g 
 Glucose     5.5 mmol/L  0.1982 g 
 Bovine serum albumin    0.35% (w/v)  0.7000 g 
 Final pH (7.4; adjusted with NaOH) 
 
Filter through a 0.2 µm syringe filter in a Class II biological safety cabinet and store at 
2–8°C for 4 weeks. Check visually for contamination before use. 
Fluo-4 (stock solution): 
 To 50 µg vial add 45.6 µL of anhydrous DMSO 
Fura Red (stock solution): 
 To 50 µg vial add 45.9 µL of anhydrous DMSO 
 
Working solutions of fluorescent dyes: 
 To 13 µL of the reconstituted dye add 13µL of Pluronic® F-127 to yield a working 
solution of 0.5 mmol/L 
Calcium ionophore (A23187): 
 Reconstitute the ionophore in anhydrous DMSO to create a stock solution of 1 mg 
per mL (2 mmol/L) 
 Aliquot into labelled cryovials and store below -30°C. 
 
Procedure 
 Two test tubes are required per assay – one labelled “test” and the second labelled 
“control”. 
 Pipette 5 µL of Fluo-4 and Fura Red working solutions into each tube. 
 Pipette 490 µL of the diluted platelet sample into both tubes. Vortex for a few 
seconds, cap and incubate in the dark for 30 minutes at ambient temperature. 
 After the incubation period, add 5 µL of 2 mmol/L A23187 to the control tube. 
Vortex for a few seconds. 
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 To both tubes add 1 mL of modified Tyrode,s buffer and acquire immediately on 
the flow cytometer. 
 
INVESTIGATION OF PLATELET AGEING DURING STORAGE IN SCOTT 
SYNDROME PATIENT 
 
Background 
Platelets from Scott Syndrome patients do not express PS on their surface in response to 
physiological agonists such as collagen/thrombin. However, it was not known whether 
they would show an increased expression in response to pro-apototic agonists such as 
the BH3-mimetic ABT-737. Scott platelets thus potentially provided a model for 
investigating whether the aminophospholipid translocation noted during storage in 
normal platelets is caused by a cell death process that may be attributable to apoptosis. 
If Scott syndrome platelets expressed aminophospholipids in response to ABT-737 an 
increased expression of aminophospholipids in Scott platelets with storage would be 
suggestive of apoptosis as a causative mechanism in the PSL rather than activation 
through a scramblase dependent mechanism.  
 
Development of the Assay 
The expression of aminophospholipid on the platelet surface was measured flow 
cytometrically as the percentage of platelets binding annexin V, using the method 
described above. The volume of whole blood that could be obtained was restricted to 7 
x 5 mL vacutainer vials. A method was thus developed to transfer the platelet-rich 
plasma (PRP) from the gently-centrifuged tubes to a neonatal PC storage pack. This 
required the vials to be opened. Preliminary trials of the method were thus undertaken 
with samples from normal volunteers to ensure that the sterility of the units could be 
maintained. 
Informed consent for this study was obtained by the University Hospital of Wales after 
review by The South East Wales Ethics Committee. 
 
Method – Unit Preparation 
 Seven 5 mL 9NC coagulation sodium citrate 3.2% vacutainers (Greiner Bio-one, 
Kremsmünster, Austria) were used to collect approximately 30 mL of peripheral 
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whole blood at the University Hospital of Wales from the patient and two controls. 
The samples were subsequently transported to the Welsh Blood Service with 
minimal delay.  
 Samples were centrifuged at 800 g for 5 minutes at 22°C. 
 The vacutainers were opened inside a Class II microbiology safety cabinet and the 
PRP transferred by syringe and 19G needle into Baxter PL2410 neonatal platelet 
storage packs via a sterile sample site coupler (Baxter Healthcare Ltd, Newbury, 
UK). An isopropyl alcohol/chlorhexidine swab was used on the surface of the 
coupler both before and after needle insertion. Approximately 3 mL of PRP was 
obtained from each vacutainer for a total sample volume of approximately 15 mL. 
 The neonatal packs were stored at 22 ± 2°C with constant horizontal agitation. (The 
packs are designed to hold between 40 and 70 mL of concentrated platelets. A 
volume of 15 mL appeared to be too low to allow for adequate mixing of the 
contents. Units were thus periodically mixed manually throughout the day). 
 Samples were taken on days 1, 2, 5, 7 and 9, with day 0 being the day of sample 
collection. Approximately 150 µL was aseptically removed from the units via a 
sample site coupler using a 1 mL syringe with 19G needle and dispensed into a 12 × 
75 mm plastic tube. (All sampling was performed in a Class II safety cabinet). 
 Flow cytometric analysis was performed immediately after sampling. 
THROMBIN GENERATION IN SCOTT PLATELETS DURING STORAGE 
An extension of the study on platelet ageing was performed by colleagues at UHW 
investigating the functional capacity of stored platelets in a Scott patient. As 
phosphatidylserine provides a procoagulant surface for the activities of the tenase and 
prothrombinase complexes in the normal coagulation response, the question arose as to 
whether an increase in aminophospholipid expression on the surface of Scott platelets 
would correlate with an increase in thrombin generation and microvesicle formation. 
The annexin V binding assay was adopted by the team at the School of Medicine, as 
was the unit preparation method described above. The thrombin generation assay was 
performed at UHW by calibrated automated thrombography (CAT).  
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CHAPTER 3. COMPARISON OF IN VITRO STORAGE 
CHARACTERISTICS OF PLATELET CONCENTRATES STORED IN 
100% AUTOLOGOUS PLASMA VERSUS A MEDIUM COMPRISED 
OF 70% SSP+/30% PLASMA 
 
INTRODUCTION  
Despite the continued interest in the use of additive solutions for the storage of PCs, 
there have been relatively few studies comparing the characteristics of such units with 
PCs suspended in 100% autologous plasma beyond five days of storage (Cardigan et al., 
2008). A study was therefore undertaken to expand on the current body of published 
data and provide a comparative data for subsequent experiments. Study 1 thus compared 
the storage characteristics of buffy coat-derived pooled platelets suspended as 
concentrates in 100% autologous plasma (the current standard storage conditions) with 
similarly prepared PC suspended in a medium comprising 70% SSP+ and 30% 
plasma over a period of 14 days, including parameters associated with mechanisms of 
cell death. The frequency of testing resulted in significant volume loss and contributed 
to median platelet yields below the UK Guidelines’ specification by the end of storage 
(226 × 109/unit and 198 × 109/unit in 100% plasma and 70% SSP+ units, 
respectively). It is unclear how this volume loss may have affected results, limiting this 
study to a comparative investigation.  
 
Data are replicates of 13 experiments for 100% plasma and 12 experiments for SSP+. 
Summary statistics are presented as the median and range in the tables and median and 
interquartile range (25th and 75th percentiles) in the graphs. Differences between groups 
were analysed by the Mann-Whitney Rank Sum test, with a p value <0.05 regarded as 
statistically significant. Comparisons within test groups over time were performed 
against baseline (day 1) results by the Wilcoxon Signed Rank test, with statistical 
significance assigned to p values <0.01.  
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RESULTS 
Platelet Yield and Volume 
The median platelet yields for units in plasma and 70% SSP+ on day 1 were 320 × 
109/unit and 301 × 109/unit, respectively, with no statistically significant difference 
between the two processes (p=0.165). Corresponding median unit volumes were 315.5 
mL and 317.1 mL (p=0.849). All units met the UK Guidelines’ specification requiring a 
platelet yield ≥ 240 × 109/unit (James, 2005). All units were successfully leucoreduced 
(WBC counts < 1 × 106/unit) and remained sterile at end of storage. 
 
Viability and Morphology 
Platelet concentration 
There was a gradual decrease in platelet concentration in both study groups over the 14-
day storage period, with median end of storage values 86.3% and 81.9% of day 1 values 
in plasma and SSP+ units, respectively (figure 3.1). Compared to baseline day 1 
values, the decrease was statistically significant in units in 100% plasma on days 10 and 
14 (p<0.001) and in units suspended in 70% SSP+ from day 6 (p=0.003 to <0.001). 
Lower median values were noted in the units suspended in 70% SSP+ throughout the 
storage period, though a statistically significant difference was not evident until day 14 
(p=0.023) (table 3.1). 
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Figure 3.1: Platelet 
concentration in PC stored in 
100% plasma vs PC stored in 
70% SSP+ 
(median ± interquartile range) 
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Table 3.1: Summary results for platelet concentration – PC in 100% plasma vs 70% 
SSP+ 
Platelet concentration (×109/L) 
100% Plasma (n=13) 70% SSP+ (n=12)  Day Tested 
Median Range Median Range p value 
1 1010 865-1323 979 814-1246 0.142 
2 1011NS 833-1290 965NS 817-1254 0.221 
3 1016NS 867-1345 951NS 801-1235 0.242 
6 1014NS 818-1290 931* 772-1213 0.355 
8 958NS 813-1356 921* 767-1171 0.068 
10 932* 807-1271 917* 734-1082 0.289 
14 872* 768-1218 802* 685-931 0.023 
*: Statistically significant difference (p<0.01) when compared against day 1 values 
NS: No statistically significant difference when compared against day 1 values 
 
Swirling 
Swirling remained strong (score of 3) throughout the 14 days of storage in all units 
suspended in 70% SSP+. In the units suspended in 100% plasma, eight of the thirteen 
units showed reduced swirling with a score of 2 by day 10, decreasing further to scores 
of 1 or 0 by day 14 in eleven of the units.  
 
Mean platelet volume  
Mean platelet volumes were lower in the platelets suspended in 70% SSP+, with 
median values of 7.9 fL compared to 9.1 fL on day 1 for platelets in 100% plasma. This 
difference was retained throughout storage and, with the exception of day 3 (p=0.079), 
was statistically significant at all time points (p=0.035 to <0.001) (table 3.2). However, 
the variation associated with the plasma results were a source of concern (figure 3.2). 
An inconsistency was identified between the last four results and those preceding them. 
The median on day 1 for the first nine units was 9.2 fL compared with 7.8 fL for the last 
four units tested, with a similar difference retained throughout the storage period. There 
was a two month gap between the two groups of results, but no clear indication of what 
could have caused the discrepancy. There were no changes to unit preparation and the 
analyser performance was routinely monitored with daily quality control material. 
Statistically significant differences were obtained from day 6 in 100% plasma units 
(p=0.002 to <0.001) when comparing results to baseline day 1 values. By contrast, 
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significant differences were obtained on days 2 (p=0.004), 3 and 14 (p=0.002 for both) 
in units in 70% SSP+ (table 3.2). 
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Table 3.2: Summary results for mean platelet volume – PC in 100% plasma vs 70% 
SSP+ 
Mean platelet volume (fL) 
100% Plasma (n=13) 70% SSP+ (n=12)  Day Tested 
Median Range Median Range p value 
1 9.1 7.7-10.2 7.9* 7.4-8.3 0.014 
2 9.1NS 7.6-10.1 8.1* 7.4-8.4 0.035 
3 9.2NS 7.2-10.2 8.1* 7.7-8.4 0.079 
6 9.3* 7.7-10.8 8.0NS 7.6-8.6 0.004 
8 9.6* 8.1-10.6 8.1NS 7.6-8.6 <0.001 
10 9.6* 8.1-10.8 8.0NS 7.6-8.4 <0.001 
14 9.7* 8.4-10.4 8.2* 7.6-8.7 <0.001 
*: Statistically significant difference (p<0.01) when compared against day 1 values 
NS: No statistically significant difference when compared against day 1 values 
 
Hypotonic shock response and extent of shape change 
The response to hypotonic shock was retained close to day 1 values until after day 3, at 
which point the response was found to decrease with further storage in both test groups 
(figure 3.3).This became statistically significant in both test groups from day 6 (p=0.003 
to <0.001) (table 3.3). A convincing difference (p<0.001) between the results for the 
two groups was not evident until day 14, when the median for units in plasma was 
30.5% compared to 40.0% for units in SSP+ (table 3.3). A similar pattern was evident 
Figure 3.2: Mean platelet volume in 
PC stored in 100% plasma vs PC 
stored in 70% SSP+ 
(median ± interquartile range) 
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for the extent of shape change assay (figure 3.4), with median levels starting at 35.2% 
and 35.1% for plasma and SSP+ units respectively (p=0.435); decreasing by day 14 to 
9.8% and 14.2% (p<0.001). As with HSR, the decrease was statistically significant from 
day 6 to the end of storage (p<0.001) (table 3.4). 
Day Tested
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
H
yp
o
to
n
ic
 
sh
o
ck
 
re
sp
o
n
se
 
(%
)
0
20
40
60
80
100
Plasma 
SSP+ 
Day tested
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Ex
te
n
t o
f s
ha
pe
 
ch
a
n
ge
 
(%
)
0
10
20
30
40
50
Plasma 
SSP+ 
 
Table 3.3: Summary results for hypotonic shock response – PC in 100% plasma vs 
70% SSP+ 
Hypotonic shock response (%) 
100% Plasma (n=12) 70% SSP+ (n=12)  Day Tested 
Median Range Median Range p value 
1 73.4 53.0-87.4 78.0 68.5-92.2 0.089 
2 71.5NS 51.5-88.2 81.8NS 68.8-93.7 (n=8) 0.034 
3 72.3NS 53.3-80.0 76.5NS 64.6-92.8 0.184 
6 66.3* 45.8-74.5 64.2* 55.9-78.0 0.583 
8 53.7* 42.0-65.1 62.5* 49.5-78.0 0.043 
10 49.2* 31.4-63.1 52.0* 39.8-61.9 0.273 
14 30.5* 2.8-42.8 40.0* 36.8-53.3 <0.001 
*: Statistically significant difference (p<0.01) when compared against day 1 values 
NS: No statistically significant difference when compared against day 1 values 
 
Figure 3.3: Hypotonic shock 
response in PC stored in 100% 
plasma vs PC stored in 70% SSP+ 
(median ± interquartile range) 
Figure 3.4: Extent of shape change 
in PC stored in 100% plasma vs PC 
stored in 70% SSP+ 
(median ± interquartile range) 
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Table 3.4: Summary results for extent of shape change – PC in 100% plasma vs 70% 
SSP+ 
Extent of shape change (%) 
100% Plasma (n=12) 70% SSP+ (n=12)  Day Tested 
Median Range Median Range p value 
1 35.2 23.5-43.3 35.1 31.4-39.2 0.435 
2 33.9NS 30.3-39.8 34.0NS 30.7-39.3 (n=8) 1.000 
3 33.2NS 25.2-38.8 32.8NS 28.2-39.1 0.977 
6 25.3* 21.4-33.5 26.0* 21.6-30.4 0.817 
8 20.5* 18.4-28.5 22.3* 18.8-27.3 0.564 
10 18.1* 14.9-23.1 19.4* 14.9-22.6 0.470 
14 9.8* 1.5-13.7 14.2* 10.6-18.8 <0.001 
*: Statistically significant difference (p<0.01) when compared against day 1 values 
NS: No statistically significant difference when compared against day 1 values 
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Platelet Metabolism 
Glucose and Lactate Levels 
Median glucose levels in plasma and SSP+ units on day 1 were 15.2 mmol/L and 4.6 
mmol/L, respectively, reflecting the lack of glucose in the SSP+ additive solution and 
resulting in statistically significant differences (p<0.001) between the two test groups 
throughout storage (table 3.5). Glucose levels declined gradually to a minimum of 3.7 
mmol/L by day 14 in plasma units, whereas stores were depleted by day 10 in units 
suspended in 70% SSP+ (figure 3.5). A statistically significant difference from 
baseline day 1 levels was present by day 2 in units in 100% plasma and by day 3 in 
units suspended in 70% SSP+ (p<0.001 in all cases) (table 3.5). 
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Table 3.5: Summary results for glucose concentration – PC in 100% plasma vs 70% 
SSP+ 
Glucose concentration (mmol/L) 
100% Plasma (n=13) 70% SSP+ (n=12)  Day Tested 
Median Range Median Range p value 
1 15.2 14.0-17.2 4.6 4.2-5.4 <0.001 
2 14.5* 13.5-16.4 4.4NS 3.8-5.2 <0.001 
3 14.3* 12.9-16.2 4.0* 3.4-4.8 <0.001 
6 12.2* 11.1-14.7 2.8* 1.9-3.3 <0.001 
8 10.5* 9.1-13.1 1.7* 0.7-2.4 <0.001 
10 8.4* 7.3-11.7 0.5* 0.0-1.4 <0.001 
14 3.7* 2.1-7.9 0.1* 0.0-0.3 <0.001 
*: Statistically significant difference (p<0.01) when compared against day 1 values 
NS: No statistically significant difference when compared against day 1 values 
Figure 3.5: Glucose concentration in 
PC stored in 100% plasma vs PC 
stored in 70% SSP+ 
(median ± interquartile range) 
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The decrease in glucose concentration was reflected in a concomitant increase in lactate 
levels, with median levels at the start of the storage period of 8.3 mmol/L increasing to 
25 mmol/L by day 14 in PC suspended in 100% plasma (table 3.6). In contrast, levels in 
units suspended in 70% SSP+ plateau at a median of 14.6 mmol/L on day 10, 
coincident with the depletion of glucose stores in these units (figure 3.6). As with 
glucose, statistically significant differences (p<0.01) were found by day 2 and by day 3 
in 100% plasma units and 70% SSP+ units, respectively. 
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Table 3.6: Summary results for lactate concentration – PC in 100% plasma vs 70% 
SSP+ 
Lactate concentration (mmol/L) 
100% Plasma (n=13) 70% SSP+ (n=12)  Day Tested 
Median Range Median Range p value 
1 8.3 7.1-10.6 7.6 6.9-8.7 0.036 
2 9.0* 7.9-11.6 8.0NS 7.1-9.0 0.002 
3 9.6* 8.6-12.2 8.4* 7.6-9.6 <0.001 
6 12.1* 11.1-16 10.5* 9.8-12.3 <0.001 
8 14.9* 13.4-18 12.5* 10.7-14.3 <0.001 
10 18* 16-21 14.6* 13.1-16 <0.001 
14 25* 21-32 14.6* 13.9-16 <0.001 
*: Statistically significant difference (p<0.01) when compared against day 1 values 
NS: No statistically significant difference when compared against day 1 values 
 
Figure 3.6: Lactate concentration in 
PC stored in 100% plasma vs PC 
stored in 70% SSP+ 
(median ± interquartile range) 
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Rates of glucose consumption increased throughout the storage period in units stored in 
100% plasma, partly as a reflection of the loss of platelets with storage evidenced by the 
decrease in platelet concentration, resulting in a statistically significant difference 
(p<0.001) compared to baseline levels beyond day 6 (table 3.7). Glucose consumption 
also increased with storage in PC suspended in 70% SSP+ until day 10. Beyond this 
point, the depletion of glucose in these units resulted in a steep decline in glucose 
consumption (figure 3.7). Statistically significant differences (p<0.001) compared to 
baseline levels of consumption were only evident between days 6 and 10 in these units.  
Glucose consumption in the SSP+ test group was lower than in the plasma units, with 
statistically significant differences between the two groups at all time points (p=0.011 to 
<0.001) (table 3.7). 
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Table 3.7: Summary results for glucose consumption – PC in 100% plasma vs 70% 
SSP+ 
Glucose consumption (mmol/day/1012plts) 
100% Plasma (n=13) 70% SSP+ (n=12)  
Period of 
glucose 
consumption 
Median Range Median Range p value 
Day 1 - 3 0.47 0.24-0.79 0.35 0.00-0.55 0.011 
Day 3 - 6 0.73NS 0.26-0.92 0.46NS 0.35-0.56 0.008 
Day 6 -10 0.92* 0.70-1.29 0.63* 0.41-0.81 <0.001 
Day 10 -14 1.28* 0.86-1.68 0.11NS 0.00-0.43 <0.001 
*: Statistically significant difference (p<0.01) when compared against day 1 values 
NS: No statistically significant difference when compared against day 1 values 
 
Figure 3.7: Glucose consumption rates in PC stored in 100% plasma vs PC stored in 70% 
SSP+ (plot shows median, 25th, 75th, 10th and 90th percentiles, with other values 
individually plotted) 
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The pattern of lactate production mirrored that observed with glucose consumption, 
with lactate production ceasing with the depletion of glucose stores (figure 3.8).  
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Table 3.8: Summary results for lactate production – PC in 100% plasma vs 70% 
SSP+ 
Lactate production (mmol/day/1012plts) 
100% Plasma (n=13) 70% SSP+ (n=12)  
Period of 
lactate 
production 
Median Range Median Range p value 
Day 1 - 3 0.68 0.55-0.99 0.38 0.12-0.68 0.011 
Day 3 - 6 0.99* 0.49-1.24 0.81* 0.71-0.94 0.008 
Day 6 -10 1.27* 0.97-2.12 1.04* 0.63-1.52 <0.001 
Day 10 -14 2.04* 1.12-2.89 0.06NS -0.33-0.44 <0.001 
*: Statistically significant difference (p<0.01) when compared against day 1 values 
NS: No statistically significant difference when compared against day 1 values 
 
Figure 3.8: Lactate production in PC stored in 100% plasma vs PC stored in 70% SSP+ 
(plot shows median, 25th, 75th, 10th and 90th percentiles, with other values individually plotted) 
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pH(22°C) 
pH22°C values were similar in both test groups on day 1, with median values of 7.070 
and 7.064 in 100% plasma and SSP+ units, respectively (p=0.231) (table 3.9). The 
pattern subsequently deviated, with units in plasma showing an increase in pH until day 
3 followed by a decline through to day 14 which showed a minimum level for the 
median of 6.613 (range: 6.521 – 6.870), resulting in statistically significant differences 
(p<0.001) compared with baseline day 1 values at all time points except day 10 
(p=0.787) (table 3.9) . Units in 70% SSP+ showed a more gradual increase to day 6, 
with a more pronounced rise after day 10 following the depletion of glucose stores in 
these units, resulting in a day 14 median value of 7.295 (figure 3.9). In these units, 
statistically significant differences (p<0.001) compared to day 1 values were evident 
throughout storage. 
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Table 3.9: Summary results for pH22°C – PC in 100% plasma vs 70% SSP+ 
pH (22°C) 
100% Plasma (n=13) 70% SSP+ (n=12)  Day Tested 
Median Range Median Range p value 
1 7.070 7.014-7.129 7.065 7.010-7.114 0.231 
2 7.251* 7.176-7.314 7.125* 7.056-7.158 <0.001 
3 7.327* 7.274-7.382 7.167* 7.092-7.202 <0.001 
6 7.299* 7.219-7.366 7.222* 7.107-7.257 <0.001 
8 7.193* 7.092-7.282 7.198* 7.071-7.241 0.913 
10 7.070NS 6.914-7.159 7.161* 7.092-7.220 <0.001 
14 6.613* 6.521-6.870 7.295* 7.162-7.346 <0.001 
*: Statistically significant difference (p<0.01) when compared against day 1 values 
NS: No statistically significant difference when compared against day 1 values 
Figure 3.9: pH22°C levels in PC stored 
in 100% plasma vs PC stored in 70% 
SSP+ 
(median ± interquartile range) 
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Bicarbonate Levels 
Bicarbonate levels in plasma units decreased gradually from a median on day 1 of 18.46 
mmol/L to 1.59 mmol/L by day 14. Levels in SSP+ units, in contrast, were relatively 
more stable, with starting levels of 7.59 mmol/L decreasing to 4.09 mmol/L by the end 
of storage, constituting 53.9% of day 1 levels compared to 8.6% of day 1 values in 
100% plasma units. Statistically significant differences compared with baseline day 1 
levels were evident in plasma units at all time-points, but after day 3 in SSP+ units 
(p<0.001 in all cases) (table 3.10). The pattern reflected the more stable pH values 
observed with SSP+ units (figures 3.10 and 3.9). Statistically significant differences 
were noted throughout storage between the two test groups (p<0.001 at all time points). 
Day tested
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Bi
ca
rb
o
n
a
te
 
le
ve
ls 
(m
m
o
l/l)
 
(37
o
C)
0
5
10
15
20
25
Plasma 
SSP+ 
 
 
Table 3.10: Summary results for bicarbonate levels – PC in 100% plasma vs 70% 
SSP+ 
Bicarbonate levels (37°C) (mmol/L) 
100% Plasma (n=13) 70% SSP+ (n=12)  Day Tested 
Median Range Median Range p value 
1 18.46 16.62-20.50 7.59 5.69-7.91 <0.001 
2 16.08* 14.91-18.08 6.93NS 6.29-8.13 <0.001 
3 14.66* 13.70-16.46 6.59NS 6.01-7.68 <0.001 
6 11.56* 9.82-13.21 5.73* 5.17-6.58 <0.001 
8 8.93* 7.13-10.36 5.20* 4.53-6.11 <0.001 
10 6.03* 4.45-7.79 4.63* 3.85-5.56 <0.001 
14 1.59* 0.43-4.09 4.09* 3.11-5.16 <0.001 
*: Statistically significant difference (p<0.01) when compared against day 1 values 
NS: No statistically significant difference when compared against day 1 values 
 
Figure 3.10: Bicarbonate levels in PC 
stored in 100% plasma vs PC stored 
in 70% SSP+ 
(median ± interquartile range) 
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Blood Gases 
Median pO2(37°C) levels increased steadily throughout the period of storage in both test 
groups, from median day 2 levels of 12.7 and 14.0 kPa in plasma and 70% SSP+ 
units, respectively, to a maximum of 18.4 and 18.8 kPa by day 14 (figure 3.11). 
Statistically significant differences between the two groups were evident only on day 1 
(p=0.027). This was reflected in the pairwise comparison with baseline day 1 values, 
with statistically significant differences (p<0.001) in plasma units at all time-points but 
no significant differences on days 2 and 3 in 70% SSP+ units (table 3.11). pCO2(37°C) 
differed significantly between the two groups from day 1 (p<0.001 at all time points), 
with median levels decreasing from 11.4 to 2.79 kPa in units suspended in 100% plasma 
compared to 4.85 to 1.58 kPa for units in 70% SSP+ (day 1 to day 14) (figure 3.12). 
The decrease in pCO2 in 100% plasma units between days 1 and 3 coincided with the 
increase in pH observed in these units during the same period, with statistically 
significant differences (p=0.009 to <0.001) compared to day 1 values at all time-points 
in both test groups (table 3.12).  
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Figure 3.11: pO2 levels in PC stored 
in 100% plasma vs PC stored in 70% 
SSP+ 
(median ± interquartile range) 
Figure 3.12: pCO2 levels in PC 
stored in 100% plasma vs PC stored 
in 70% SSP+ 
(median ± interquartile range) 
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Table 3.11: Summary results for pO2 – PC in 100% plasma vs 70% SSP+ 
pO2 (37°C) (kPa) 
100% Plasma (n=13) 70% SSP+ (n=12)  Day Tested 
Median Range Median Range p value 
1 12.7 10.5-14.6 14.0 10.5-15.6 0.027 
2 13.5* 10.6-15.1 13.7NS 12.4-15.8 0.586 
3 14.7* 12.4-15.8 14.3NS 12.6-16.1 0.913 
6 15.4* 14.0-17.7 15.5* 13.7-16.5 0.785 
8 16.0* 14.1-17.9 15.7* 14.7-17.7 0.275 
10 16.5* 15.5-18.7 17.0* 15.2-18.0 0.723 
14 18.4* 16.0-22.5 18.8* 17.2-19.8 0.913 
*: Statistically significant difference (p<0.01) when compared against day 1 values 
NS: No statistically significant difference when compared against day 1 values 
 
 
 
Table 3.12: Summary results for pCO2 – PC in 100% plasma vs 70% SSP+ 
pCO2 (37°C) (kPa) 
100% Plasma (n=13) 70% SSP+ (n=12)  Day Tested 
Median Range Median Range p value 
1 11.4 9.8-12.9 4.85 3.45-5.18 <0.001 
2 7.04* 6.34-7.49 3.89* 3.53-4.33 <0.001 
3 5.32* 4.96-5.71 3.39* 3.13-3.75 <0.001 
6 4.44* 4.03-4.66 2.72* 2.42-3.08 <0.001 
8 4.21* 3.67-4.57 2.57* 2.31-2.87 <0.001 
10 3.83* 2.97-4.16 2.38* 2.09-2.58 <0.001 
14 2.79* 1.38-3.32 1.58* 1.47-1.89 <0.001 
*: Statistically significant difference (p<0.01) when compared against day 1 values 
NS: No statistically significant difference when compared against day 1 values 
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Oxygen consumption rates were similar, with levels in both test groups gradually 
decreasing after day 3 (figure 3.13). Statistically significant differences (p<0.01) 
compared to baseline day 1 levels were present after days 2 and 3 in plasma units and 
units in 70% SSP+, respectively. Although statistically significant differences between 
the two groups were evident on days 6 (p=0.041), day 8 (p=0.010) and day 14 
(p=0.040) (table 3.13), the differences were not convincing and may be related to the 
higher platelet concentrations measured in the units suspended in 100% plasma (figure 
3.1).  
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Table 3.13: Summary results for oxygen consumption rate (22°C) – PC in 100% 
plasma vs 70% SSP+ 
Oxygen consumption rate (22°C) – (nmol/min/109plts) 
100% Plasma (n=13) 70% SSP+ (n=12)  Day Tested 
Median Range Median Range p value 
1 0.211 0.182-0.270 0.211 0.169-0.247 0.683 
2 0.206NS 0.184-0.241 0.215NS 0.173-0.231 0.242 
3 0.186* 0.163-0.226 0.202NS 0.183-0.227 0.053 
6 0.173* 0.153-0.195 0.188* 0.165-0.214 0.041 
8 0.159* 0.126-0.178 0.184* 0.151-0.218 0.010 
10 0.159* 0.118-0.189 0.170* 0.142-0.181 0.165 
14 0.136* 0.048-0.182 0.148* 0.122-0.160 0.040 
*: Statistically significant difference (p<0.01) when compared against day 1 values 
NS: No statistically significant difference when compared against day 1 values 
 
Figure 3.13: Oxygen consumption 
rate (22°C) for PC stored in 100% 
plasma vs PC stored in 70% 
SSP+ 
(median ± interquartile range) 
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ATP and ADP Levels 
ATP levels decreased in plasma units from a median of 7.37 µmol/1011plts on day 1 to 
4.01 µmol/1011plts on day 14 in units suspended in 100% plasma. Levels in units with 
SSP+ were not significantly different until day 14 (p=0.023), with a higher median of 
4.845 µmol/1011plts at this time point compared to plasma units (table 3.14). End of 
storage levels in 100% plasma units were thus 54% of day 1 values and 61% of starting 
values for units in SSP+ units. An initial increase in ATP levels was found in both test 
groups; a pattern previously observed in some published studies (figure 3.14) (Wallvik 
and Akerblom, 1983, Sandgren et al., 2010). Despite the similar pattern of ATP levels 
with storage, a statistically significant difference (p<0.01) compared to baseline day 1 
values was only obtained on day 14 in SSP+ units compared with days 2, 3, 6 and 14 
in plasma units (table 3.14). 
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Table 3.14: Summary results for ATP levels – PC in 100% plasma vs 70% SSP+ 
ATP levels – (µmol/1011plts) 
100% Plasma (n=13) 70% SSP+ (n=12)  Day Tested 
Median Range Median Range p value 
1 7.37 5.68-8.69 7.95 6.38-8.98 0.399 
2 8.20* 6.40-9.58 7.91NS 5.96-10.36 0.497 
3 8.60* 7.58-9.89 8.86NS 6.37-10.88 0.935 
6 8.83* 6.83-9.81 8.09NS 7.24-9.74 0.087 
8 7.77NS 6.53-9.62 7.84NS 6.33-9.44 0.892 
10 7.30NS 5.77-9.07 6.85NS 5.85-9.10 0.497 
14 4.01* 1.95-5.32 4.85* 3.69-5.75 0.023 
*: Statistically significant difference (p<0.01) when compared against day 1 values 
NS: No statistically significant difference when compared against day 1 values 
Figure 3.14: ATP levels for PC stored 
in 100% plasma vs PC stored in 70% 
SSP+ 
(median ± interquartile range) 
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ADP levels also decreased with storage, from a median on day 1 of 5.99 µmol/1011plts 
for 100% plasma units to 1.66 µmol/1011plts by day 14. Respective levels in SSP+ 
units were 5.70 and 2.55 µmol/1011plts, with a statistically significant difference only 
evident at end of storage (p<0.001). In both test groups, statistically significant 
differences (p<0.001) compared to baseline day 1 levels were obtained after day 6 (table 
3.15). Although the error bars indicate a greater degree of variation in the results 
compared with the ATP data, the overall pattern indicates a decrease in ADP levels 
unrelated to the levels of ATP in both test groups (figure 3.15).    
Day sampled
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
AD
P 
le
ve
ls
 
(µ m
ol
/1
01
1 p
lts
)
0
2
4
6
8
10
12
Plasma 
SSP+ 
     
 
Table 3.15: Summary results for ADP levels – PC in 100% plasma vs 70% SSP+ 
ADP levels – (µmol/1011plts) 
100% Plasma (n=13) 70% SSP+ (n=12)  Day Tested 
Median Range Median Range p value 
1 5.99 4.03-8.80 5.70 3.53-10.32 0.765 
2 5.74NS 3.48-9.02 6.34NS 3.49-10.66 0.807 
3 5.70NS 3.12-8.02 5.62NS 2.98-8.18 0.644 
6 4.31NS 2.45-7.82 4.55NS 2.69-7.13 0.978 
8 3.78* 2.06-6.76 4.37* 2.88-6.02 0.221 
10 3.02* 1.69-4.75 3.58* 1.60-4.25 0.183 
14 1.66* 1.03-2.34 2.55* 1.62-4.26 <0.001 
*: Statistically significant difference (p<0.01) when compared against day 1 values 
NS: No statistically significant difference when compared against day 1 values 
 
Figure 3.15: ADP levels for PC 
stored in 100% plasma vs PC stored 
in 70% SSP+ 
(median ± interquartile range) 
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Platelet Activation 
CD62P – Surface Expression and Soluble Concentration 
Surface expression of CD62P is reported as percentage positive expression and median 
fluorescence intensity. The percentage of platelets expressing CD62P in 100% plasma 
units increased from median levels of 53.5% on day 1 to 89.5% on day 14, with 
corresponding expressions of 55.7% and 72.7% in SSP+ units. In both groups, the 
percentage positive expression decreased before increasing again in the latter half of the 
storage period, though a delay was evident in the pattern provided by the SSP+ units 
compared with the units in 100% plasma (figure 3.16). A comparison with baseline day 
1 levels showed statistically significant differences (p=0.009 to <0.001) at all time-
points except day 6 in plasma units. The shallower decrease in expression in SSP+ in 
the first half of the storage period resulted in significant differences compared to day 1 
only on days 6 and 14 (p<0.001) (table 3.16). Statistically significant differences 
between the groups were noted at various points during storage (p=0.002 on day 2, 
p=0.011 on day 3 and finally p <0.001 on day 14) (table 3.16). 
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Figure 3.16: Surface CD62P 
expression (% positive) for PC stored 
in 100% plasma vs PC stored in 70% 
SSP+ 
(median ± interquartile range) 
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Table 3.16: Summary results for surface expression of CD62P (% positive) – PC in 
100% plasma vs 70% SSP+ 
Surface expression of CD62P – (% positive) 
100% Plasma (n=13) 70% SSP+ (n=12)  Day Tested 
Median Range Median Range p value 
1 53.45 38.06-67.20 55.71 46.93-69.33 0.221 
2 43.87* 29.54-64.36 54.84NS 47.03-71.23 0.002 
3 43.86* 27.59-59.16 52.27NS 39.36-62.98 0.011 
6 51.64NS 37.61-63.42 49.99* 38.89-57.98 0.312 
8 57.86* 49.84-71.59 56.22NS 39.78-61.84 0.201 
10 68.90* 58.17-78.18 63.84NS 57.43-73.75 0.202 
14 89.51* 80.17-94.68 72.65* 67.11-82.11 <0.001 
*: Statistically significant difference (p<0.01) when compared against day 1 values 
NS: No statistically significant difference when compared against day 1 values 
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Median fluorescence intensity was similar between the two test groups until day 10, 
with no statistically significant differences from days 1 to 8 (table 3.17). In both test 
groups, a slight decrease in median fluorescence intensity was observed from day 1 to 
day 6. Statistically significant differences compared to day 1 levels were noted on days 
2 (p=0.006) and 3 (p=0.003) in 100% plasma units. In both test groups significant 
differences were also obtained on day 14 (p=0.007 in SSP+ and <0.001 in 100% 
plasma) (table 3.17). Beyond day 10 MFI increased at a markedly greater rate in 100% 
plasma units, resulting in statistically significant differences between the groups on days 
10 and 14 (p=0.046 and <0.001, respectively); with median values at end of storage of 
2.88 and 1.75 in 100% plasma and SSP+ (figure 3.17). 
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Table 3.17: Summary results for surface expression of CD62P (median fluorescence 
intensity) – PC in 100% plasma vs 70% SSP+ 
Surface expression of CD62P – (median fluorescence intensity) 
100% Plasma (n=13) 70% SSP+ (n=12)  Day Tested 
Median Range Median Range p value 
1 1.42 1.05-2.24 1.39 1.05-1.99 0.683 
2 1.31* 1.00-1.85 1.29NS 1.01-1.82 0.605 
3 1.21* 0.93-1.66 1.21NS 1.07-1.76 0.764 
6 1.22NS 1.06-1.65 1.18NS 1.05-1.43 0.174 
8 1.34NS 1.12-2.01 1.31NS 1.12-1.61 0.157 
10 1.60NS 1.31-2.14 1.44NS 1.14-1.74 0.046 
14 2.88* 2.30-4.72 1.75* 1.62-2.49 <0.001 
*: Statistically significant difference (p<0.01) when compared against day 1 values 
NS: No statistically significant difference when compared against day 1 values 
Figure 3.17: Surface CD62P 
expression (MFI) for PC stored in 
100% plasma vs PC stored in 70% 
SSP+ 
(median ± interquartile range) 
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Soluble CD62P levels were significantly lower in units suspended in 70% SSP+ 
throughout the storage period due to the lower volume of plasma in the suspending 
medium (p=0.001 to <0.001) (figure 3.18). Starting levels were 89.7 and 52.0 ng/mL for 
units in plasma and SSP+ respectively, increasing at a constant rate with storage to 
median levels on day 14 of 160.3 and 134.8 ng/mL (table 3.18). Statistically significant 
differences compared to baseline day 1 levels were obtained at all time points in both 
test groups with the exception of day 2 in 100% plasma units (p<0.001 in all cases) 
(table 3.18). 
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Table 3.18: Summary results for soluble CD62P levels – PC in 100% plasma vs 70% 
SSP+ 
Soluble CD62P levels (ng/mL) 
100% Plasma (n=11) 70% SSP+ (n=12)  Day Tested 
Median Range Median Range p value 
1 89.72 66.78-139.29 52.03 25.02-73.77 <0.001 
2 100.11NS 69.77-141.52 58.48* 26.74-84.03 <0.001 
3 101.24* 80.93-140.18 64.07* 28.46-87.97 <0.001 
6 116.49* 96.08-167.43 75.51* 40.61-100.08 <0.001 
8 123.13* 101.88-193.52 87.35* 45.20-108.47 <0.001 
10 131.42* 115.79-206.55 99.40* 55.00-121.77 <0.001 
14 160.33* 137.98-241.45 134.77* 75.10-157.17 0.001 
*: Statistically significant difference (p<0.01) when compared against day 1 values 
NS: No statistically significant difference when compared against day 1 values 
 
Figure 3.18: Soluble CD62P levels 
for PC stored in 100% plasma vs PC 
stored in 70% SSP+ 
(median ± interquartile range) 
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Markers of Cell Death 
Annexin V Binding 
Annexin V binding to the platelet surface, measured as percentage positive expression, 
increased gradually in both test groups until day 8, with the 100% plasma units 
displaying a proportionately higher rate of aminophospholipid expression leading to 
statistically significant differences on days 3 to 8 (p=0.041 to <0.001) (table 3.19). 
Beyond day 8, the rate of annexin V binding increased in both test groups, resulting in 
median values on day 14 of 30.07% and 29.07% in 100% plasma and SSP+ units, 
respectively (p=0.532) (figure 3.19). A comparison with baseline day 1 levels showed 
statistically significant differences (p<0.001 in all cases) after day 3 in both test groups 
(table 3.19). 
Day tested
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
An
n
e
xin
 
V 
bi
n
di
n
g 
-
 
%
 
po
si
tiv
e
0
10
20
30
40
50
Plasma 
SSP+ 
 
Table 3.19: Summary results for annexin V binding (% positive) – PC in 100% plasma 
vs 70% SSP+ 
Annexin V binding (% positive) 
100% Plasma (n=13) 70% SSP+ (n=12)  Day Tested 
Median Range Median Range p value 
1 4.10 2.63-15.56 3.67 2.42-6.81 0.568 
2 4.55NS 2.82-14.86 4.31NS 2.33-6.49 0.463 
3 5.49NS 3.28-13.18 4.14NS 3.24-6.34 0.041 
6 9.11* 6.35-17.44 5.70* 3.76-10.05 <0.001 
8 10.44* 8.17-20.91 6.69* 4.99-9.14 <0.001 
10 18.21* 9.04-31.71 9.91* 7.83-15.88 0.001 
14 30.07* 23.75-46.47 29.07* 21.46-35.48 0.532 
*: Statistically significant difference (p<0.01) when compared against day 1 values 
NS: No statistically significant difference when compared against day 1 values 
Figure 3.19: Annexin V binding (% 
positive) for PC stored in 100% 
plasma vs PC stored in 70% SSP+ 
(median ± interquartile range) 
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When analysed as mean fluorescence intensity, annexin V binding was found to be 
significantly lower throughout storage in the 100% plasma units (p=002 to <0.001) 
(figure 3.20). Median day 1 results of 24.7 and 31.6 for plasma and SSP+ units, 
respectively, decreased to 11.2 and 21.8 by day 10; subsequently increasing to 
corresponding median values of 12.4 and 29.5 on day 14. A comparison with baseline 
day 1 values showed statistically significant differences (p=0.003 to <0.001) after day 3 
in 100% plasma units. A similar pattern was obtained with 70% SSP+ units, with the 
exception of day 14 where the increase in MFI after day 10 resulted in similar values to 
day 1 (p=0.413) (table 3.20). 
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Table 3.20: Summary results for annexin V binding (mean fluorescence intensity) – PC 
in 100% plasma vs 70% SSP+ 
Annexin V binding (mean fluorescence intensity) 
100% Plasma (n=13) 70% SSP+ (n=12)  Day Tested 
Median Range Median Range p value 
1 24.7 18.2-27.7 31.6 25.6-38.5 <0.001 
2 24.1NS 20.2-27.6 34.3NS 26.7-44.5 <0.001 
3 24.0NS 19.3-33.3 32.2NS 25.6-45.2 <0.001 
6 18.9* 12.2-27.0 27.3* 19.4-34.2 0.002 
8 15.1* 8.3-21.8 22.4* 18.4-30.0 <0.001 
10 11.2* 8.0-19.0 21.8* 12.4-37.8 <0.001 
14 12.4* 11.1-15.8 29.5NS 23.2-35.2 <0.001 
*: Statistically significant difference (p<0.01) when compared against day 1 values 
NS: No statistically significant difference when compared against day 1 values 
 
 
Figure 3.20: Annexin V binding 
expressed as mean fluorescence 
intensity for PC stored in 100% 
plasma vs PC stored in 70% SSP+ 
(median ± interquartile range) 
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Mitochondrial Membrane Potential 
Mitochondrial membrane potential, analysed as the ratio of red to green fluorescence for 
the JC-1 dye, decreased in both groups with storage (figure 3.21). Median values of 
5.44 and 6.75 on day 1 in plasma and SSP+ units respectively (p=0.009) decreased to 
corresponding levels of 3.74 and 3.43 by end of storage. A comparison against baseline 
day 1 levels showed statistically significant differences in both test groups after day 2 
(p=0.007 to <0.001). Statistically significant differences between the two groups were 
evident at a number of time points, but were interspersed with non-statistically 
significant changes on days 6 (p=0.121) and 10 (p=0.849) (table 3.21).   
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Table 3.21: Summary results for annexin V binding (mean fluorescence intensity) – PC 
in 100% plasma vs 70% SSP+ 
Mitochondrial membrane potential (FL2/FL1 JC-1 ratio) 
100% Plasma (n=13) 70% SSP+ (n=12)  Day Tested 
Median Range Median Range p value 
1 5.44 4.49-7.48 6.75 5.88-7.23 0.009 
2 5.13NS 4.77-7.44 6.22NS 5.82-6.63 0.036 
3 4.81* 4.16-6.58 5.61* 4.94-6.43 0.005 
6 4.57* 3.67-6.11 4.94* 3.45-5.57 0.121 
8 4.32* 3.97-5.99 4.97* 4.35-5.47 0.008 
10 4.23* 3.73-5.57 4.57* 3.31-5.02 0.849 
14 3.74* 3.30-5.18 3.43* 3.04-3.69 0.003 
*: Statistically significant difference (p<0.01) when compared against day 1 values 
NS: No statistically significant difference when compared against day 1 values 
 
Figure 3.21: Mitochondrial 
membrane potential (FL2/FL1JC-1 
ratio) for PC stored in 100% plasma 
vs PC stored in 70% SSP+ 
(median ± interquartile range) 
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DISCUSSION  
The platelets suspended in a medium containing 70% SSP+ performed at least as well 
as platelets in 100% autologous plasma for up to 10 days of storage. From this point, the 
exhaustion of glucose in these units may lead to accelerated deterioration of platelet 
viability which may not be reflected by the standard quality monitoring parameters of 
pH and swirling. The increase in the percentage positive expression of annexin V 
binding and decrease in mitochondrial membrane potential suggest an apoptosis-like 
process may be involved in the platelet storage lesion, with mitochondrial changes 
preceding an increase in the percentage of platelets expressing annexin V. However, 
more targeted studies would be required to define the time course of events and their 
relation to platelet death, with the expectation that the studies to follow employing 
additive solutions manipulated to isolate the role of particular components of the 
solution may offer further insight into this process. From the perspective of clinical 
transfusion practice, although the assessment of platelet in vitro characteristics is a 
logical starting point for the investigation of platelet viability beyond 7 days of storage, 
the questions of haemostatic function as well as platelet recovery and survival following 
transfusion would need to be addressed prior to any consideration of extending the 
storage period of PCs beyond seven days. 
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 CHAPTER 4. IMPACT ON PLATELET IN VITRO STORAGE 
CHARACTERISTICS OF THE INCLUSION OF ALBUMIN TO 
ADDITIVE SOLUTIONS 
 
INTRODUCTION  
In Europe, the approved use of platelet additive solutions for the storage of platelet 
concentrates requires the retention of approximately 30% of autologous plasma in the 
suspending medium, though some studies suggest a reduction of the plasma fraction to 
20% is sufficient to retain acceptable platelet function and viability for 7 days 
(Gulliksson et al., 2003, Sweeney et al., 2006). Similar restrictions apply to the only 
platelet additive solution approved for use by the US Food and Drug Administration – 
PAS-III (marketed as InterSol; Fenwal Inc., Lake Zurich, IL) – which requires the 
carry-over of 65% of autologous plasma (www.fda.gov; accessed on 08/09/2012). The 
question remains as to why this contribution by plasma should be necessary. One 
hypothesis is that plasma contains survival factors that retard the progressive 
deterioration of platelets stored as concentrates (Brown et al., 2000), with a possible 
candidate in the form of plasma proteins such as albumin which have been postulated to 
play a role in the maintenance of platelet membrane integrity (Holme, 1992). Other 
potentially beneficial roles for albumin include the scavenging of reactive oxygen 
species (Nicholson et al., 2000) and a possible role in the delay of apoptosis, with the 
latter having been reported in cultured endothelial cells (Zoellner et al., 1996). The aim 
of the study was thus to determine whether human albumin (in the form of a 
commercially available therapeutic formulation) would delay the onset of the platelet 
storage lesion, with emphasis on markers indicative of an apoptosis-like process. 
 
Statistical comparisons between the test groups were not undertaken due to the small 
number of replicates and the results from all three experiments are provided in the text, 
(with the exception of unit platelet yield and volume). Graphical representations of the 
results are restricted to displaying the mean only.  
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The four test groups are: 
ALB-000-nn (no albumin added) 
ALB-030-nn (30 mL albumin added; equivalent to 2 g/dL) 
ALB-060-nn (60 mL albumin added; equivalent to 4 g/dL) 
ALB-120-nn (120 mL albumin added: equivalent to 8 g/dL) 
(In each case, nn refers to a unique test number) 
 
RESULTS 
Platelet Yield and Volume 
The mean platelet yield and volume for the four test groups are presented in table 4.1. 
Although the small numbers in each group preclude the use of a statistical comparison, 
all the units met the specification for platelet yield of ≥240 × 109 plts/unit set out in the 
UK Guidelines for Transfusion Services (James, 2005). The unit volumes also confirm 
that the units in all four test groups were consistent at the start of the storage period. All 
pools had residual white cell counts <1×106/unit and all units were confirmed negative 
for bacterial contamination at the end of storage. 
 
Table 4.1: Platelet yield and unit volume prior to sampling  
Test Group Platelet Yield (×109/unit) Volume (mL) 
ALB-000-nn 303 ± 29 337.5 ± 5.0 
ALB-030-nn 304 ± 17 341.8 ± 7.6 
ALB-060-nn 307 ± 16 342.4 ± 4.1 
ALB-120-nn 301 ± 22 338.6 ± 11.2 
Data presented as mean ± SD (n=3) 
Function and Morphology 
Platelet Concentration 
Platelet concentration in all four test groups was very similar on days 2 and 3. 
Subsequent to this, the platelet concentration in the three albumin-containing groups 
declined with storage in a dose-dependent manner, with units containing the highest 
levels of albumin showing the most marked decline. By the end of storage on day 10, 
mean concentrations in units containing 30 mL, 60 mL and 120 mL added albumin were 
360 × 109/L, 260 × 109/L and 169 × 109/L, respectively (table 4.2). In contrast, units in 
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the test group without albumin showed a minimal decrease towards the end of storage, 
with mean day 10 levels of 840 × 109/L corresponding to 93.6% of the mean platelet 
concentration on day 2 (897 × 109/L) (figure 4.1). A similar pattern of sustained platelet 
concentration throughout storage was present in units re-constituted with plasma. 
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Table 4.2: Platelet concentration in albumin study 
Platelet concentration (×109/L) 
TEST NUMBER 
DAY 2 DAY 3 DAY 6 DAY 8 DAY 10 
ALB-000-01 807 897 894 890 824 
ALB-000-09 951 952 949 940 853 
ALB-000-17 933 904 893 898 844 
Mean 897 918 912 909 840 
ALB-030-02 817 829 800 612 432 
ALB-030-10 942 958 786 533 382 
ALB-030-18 909 928 710 515 267 
Mean 889 905 765 553 360 
ALB-060-03 834 878 611 402 227 
ALB-060-11 930 967 562 312 368 
ALB-060-19 931 911 433 239 185 
Mean 898 919 535 318 260 
ALB-120-04 784 843 350 225 238 
ALB-120-12 960 988 344 233 185 
ALB-120-20 924 923 241 151 83 
Mean 889 918 312 203 169 
 
Mean Platelet Volume 
As with the platelet concentration, the mean platelet volume between the four test 
groups was similar on days 2 and 3. Day 6 saw a marked increase in MPV in all the 
units containing albumin, with a suggestion that the highest MPVs were present in the 
Figure 4.1: Platelet concentration 
(albumin study; mean, n=3) 
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group with the highest concentration of albumin (figure 4.2). The rate of increase in 
MPV declined between days 6 and 10, with mean values on day 10 of 10.0, 10.1 and 
10.4 fL in the groups containing 30 mL, 60 mL and 120 mL added albumin, 
respectively. This may be due to the lysis of platelets – a conclusion corroborated by the 
sharp decrease in platelet concentration in these units. Mean platelet volume also 
increased after day 3 in the test group lacking albumin, but the increase was not as 
marked and the mean MPV on day 10 peaked at 9.0 fL (table 4.3). 
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Table 4.3: Mean platelet volume in albumin study 
Mean platelet volume (fL) TEST 
NUMBER DAY 2 DAY 3 DAY 6 DAY 8 DAY 10 
ALB-000-01 7.6 7.7 8.1 8.6 9.1 
ALB-000-09 7.7 7.7 7.9 8.1 8.6 
ALB-000-17 7.8 7.8 7.9 8.4 9.2 
Mean 7.7 7.7 8.0 8.4 9.0 
ALB-030-02 7.3 7.7 9.0 9.7 9.7 
ALB-030-10 7.4 7.6 9.6 9.7 10.1 
ALB-030-18 7.8 8.2 9.2 10.0 10.2 
Mean 7.5 7.8 9.3 9.8 10.0 
ALB-060-03 7.3 7.8 9.3 9.9 10.1 
ALB-060-11 7.4 7.9 9.3 9.1 10.1 
ALB-060-19 7.8 8.2 9.3 9.6 10.2 
Mean 7.5 8.0 9.3 9.5 10.1 
ALB-120-04 7.3 7.7 10.0 10.1 10.2 
ALB-120-12 7.7 7.9 9.7 9.7 10.6 
ALB-120-20 7.6 8.3 9.5 10.6 10.4 
Mean 7.5 8.0 9.7 10.1 10.4 
Figure 4.2: Mean platelet volume 
(albumin study; mean, n=3) 
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Swirling 
Swirling remained moderate throughout the storage period in the test group lacking 
albumin, with all units having a score of 2. In the three test groups containing albumin, 
swirling appeared stronger in days 2 and 3, with most units assigned a score of 3. 
However, on day 6, units in these test groups scored either 1 or 0 and by day 8, swirling 
was judged to be absent in all units (table 4.4). No distinction was evident between the 
three test groups with added albumin. 
 
 
Table 4.4: Swirling in albumin study 
DAY 2 DAY 3 DAY 6 DAY 8 DAY 10
ALB-000-01 2 2 2 2 2
ALB-000-09 2 2 2 2 2
ALB-000-17 2 2 2 3 2
ALB-030-02 2 3 1 0 0
ALB-030-10 3 3 1 0 0
ALB-030-18 3 3 1 0 0
ALB-060-03 3 3 1 0 0
ALB-060-11 3 3 1 0 0
ALB-060-19 3 3 1 0 0
ALB-120-04 3 3 1 0 0
ALB-120-12 3 3 1 0 0
ALB-120-20 3 3 0 0 0
SwirlingTEST NUMBER
 
 
Hypotonic Shock Response and Extent of Shape Change 
The summary results for the hypotonic shock response and the extent of shape change 
are presented in tables 4.5 and 4.6. Values for both the HSR and ESC parameters were 
similar in all four test groups on days 2 and 3. Subsequent to this, results for the three 
test groups containing albumin were unreliable, based on the pattern of the graph 
output. Figure 4.3 illustrates the difficulties encountered, with representative HSR and 
ESC results on days 2 and 10 for one of the units with 30 mL added albumin. By 
contrast, the graphs from the test group lacking albumin were judged to be acceptable, 
showing a gradual decrease in both parameters with storage. Figures 4.4 and 4.5 
compare the ESC and HSR results between the test group lacking albumin and units re-
constituted in 100% plasma. In both cases, responses steadily decline with storage. The 
graphs also clearly display lower values for both parameters in the units suspended in 
additive solution compared with units re-suspended in autologous plasma, even though 
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sample dilutions were prepared with autologous plasma in both cases. Lower values for 
these assays have been reported in PCs suspended in a medium of additive solution and 
plasma (ratios of 70:30 and 80:20) compared to PCs in 100% plasma (Gulliksson et al., 
2003, Sandgren et al., 2008) and are likely related to the performance of these assays in 
a suspending medium other than plasma, as suggested by Sandgren et al (Sandgren et 
al., 2008), possibly in combination with the harsh unit processing methodology.   
 
 
 
 
 
 
 
ESC 
ESC 
HSR 
HSR 
ALB-030-18 
Day 2 
21/01/2010 
ALB-030-18 
Day 10 
21/01/2010 
Figure 4.3: ESC and HSR outputs for ALB-030-18 on days 2 and 10 (all results in 
duplicate) illustrating the difficulties of interpreting results after day 3 in the test 
groups containing albumin. 
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Table 4.5: Hypotonic shock response in albumin study 
Hypotonic shock response (%) TEST 
NUMBER DAY 2 DAY 3 DAY 6 DAY 8 DAY 10 
ALB-000-01 44.6 45.0 31.7 29.3 30.0 
ALB-000-09 37.5 28.2 23.1 29.9 23.5 
ALB-000-17 31.4 39.2 49.2 26.7 24.8 
Mean 37.8 37.5 34.7 28.6 26.1 
ALB-030-02 37.1 49.3 NM NM NM 
ALB-030-10 32.5 28.7 NM NM NM 
ALB-030-18 38.2 32.5 NM NM NM 
Mean 35.9 36.8 N/A N/A N/A 
ALB-060-03 32.3 36.9 NM NM NM 
ALB-060-11 35.2 25.3 NM NM NM 
ALB-060-19 32.9 33.4 NM NM NM 
Mean 33.5 31.9 N/A N/A N/A 
ALB-120-04 40.3 42.0 NM NM NM 
ALB-120-12 37.1 36.0 NM NM NM 
ALB-120-20 40.8 39.6 NM NM NM 
Mean 39.4 39.2 N/A N/A N/A 
NM: Not measured (graph not accepted)   N/A: Not applicable 
 
Figure 4.4: Hypotonic shock 
response (albumin study; mean, 
n=3) 
Figure 4.5: Extent of shape change 
(albumin study; mean, n=3 except 
for day 2 in 100% plasma, where 
n=2) 
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Table 4.6: Extent of shape change in albumin study 
Extent of shape change (%) TEST 
NUMBER DAY 2 DAY 3 DAY 6 DAY 8 DAY 10 
ALB-000-01 20.7 18.0 14.1 10.7 8.2 
ALB-000-09 21.1 15.0 13.0 13.4 11.6 
ALB-000-17 19.8 18.6 13.9 11.3 8.7 
Mean 20.5 17.2 13.7 11.8 9.5 
ALB-030-02 17.5 20.0 NM NM NM 
ALB-030-10 19.0 15.2 NM NM NM 
ALB-030-18 20.0 18.7 2.3 NM NM 
Mean 18.8 18.0 N/A N/A N/A 
ALB-060-03 18.1 19.1 NM NM NM 
ALB-060-11 19.8 17.4 NM NM NM 
ALB-060-19 19.2 16.7 NM NM NM 
Mean 19.0 17.7 N/A N/A N/A 
ALB-120-04 20.0 18.1 NM NM NM 
ALB-120-12 12.8 16.3 NM NM NM 
ALB-120-20 20.5 18.9 NM NM NM 
Mean 17.8 17.8 N/A N/A N/A 
NM: Not measured (graph not accepted)   N/A: Not applicable 
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Platelet Metabolism 
pH (37°C) 
From day 2, pH(37°C) levels were markedly lower in the units containing albumin, with a 
dose-dependent effect apparent from day 2. pH(37°C) levels reached a minimum on day 6 
in the albumin-containing test groups, with mean levels of 6.730, 6.699 and 6.648 in 
groups containing 30 mL, 60 mL and 120 mL of albumin, respectively. After day 6, 
levels marginally increased (figure 4.6). Contrary to the pattern noted in the other three 
test groups, units without albumin showed a gradual decrease in pH(37°C) throughout 
storage, but due to the higher levels at the start of the storage period, levels in all three 
units in this test group remained above 6.9 on day 10 (table 4.7). A similar pattern was 
present in units re-constituted in plasma, with the exception of a modest increase at the 
beginning of the storage period. 
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Figure 4.6: pH (37°C)   
(albumin study; mean,  n=3) 
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Table 4.7: pH (37°C) in albumin study 
pH (37°C) TEST 
NUMBER DAY 2 DAY 3 DAY 6 DAY 8 DAY 10 
ALB-000-01 7.227 7.214 7.114 7.001 6.944 
ALB-000-09 7.241 7.218 7.115 7.020 6.968 
ALB-000-17 7.273 7.262 7.167 7.068 6.937 
Mean 7.247 7.231 7.132 7.030 6.950 
ALB-030-02 7.123 7.014 6.705 6.763 6.779 
ALB-030-10 7.078 6.921 6.734 6.777 6.792 
ALB-030-18 7.079 6.895 6.752 6.788 6.799 
Mean 7.093 6.943 6.730 6.776 6.790 
ALB-060-03 7.036 6.884 6.693 6.729 6.743 
ALB-060-11 7.002 6.828 6.686 6.721 6.731 
ALB-060-19 6.998 6.797 6.717 6.744 6.752 
Mean 7.012 6.836 6.699 6.731 6.742 
ALB-120-04 6.968 6.801 6.609 6.632 6.641 
ALB-120-12 6.927 6.719 6.623 6.648 6.655 
ALB-120-20 6.877 6.657 6.713 6.736 6.740 
Mean 6.924 6.726 6.648 6.672 6.679 
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Glucose and Lactate 
The glucose levels decreased in the units containing albumin, with all the exogenous 
glucose consumed by day 6 in all three groups. The decrease was more gradual in the 
units without added albumin, with all glucose depleted by day 10 (figure 4.7). The 
concentration of glucose added was 15 mmol/L and the fall in glucose, in the absence of 
albumin, was similar to that seen in other experiments where glucose was also depleted 
at day 10 (figure 5.6). The pattern was mirrored by lactate concentrations, with levels 
reaching a plateau in test groups containing albumin at approximately 24 mmol/L on 
day 6, coincident with the depletion of glucose (figure 4.8). Lactate levels in units 
lacking albumin continued to increase throughout storage, to a mean level of 19 mmol/L 
on day 10 (table 4.9). 
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Figure 4.7: Glucose levels  
(albumin study; mean, n=3) 
 
Figure 4.8: Lactate levels  
(albumin study; mean, n=3) 
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Table 4.8: Glucose levels in albumin study 
Glucose concentration (mmol/L) TEST 
NUMBER DAY 2 DAY 3 DAY 6 DAY 8 DAY 10 
ALB-000-01 8.9 8.6 5.3 2.3 0.0 
ALB-000-09 9.4 8.7 4.9 2.1 0.0 
ALB-000-17 12.3 11.4 7.5 4.3 0.8 
Mean 10.2 9.6 5.9 2.9 0.3 
ALB-030-02 10.7 8.2 0.0 0.0 0.0 
ALB-030-10 10.5 6.4 0.0 0.0 0.0 
ALB-030-18 9.8 5.7 0.0 0.0 0.0 
Mean 10.3 6.8 0.0 0.0 0.0 
ALB-060-03 9.7 6.3 0.0 0.0 0.0 
ALB-060-11 9.8 5.4 0.0 0.0 0.0 
ALB-060-19 9.3 4.5 0.0 0.0 0.0 
Mean 9.6 5.4 0.0 0.0 0.0 
ALB-120-04 9.2 5.9 0.0 0.0 0.0 
ALB-120-12 9.6 4.3 0.0 0.0 0.0 
ALB-120-20 6.4 1.4 0.0 0.0 0.0 
Mean 8.4 3.9 0.0 0.0 0.0 
 
Table 4.9: Lactate levels in albumin study  
Lactate concentration (mmol/L) TEST 
NUMBER DAY 2 DAY 3 DAY 6 DAY 8 DAY 10 
ALB-000-01 1.8 3.5 10.0 15 19 
ALB-000-09 2.3 4.0 10.2 16 20 
ALB-000-17 2.0 3.9 10.7 15 19 
Mean 2.0 3.8 10.3 15 19 
ALB-030-02 4.8 10.3 26 26 25 
ALB-030-10 6.1 12.8 25 25 26 
ALB-030-18 6.2 14.1 22 22 21 
Mean 5.7 12.4 24 24 24 
ALB-060-03 6.9 14.4 26 26 25 
ALB-060-11 7.8 16 25 26 26 
ALB-060-19 8.0 17 22 22 21 
Mean 7.6 15.8 24 25 24 
ALB-120-04 7.5 17 27 26 26 
ALB-120-12 8.9 18 25 26 27 
ALB-120-20 9.3 18 19 19 19 
Mean 8.6 18 24 24 24 
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Glucose consumption initially increased in the test group lacking albumin from a mean 
rate of 0.69 mmol/L/day/1012plts between days 2 and 3 to 1.65 mmol/L/day/1012plts 
between days 6 and 8. Beyond day 8, a slight decrease was observed to a mean rate of 
1.51 mmol/L/day/1012plts (table 4.10). This pattern was replicated in the lactate 
production rates for the same units, with a maximum mean rate of 2.76 
mmol/L/day/1012plts between days 6 to 8, and was similar to the rates in plasma-
reconstituted units (figures 4.9 and 4.10). In the test groups containing albumin, initial 
rates of glucose consumption and lactate production were markedly higher than in the 
units lacking albumin, with mean rates between days 2 and 3 in units with 30 ml added 
albumin of 3.94 mmol/L/day/1012plts and 7.45 mmol/L/day/1012plts, respectively. Rates 
sharply declined as the stores of exogenous glucose were consumed, with no further 
lactate production beyond day 6 coincident with the depletion of glucose stores. 
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Figure 4.9: Glucose consumption 
(albumin study; mean, n=3) 
 
Figure 4.10: Lactate production 
(albumin study; mean, n=3) 
 
131 
 
Table 4.10: Glucose consumption in albumin study      
Glucose consumption (mmol/L/day/1012plts) 
TEST NUMBER 
DAY 2-3 DAY 3-6 DAY 6-8 DAY 8-10 
ALB-000-01 0.35 1.23 1.68 1.34 
ALB-000-09 0.74 1.33 1.48 1.17 
ALB-000-17 0.98 1.45 1.79 2.01 
Mean 0.69 1.34 1.65 1.51 
ALB-030-02 3.04 3.36 0.00 0.00 
ALB-030-10 4.32 2.45 0.00 0.00 
ALB-030-18 4.46 2.32 0.00 0.00 
Mean 3.94 2.71 0.00 0.00 
ALB-060-03 3.97 2.82 0.00 0.00 
ALB-060-11 4.64 2.35 0.00 0.00 
ALB-060-19 5.21 2.23 0.00 0.00 
Mean 4.61 2.47 0.00 0.00 
ALB-120-04 4.06 3.30 0.00 0.00 
ALB-120-12 5.44 2.15 0.00 0.00 
ALB-120-20 5.41 0.80 0.00 0.00 
Mean 4.97 2.08 0.00 0.00 
 
Table 4.11: Lactate production in albumin study  
Lactate production (mmol/L/day/1012plts) 
TEST NUMBER 
DAY 2-3 DAY 3-6 DAY 6-8 DAY 8-10 
ALB-000-01 2.00 2.42 2.80 2.33 
ALB-000-09 1.79 2.17 3.07 2.23 
ALB-000-17 2.07 2.52 2.40 2.30 
Mean 1.95 2.37 2.76 2.29 
ALB-030-02 6.68 6.43 0.00 -0.96 
ALB-030-10 7.05 4.66 0.00 1.09 
ALB-030-18 8.60 3.22 0.00 -1.28 
Mean 7.45 4.77 0.00 -0.38 
ALB-060-03 8.76 5.19 0.00 -1.59 
ALB-060-11 8.65 3.92 1.14 0.00 
ALB-060-19 9.77 2.48 0.00 -2.36 
Mean 9.06 3.87 0.38 -1.32 
ALB-120-04 11.68 5.59 -1.74 0.00 
ALB-120-12 9.34 3.50 1.73 2.39 
ALB-120-20 9.42 0.57 0.00 0.00 
Mean 10.15 3.22 0.00 0.80 
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Bicarbonate 
The concentration of bicarbonate mirrored the pattern observed with glucose, with 
levels decreasing more rapidly in units with added albumin until day 6 (figure 4.11). By 
contrast, bicarbonate levels steadily decreased in units without added albumin from a 
similar mean concentration on day 1 of 14.05 mmol/L to 5.13 mmol/L by day 10 (table 
4.12). 
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Table 4.12: Bicarbonate levels (37°C) in albumin study  
Bicarbonate concentration (mmol/L) TEST 
NUMBER DAY 2 DAY 3 DAY 6 DAY 8 DAY 10 
ALB-000-01 11.99 12.04 9.24 6.56 4.95 
ALB-000-09 13.58 12.78 9.74 7.13 5.14 
ALB-000-17 16.56 15.26 11.22 8.32 5.29 
Mean 14.05 13.36 10.07 7.33 5.13 
ALB-030-02 14.95 12.07 3.01 1.29 1.16 
ALB-030-10 15.13 11.10 2.17 1.25 0.75 
ALB-030-18 14.80 10.28 1.90 0.88 0.56 
Mean 14.96 11.15 2.36 1.14 0.82 
ALB-060-03 14.92 10.61 1.97 1.13 0.91 
ALB-060-11 14.59 9.94 1.78 0.92 0.65 
ALB-060-19 14.90 9.46 1.45 0.75 0.48 
Mean 14.80 10.00 1.73 0.93 0.68 
ALB-120-04 14.09 9.54 1.40 0.87 1.08 
ALB-120-12 15.19 8.92 1.53 0.82 0.79 
ALB-120-20 11.80 6.46 1.27 0.78 0.53 
Mean 13.69 8.31 1.40 0.82 0.80 
 
 
Figure 4.11: Bicarbonate levels 
(37°C) 
 (albumin study; mean, n=3) 
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Blood Gases 
The partial pressures of oxygen and carbon dioxide in the albumin-containing test 
groups showed markedly different patterns over the ten days of storage compared with 
non-albumin units (figures 4.12 and 4.13). pO2(37°C) levels were higher in all three 
albumin-containing test groups throughout the storage period with a suggestion of a 
dose-dependent effect on days 2 and 3, with mean pO2(37°C) of 21.1 kPa in units with 120 
mL albumin compared with 18.6 kPa in units with 30 ml added albumin. By day 6, 
levels plateau at maximum mean values of approximately 24-25 kPa, suggesting an 
equilibration of pO2 with atmospheric partial pressure of oxygen. In non-albumin units, 
pO2(37°C) levels increased steadily after day 3 (mean pO2(37°C) of 13.7 kPa), reaching a 
mean value on day 10 of 17.3 kPa (table 4.13). pCO2(37°C) levels were also higher at the 
start of storage in albumin-containing units, with a similar suggestion of a dose-
dependent effect. However, between days 3 and 6, levels steeply declined, with mean 
values below 1 kPa by day 8 in all three test groups with added albumin (figure 4.13). 
By contrast, pCO2(37°C) levels in non-albumin-containing units decreased gradually from 
mean values of 3.91 kPa on day 2 to 2.84 kPa by day 10 (table 4.14). 
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Figure 4.12: pO2 levels (37°C) 
 (albumin study; mean, n=3) 
 
Figure 4.13: pCO2 levels (37°C) 
(albumin study; mean, n=3) 
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Table 4.13: Partial pressure of oxygen in albumin study 
pO2 (37°C) (kPa) TEST 
NUMBER DAY 2 DAY 3 DAY 6 DAY 8 DAY 10 
ALB-000-01 14.6 14.2 15.3 16.0 17.6 
ALB-000-09 13.0 13.0 14.8 16.2 16.8 
ALB-000-17 13.6 13.8 15.7 17.3 17.6 
Mean 13.7 13.7 15.3 16.5 17.3 
ALB-030-02 16.9 18.7 22.8 24.2 24.6 
ALB-030-10 18.1 20.4 24.5 24.9 24.8 
ALB-030-18 20.8 21.7 24.8 25.3 24.2 
Mean 18.6 20.3 24.0 24.8 24.5 
ALB-060-03 18.8 20.7 24.3 24.7 24.9 
ALB-060-11 19.7 21.6 24.8 25.0 24.8 
ALB-060-19 22.0 22.7 25.2 25.2 24.5 
Mean 20.2 21.7 24.8 25.0 24.7 
ALB-120-04 20.2 21.8 24.2 24.7 24.7 
ALB-120-12 21.0 22.6 24.7 24.8 24.7 
ALB-120-20 22.0 22.8 25.0 25.2 24.2 
Mean 21.1 22.4 24.6 24.9 24.5 
 
 
Table 4.14: Partial pressure of carbon dioxide in albumin study 
pCO2 (37°C) (kPa) TEST 
NUMBER DAY 2 DAY 3 DAY 6 DAY 8 DAY 10 
ALB-000-01 3.51 3.63 3.51 3.23 2.78 
ALB-000-09 3.85 3.82 3.69 3.36 2.73 
ALB-000-17 4.36 4.12 3.77 3.51 3.02 
Mean 3.91 3.86 3.66 3.37 2.84 
ALB-030-02 5.56 5.77 2.93 1.10 0.95 
ALB-030-10 6.24 6.57 1.98 1.03 0.60 
ALB-030-18 6.09 6.46 1.66 0.71 0.44 
Mean 5.96 6.27 2.19 0.95 0.66 
ALB-060-03 6.78 6.84 1.97 1.04 0.81 
ALB-060-11 7.17 7.29 1.81 0.86 0.60 
ALB-060-19 7.39 7.45 1.37 0.67 0.42 
Mean 7.11 7.19 1.72 0.86 0.61 
ALB-120-04 7.49 7.45 1.70 1.00 1.22 
ALB-120-12 8.87 8.41 1.80 0.91 0.86 
ALB-120-20 7.73 7.02 1.21 0.71 0.48 
Mean 8.03 7.63 1.57 0.87 0.85 
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Oxygen consumption rates were relatively stable in the test group lacking albumin, with 
mean values of 0.17 nmol/min/109plts on day 10 compared with 0.23 nmol/min/109plts 
on day 2, with a similar pattern observed from units re-constituted in plasma (figure 
4.14). Rates were lower throughout the storage period in units containing albumin, with 
mean values on day 2 ranging between 0.08 nmol/min/109plts in units with 120 mL 
albumin to 0.13 nmol/min/109plts in units with 30 ml albumin (table 4.15). Oxygen 
consumption had essentially ceased in units containing albumin after day 6 of storage 
(figure 4.14).  
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Table 4.15: Oxygen consumption rate in albumin study (22°C) 
Oxygen consumption rate (nmol/min/109plts) 
TEST NUMBER 
DAY 2 DAY 3 DAY 6 DAY 8 DAY 10 
ALB-000-01 0.24 0.22 0.20 0.19 0.16 
ALB-000-09 0.23 0.23 0.20 0.17 0.18 
ALB-000-17 0.22 0.23 0.19 0.16 0.16 
Mean 0.23 0.23 0.20 0.17 0.17 
ALB-030-02 0.18 0.14 0.05 0.02 0.01 
ALB-030-10 0.13 0.09 0.01 0.00 0.00 
ALB-030-18 0.08 0.06 0.00 -0.02 0.05 
Mean 0.13 0.10 0.02 0.00 0.02 
ALB-060-03 0.14 0.09 0.02 0.01 0.00 
ALB-060-11 0.10 0.06 0.00 -0.01 0.00 
ALB-060-19 0.06 0.04 -0.01 -0.02 0.04 
Mean 0.10 0.07 0.00 -0.01 0.01 
ALB-120-04 0.11 0.07 0.04 0.02 0.01 
ALB-120-12 0.08 0.04 0.01 0.01 0.02 
ALB-120-20 0.05 0.04 -0.01 -0.04 0.15# 
Mean 0.08 0.05 0.01 -0.01 0.06 
#: Outlier value related to low platelet concentration 
 
Figure 4.14: Oxygen consumption 
rates (22°C) in albumin study (mean, 
n=3) 
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ATP and ADP Levels 
ATP levels moderately declined with storage in units lacking albumin, decreasing from 
mean levels of 5.56 µmol/1011plts on day 2 to 3.44 µmol/1011plts by the end of storage, 
corresponding to 62% of day 2 levels. A similar gradual decrease in ATP was noted 
from days 2 to 3 in the albumin test groups, with all units maintaining ATP levels above 
4 µmol/1011plts. Beyond this time point, ATP levels decreased steeply in all test groups 
containing albumin (figure 4.15). By day 6, mean ATP levels were 1.05, 0.49 and 0.43 
µmol/1011plts in units with 30 mL, 60 mL and 120 mL added albumin, respectively, and 
continued to decline to corresponding mean values at end of storage of 0.30, 0.16 and 
0.19 µmol/1011plts (table 4.16).  
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Figure 4.15: ATP levels 
 (albumin study; mean, n=3) 
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Table 4.16: Adenosine triphosphate levels in albumin study 
ATP (µmol/1011plts) TEST 
NUMBER DAY 2 DAY 3 DAY 6 DAY 8 DAY 10 
ALB-000-01 5.67 4.84 4.92 4.23 3.62 
ALB-000-09 6.49 4.88 6.20 4.62 3.09 
ALB-000-17 4.51 4.26 3.64 3.73 3.59 
Mean 5.56 4.66 4.92 4.19 3.43 
ALB-030-02 5.37 4.87 1.56 0.52 0.40 
ALB-030-10 5.87 5.26 0.94 0.40 0.28 
ALB-030-18 5.00 4.89 0.65 0.34 0.22 
Mean 5.41 5.01 1.05 0.42 0.30 
ALB-060-03 5.66 4.53 0.55 0.28 0.19 
ALB-060-11 5.88 5.05 0.54 0.27 0.21 
ALB-060-19 4.42 4.51 0.37 0.25 0.10 
Mean 5.32 4.70 0.49 0.26 0.16 
ALB-120-04 5.33 5.07 0.55 0.25 0.19 
ALB-120-12 5.91 5.01 0.45 0.28 0.21 
ALB-120-20 5.01 5.30 0.28 0.20 0.17 
Mean 5.42 5.13 0.43 0.24 0.19 
 
 
ADP levels decreased with storage in all test groups, with similar day 2 levels ranging 
from mean levels of 3.40 µmol/1011plts in units with no albumin to 4.13 µmol/1011plts 
in units with 30 ml albumin (table 4.17). In the test groups with added albumin, mean 
levels had decreased by day 10 to 0.40, 0.41 and 0.52 µmol/1011plts in units with 120 
mL, 60 mL and 30 mL albumin, respectively; equating to approximately 11.5% of 
levels on day 2. Although ADP levels also decreased with storage in units lacking 
albumin, levels remained at 49% of day 2 levels by end of storage (mean of 1.66 
µmol/1011plts) (figure 4.16).  
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Table 4.17: Adenosine diphosphate levels in albumin study 
ADP (µmol/1011plts) TEST 
NUMBER DAY 2 DAY 3 DAY 6 DAY 8 DAY 10 
ALB-000-01 3.31 1.91 2.09 1.99 1.79 
ALB-000-09 3.04 3.35 2.78 1.06 2.18 
ALB-000-17 3.84 3.32 1.65 1.59 1.01 
Mean 3.40 2.86 2.17 1.54 1.66 
ALB-030-02 3.54 3.43 2.00 1.01 0.59 
ALB-030-10 4.45 3.05 1.68 0.75 0.64 
ALB-030-18 4.41 10.07* 1.32 0.59 0.34 
Mean 4.13 3.24# 1.67 0.78 0.52 
ALB-060-03 2.90 2.13 1.31 0.76 0.52 
ALB-060-11 3.96 3.72 0.89 0.51 0.45 
ALB-060-19 4.81 3.42 0.58 0.33 0.26 
Mean 3.89 3.09 0.92 0.53 0.41 
ALB-120-04 2.81 3.77 1.17 0.59 0.45 
ALB-120-12 4.07 4.55 0.83 0.51 0.40 
ALB-120-20 14.86* 11.57* 0.67 0.38 0.35 
Mean 3.44# 4.16# 0.89 0.49 0.40 
*: Results considered outliers and not used in mean calculation or graph 
#: Mean n=2 
 
 
Figure 4.16: ADP levels  
(albumin study; mean, n=3; except 
for ALB-030-nn day 3; ALB-120-nn 
days 2 and 3 where n=2) 
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Platelet Activation 
Surface Expression and Soluble Levels of CD62P  
The percentage of platelets expressing CD62P on day 2 ranged from mean levels of 
76.81% in the test group with no albumin to 84.13% in units with 30 mL albumin. 
Percent positive expression remained relatively stable in the test group with no albumin, 
increasing marginally to a mean value of 85.49% at end of storage (table 4.18). In units 
containing albumin, the suggestion of a dose-dependent response during the early 
storage period was evident from day 6 (figure 4.17). Mean values on day 6 in these 
three test groups were 92.65, 89.77 and 78.12% in units with 30 mL, 60 mL and 120 
mL added albumin, respectively. CD62P expression decreased from this time point in 
all three groups in a dose-dependent pattern, resulting in mean day 10 values of 81.52, 
62.01 and 48.70% in units with 30 mL, 60 mL and 120 mL albumin, respectively.  
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Figure 4.17: Percent positive 
expression of CD62P  
(albumin study; mean, n=3) 
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Table 4.18: Surface expression of CD62P in albumin study (percent positive 
expression) 
Surface CD62P expression (% positive) TEST 
NUMBER DAY 2 DAY 3 DAY 6 DAY 8 DAY 10 
ALB-000-01 77.95 82.96 85.36 85.23 87.22 
ALB-000-09 73.27 80.08 82.77 83.12 84.98 
ALB-000-17 79.22 83.89 85.93 83.46 84.27 
Mean 76.81 82.31 84.69 83.94 85.49 
ALB-030-02 85.06 89.08 92.73 94.60 86.71 
ALB-030-10 83.17 87.05 94.07 90.25 83.62 
ALB-030-18 84.16 85.39 91.16 85.20 74.22 
Mean 84.13 87.17 92.65 90.02 81.52 
ALB-060-03 84.89 88.18 92.14 82.94 66.74 
ALB-060-11 82.56 85.19 90.35 75.48 63.70 
ALB-060-19 84.24 85.87 86.83 62.78 55.58 
Mean 83.90 86.41 89.77 73.73 62.01 
ALB-120-04 82.19 83.28 82.19 78.23 46.41 
ALB-120-12 79.10 81.73 75.93 53.28 39.30 
ALB-120-20 78.72 79.06 76.23 43.68 60.38 
Mean 80.00 80.36 78.12 58.40 48.70 
 
 
Surface CD62P expression reported as the median fluorescence intensity increased 
initially in units lacking albumin up to day 6 (mean MFI of 3.70) before showing a 
slight decrease during the remainder of the storage period, resulting in a mean value on 
day 10 of 3.37 (table 4.19). In units with 120 mL albumin, MFI decreased progressively 
with storage from a mean value on day 2 to of 2.24 to a mean day 10 value of 1.44. 
Units with 30 mL and 60 mL albumin showed a mean increase in MFI values between 
days 2 to 3 which subsequently decreased to values similar to units with 120 mL 
albumin by day 10 of storage (figure 4.18).  
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Table 4.19: Surface expression of CD62P in albumin study (median fluorescence 
intensity) 
Surface CD62P expression (median fluorescence intensity) TEST 
NUMBER DAY 2 DAY 3 DAY 6 DAY 8 DAY 10 
ALB-000-01 2.38 3.21 4.02 4.02 3.64 
ALB-000-09 2.12 2.73 3.64 3.54 3.36 
ALB-000-17 2.07 2.75 3.45 3.24 3.12 
Mean 2.19 2.90 3.70 3.60 3.37 
ALB-030-02 2.91 3.61 2.96 2.71 1.92 
ALB-030-10 2.61 3.12 2.66 2.03 1.49 
ALB-030-18 2.45 2.80 2.08 1.58 1.25 
Mean 2.66 3.18 2.57 2.11 1.55 
ALB-060-03 3.10 3.27 2.38 1.84 1.49 
ALB-060-11 2.56 2.75 1.94 1.69 1.68 
ALB-060-19 2.49 2.47 1.71 1.40 1.11 
Mean 2.72 2.83 2.01 1.64 1.43 
ALB-120-04 2.52 2.34 1.94 1.52 1.43 
ALB-120-12 2.20 2.05 2.07 2.01 1.90 
ALB-120-20 2.01 1.82 1.56 1.73 1.00 
Mean 2.24 2.07 1.86 1.75 1.44 
 
 
Figure 4.18: Median 
fluorescence intensity of CD62P  
(albumin study; mean, n=3) 
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Soluble CD62P levels on day 2 were similar in all four test groups, with mean levels 
ranging from 35.94 ng/mL in units with no added albumin to 37.67 ng/mL in units with 
30 mL albumin (table 4.20). Levels increased in all test groups after day 3, though the 
rate of increase was higher in the albumin-containing units. By day 10, mean values in 
units lacking added albumin were 101.83 ng/mL, compared to 210.92 ng/mL and 
200.80 ng/mL in units with 30 mL and 60 mL albumin, respectively. Units with the 
highest concentration of albumin showed a more modest increase to a mean day 10 level 
of 162.18 ng/mL. The dose-dependent pattern of surface CD62P expression most 
clearly illustrated by the percent positive expression was not as evident with the soluble 
marker.  
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Figure 4.19: Soluble CD62P 
levels (albumin study; mean, 
n=3) 
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Table 4.20: Soluble CD62P levels in albumin study 
Soluble CD62P levels (ng/mL) TEST 
NUMBER DAY 2 DAY 3 DAY 6 DAY 8 DAY 10 
ALB-000-01 35.40 38.75 76.95 86.55 101.45 
ALB-000-09 28.55 35.91 60.58 77.10 99.95 
ALB-000-17 43.87 52.76 80.78 96.69 104.10 
Mean 35.94 42.47 72.77 86.78 101.83 
ALB-030-02 43.10 57.61 86.55 134.82 212.71 
ALB-030-10 28.12 40.53 101.59 179.46 219.88 
ALB-030-18 41.79 50.75 112.04 182.46 200.18 
Mean 37.67 49.63 100.06 165.58 210.92 
ALB-060-03 42.36 49.02 110.39 184.40 227.13 
ALB-060-11 30.43 42.69 121.73 178.42 185.87 
ALB-060-19 38.98 45.91 148.20 176.87 189.38 
Mean 37.26 45.87 126.77 179.90 200.80 
ALB-120-04 37.98 45.85 99.09 133.87 153.73 
ALB-120-12 32.45 39.37 123.08 158.53 172.20 
ALB-120-20 37.82 43.87 136.09 164.84 160.62 
Mean 36.08 43.03 119.42 152.41 162.18 
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Indicators of Cell Death 
Annexin V Binding 
The percentage of platelets binding annexin V in all four test groups was similar at the 
start of storage, with mean values on days 2 and 3 of approximately 11 to 12%. After 
day 3, there was a significant increase in the percentage positive expression in all three 
albumin-containing groups, with levels exceeding 90% by day 6 in units with 60 mL 
and 120 mL added albumin (figures 4.20 and 4.21). By contrast, the test group with no 
added albumin showed only a modest increase in the percent positive expression by day 
8 (mean value 17.04%), after which there was a moderately enhanced increase to a 
mean level of 30.5% by the end of storage (table 4.21).  
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Figure 4.20: Annexin V binding 
expressed as percentage positive 
expression (albumin study; mean, 
n=3) 
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Figure 4.21: Annexin V binding expressed as percentage positive expression (albumin study; 
representative sample with 60 mL added albumin), illustrating the marked increase in the 
percentage of platelets expressing aminophospholipids on their surface by day 6 in units with 
added albumin 
 
Table 4.21: Annexin V binding in albumin study (percent positive expression) 
Annexin V binding (% positive expression) TEST 
NUMBER DAY 2 DAY 3 DAY 6 DAY 8 DAY 10 
ALB-000-01 7.50 8.11 11.02 11.73 30.20 
ALB-000-09 7.60 7.94 12.65 16.04 35.23 
ALB-000-17 19.48 19.93 21.91 23.35 26.12 
Mean 11.53 11.99 15.19 17.04 30.52 
ALB-030-02 7.30 9.36 63.54 92.48 94.14 
ALB-030-10 9.10 10.11 90.10 93.86 98.09 
ALB-030-18 18.62 16.96 89.31 95.38 98.34 
Mean 11.67 12.14 80.98 93.91 96.86 
ALB-060-03 8.44 7.45 93.50 94.84 96.88 
ALB-060-11 8.80 11.45 94.32 96.19 98.13 
ALB-060-19 17.61 15.54 93.82 94.09 98.54 
Mean 11.62 11.48 93.88 95.04 97.85 
ALB-120-04 8.30 7.22 92.04 96.51 96.57 
ALB-120-12 13.04 15.79 92.72 95.88 97.36 
ALB-120-20 16.16 15.21 94.54 95.82 98.07 
Mean 12.50 12.74 93.10 96.07 97.33 
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Annexin V binding expressed as the mean fluorescence intensity did not result in the 
marked differences between the albumin and non-albumin-containing test groups 
described above for the percent positive expression, though the test group lacking added 
albumin showed a generally lower MFI and a more stable pattern throughout storage 
(figure 4.22). Mean MFI expression increased modestly in these units from 35.6 on day 
2 to 41.7 by end of storage. The test groups containing albumin showed an increase in 
MFI from days 2 to 6, beyond which MFI stabilised or moderately decreased. Units 
with 120 mL added albumin displayed the most marked increase in MFI, with a mean 
value of 29.2 on day 3 increasing to a maximum of 60.8 by day 6 before decreasing to a 
mean of 55.0 by end of storage.  
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Figure 4.22: Annexin V binding 
expressed as mean fluorescence 
intensity (albumin study; mean, n=3) 
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Table 4.22: Annexin V binding in albumin study (mean fluorescence intensity) 
Annexin V binding (mean fluorescence intensity) 
TEST NUMBER 
DAY 2 DAY 3 DAY 6 DAY 8 DAY 10 
ALB-000-01 38.6 33.3 45.0 39.4 44.2 
ALB-000-09 32.8 36.4 38.9 41.5 42.1 
ALB-000-17 35.5 37.9 39.5 39.1 38.9 
Mean 35.6 35.9 41.1 40.0 41.7 
ALB-030-02 36.2 34.3 57.5 45.2 43.2 
ALB-030-10 36.2 38.2 52.8 46.6 49.5 
ALB-030-18 31.0 36.9 48.2 42.5 40.2 
Mean 34.5 36.5 52.8 44.8 44.3 
ALB-060-03 37.6 38.1 48.9 44.5 43.9 
ALB-060-11 34.7 35.3 48.2 54.1 59.5 
ALB-060-19 30.3 37.4 51.6 36.0 41.9 
Mean 34.2 36.9 49.6 44.9 48.4 
ALB-120-04 28.4 31.2 56.3 58.5 46.5 
ALB-120-12 26.6 30.4 61.1 69.0 62.9 
ALB-120-20 32.7 37.5 64.9 58.3 55.5 
Mean 29.2 33.0 60.8 61.9 55.0 
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Figure 4.23 illustrates the four species of PE-esterified 12S-HETEs detected by the mass 
spectrometric assay. The assay identifies PE- or PS-esterified 12S-HETEs that normally 
remain associated with the plasma membrane, with the various forms identified by the 
mass/charge ratio of characteristic daughter ions.  
 
Figure 4.23: Four PE-esterified isoforms of 12S-HETE. (Biotinylation of the sample adds 226.3 
amu to the mass.Ionisation for mass spectrometric measurements reduces the amu by 1 due to 
the loss of a hydrogen ion. In addition,the values for the isoforms presented in the graphs 
represent the un-oxidised substrate lipid. This accounts for the molecular weight differences 
quoted above and the values presented on the graphs) (O'Donnell and Murphy, 2012). 
 
Figure 4.24 shows the concentrations of the four phosphatidylethanolamine and one 
phosphatidylserine aminophospholipids known to be expressed on the surface of 
platelets following activation. Results for the biotinylated samples of one representative 
experiment are reported as the ratio of analyte to an internal standard. On days 2 and 3, 
the expression of the four PE phospholipids remained relatively low in all four test 
groups. Between days 3 and 6, the expression of PE in the three albumin-containing 
units increased markedly and generally remained at this elevated level for the remainder 
of the storage period. In contrast, the relatively low levels of expressed PE in the unit 
lacking albumin were retained throughout the ten days of storage, reflecting the 
relatively low percent positive results obtained with the annexin V binding assay. With 
PS, the pattern suggests a progressive increase in concentration with storage. Although 
the levels of PS in the unit lacking albumin remained below those of the albumin-
containing units after day 3, levels of PS continued to increase with storage in this unit 
as well.  
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Mitochondrial Membrane Potential 
Day 2 levels of mitochondrial membrane potential were similar for all four test groups, 
with mean red/green fluorescence ratios of 8.5 to 9.0 and a decrease evident in all four 
groups from day 2. The rate of decline was markedly increased with the addition of 
albumin - all three of these test groups attaining a minimal ratio of 2.7 by day 6 
(considered as the limit of the assay). A mean ratio of 3.3 was noted in the non-albumin 
containing test group by end of storage (table 4.23). This decrease in potential with 
storage, suggested by the decrease in the fluorescence ratio, was not evident with the 
Figure 4.24: Expression of 
aminophospholipids on platelet surface 
(albumin study; representative experiment) 
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units re-constituted in plasma, which showed a relatively minor decrease in the ratio 
with storage (figure 4.25).  
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Table 4.23: Mitochondrial membrane potential in albumin study 
MMP (median red/green JC-1 fluorescence) TEST 
NUMBER DAY 2 DAY 3 DAY 6 DAY 8 DAY 10 
ALB-000-01 9.1 8.9 7.6 6.6 3.1 
ALB-000-09 9.2 8.5 7.6 6.3 3.2 
ALB-000-17 7.9 7.6 5.9 3.9 3.7 
Mean 8.7 8.3 7.0 5.6 3.3 
ALB-030-02 9.1 7.9 2.8 2.7 2.7 
ALB-030-10 9.3 8.8 2.7 2.7 2.7 
ALB-030-18 8.7 7.4 2.7 2.7 2.7 
Mean 9.0 8.1 2.7 2.7 2.7 
ALB-060-03 9.1 8.5 2.7 2.7 2.7 
ALB-060-11 9.3 8.4 2.7 2.7 2.7 
ALB-060-19 7.8 7.6 2.7 2.7 2.7 
Mean 8.7 8.1 2.7 2.7 2.7 
ALB-120-04 9.3 8.0 2.7 2.8 2.7 
ALB-120-12 8.3 7.3 2.7 2.7 2.7 
ALB-120-20 7.8 6.7 2.7 2.7 2.7 
Mean 8.5 7.3 2.7 2.7 2.7 
 
 
 
Figure 4.25: Mitochondrial 
membrane potential expressed as 
fluorescence of red/green 
fluorescence with JC-1 (albumin 
study; mean, n=3) 
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Intracellular free calcium 
Levels of intracellular free calcium were minimal in all four test groups on days 2 and 3, 
with mean Fluo-4/FuraRed ratios of 0.23 to 0.27 in units with 120 mL and 30 mL 
albumin, respectively. (By comparison, mean ratios in control samples prepared with 
the calcium ionophore A23187 were 9.60 and 10.47 in the same test groups). Ratios in 
units without added albumin remained low throughout storage, increasing marginally 
between days 8 and 10 to a mean of 0.39 and mirroring the results obtained with units 
re-constituted in plasma (figure 4.26). In units with added albumin, ratios increased 
after day 3 in a dose-dependent manner, with the highest concentration of albumin 
resulting in the highest levels of free calcium. Mean ratios in units with 120 mL 
albumin reached a maximum on day 8 of 8.75, before decreasing to 6.40 on day 10. 
Units with 60 ml albumin followed a similar pattern, attaining a lower mean ratio of 
6.60 on day 8. Units with 30 mL albumin attained a maximum mean ratio of 5.65 on 
day 10 (table 4.24).  
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Figure 4.26: Intracellular free calcium 
expressed as fluorescence of fluo-4/ 
FuraRed fluorescence  
(albumin study; mean, n=3) 
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Table 4.24: Intracellular free calcium in albumin study 
Intracellular free calcium (Fluo-4/FuraRed) TEST 
NUMBER DAY 2 DAY 3 DAY 6 DAY 8 DAY 10 
ALB-000-01 0.19 0.23 0.20 0.20 0.29 
ALB-000-09 0.32 0.28 0.29 0.31 0.49 
ALB-000-17 0.27 0.28 0.27 0.27 0.40 
Mean 0.26 0.26 0.25 0.26 0.39 
ALB-030-02 0.22 0.23 0.68 3.80 4.20 
ALB-030-10 0.33 0.29 2.09 5.86 7.78 
ALB-030-18 0.27 0.28 2.72 5.63 4.98 
Mean 0.27 0.27 1.83 5.10 5.65 
ALB-060-03 0.23 0.22 3.30 7.40 4.40 
ALB-060-11 0.28 0.29 4.44 6.70 7.55 
ALB-060-19 0.24 0.30 4.95 5.71 6.05 
Mean 0.25 0.27 4.23 6.60 6.00 
ALB-120-04 0.20 0.21 5.10 6.20 5.30 
ALB-120-12 0.29 0.36 6.30 7.76 7.60 
ALB-120-20 0.21 0.26 5.93 12.30 6.31 
Mean 0.23 0.28 5.78 8.75 6.40 
 
 
DISCUSSION  
The study investigated the impact on platelet in vitro characteristics of adding 
exogenous albumin to an artificial storage medium, with the inclusion of albumin 
expected to confer a beneficial effect on platelet viability over the course of the ten-day 
storage period. The hypothesis was not upheld by the results, with the presence of 
albumin in the storage medium having a detrimental effect on all the parameters 
measured. Early indications were evident in the measures for metabolism. Relatively 
high pCO2 levels in albumin-containing units were already evident on day 2, suggestive 
of a burst of oxidative metabolism during this early time period which may already have 
been declining before this first measurement, since the oxygen partial pressure was 
found to be significantly higher than in non-albumin containing units by day 2. Rapid 
rates of glucose consumption between days 2 and 3 culminated in the depletion of 
glucose stores in all albumin-containing units by day 6. This coincided with a 
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precipitous decline in ATP levels in albumin-containing units between days 3 and 6. 
Between days 3 and 6 there was a marked fall in platelet viability in the study groups 
containing albumin which was consistently reproduced by all the parameters tested. 
Annexin V binding and intracellular calcium levels did not increase in any of the test 
groups until after day 3, with calcium levels responding more directly to the varying 
concentrations of albumin in the suspending media. Mitochondrial membrane potential 
was already declining at the beginning of the storage period. The gradual decline in 
MMP in the non-albumin test group contrasted with the relatively static nature of 
annexin V binding and calcium levels in the same units and suggests that changes in 
MMP pre-empt the increase in intracellular calcium and phospholipid changes related to 
apoptosis and may not be related to the latter. A suggestion of a concentration-
dependent phenomenon was provided by certain of the parameters; in particular pH, 
platelet concentration, surface CD62P expression, annexin V binding and intracellular 
calcium levels, although statistical comparison was not performed due to insufficient 
replicates.  
 
The addition of human albumin to the additive solution resulted in a clear degradation 
of platelet viability in excess of changes associated with the platelet storage lesion in 
more conventional media. The human albumin solution used was a 20% solution of 
commercially available human albumin (Zenalb®20, Bio Products Laboratory, Elstree, 
UK). This product is infused into humans without reported adverse effects on platelet 
number. In order to establish whether the changes observed were specific to this 
formulation of albumin or generic to albumin products, further studies were undertaken 
with a different commercially available solution, as well as with fatty acid-free 
lyophilised albumin from human serum. 
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SUPPLEMENTARY INVESTIGATIONS – ALBUMIN STUDY 
PLATELET CONCENTRATE PREPARATION WITH ALTERNATIVE ALBUMIN 
SOLUTION 
A supplementary experiment was performed using a 20% human albumin solution from 
Baxter Healthcare. A limited number of parameters were investigated, concentrating on 
the markers of cell death. The same protocol was used to prepare and store the units, 
with sampling occurring at the same time points. The results are presented below in 
table and graph format, with the corresponding graph from the units manufactured with 
the BPL formulation reproduced to scale alongside for ease of comparison.  
 
RESULTS 
Platelet Concentration 
Table 4.25: Platelet Concentration in units prepared with Baxter albumin solution 
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TEST NUMBER
DAY 2 DAY 3 DAY 6 DAY 8 DAY 10
ALB-000-21 903 832 856 871 938
ALB-030-22 830 819 818 785 757
ALB-060-23 863 877 876 745 772
ALB-120-24 796 799 752 714 711
Platelet Concentration (x10
9/L)
Figure 4.27: Comparison of platelet concentration in units suspended in Baxter’s 
albumin solution versus BPL’s Zenalb® 20 
BPL solution (mean; n=3)
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Lactate Levels 
Table 4.26: Lactate levels in units prepared with Baxter albumin solution 
DAY 2 DAY 3 DAY 6 DAY 8 DAY 10
ALB-000-21 2.2 3.9 10.1 14.7 20.0
ALB-030-22 2.4 4.2 10.3 15.0 17.0
ALB-060-23 2.7 4.7 11.0 16.0 21.0
ALB-120-24 2.5 4.2 9.7 13.6 18.0
TEST NUMBER
Lactate concentration (mmol/L)
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Figure 4.28: Comparison of lactate levels in units suspended in Baxter’s albumin solution 
versus BPL’s Zenalb® 20 
BPL solution (mean; n=3)
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Mitochondrial Membrane Potential 
Table 4.27: MMP in units prepared with Baxter albumin solution 
DAY 2 DAY 3 DAY 6 DAY 8 DAY 10
ALB-000-21 8.58 8.66 3.86 5.63 4.23
ALB-030-22 8.90 8.43 7.50 7.17 3.28
ALB-060-23 8.51 8.21 7.78 7.17 5.85
ALB-120-24 7.50 7.50 7.56 6.98 6.27
Mitochondrial Membrane Potential (Median R/G)
TEST NUMBER
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Figure 4.29: Comparison of JC-1 red/green fluorescence ratio in units suspended in 
Baxter’s albumin solution versus BPL’s Zenalb® 20 
BPL solution (mean; n=3)
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Annexin V Binding 
Table 4.28: Annexin V binding in units prepared with Baxter albumin solution 
DAY 2 DAY 3 DAY 6 DAY 8 DAY 10
ALB-000-21 10.58 11.21 13.13 13.28 18.58
ALB-030-22 9.77 10.66 13.33 13.35 38.04
ALB-060-23 8.53 10.36 10.97 13.51 17.89
ALB-120-24 14.4 9.22 16.31 15.96 19.91
Annexin V Binding (% Positive)
TEST NUMBER
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Figure 4.30: Comparison of annexin V binding (% positive expression) in units 
suspended in Baxter’s albumin solution versus BPL’s Zenalb® 20 
BPL solution (mean; n=3)
Day tested
1 2 3 4 5 6 7 8 9 10 11
An
n
e
xi
n
 
V 
Bi
n
di
n
g 
(%
 
po
si
tiv
e)
0
20
40
60
80
100
120
ALB-000-nn
ALB-030-nn
ALB-060-nn
ALB-120-nn
158 
 
 
Intracellular Free Calcium 
Table 4.29: Intracellular free calcium in units prepared with Baxter albumin solution 
DAY 2 DAY 3 DAY 6 DAY 8 DAY 10
ALB-000-21 0.29 0.30 0.25 0.22 0.25
ALB-030-22 0.33 0.35 0.32 0.25 0.49
ALB-060-23 0.31 0.27 0.27 0.25 0.25
ALB-120-24 0.47 0.26 0.31 0.24 0.37
Ca (Fluo-4/Fura Red)
TEST NUMBER
 
 
BPL solution (mean; n=3)
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DISCUSSION 
The disruption of the platelets evident after day 3 in the units prepared with the 
Zenalb®20 solution was not evident in the experiment utilising the formulation from 
Baxter. Platelet concentration was maintained relatively constant throughout the ten-day 
storage period, without the dose-dependent decrease noted in the BPL units and 
attributed to platelet lysis. The increased rate of metabolism evident in the same units 
from the beginning of the storage period – here depicted solely by lactate levels – was 
also not observed in the Baxter experiment. Finally, the platelets prepared and stored 
with the Baxter albumin solution did not display the marked changes in the markers of 
cell death after day 3 that were seen in units stored with the BPL solution.  
 
Although storage of platelets in the Baxter formulation did not result in the adverse 
changes noted with the BPL formulation, there was also no suggestion that storage in an 
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Figure 4.31: Comparison of intracellular free calcium levels in units suspended in Baxter’s 
albumin solution versus BPL’s Zenalb® 20 
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additive solution containing albumin resulted in any benefits compared to the unit 
lacking albumin, though it would be premature to reach any firm conclusions from a 
single experiment. 
 
PC PREPARATION WITH POWDERED HUMAN SERUM ALBUMIN 
A further experiment was undertaken using a powdered form of fatty acid-free 
(≤0.007%) albumin derived from human serum (Sigma-Aldrich, Dorset, UK: code 
A3782). By minimising the presence of components other than albumin, the aim was to 
directly determine whether albumin was the causative agent of the deleterious effects on 
the in vitro platelet characteristics. As before, four ABO blood group-specific PCs were 
pooled and re-split into four identical units, followed by hard centrifugation to pellet the 
platelets and remove the majority of the suspending plasma. Two of the units were re-
suspended in SAS into which 3 g of powdered albumin had been dissolved, whilst one 
unit was re-suspended with a similar volume of SAS containing 15 mL of Zenalb® 20 
albumin solution (calculated to contain 3 g of albumin). This concentration of albumin 
was half the lowest concentration used in the initial experiments. A lower concentration 
was chosen due to the marked effects noted over the ten day storage period in the latter.  
The fourth unit broke in the centrifuge, negating the opportunity to include a negative 
control planned to consist of a PC suspended in SAS lacking albumin. 
 
As above, the corresponding graphs from the units manufactured with the BPL 
formulation are reproduced to scale for ease of comparison. 
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RESULTS 
Platelet Concentration 
Table 4.30: Platelet concentration for units in HSA study 
Platelet Concentration (x10
9/L) 
TEST NUMBER 
DAY 2 DAY 3 DAY 6 DAY 8 DAY 10 
ALB-HS3-005 832 786 770 751 664 
ALB-HS3-006 833 818 793 725 693 
ALB-Z15-007 766 809 743 598 477 
ALB-HS3-nnn: unit with human serum album 
ALB-Z15-nnn: unit with 15 mL Zenalb® 20 albumin solution 
 
 
BPL solution (mean; n=3)
Day tested
1 2 3 4 5 6 7 8 9 10 11
Pl
a
te
le
t c
o
n
ce
n
tra
tio
n
 
(x1
09
/L
)
0
200
400
600
800
1000
ALB-000-nn 
ALB-030-nn 
ALB-060-nn 
ALB-120-nn 
 
 
 
 
Figure 4.32: Comparison of platelet concentration in units suspended in powdered 
human serum albumin versus BPL’s Zenalb® 20 (ALB-Z15-007).  
Human serum albumin study
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Lactate Levels 
Table 4.31: Lactate levels for units in HSA study  
DAY 2 DAY 3 DAY 6 DAY 8 DAY 10
ALB-HS3-005 2.4 4.6 11.1 17 23
ALB-HS3-006 2.6 4.6 10.8 17 21
ALB-Z15-007 5.7 12.7 27 27 27
Lactate (mmol/L)
TEST NUMBER
 ALB-HS3-nnn: unit with human serum album 
ALB-Z15-nnn: unit with 15 mL Zenalb® 20 albumin solution 
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Figure 4.33: Comparison of lactate levels in units suspended in powdered human 
serum albumin versus BPL’s Zenalb® 20 (ALB-Z15-007) 
BPL solution (mean; n=3)
Day tested
1 2 3 4 5 6 7 8 9 10 11
La
ct
a
te
 
co
n
ce
n
tra
tio
n
 
(m
m
o
l/L
)
0
5
10
15
20
25
30
ALB-000-nn
ALB-030-nn
ALB-060-nn
ALB-120-nn
162 
 
Mitochondrial Membrane Potential 
 
Table 4.32: MMP for units in human serum albumin study  
DAY 2 DAY 3 DAY 6 DAY 8 DAY 10
ALB-HS3-005 10.6 9.8 7.8 5.9 5.2
ALB-HS3-006 6.9 9.6 8.6 6.9 3.1
ALB-Z15-007 9.7 8.8 2.8 2.8 2.7
Mitochondrial Membrane Potential (Median R/G)
TEST NUMBER
 ALB-HS3-nnn: unit with human serum album 
ALB-Z15-nnn: unit with 15 ml Zenalb® 20 albumin solution 
 
 
 
 
 
 
 
 
 
 
 
 
  
Human serum albumin study
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Figure 4.34: Comparison of JC-1 red/green fluorescence ratio in units suspended in 
powdered human serum albumin versus BPL’s Zenalb® 20 (ALB-Z15-007) 
BPL solution (mean; n=3)
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Annexin V Binding 
Table 4.33: Annexin V binding (human serum albumin study) 
DAY 2 DAY 3 DAY 6 DAY 8 DAY 10
ALB-HS3-005 9.12 9.80 11.93 17.43 19.51
ALB-HS3-006 10.03 7.69 12.27 13.63 38.15
ALB-Z15-007 9.63 11.64 61.33 91.88 94.79
Annexin V Binding (% Positive)
TEST NUMBER
ALB-HS3-nnn: unit with human serum album 
ALB-Z15-nnn: unit with 15 ml Zenalb® 20 albumin solution 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Human serum albumin study
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Figure 4.35: Comparison of annexin V binding in units suspended in powdered 
human serum albumin versus BPL’s Zenalb® 20 (ALB-Z15-007) 
BPL solution (mean; n=3)
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Intracellular free calcium 
Table 4.34: Intracellular free calcium (human serum albumin study) 
DAY 2 DAY 3 DAY 6 DAY 8 DAY 10
ALB-HS3-005 0.32 0.32 0.35 0.38 0.41
ALB-HS3-006 0.28 0.40 0.37 0.35 0.45
ALB-Z15-007 0.27 0.44 1.04 4.22 7.0
Intracellular free calcium (Fluo-4/Fura Red)
TEST NUMBER
 
ALB-HS3-nnn: unit with human serum album 
ALB-Z15-nnn: unit with 15 ml Zenalb® 20 albumin solution 
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DISCUSSION 
The supplementary experiments confirmed that albumin per se did not cause the 
accelerated deterioration of platelets during the ten day storage period observed with 
Zenalb® 20 albumin solution and confirmed that the effect of Zenalb® 20 albumin was 
reproducible. The generation of lactate in the unit containing Zenalb® 20 occurred at the 
same accelerated rate as observed in the original experiments, despite the lower initial 
concentration of albumin solution. The lactate level reached a plateau of 27 mmol/L by 
day 6. At the same time point, lactate levels in units with the powdered albumin were 
11.1 and 10.8 mmol/L. Among the parameters reflecting apoptotic changes, the two 
units incorporating the lyophilysed serum albumin provided results similar to those 
obtained in the original experiments in units lacking albumin or re-suspended in 
autologous plasma. By contrast, unit ALB-Z15-007, containing 15 mL of Zenalb® 20, 
Figure 4.36: Comparison of intracellular free calcium in units suspended in powdered human 
serum albumin versus BPL’s Zenalb® 20 (ALB-Z15-007) 
BPL solution (mean; n=3)
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displayed accelerated disruption of the mitochondrial membrane potential as well as 
increased binding of annexin V and higher levels of intracellular free calcium. 
Interestingly, the lower concentration of albumin used in this experiment provided the 
suggestion of a time course for these changes. Mitochondrial membrane potential 
already attained minimal levels by day 6, with no clear difference between the rate of 
potential loss and Zenalb® 20 concentration. The suggestion of a concentration-
dependent effect for annexin V binding in the initial study was reinforced with the 
results from ALB-Z15-007, whilst the clear influence of Zenalb® 20 concentration on 
intracellular calcium was also confirmed by this supplementary study. Thus, full 
disruption of the mitochondrial membrane potential occurred by day 6, followed by 
nearly maximal annexin V binding (% positive expression) by day 8 and intracellular 
free calcium levels similar to the maximal levels attained in the initial study by day 10 – 
the degree of platelet disruption being indicative of a toxic process in the model studied.  
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CHAPTER 5. IMPACT ON PLATELET IN VITRO STORAGE 
CHARACTERISTICS OF THE INCLUSION OF GLUCOSE TO ADDITIVE 
SOLUTIONS 
 
INTRODUCTION 
Commercial additive solutions currently available in Europe and North America do not 
include glucose due to manufacturing difficulties associated with its incorporation. In 
Japan, studies have been undertaken with an additive solution (M-Sol) derived from the 
mixing of commercial solutions pre-approved for clinical use and containing 15 mmol/L 
glucose, with encouraging results (Azuma et al., 2009, Hirayama et al., 2010). Debate 
has continued over the past 20 years regarding the benefits of including glucose, with 
some authors suggesting it is necessary for maintaining platelet viability in vitro 
(Gulliksson, 2000), despite metabolic studies which show it is not a principal substrate 
for oxidative metabolism (Kilkson et al., 1984, Guppy et al., 1990) and concern 
regarding its role in lactate production and associated lowering of extracellular pH. It is 
possible that glucose is required for the maintenance of other mechanisms related to 
platelet function and viability (Murphy, 1999, Li et al., 2005a). It is in this context that 
this study sought to investigate the impact of glucose on the platelet storage lesion, with 
emphasis on platelet activation and markers of cell death.  
 
All results are presented as mean ± standard deviation of 5 replicate experiments, with 
statistical comparisons undertaken by a one way ANOVA. A p-value below 0.01 was 
considered statistically significant. Subsequent multiple comparisons were performed 
by the Holm-Sidak method, with an overall significance level of 0.05. The four test 
groups are: 
GLU-000-nn (no glucose added) 
GLU-075-nn (final concentration of 7.5 mmol/L) 
GLU-150-nn (final concentration of 15 mmol/L) 
GLU-300-nn (final concentration of 30 mmol/L) 
(In each case, nn refers to a unique test number) 
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The graphs also show the median ± range of 3 replicate experiments performed with PC 
manufactured by the same method but re-suspended in 100% autologous plasma, in 
order to provide a visual estimation of the possible impact of the harsh processing on 
the platelet in vitro characteristics. 
RESULTS 
Platelet Yield and Volume 
The mean platelet yield and volume at the start of the storage period for the four test 
groups are presented in table 5.1. All the units met the specification for platelet yield of 
≥240 × 109 plts/unit set out in the UK Guidelines for Transfusion Services (James, 
2005), with no statistically significant differences between the four test groups 
(p=0.939). The unit volumes also confirm that the preparation of the units in all four test 
groups was consistent (p=0.711). All units were successfully leucodepleted (residual 
WBC counts <1×106/unit), with bacterial cultures at the end of storage proving 
negative. 
 
Table 5.1: Platelet yield and unit volume prior to sampling  
Test Group Platelet Yield (×109/unit) Volume (mL) 
GLU-000-nn 296.6
 
± 21.6 337.8 ± 4.9 
GLU-075-nn 295.3 ± 15.3 340.3 ± 3.9 
GLU-150-nn 302.4 ± 20.8 340.0 ± 3.0 
GLU-300-nn 298.6 ± 17.0 341.2 ± 6.1 
Data are presented as mean ± SD (n=5) 
Function and Morphology 
Platelet Concentration 
Platelet concentration was similar in all four test groups until day 6 of storage (p=0.720 
on day 6). Beyond this time point, there was a clear decline in platelet concentration in 
the group lacking additional glucose in relation to the other three test groups, with 
statistically significant differences present on days 8 and 10 (p<0.001 in both cases) 
(table 5.2) (figure 5.1). The mean platelet concentration on day 10 in units with no 
added glucose was 63% of the starting concentration, compared to 96% for units with 
30 mmol/L of added glucose  (549 ± 34 ×109/L versus 838 ± 26 ×109/L) (table 5.3). The 
difference between the starting concentrations in the four test groups and units 
reconstituted in 100% plasma may be due to variability during the processing of the 
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components, as a different operator was involved in the packing and centrifugation of 
the units in plasma. 
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Table 5.2: Statistical comparison between test groups for platelet concentration -
glucose study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA 0.930 0.686 0.720 <0.001 <0.001 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 8 Day 10 
GLU-300 vs. GLU-000 <0.001 (0.002) <0.001 (0.002) 
GLU-150 vs. GLU-000 <0.001 (0.002) <0.001 (0.002) 
GLU-075 vs. GLU-000 0.001 (0.003) <0.001 (0.003) 
GLU-300 vs. GLU-075 NS NS 
GLU-300 vs. GLU-150 NS NS 
GLU-150 vs. GLU-075 NS NS 
Statistical significance: Unadjusted P value (critical Level)  NS = Not significant  
 
 
Table 5.3: Summary results for platelet concentration - glucose study 
Platelet Concentration (x109/L) Final 
Concentration 
of Added 
Glucose 
Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 878 ± 55 892 ± 43 821 ± 38 713 ± 47 549 ± 34 
7.5 mmol/L 868 ± 38 855 ± 44 855 ± 48 819 ± 42 754 ± 50 
15 mmol/L 889 ± 61 870 ± 57 851 ± 57 848 ± 45 826 ± 45 
30 mmol/L 876 ± 54 863 ± 58 846 ± 57 843 ± 39 838 ± 26 
Mean ± SD (n=5) 
 
Figure 5.1: Platelet 
concentration 
 (glucose study; mean ± SD; 
n=5; 100% plasma n=3) 
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Mean Platelet Volume 
The most pronounced increase in mean platelet volume over the period of storage was 
noted with units lacking additional glucose (figure 5.2). Mean MPV on day 10 in these 
units was 9.5 ± 0.3 fL compared with 8.7 ± 0.6 fL in units containing 30 mmol/L of 
glucose (table 5.5). However, these differences were not found to be statistically 
significant between any of the test groups at any time point (table 5.4).  
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Table 5.4: Statistical comparison between test groups for mean platelet volume – 
glucose study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA 0.997 0.824 0.093 0.052 0.033 
            
 
 
Table 5.5: Summary results for mean platelet volume - glucose study 
Mean platelet volume (fL) Final 
Concentration 
of Added 
Glucose Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 8.0 ± 0.3 8.2 ± 0.4 8.7 ± 0.5 9.0 ± 0.3 9.5 ± 0.3 
7.5 mmol/L 7.9 ± 0.4 8.0 ± 0.3 8.2 ± 0.4 8.5 ± 0.4 9.0 ± 0.4 
15 mmol/L 7.9 ± 0.4 8.0 ± 0.3 8.1 ± 0.5 8.2 ± 0.4 8.7 ± 0.5 
30 mmol/L 7.9 ± 0.3 8.0 ± 0.3 8.0 ± 0.3 8.3 ± 0.5 8.7 ± 0.6 
Mean ± SD (n=5) 
 
Figure 5.2: Mean platelet 
volume 
 (glucose study; mean ± SD, 
n=5; 100% plasma n=3) 
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Swirling 
Swirling was not as distinct as in units suspended in plasma, with only one unit with 30 
mmol/l added glucose having a score of 3 (day 10). However, even within these 
constraints, swirling was weaker from the start of the storage period in units lacking 
glucose and reported as absent in these units by day 10 (table 5.6). In units with 15 and 
30 mmol/L of added glucose swirling was maintained with a score of 2 throughout 
storage, whilst in the test group with 7.5 mmol/L of added glucose, a decrease from a 
score of 2 to 1 was observed in four of the five units by day 10. 
 
Table 5.6: Swirling - glucose study 
DAY 2 DAY 3 DAY 6 DAY 8 DAY 10
GLU-000-01 1 2 1 0 0
GLU-000-05 2 1 1 1 0
GLU-000-09 1 1 1 1 0
GLU-000-13 1 1 1 0 0
GLU-000-17 1 1 1 0 0
GLU-075-02 1 2 2 2 1
GLU-075-06 2 2 2 2 1
GLU-075-10 2 2 2 2 2
GLU-075-14 2 2 2 2 1
GLU-075-18 1 2 2 1 1
GLU-150-03 1 2 2 2 2
GLU-150-07 2 2 2 2 2
GLU-150-11 2 2 2 2 2
GLU-150-15 2 2 2 2 2
GLU-150-19 1 2 2 2 2
GLU-300-04 1 2 2 2 2
GLU-300-08 2 2 2 2 2
GLU-300-12 2 2 2 2 2
GLU-300-16 2 2 2 2 3
GLU-300-20 1 2 2 2 2
7.5 mmol/l
15 mmol/l
Swirling
30 mmol/l
Final Concentration 
of Added Glucose 
(mmol/l) 
TEST NUMBER
0 mmol/l
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Hypotonic Shock Response and Extent of Shape Change 
The hypotonic shock response was depressed in all four test groups compared to units 
re-suspended in plasma, with day 2 levels of approximately 20-30% compared to 67% 
for the latter (figure 5.3). It is possible that this is an artefact of the assay associated 
with platelet concentrates suspended in additive solution, despite autologous plasma 
being utilised as the sample diluent. The resulting graphs were at the limit of what was 
considered possible to interpret, based on the chart recordings of the responses. Despite 
this, mean levels resulted in a decrease in the HSR over the course of the storage period 
with all four test groups. There was also the suggestion of a dose-dependent response, 
with units lacking glucose having the lowest HSR values (Table 5.8); though a 
statistically significant difference between this group and the test groups containing 
glucose was only observed on day 8 (p<0.001) (table 5.7).  
Day tested
1 2 3 4 5 6 7 8 9 10 11
H
yp
ot
on
ic 
sh
o
ck
 
re
sp
o
n
se
 
(%
)
0
20
40
60
80
GLU-000-nn 
GLU-075-nn 
GLU-150-nn 
GLU-300-nn 
100% PLASMA 
 
 
Figure 5.3: Hypotonic shock 
response 
 (glucose study; mean ± SD, 
n=5; 100% plasma n=3) 
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Table 5.7: Statistical comparison between test groups of hypotonic shock response – 
glucose study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA 0.079 0.058 0.030 <0.001 0.038 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 8 
GLU-300 vs. GLU-000 <0.001 (0.009) 
GLU-150 vs. GLU-000 <0.001 (0.010) 
GLU-075 vs. GLU-000 0.001 (0.013) 
GLU-300 vs. GLU-075 NS 
GLU-300 vs. GLU-150 NS 
GLU-150 vs. GLU-075 NS 
Statistical significance: Unadjusted P value (critical Level)  NS = Not significant  
 
 
Table 5.8: Summary results for hypotonic shock response - glucose study 
Hypotonic shock response (%) Final 
Concentration 
of Added 
Glucose Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 22.1 ± 3.7 22.4 ± 2.0 16.6 ± 4.8 14.1 ± 3.9 15.4 ± 2.9 
7.5 mmol/L 25.7 ± 2.3 28.7 ± 3.9 19.4 ± 4.7 21.6 ± 3.1 17.3 ± 3.9 
15 mmol/L 26.0 ± 3.4 29.1 ± 4.5 24.3 ± 5.8 22.6 ± 2.5 19.6 ± 3.9 
30 mmol/L 28.6 ± 4.6 28.4 ± 5.2 26.2 ± 4.6 23.6 ± 2.3 23.7 ± 5.6 
Mean ± SD (n=5) 
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Extent of shape change showed a similar pattern between the test groups to that 
described for the hypotonic shock response, with units lacking glucose having the 
lowest responses, and a gradual decline evident in all groups with increased storage 
(figure 5.4). ESC decreased in units lacking glucose from day 2 values of 11.8 ± 4.3% 
to 3.0 ± 1.6% by day 10. Results for units with 30 mmol/L glucose at the same time 
points were 13.0 ± 6.4% (p=0.974) and 9.8 ± 1.5% (p=0.002), respectively (table 5.10). 
Dose-dependency between the three test groups containing added glucose was not 
observed with this parameter, with no statistically significant differences in evidence at 
any point during storage (table 5.9). A depressed response compared to units re-
suspended in plasma was again observed.  
 
Day tested
1 2 3 4 5 6 7 8 9 10 11
Ex
te
n
t o
f s
ha
pe
 
ch
an
ge
 
(%
)
0
5
10
15
20
25
30
GLU-000-nn 
GLU-075-nn 
GLU-150-nn 
GLU-300-nn 
100% PLASMA 
 
 
 
 
Figure 5.4: Extent of shape 
change 
 (glucose study; mean ± SD, 
n=5; 100% plasma n=3) 
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Table 5.9: Statistical comparison between test groups for extent of shape change – 
glucose study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA 0.974 0.242 0.077 0.002 0.002 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 8 Day 10 
GLU-300 vs. GLU-000 0.001 (0.009) <0.001 (0.009) 
GLU-150 vs. GLU-000 0.001 (0.010) 0.007 (0.010) 
GLU-075 vs. GLU-000 0.006 (0.013) NS 
GLU-300 vs. GLU-075 NS NS 
GLU-300 vs. GLU-150 NS NS 
GLU-150 vs. GLU-075 NS NS 
Statistical significance: Unadjusted P value (critical Level)  NS = Not significant  
 
Table 5.10: Summary results for extent of shape change - glucose study 
Extent of shape change (%) Final 
Concentration 
of Added 
Glucose Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 11.8 ± 4.3 12.1 ± 2.9 6.6 ± 2.9 4.2 ± 2.8 3.0 ± 1.6 
7.5 mmol/L 13.4 ± 5.9 15.4 ± 1.9 10.2 ± 3.3 8.7 ± 2.0 6.1 ± 2.9 
15 mmol/L 12.4 ± 5.4 14.9 ± 2.4 11.4 ± 4.0 9.7 ± 2.5 7.5 ± 2.8 
30 mmol/L 13.0 ± 6.4 14.4 ± 2.9 11.1 ± 0.6 10.2 ± 1.0 9.8 ± 1.5 
Mean ± SD (n=5) 
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Platelet Metabolism 
Extracellular pH37°C  
Day 2 levels of pH37°C were similar in all four test groups, with mean levels of 
approximately 7.45 (p=0.233). The units lacking glucose showed a steady increase in 
pH37°C with storage, resulting in a mean level on day 10 of 7.952 ± 0.035 (table 5.12). In 
contrast, pH37°C levels gradually decreased in all the units containing glucose up to day 
6, with the rate of decrease closely matched in the three test groups (figure 5.5). By this 
point, glucose stores in units with starting glucose levels of 7.5 mmol/L had been 
depleted (Figure 5.6) and pH37°C in this test group increased, with the slope of the line 
similar to the slope generated with the test group lacking glucose. The rate of decrease 
in units with 15 mmol/L and 30 mmol/L of glucose remained similar up to day 8, when 
the rate of decrease fell in the former group as glucose levels neared zero (figure 5.5). 
This is reflected in the statistical comparison, with significant differences evident on 
days 8 and 10 between all the groups with the exception of the units with 15 mmol/L 
and 30 mmol/L of added glucose (table 5.11). Despite the decrease over time, all 
glucose-containing units retained pH37°C levels above 6.95 throughout the ten-day 
storage period (table 5.12).  
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Figure 5.5: pH37°C levels 
 (glucose study; mean ± 
SD, n=5; 100% plasma 
n=3) 
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Table 5.11: Statistical comparison between test groups for pH (37°C) – glucose Study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA 0.225 <0.001 <0.001 <0.001 <0.001 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 3 Day 6 Day 8 Day 10 
GLU-300 vs. GLU-000 <0.001 (0.010) 
<0.001 
(0.009) 
<0.001 
(0.010) 
<0.001 
(0.009) 
GLU-150 vs. GLU-000 <0.001 (0.013) 
<0.001 
(0.010) 
<0.001 
(0.009) 
<0.001 
(0.010) 
GLU-075 vs. GLU-000 <0.001 (0.009) 
<0.001 
(0.013) 
<0.001 
(0.013) 
<0.001 
(0.017) 
GLU-300 vs. GLU-075 NS NS <0.001 (0.025) 
<0.001 
(0.013) 
GLU-300 vs. GLU-150 NS NS NS NS 
GLU-150 vs. GLU-075 NS NS <0.001 (0.017) 
<0.001 
(0.025) 
Statistical significance: Unadjusted P value (critical Level)  NS = Not significant  
 
Table 5.12: pH (37°C) levels in glucose study 
pH (37°C) Final 
Concentration 
of Added 
Glucose Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 7.271 ± 0.013 
7.342 ± 
0.017 
7.502 ± 
0.024 
7.602 ± 
0.029 
7.704 ± 
0.033 
7.5 mmol/L 7.243 ± 0.035 
7.228 ± 
0.048 
7.138 ± 
0.065 
7.237 ± 
0.101 
7.323 ± 
0.114 
15 mmol/L 7.253 ± 0.011 
7.239 ± 
0.018 
7.133 ± 
0.027 
7.025 ± 
0.032 
6.955 ± 
0.077 
30 mmol/L 7.251 ± 0.015 
7.238 ± 
0.017 
7.132 ± 
0.028 
7.028 ± 
0.034 
6.875 ± 
0.066 
Mean ± SD (n=5) 
 
177 
 
 
Glucose and Lactate  
Glucose levels decreased with storage at a similar rate in all three test groups containing 
exogenous glucose until stores were depleted, which occurred on day 6 for units with 
7.5 mmol/L of added glucose and day 10 for units with 15 mmol/L of glucose (figure 
5.6). Units with the highest concentration of added glucose at 30 mmol/L maintained 
glucose levels of 9.2 ± 0.5 mmol/L by day 10 (table 5.14); similar to levels in units re-
suspended in plasma (mean of 9.9 mmol/L). The statistical comparison reflected the 
gradual consumption of glucose with storage, with statistically significant differences 
evident at all time points but restricted by day 10 to differences between the units with 
30 mmol/L added glucose and the other three test groups (p<0.001) (table 5.13).  
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Figure 5.6: Glucose levels 
 (glucose study; mean ± 
SD, n=5; 100% plasma 
n=3) 
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Table 5.13: Statistical comparison between test groups for glucose concentration – 
glucose study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA <0.001 <0.001 <0.001 <0.001 <0.001 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 2 Day 3 Day 6 Day 8 Day 10 
GLU-300 vs. GLU-000 <0.001 (0.009) 
<0.001 
(0.009) 
<0.001 
(0.009) 
<0.001 
(0.010) 
<0.001 
(0.013) 
GLU-150 vs. GLU-000 <0.001 (0.013) 
<0.001 
(0.017) 
<0.001 
(0.017) 
<0.001 
(0.025) NS 
GLU-075 vs. GLU-000 <0.001 (0.050) 
<0.001 
(0.050) NS NS NS 
GLU-300 vs. GLU-075 <0.001 (0.010) 
<0.001 
(0.010) 
<0.001 
(0.010) 
<0.001 
(0.009) 
<0.001 
(0.010) 
GLU-300 vs. GLU-150 <0.001 (0.017) 
<0.001 
(0.013) 
<0.001 
(0.013) 
<0.001 
(0.013) 
<0.001 
(0.009) 
GLU-150 vs. GLU-075 <0.001 (0.025) 
<0.001 
(0.025) 
<0.001 
(0.025) 
<0.001 
(0.017) NS 
Statistical significance: Unadjusted P value (critical Level)  NS = Not significant  
 
Table 5.14: Summary results for glucose concentrations - glucose study 
Glucose concentration (mmol/L) Final 
Concentration 
of Added 
Glucose Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 0.1 ± 0.1 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
7.5 mmol/L 4.4 ± 0.2 3.5 ± 0.1 0.1 ± 0.2 0.0 ± 0.0 0.0 ± 0.0 
15 mmol/L 9.9 ± 0.6 9.3 ± 0.7 5.5 ± 0.8 2.4 ± 0.8 0.0 ± 0.0 
30 mmol/L 19.7 ± 1.7 19.4 ± 1.4 15.8 ± 1.4 12.9 ± 1.3 9.2 ± 1.5 
Mean ± SD (n=5) 
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The calculated glucose consumption takes into account the platelet concentration over 
the 10-day storage period. As suggested by the levels of glucose in the units, rates of 
consumption were independent of the starting concentration of glucose, with no 
statistically significant differences between the test groups between days 2 and 3 
(p=0.412) and differences thereafter confined to confirming the presence or absence of 
glucose (table 5.15). Though independent of starting levels of added glucose, the rate of 
glucose consumption was noted to increase with storage (figure 5.7; table 5.16). 
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Figure 5.7: Glucose consumption 
 (glucose study; mean ± SD, n=5; 
100% plasma n=3) 
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Table 5.15: Statistical comparison between test groups for glucose consumption – 
glucose study 
Comparison Between Groups 
 Day 2-3 Day 3-6 Day 6-8 Day 8-10 
One Way ANOVA 0.413 <0.001 <0.001 <0.001 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 3-6 Day 6-8 Day 8-10 
GLU-300 vs. GLU-000 <0.001 (0.002) <0.001 (0.003) <0.001 (0.002) 
GLU-150 vs. GLU-000 <0.001 (0.002) <0.001 (0.002) <0.001 (0.003) 
GLU-075 vs. GLU-000 <0.001 (0.003) NS NS 
GLU-300 vs. GLU-075 NS <0.001 (0.003) <0.001 (0.002) 
GLU-300 vs. GLU-150 NS NS NS 
GLU-150 vs. GLU-075 NS <0.001 (0.002) <0.001 (0.003) 
Statistical significance: Unadjusted P value (critical Level)  NS = Not significant  
 
Table 5.16: Summary results for glucose consumption - glucose study 
Glucose consumption (mmol/day/1012 plts) Final Concentration 
of Added 
Glucose Day 2-3 Day 3-6 Day 6-8 Day 8-10 
0 mmol/L 0.07 ± 0.15 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
7.5 mmol/L 1.07 ± 0.14 1.33 ± 0.12 0.06 ± 0.14 0.00 ± 0.00 
15 mmol/L 0.73 ± 0.85 1.46 ± 0.06 1.80 ± 0.07 1.46 ± 0.50 
30 mmol/L 0.35 ± 1.74 1.38 ± 0.13 1.73 ± 0.19 2.19 ± 0.51 
Mean ± SD (n=5) 
 
181 
 
 
Lactate levels on day 2 were similar in all four test groups, despite the different starting 
concentrations of glucose (p=0.060). Mean values ranged from 2.0 ± 0.3 mmol/L in 
units lacking glucose to 2.5 ± 0.3 mmol/L in units with 30 mmol/L added glucose (table 
5.18). Lactate levels in the former are likely to be due to residual levels due to the lack 
of a washing stage in the processing method of the units. As expected, no further lactate 
was produced in this test group. In the remaining three groups, lactate levels were 
affected by the glucose concentrations over the storage period, with levels reaching a 
plateau following the depletion of glucose (figure 5.8). This was best illustrated in units 
with 7.5 mmol/L added glucose, in which glucose stores were consumed by day 6 and 
levels of lactate were retained at approximately 10 mmol/L for the remainder of the 
storage period. Statistically significant differences were evident between all the test 
groups by day 10 (p<0.001) (table 5.17).  
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Figure 5.8: Lactate levels 
 (glucose study; mean ± 
SD, n=5; 100% plasma 
n=3) 
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Table 5.17: Statistical comparison between test groups for lactate concentrations – 
glucose study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA 0.060 <0.001 <0.001 <0.001 <0.001 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 3 Day 6 Day 8 Day 10 
GLU-300 vs. GLU-000 <0.001 (0.009) <0.001 (0.009) <0.001 (0.010) <0.001 (0.009) 
GLU-150 vs. GLU-000 <0.001 (0.010) <0.001 (0.010) <0.001 (0.009) <0.001 (0.010) 
GLU-075 vs. GLU-000 <0.001 (0.013) <0.001 (0.013) <0.001 (0.013) <0.001 (0.025) 
GLU-300 vs. GLU-075 NS NS <0.001 (0.025) <0.001 (0.013) 
GLU-300 vs. GLU-150 NS NS NS 0.029 (0.050) 
GLU-150 vs. GLU-075 NS NS <0.001 (0.017) <0.001 (0.017) 
Statistical significance: Unadjusted P value (critical Level)  NS = Not significant  
 
 
Table 5.18: Summary results for lactate concentration - glucose study 
Lactate concentration (mmol/L) Final 
Concentration 
of Added 
Glucose Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 2.0 ± 0.3 2.0 ± 0.4 1.7 ± 0.4 1.6 ± 0.4 1.4 ± 0.4 
7.5 mmol/L 2.3 ± 0.3 4.0 ± 0.4 10.3 ± 0.9 10.7 ± 0.6 10.4 ± 0.6 
15 mmol/L 2.4 ± 0.3 4.3 ± 0.5 11.1 ± 1.3 17 ± 1.6 21 ± 1.2 
30 mmol/L 2.5 ± 0.3 4.3 ± 0.6 11.2 ± 1.6 17 ± 2.1 23 ± 2.2 
Mean ± SD (n=5) 
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The pattern for rates of lactate production over the storage period mirrored those of 
glucose consumption, with the rates of both increasing with storage until glucose stores 
were depleted (figures 5.7 and 5.9). Statistically significant differences were observed at 
all time-points (p<0.001); the pairwise comparison confirming the visual interpretation 
of the results (table 5.19).  
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Figure 5.9: Lactate production 
 (glucose study; mean ± SD, 
n=5; 100% plasma n=3) 
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Table 5.19: Statistical comparison between test groups for lactate production – glucose 
study 
Comparison Between Groups 
 Day 2-3 Day 3-6 Day 6-8 Day 8-10 
One Way ANOVA <0.001 <0.001 <0.001 <0.001 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 2-3 Day 3-6 Day 6-8 Day 8-10 
GLU-300 vs. GLU-000 <0.001 (0.002) <0.001 (0.002) <0.001 (0.002) <0.001 (0.002) 
GLU-150 vs. GLU-000 <0.001 (0.002) <0.001 (0.002) <0.001 (0.002) <0.001 (0.003) 
GLU-075 vs. GLU-000 <0.001 (0.003) <0.001 (0.003) NS NS 
GLU-300 vs. GLU-075 NS NS <0.001 (0.003) <0.001 (0.002) 
GLU-300 vs. GLU-150 NS NS NS NS 
GLU-150 vs. GLU-075 NS NS <0.001 (0.003) <0.001 (0.003) 
Statistical significance: Unadjusted P value (critical Level)  NS = Not significant  
 
Table 5.20: Lactate production in glucose study 
Lactate production (mmol/day/1012 plts) Final Concentration 
of Added 
Glucose Day 2-3 Day 3-6 Day 6-8 Day 8-10 
0 mmol/L 0.05 ± 0.13 -0.10 ± 0.03 -0.09 ± 0.04 -0.13 ± 0.05 
7.5 mmol/L 1.93 ± 0.09 2.46 ± 0.19 0.23 ± 0.35 -0.18 ± 0.26 
15 mmol/L 2.11 ± 0.18 2.62 ± 0.16 3.50 ± 0.29 2.41 ± 1.22 
30 mmol/L 2.09 ± 0.17 2.66 ± 0.25 3.24 ± 0.26 3.77 ± 0.46 
Mean ± SD (n=5) 
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Bicarbonate Levels 
Bicarbonate levels in the group lacking added glucose remained stable throughout the 
ten days of storage at approximately 16 mmol/L (figure 5.10). In units with added 
glucose, levels decreased at a similar rate in all test groups until glucose stores were 
depleted. This was best observed in units with 7.5 mmol/L added glucose; with the 
depletion of glucose on day 6, the rate of bicarbonate loss decreased so that the mean 
concentration on day 10 (8.73 ± 2.28 mmo/l) was 85% of that measured on day 6 (10.23 
± 2.19 mmol/L). By comparison, the mean bicarbonate level on day 10 in units with 30 
mmol/L added glucose was 47% of the mean on day 6 (4.90 ± 0.73 versus 10.42 ± 0.58 
mmol/L, respectively) (table 5.22). Statistically significant differences on days 6 and 8 
between the group with 30 mmol/L added glucose and the other test groups were 
confined to the test group with no added glucose. By day 10, a statistically significant 
difference was also evident with the units containing 7.5 mmol/L added glucose 
(p<0.001 in all cases) (table 5.21).  
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Figure 5.10: Bicarbonate 
levels (37°C) (glucose study; 
mean ± SD, n=5; 100% 
plasma n=3) 
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Table 5.21: Statistical comparison between test groups for bicarbonate levels – glucose 
study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA 0.665 0.285 <0.001 <0.001 <0.001 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 6 Day 8 Day 10 
GLU-300 vs. GLU-000 <0.001 (0.010) <0.001 (0.009) <0.001 (0.009) 
GLU-150 vs. GLU-000 <0.001 (0.013) <0.001 (0.010) <0.001 (0.010) 
GLU-075 vs. GLU-000 <0.001 (0.009) <0.001 (0.013) <0.001 (0.013) 
GLU-300 vs. GLU-075 NS NS 0.001 (0.017) 
GLU-300 vs. GLU-150 NS NS NS 
GLU-150 vs. GLU-075 NS NS 0.002 (0.025) 
Statistical significance: Unadjusted P value (critical Level)  NS = Not significant  
 
Table 5.22: Summary results for bicarbonate levels - glucose study  
Bicarbonate concentration (mmol/L) (37°C) Final 
Concentration 
of Added 
Glucose Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 16.16 ±1.25 15.75 ± 1.16 15.96 ± 1.47 16.36 ± 2.22 15.81 ± 1.50 
7.5 mmol/L 14.49 ± 3.32 13.47 ± 3.09 10.23 ± 2.19 9.05 ± 2.17 8.73 ± 2.28 
15 mmol/L 15.43 ± 1.74 14.10 ± 1.46 10.49 ± 1.12 7.77 ± 0.91 5.25 ± 0.87 
30 mmol/L 15.22 ± 1.44 13.97 ± 1.08 10.42 ± 0.58 7.76 ± 0.45 4.90 ± 0.73 
Mean ± SD (n=5) 
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Blood Gases 
The partial pressure of oxygen increased with storage, with the three test groups 
containing glucose generating similar results throughout the storage period and 
finishing with mean levels of approximately 18 kPa by end of storage (figure 5.11). No 
statistically significant differences were evident between these three test groups at any 
point in the storage period (table 5.23). The test group lacking glucose showed a steeper 
increase in pO2 after the initial three days of storage, with a mean day 10 partial 
pressure of 20.0 ± 0.5 kPa (p=0.006) (table 5.24).  
Day tested
1 2 3 4 5 6 7 8 9 10 11
pO
2 
(37
o
C)
 
(kP
a)
10
12
14
16
18
20
22
GLU-000-nn 
GLU-075-nn 
GLU-150-nn 
GLU-300-nn 
100% PLASMA 
 
 
Figure 5.11: Partial pressure of 
oxygen  
(glucose study; mean ± SD, n=5; 
100% plasma n=3) 
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Table 5.23: Statistical comparison between test groups for partial pressure of oxygen – 
glucose study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA 0.643 0.079 0.587 0.336 0.006 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 10 
GLU-300 vs. GLU-000 0.009 (0.013) 
GLU-150 vs. GLU-000 0.002 (0.009) 
GLU-075 vs. GLU-000 0.003 (0.010) 
GLU-300 vs. GLU-075 NS 
GLU-300 vs. GLU-150 NS 
GLU-150 vs. GLU-075 NS 
Statistical significance: Unadjusted P value (critical Level)  NS = Not significant  
 
Table 5.24: Summary results for partial pressure of oxygen - glucose study 
Partial pressure of oxygen (kPa) (37°C) Final Concentration 
of Added 
Glucose Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 13.4 ± 1.1 12.8 ± 1.3 15.0 ± 1.2 17.7 ± 1.0 20.0 ± 0.5 
7.5 mmol/L 13.6 ± 0.9 14.3 ± 1.0 15.2 ± 0.5 16.6 ± 0.8 18.2 ± 0.8 
15 mmol/L 14.1 ± 1.0 14.2 ± 0.9 15.7 ± 1.2 17.3 ± 0.8 18.0 ± 0.9 
30 mmol/L 14.0 ± 1.2 14.4 ± 0.9 15.5 ± 0.7 17.1 ± 0.9 18.4 ± 1.0 
Mean ± SD (n=5) 
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The partial pressures of carbon dioxide over the ten days of storage reflected the pattern 
of glucose and bicarbonate metabolism more closely than pO2 (figure 5.12). In units 
lacking added glucose, pCO2 decreased steadily with storage from day 2 pressures of 
4.27 ± 0.25 kPa to a mean of 1.54 ± 0.09 kPa on day 10. By contrast, from similar day 2 
values (p=0.829), partial pressures in units with 30 mmol/L added glucose had 
decreased to a mean of 3.20 ± 0.08 kPa by day 10 (table 5.26). Statistically significant 
differences on day 6 were limited to differences between the units with no added 
glucose and units with glucose. By day 10, significant differences were evident between 
all the test groups (p<0.001) (table 5.25) 
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Figure 5.12: Partial pressure of 
carbon dioxide 
 (glucose study; mean ± SD, n=5; 
100% plasma n=3) 
190 
 
Table 5.25: Statistical comparison between test groups for partial pressure of carbon 
dioxide – glucose study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA 0.829 0.144 <0.001 <0.001 <0.001 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 6 Day 8 Day 10 
GLU-300 vs. GLU-000 <0.001 (0.010) <0.001 (0.010) <0.001 (0.009) 
GLU-150 vs. GLU-000 <0.001 (0.009) <0.001 (0.009) <0.001 (0.010) 
GLU-075 vs. GLU-000 <0.001 (0.013) <0.001 (0.025) 0.001 (0.025) 
GLU-300 vs. GLU-075 NS <0.001 (0.017) <0.001 (0.013) 
GLU-300 vs. GLU-150 NS NS 0.007 (0.050) 
GLU-150 vs. GLU-075 NS <0.001 (0.013) <0.001 (0.017) 
Statistical significance: Unadjusted P value (critical Level)  NS = Not significant  
 
Table 5.26: Summary results for partial pressure of carbon dioxide - glucose study 
Partial pressure of carbon dioxide (kPa) (37°C) Final 
Concentration 
of Added 
Glucose Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 4.27 ± 0.25 3.53 ± 0.15 2.48 ± 0.14 2.01 ± 0.20 1.54 ± 0.09 
7.5 mmol/L 4.03 ± 0.68 3.87 ± 0.57 3.61 ± 0.36 2.52 ± 0.14 1.98 ± 0.14 
15 mmol/L 4.25 ± 0.42 4.00 ± 0.27 3.80 ± 0.29 3.61 ± 0.24 2.86 ± 0.30 
30 mmol/L 4.21 ± 0.29 3.98 ± 0.21 3.80 ± 0.15 3.59 ± 0.12 3.20 ± 0.08 
Mean ± SD (n=5) 
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Oxygen consumption rates decreased similarly with storage in all test groups, with 
starting levels of approximately 0.23 nmol/min/109plts decreasing to mean levels of 
approximately 0.16 nmol/min/109plts by end of storage (figure 5.13; table 5.28). No 
statistically significant differences were noted between the test groups at any time point 
(table 5.27). Thus, the concentration of glucose, or even its absence, did not appear to 
impact on oxygen consumption rate. The gradual decrease in consumption reflects the 
gradual accumulation of oxygen in the units with storage. With a continued decrease in 
oxygen consumption, the partial pressure of oxygen would be expected to continue to 
increase until levels equilibrated with the atmospheric partial pressure.   
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Table 5.27: Statistical comparison between test groups for oxygen consumption rate – 
glucose study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA  0.533 0.313 0.548 0.490 0.273 
 
Table 5.28: Summary results for oxygen consumption rates - glucose study 
Oxygen consumption rate (nmol/min/109plts) (22°C) Final 
Concentration 
of Added 
Glucose Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 0.24 ± 0.03 0.25 ± 0.02 0.22 ± 0.02 0.19 ± 0.03 0.17 ± 0.01 
7.5 mmol/L 0.24 ± 0.02 0.23 ± 0.02 0.21 ± 0.02 0.19 ± 0.02 0.17 ± 0.02 
15 mmol/L 0.22 ± 0.02 0.23 ± 0.02 0.20 ± 0.04 0.17 ± 0.02 0.16 ± 0.03 
30 mmol/L 0.23 ± 0.02 0.23 ± 0.02 0.21 ± 0.02 0.17 ± 0.02 0.14 ± 0.02 
Mean ± SD (n=5) 
Figure 5.13: Oxygen consumption 
rate 
 (glucose study; mean ± SD, n=5; 
100% plasma n=3) 
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ATP and ADP Levels 
Levels of ATP were similar at the start of the storage period in the three test groups 
containing glucose, with mean values on day 2 of approximately 5.4 µmol/1011plts. 
Mean levels in the test group lacking glucose were lower at 4.38 ± 0.56 µmol/1011plts, 
though this difference did not achieve statistical significance (p=0.016) (table 5.30). 
ATP levels decreased steadily with storage in units lacking glucose to a mean of 1.09 ± 
0.09 µmol/1011plts by day 10 (table 5.30). The rate of decline was lower in the other 
three test groups until glucose stores were depleted, at which point ATP levels were 
observed to decrease at an accelerated rate that more closely resembled that seen in 
units lacking added glucose (figure 5.14). Day 10 ATP levels were thus relatively well 
maintained in units with 30 mmol/L added glucose, with a mean of 4.18 ± 0.64 
µmol/1011plts. This constituted 78% of the day 2 levels compared with only 25% of day 
2 levels in the test group lacking added glucose. Statistically significant differences 
were evident between all the test groups by day 10 (p<0.001) (table 5.29). 
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Figure 5.14: ATP Levels 
(glucose study; mean ± SD, 
n=5; 100% plasma n=3) 
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Table 5.29: Statistical comparison between test groups for ATP levels – glucose study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA 0.016 0.003 <0.001 <0.001 <0.001 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 3 Day 6 Day 8 Day 10 
GLU-300 vs. GLU-000 0.001 (0.009) <0.001 (0.009) <0.001 (0.009) <0.001 (0.009) 
GLU-150 vs. GLU-000 0.002 (0.010) <0.001 (0.010) <0.001 (0.010) <0.001 (0.013) 
GLU-075 vs. GLU-000 0.002 (0.013) <0.001 (0.013) <0.001 (0.025) 0.003 (0.025) 
GLU-300 vs. GLU-075 NS 0.016 (0.017) <0.001 (0.013) <0.001 (0.010) 
GLU-300 vs. GLU-150 NS NS NS 0.001 (0.017) 
GLU-150 vs. GLU-075 NS NS <0.001 (0.017) 0.007 (0.050) 
Statistical significance: Unadjusted P value (critical Level)  NS = Not significant  
 
Table 5.30: Summary results for ATP levels - glucose study 
ATP Levels (µmol/1011plts) Final Concentration 
of Added 
Glucose Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 4.38 ± 0.56 3.89 ± 0.74 2.57 ± 0.40 1.91 ± 0.20 1.09 ± 0.09 
7.5 mmol/L 5.44 ± 0.69 5.08 ± 0.38 4.21 ± 0.51 2.79 ± 0.31 2.12 ± 0.36 
15 mmol/L 5.31 ± 0.31 5.15 ± 0.39 4.73 ± 0.66 4.19 ± 0.26 3.03 ± 0.57 
30 mmol/L 5.39 ± 0.45 5.21 ± 0.50 5.07 ± 0.41 4.30 ± 0.23 4.18 ± 0.64 
Mean ± SD (n=5) 
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ADP levels decreased with storage in all the test groups. Although mean levels were 
lower in the test group lacking added glucose, no statistically significant differences 
were noted between any of the test groups at any of the time points (table 5.31). In all 
test groups, levels on day 10 were between 20- 30% of levels on day 2 (table 5.32). 
Unlike ATP, loss of ADP appeared unrelated to glucose levels and other metabolic 
parameters (figure 5.15).  
Day sampled
1 2 3 4 5 6 7 8 9 10 11
AD
P 
(µm
o
l/1
01
1  
pl
a
te
le
ts
)
0
2
4
6
8 GLU-000-nn 
GLU-075-nn 
GLU-150-nn 
GLU-300-nn 
100% PLASMA 
  
Table 5.31: Statistical comparison for ADP levels – glucose study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA 0.037 0.121 0.488 0.114 0.014 
 
Table 5.32: Summary results for ADP - glucose study 
ADP Levels (µmol/1011plts) Final Concentration 
of Added 
Glucose Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 3.40 ± 0.50 2.79 ± 0.36 1.59 ± 0.43 1.04 ± 0.16 0.70 ± 0.16 
7.5 mmol/L 4.42 ± 0.55 3.16 ± 0.35 2.02 ± 0.93 1.49 ± 0.51 1.04 ± 0.16 
15 mmol/L 4.66 ± 0.71 2.71 ± 0.66 2.10 ± 0.39 1.26 ± 0.07 1.29 ± 0.39 
30 mmol/L 4.22 ± 0.79 3.55 ± 0.78 1.75 ± 0.34 1.45 ± 0.28 1.26 ± 0.32 
Mean ± SD (n=5) 
 
Figure 5.15: ADP Levels 
(glucose study; mean ± SD, n=5; 
100% plasma n=3) 
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Platelet Activation 
Surface Expression and Soluble Levels of CD62P 
Surface expression of CD62P resulted in similar percentage positive expression in all 
four test groups on day 2, with mean levels of approximately 80% (p=0.826) (table 
5.34); markedly higher than the mean of 60.08% obtained from units re-suspended in 
plasma, despite the use of the same processing method. Percentage positive expression 
increased between days 2 and 3 in all four test groups, after which the expression 
remained relatively stable in the three test groups containing glucose (figure 5.16). The 
test group lacking glucose continued to increase in percent positive expression until day 
6, resulting in a mean level of 94.04 ± 0.97 % and a statistically significant difference 
against the test groups with added glucose (p<0.001) (table 5.33). Beyond this time 
point, a gradual decrease was observed, resulting in levels at the end of storage similar 
to those obtained with the test groups containing exogenous glucose (p=0.577).  
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Figure 5.16: Percent positive 
expression of surface CD62P 
(glucose study; mean ± SD, n=5; 
100% plasma n=3) 
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Table 5.33: Statistical comparison between test groups for CD62P surface expression 
(% positive) – glucose study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA 0.826 0.039 <0.001 0.041 0.577 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 6 
GLU-300 vs. GLU-000 <0.001 (0.009) 
GLU-150 vs. GLU-000 0.001 (0.010) 
GLU-075 vs. GLU-000 0.001 (0.013) 
GLU-300 vs. GLU-075 NS 
GLU-300 vs. GLU-150 NS 
GLU-150 vs. GLU-075 NS 
Statistical significance: Unadjusted P value (critical Level)  NS = Not significant  
 
 
Table 5:34: Summary results for percent positive expression of CD62P - glucose study 
Surface expression of CD62P (% positive) Final 
Concentration 
of Added 
Glucose Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 81.29 ± 2.30 89.39 ± 1.11 94.04 ± 0.97 91.18 ± 1.62 86.87 ± 2.80 
7.5 mmol/L 79.47 ± 4.23 84.83 ± 2.51 87.60 ± 3.65 88.93 ± 3.69 88.71 ± 4.63 
15 mmol/L 80.43 ± 3.88 85.65 ± 2.16 87.15 ± 2.27 86.80 ± 2.75 87.67 ± 2.56 
30 mmol/L 81.30 ± 3.53 84.47 ± 4.07 85.25 ± 2.49 85.93 ± 2.80 85.91 ± 2.37 
Mean ± SD (n=5) 
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Surface CD62P median fluorescence intensity was higher on days 6 and 8 in the test 
group lacking glucose, with mean levels of 4.25 ± 0.33 and 4.32 ± 0.76, respectively 
(table 5.36). However, this was not a statistically significant difference compared with 
the units with added glucose (p=0.031 on day 6 and p=0.055 on day 8) (table 5.35). MFI 
increased in all four test groups (from mean day 2 levels between 2.33 ± 0.12 and 2.49 ± 
0.21 in units lacking glucose and units with 30 mmol/L added glucose (p=0.544)), until 
days 6 – 8; beyond which a gradual decrease or stabilisation in MFI was evident. As 
with percent positive expression, MFI results for surface CD62P were markedly lower 
in the units re-suspended in autologous plasma (figure 5.17). 
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Table 5.35: Statistical comparison for CD62P surface expression (MFI) – glucose    
study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA 0.544 0.414 0.031 0.055 0.196 
 
Table 5.36: Summary results for median fluorescence intensity of surface CD62P - 
glucose study 
Surface expression of CD62P (median fluorescence intensity) Final 
Concentration 
of Added 
Glucose Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 2.33 ± 0.12 3.34 ± 0.30 4.25 ± 0.33 4.32 ± 0.76 3.85 ± 0.86 
7.5 mmol/L 2.40 ± 0.20 3.09 ± 0.22 3.76 ± 0.35 3.54 ± 0.30 3.19 ± 0.27 
15 mmol/L 2.48 ± 0.21 3.19 ± 0.20 3.77 ± 0.24 3.81 ± 0.24 3.50 ± 0.18 
30 mmol/L 2.49 ± 0.21 3.15 ± 0.23 3.69 ± 0.24 3.67 ± 0.19 3.59 ± 0.11 
Mean ± SD (n=5) 
Figure 5.17: Surface CD62P 
expressed as median fluorescence 
intensity 
(glucose study; mean ± SD, n=5; 
100% plasma n=3) 
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Levels of soluble CD62P increased with storage in all test groups from similar starting 
levels of approximately 35 to 45 ng/mL (p=0.345) (table 5.38). Levels increased at a 
faster rate in units lacking added glucose, leading to a statistically significant difference 
between these units and units with added glucose by day 6 (p<0.001). Beyond day 6, 
soluble CD62P  increase at a faster rate in both units lacking added glucose and units 
with 7.5 mmol/L, resulting in a statistically significant difference (p<0.001) between 
these test groups and units with 15 mmol/L and 30 mmol/L added glucose (table 5.37) 
(figure 5.18). Mean soluble CD62P levels on day 10 were 268.27 ± 23.46 ng/mL in 
units lacking glucose and 92.30 ± 12.31 ng/mL in units with 30 mmol/L. 
   
 
 
 
 
 
 
 
 
 
 
 
Figure 5.18: Soluble CD62P 
(glucose study; mean ± SD, n=5; 
100% plasma n=3) 
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Table 5.37: Statistical comparison between test groups for soluble CD62P levels – 
glucose study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA 0.345 0.189 <0.001 <0.001 <0.001 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 6 Day 8 Day 10 
GLU-300 vs. GLU-000 <0.001 (0.010) <0.001 (0.009) <0.001 (0.009) 
GLU-150 vs. GLU-000 <0.001 (0.009) <0.001 (0.010) <0.001 (0.010) 
GLU-075 vs. GLU-000 <0.001 (0.013) <0.001 (0.013) <0.001 (0.013) 
GLU-300 vs. GLU-075 NS NS <0.001 (0.017) 
GLU-300 vs. GLU-150 NS NS NS 
GLU-150 vs. GLU-075 NS NS <0.001 (0.025) 
Statistical significance: Unadjusted P value (critical Level)  NS = Not significant  
 
Table 5.38: Summary results for soluble CD62P levels - glucose study 
Soluble CD62P (ng/mL) Final 
Concentration 
of Added 
Glucose Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 44.58 ± 9.66 63.14 ± 14.43 117.99 ± 16.92 
189.96 ± 
15.88 
268.27 ± 
23.46 
7.5 mmol/L 38.53 ± 8.20 52.28 ± 10.12 75.70 ± 15.39 105.12 ± 15.44 
158.88 ± 
24.30 
15 mmol/L 36.11 ± 9.47 49.23 ± 11.95 70.25 ± 12.74 84.37 ± 13.94 103.36 ± 17.84 
30 mmol/L 34.34 ± 9.25 46.98 ± 10.89 70.37 ± 12.94 81.34 ± 14.42 92.30 ± 12.31 
Mean ± SD (n=5) 
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Markers of Cell Death 
Surface Expression of Aminophospholipids 
Annexin V binding to the platelet surface, measured as percentage positive expression, 
was similar in all four test groups at the start of storage. Day 2 levels in units lacking 
glucose (13.53 ± 3.60 %) were higher than in test groups with added glucose (9.42 ± 
2.96 % in 30 mmol/L added glucose), but this difference was not found to be 
statistically significant (p=0.094) (table 5.39). Annexin V binding continued to increase 
in units lacking glucose throughout storage, with mean levels on day 10 of 66.31 ± 4.88 
%. Annexin V binding in the test groups with added glucose also increased with 
storage, with the rate of increase accelerating in units with 7.5 mmol/L added glucose 
around day 6 and in units with 15 mmol/L after day 8 (figure 5.19). In contrast, no such 
accelerated rise in annexin V binding was observed in units with 30 mmol/L added 
glucose, with day 10 percent positive binding remaining at relatively low levels (15.73 
± 3.60 %) (table 5.40). Statistically significant differences were evident between all the 
test groups by end of storage (p<0.001).  
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Figure 5.19: Percent positive 
expression of annexin V binding 
(glucose study; mean ±SD, n=5; 
100%plasma n=3) 
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Table 5.39: Statistical comparison between test groups for Annexin V binding (% 
positive expression) – glucose study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA 0.094 <0.001 <0.001 <0.001 <0.001 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 3 Day 6 Day 8 Day 10 
GLU-300 vs. GLU-000 <0.001 (0.009) <0.001 (0.009) <0.001 (0.009) <0.001 (0.009) 
GLU-150 vs. GLU-000 <0.001 (0.013) <0.001 (0.010) <0.001 (0.010) <0.001 (0.013) 
GLU-075 vs. GLU-000 <0.001 (0.010) <0.001 (0.013) <0.001 (0.025) 0.008 (0.050) 
GLU-300 vs. GLU-075 NS 0.005 (0.017) <0.001 (0.013) <0.001 (0.010) 
GLU-300 vs. GLU-150 NS NS NS 0.001 (0.025) 
GLU-150 vs. GLU-075 NS NS <0.001 (0.017) 0.001 (0.017) 
Statistical significance: Unadjusted P value (critical Level)  NS = Not significant  
 
 
 
Table 5.40: Summary results for Annexin V binding (% positive expression) - 
glucosestudy 
Annexin V binding (% positive) Final Concentration 
of Added 
Glucose Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 13.53 ± 3.60 26.02 ± 3.57 48.94 ± 3.66 60.40 ± 4.04 66.31 ± 4.88 
7.5 mmol/L 9.11 ± 2.86 10.13 ± 3.16 18.95 ± 5.76 40.98 ± 3.60 52.65 ± 4.40 
15 mmol/L 9.49 ± 2.22 10.79 ± 3.04 12.87 ± 3.72 16.25 ± 3.68 33.35 ± 12.15 
30 mmol/L 9.42 ± 2.96 9.60 ± 2.24 10.67 ± 2.35 15.35 ± 3.80 15.73 ± 3.60 
Mean ± SD (n=5) 
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Mean fluorescence intensity (MFI) was higher throughout storage in the test group 
lacking glucose (figure 5.20). This resulted in statistically significant differences on day 
3, 6 and 8 between units lacking glucose and at least two of the other test groups 
(p<0.001, p=0.009 and p=0.001, respectively) (table 5.41). However, no association 
between glucose concentration in the medium and annexin V binding MFI was seen. 
MFI was retained at relatively stable levels in all test groups to the end of storage, with 
no statistically significant difference between any of the test groups by day 10 
(p=0.107) (table 5.41).  
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Figure 5.20: Annexin V 
binding expressed as MFI 
(glucose study; mean ± 
SD, n=5; 100%plasma 
n=3) 
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Table 5.41: Statistical comparison for Annexin V binding (MFI) – glucose study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA 0.134 <0.001 0.009 0.001 0.107 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 3 Day 6 Day 8 
GLU-300 vs. GLU-000 <0.001 (0.009) NS <0.001 (0.009) 
GLU-150 vs. GLU-000 0.001 (0.013) 0.006 (0.010) 0.001 (0.010) 
GLU-075 vs. GLU-000 <0.001 (0.010) 0.004 (0.009) NS 
GLU-300 vs. GLU-075 NS NS NS 
GLU-300 vs. GLU-150 NS NS NS 
GLU-150 vs. GLU-075 NS NS NS 
Statistical significance: Unadjusted P value (critical Level)  NS = Not significant  
 
Table 5.42: Summary results for Annexin V binding expressed as MFI - glucose study 
Annexin V binding (mean fluorescence intensity) Final 
Concentration 
of Added 
Glucose Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 39.9 ± 7.3 50.4 ± 5.6 48.2 ± 7.4 49.7 ± 7.8 46.5 ± 4.3 
7.5 mmo/L 31.7 ± 5.8 34.7 ± 6.1 35.5 ± 3.1 42.4 ± 5.5 39.9 ± 7.0 
15 mmol/L 35.6 ± 6.6 36.3 ± 5.5 36.2 ± 6.6 36.2 ± 2.5 38.7 ± 5.0 
30 mmol/L 31.0 ± 5.2 34.5 ± 4.8 44.1 ± 5.7 35.3 ± 1.4 41.9 ± 2.4 
Mean ± SD (n=5) 
 
The concentrations of the four phosphatidylethanolamine (PE) species are shown in 
figure 5.21. Levels of all four forms of PE increased with storage, with the expressions 
in the unit lacking glucose consistently higher than in the units containing added 
glucose. A suggestion of a dose-dependent pattern in the three units containing glucose 
may be evident in that the expression of all PE forms was lower in the unit with 30 
mmol/L added glucose. However, it would be premature to infer a relationship between 
the extent of PE expression and glucose concentration from one result. Initial 
determination of surface phospholipid exposure by mass spectrometry generated results 
for phosphatidylserine that did not confirm the pattern obtained by flow cytometric 
annexin V binding (percent positive results) in that a decrease in expression with 
storage was noted in all four test groups and no clear difference in results between the 
different concentrations of glucose was seen. To confirm whether these results were 
204 
 
reproducible, a further set of mass spectrometry measurements were undertaken and it is 
the results from this second experiment that are reproduced here. The expression of 
phosphatidylserine obtained by mass spectrometry showed a decrease in expression 
with storage, noted in all four test groups, and no clear difference in results between the 
different concentrations of glucose – a marked deviation from the pattern obtained by 
annexin V binding. A similar set of results was obtained with both experiments, 
suggesting that the discrepant results are not necessarily due to an error in the 
preparation of the samples for mass spectrometry.  
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Figure 5.21: Expression of 
aminophospholipids on platelet surface, 
showing an increase in PE expression with 
storage with a concomitant decrease in PS 
expression 
(glucose study; representative sample) 
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Mitochondrial Membrane Potential 
Mitochondrial membrane potential on day 2 showed similar activity in all three test 
groups containing glucose, with mean ratios between 8.66 ± 1.23 for units with 7.5 
mmol/L to 9.03 ± 1.01 in units with 30 mmol/L. By contrast, units lacking glucose had 
significantly lower mean ratios of 5.98 ± 1.15 (p=0.004) (table 5.43). Levels decreased 
with storage in all four test groups. In units without added glucose, MMP ratios 
stabilised by day 6 at approximately 3 (2.95 ± 0.10 on day 10); close to the assay limit 
of 2.7 suggested by the albumin-containing units in study 2. Figure 5.22 suggests an 
accelerated disruption of the MMP occurred with lower concentrations of added 
glucose, with mean day 8 ratios of 3.30 ± 0.16 and 5.65 ± 1.76 in units with 7.5 mmol/L 
and 30mmol/L added glucose, respectively (p=0.006) (table 5.44). 
 
 
 
 
 
 
 
 
 
 
Figure 5.22: Mitochondrial 
membrane potential (red/green ratio) 
(glucose study; mean ± SD, n=5; 
100% plasma n=3) 
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Table 5.43: Statistical comparison for MMP (JC-1 Red/Green Fluorescence) – glucose 
study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA 0.004 <0.001 <0.001 0.006 0.022 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 2 Day 3 Day 6 Day 8 
GLU-300 vs. GLU-000 0.001 (0.009) <0.001 (0.013) 
<0.001 
(0.009) 0.003 (0.009) 
GLU-150 vs. GLU-000 0.003 (0.010) <0.001 (0.009) 0.001 (0.010) NS 
GLU-075 vs. GLU-000 0.004 (0.013) <0.001 (0.010) 0.002 (0.013) NS 
GLU-300 vs. GLU-075 NS NS NS 0.006 (0.010) 
GLU-300 vs. GLU-150 NS NS NS NS 
GLU-150 vs. GLU-075 NS NS NS NS 
Statistical significance: Unadjusted P value (critical Level)  NS = Not significant  
 
Table 5.44: Summary results for mitochondrial membrane potential - glucose study  
Mitochondrial membrane potential (JC-1 Red/Green MFI) Final 
Concentration 
of Added 
Glucose Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 5.98 ± 1.15 4.15 ± 0.59 3.18 ± 0.13 3.01 ± 0.06 2.95 ± 0.10 
7.5 mmol/L 8.66 ± 1.23 8.34 ± 0.74 5.64 ± 1.14 3.30 ± 0.16 3.17 ± 0.06 
15 mmol/L 8.73 ± 1.53 8.46 ± 0.61 5.74 ± 1.57 5.00 ± 1.53 3.67 ± 1.02 
30 mmol/L 9.03 ± 1.01 7.90 ± 1.30 6.67 ± 0.71 5.65 ± 1.76 4.73 ± 1.39 
Mean ± SD; n=5 
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Intracellular free calcium 
Intracellular free calcium levels were similar on days 2 and 3, with no statistically 
significant differences evident between the four test groups (p=0.745 on day 2 and 
p=0.929 on day 3) (table 5.45). Beyond this time point levels deviated (figure 5.23). 
They remained stable in units with 30 mmol/L throughout the storage period. In units 
with 15 mmol/L added glucose, levels remained similarly stable until day 8, increasing 
to a mean ratio of 0.46 ± 0.17 on day 10 from a mean of 0.34 ± 0.05 on day 8. A similar 
increase was observed earlier in the storage period in units with 7.5 mmol/L added 
glucose, with day 8 levels increasing to a mean of 0.52 ± 0.9 on day 8 from a mean ratio 
of 0.35 ± 0.05 on day 6 (table 5.46). Levels in this last test group continued to increase, 
with no statistically significant differences observed between this test group and units 
lacking added glucose on either day 8 or 10 (table 5.45). Of note is that the numerical 
values for the ratios of Fluo-4/Fura-Red observed in this study were markedly lower 
than the levels observed with the addition of the calcium ionophore A23187 (14.95 ± 
3.41 in units with no added glucose on day 10) and suggest that the release of calcium 
into the cytosol was relatively low.  
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Figure 5.23: Intracellular free 
calcium 
(glucose study; mean ± SD, n=5; 
100% plasma n=3) 
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Table 5.45: Statistical comparison for intracellular free calcium – glucose study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA 0.745 0.929 0.003 <0.001 <0.001 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 6 Day 8 Day 10 
GLU-300 vs. GLU-000 0.001 (0.009) <0.001 (0.009) <0.001 (0.009) 
GLU-150 vs. GLU-000 0.002 (0.010) <0.001 (0.010) 0.001 (0.013) 
GLU-075 vs. GLU-000 0.008 (0.013) NS NS 
GLU-300 vs. GLU-075 NS 0.001 (0.013) <0.001 (0.010) 
GLU-300 vs. GLU-150 NS NS NS 
GLU-150 vs. GLU-075 NS 0.002 (0.017) 0.004 (0.017) 
Statistical significance: Unadjusted P value (critical Level)  NS = Not significant  
 
Table 5.46: Summary results for intracellular free calcium - glucose study 
Intracellular free calcium (Fluo-4/FuraRed) Final 
Concentration 
of Added 
Glucose Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 0.35 ± 0.06 0.33 ± 0.05 0.51 ± 0.15 0.62 ± 0.11 0.89 ± 0.20 
7.5 mmol/L 0.33 ± 0.04 0.31 ± 0.04 0.35 ± 0.05 0.52 ± 0.09 0.81 ± 0.20 
15 mmol/L 0.35 ± 0.05 0.32 ± 0.05 0.31 ± 0.05 0.34 ± 0.05 0.46 ± 0.17 
30 mmol/L 0.32 ± 0.03 0.32 ± 0.04 0.30 ± 0.03 0.33 ± 0.03 0.31 ± 0.02 
Mean ±SD; n=5 
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A more detailed examination of the flow cytometry histograms revealed a distinct sub-
population of platelets was responsible for the overall increase in the Fluo-4/FuraRed 
ratios, and that this sub-population failed to respond to the addition of A23187 (figure 
5.24).  
 
 
Figure 5.24: Staining characteristics of platelets incubated with Fluo-4 and FuraRed in a 
representative unit with no added glucose. A) Day 2 platelets showing minimal uptake  of the 
dyes compared with B) which displays the response following the addition of 5 µL of 2 mM 
A23187. C + D) Histograms of platelets from the same unit on day 10 showing a sub-population 
of platelets in D3 with substantially reduced fluorescence from FuraRed and a lack of response 
to the addition of the calcium ionophore. 
  
 
A B 
C D 
TEST + A23187 
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DISCUSSION 
The depletion of glucose coincided with an increase in annexin V binding (% positive), 
as well as a decrease in ATP and platelet concentration (the last indicating platelet 
disruption), with a statistically significant loss of platelets with ATP levels below 2 
µmol/1011plts (p<0.001). The observed increase in soluble CD62P followed this 
timeline and may reflect platelet disruption in addition to shedding of surface of 
CD62P. The aminophospholipid translocase believed to be responsible for preferentially 
maintaining PE and PS on the inner leaflet of the plasma membrane is ATP-dependent 
(Zwaal and Schroit, 1997). Thus, a loss of translocase activity as ATP levels declined 
could at least partly explain the increase in phospholipid expression with storage. The 
steep rise in annexin V binding as glucose stores are depleted was coincident with 
increased levels of intracellular free calcium, though quantitatively the increases may be 
small and may not attain the micromolar concentrations that have been reported to 
accelerate the adverse effect on the translocase (Zwaal and Schroit, 1997). The increase 
in intracellular free calcium may also be directly related to the decline in ATP, since 
calcium-regulatory channels such as the sarco/endoplasmic Ca2+ ATPase (SERCA) and 
the plasma membrane Ca2+ ATPases (PMCA) are ATP-dependent (Varga-Szabo et al., 
2009). 
 
The synthesis of ATP is a critical role of mitochondria, driven by the electron transport 
chain on the inner mitochondrial membrane. Disruption of the proton motive force 
would result in depolarisation of the membrane potential, regarded in some studies as an 
early event in apoptosis (Mignotte and Vayssiere, 1998). The mitochondrial membrane 
potential (∆Ψm) was observed to decline from the start of the storage period in all units, 
indicating impaired function of the organelle with storage, irrespective of the glucose 
concentration. In addition, however, there were significantly lower levels in units 
lacking glucose. The results suggest a relationship between the presence of glucose and 
improved mitochondrial function (though care is required in the interpretation of the 
results due to the relatively high variability between replicates).  
 
The observations seemed consistent with the proposal that a process akin to apoptosis 
was a central component of the platelet storage lesion. However, the loss of ATP and 
cellular disruption coincident with the exhaustion of glucose stores is not consistentwith 
211 
 
the classical description of apoptosis, since this is an energy dependent process (Kung et 
al., 2011). A possible scenario is that platelets stored as concentrates in conditions 
where glucose is absent become progressively depleted in ATP, leading to the surface 
expression of aminophospholipids in a non-energy dependent process more reminiscent 
of necrosis. 
 
HSR and ESC values in SAS-suspended PCs were low compared with PCs re-
suspended in 100% plasma, as well as values reported in the literature for platelets 
stored in additive solutions containing potassium and magnesium (Gulliksson et al., 
2002, VandenBroeke et al., 2004). A possible explanation may lie in the harsh PC 
processing method in combination with the low residual plasma levels, which may have 
activated the platelets prior to storage. A further factor may be the lack of calcium in the 
SAS, with Wagner et al reporting lower ESC and higher surface CD62P expression in 
platelets suspended in M-Sol without Ca2+; an observation that concurs with the results 
in the present study (Wagner et al., 2010). The relatively high phosphate concentration 
may have also promoted glycolysis and may explain the relatively high glucose 
consumption rates compared to published results (Cardigan et al., 2008, Gulliksson et 
al., 2003).  
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CHAPTER 6. IMPACT ON PLATELET IN VITRO STORAGE 
CHARACTERISTICS OF THE INCLUSION OF ACETATE TO ADDITIVE 
SOLUTIONS 
 
INTRODUCTION  
Acetate is one of four reagents regarded by some authors as a beneficial, or even 
essential, component of platelet additive solutions (de Wildt-Eggen and Gulliksson, 
2003). It is believed to function as a substrate for aerobic metabolism, and has been 
found to decrease the requirement for glucose in the suspending medium (Ringwald et 
al., 2006). It is also expected to act as a buffer since its entry into the tricarboxylic acid 
cycle requires a hydrogen ion (Murphy, 1999), thus resulting in the maintenance of a 
higher extracellular pH. In addition, it is known to reduce the production of lactate, 
possibly due to an inhibitory effect on phosphofructokinase – a rate-limiting enzyme in 
glycolysis (Murphy, 1995). The majority of publications on the impact of acetate on 
platelet characteristics have concentrated on the metabolic effects, with less emphasis 
placed on its role on other aspects of the platelet storage lesion. This study thus aimed to 
determine the impact of different concentrations of acetate on platelet activation and 
indicators of cell death. 
 
All results are presented as mean ± standard deviation of 5 separate experiments, with 
statistical comparisons undertaken by a one way ANOVA. A p-value below 0.01 was 
considered statistically significant. Subsequent multiple comparisons were performed 
by the Holm-Sidak method, with an overall significance level of 0.05. The four test 
groups are: 
ACE-000-nn (no acetate added) 
ACE-014-nn (final concentration of 14 mmol/L) 
ACE-028-nn (final concentration of 28 mmol/L) 
ACE-056-nn (final concentration of 56 mmol/L) 
(In each case, nn refers to a unique test number) 
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The graphs also show the median ± range of 3 replicate experiments performed with PC 
manufactured by the same method but re-suspended in 100% autologous plasma to 
provide a visual estimation of the possible impact of the harsh processing on the platelet 
in vitro characteristics. 
  
RESULTS 
Platelet Yield and Volume 
The mean platelet yield and volume is reported in table 6.1, with all units meeting the 
UK Guidelines’ specification for platelet yield ≥240 × 109 per unit (James, 2005). 
Volumes were comparable to those obtained in studies 2 and 3. No statistically 
significant differences were evident between any of the groups for either platelet yield 
(p=0.988) or volume (p=0.952). All units were successfully leucedepleted (residual 
WBC count <1×106/unit) and were confirmed negative for bacterial contamination at 
the end of storage. 
 
Table 6.1: Platelet yield and unit volume prior to sampling  
Treatment Group Platelet Yield (×109/unit) Volume (mL) 
ACE-000-nn 286.2 ± 23.5 340.6 ± 3.1 
ACE-014-nn 283.5 ± 23.1 340.2 ± 6.5 
ACE-028-nn 282.1 ± 24.2 341.5 ± 4.7 
ACE-056-nn 281.3 ± 20.7 340.1 ± 1.7 
Data are presented as mean ± SD (n=5) 
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Function and Morphology 
Platelet Concentration and Mean Platelet Volume 
Platelet concentration decreased in all treatment groups with storage (figure 6.1). There 
was no statistically significant difference between groups at any time point (table 6.2). 
The loss of platelets was similar in all four test groups, with concentrations at the end of 
the storage period being 93.2 – 95.2% of day 2 levels (table 6.3). This loss was 
comparable to the decrease noted in conventionally manufactured platelet concentrates 
in plasma (92.8%) reported in chapter 3.  
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Table 6.2: Statistical comparison for platelet concentration - acetate study 
Comparison Between Groups (One Way ANOVA) 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA 0.985 0.824 0.974 0.952 0.949 
 
Table 6.3: Summary results for platelet concentration - acetate study 
Platelet concentration (x109/L) Final Concentration 
of Added 
Acetate Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 840 ± 65 849 ± 61 835 ± 62 824 ± 52 791 ± 72 
14 mmol/L 834 ± 73 846 ± 75 832 ± 78 812 ± 69 794 ± 73 
28 mmol/L 826 ± 64 816 ± 62 824 ± 72 814 ± 66 779 ± 73 
56 mmol/L 827 ± 62 815 ± 64 815 ± 79 800 ± 72 771 ± 63 
Mean ± SD (n=5) 
 
Figure 6.1: Platelet concentration 
 (acetate study; mean, n=5; 100% 
plasma n=3) 
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Day 2 values for mean platelet volume ranged from a mean of 7.9 ± 0.2 fL in units with 
no added acetate to 8.1 ± 0.2 fL in units with 56 mmol/L added acetate (p=0.444) (Table 
6.5). MPV increased with storage in all test groups. The increase was greater in units 
with no added acetate and units with the highest concentration of acetate (56 mmol/L), 
with statistically significant differences between these units and the remaining two test 
groups on day 8 (p<0.001) (table 6.4). It should be noted, however, that the mean 
differences in MPV on day 10 between the test groups was a maximum of 0.5 fL but 
this was not associated with platelet disruption, as shown by the lack of significant 
differences in the platelet concentration.  
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Figure 6.2: Mean platelet volume 
 (acetate study; mean, n=5; 
100% plasma n=3) 
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Table 6.4: Statistical comparison for mean platelet volume - acetate study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA 0.444 0.261 <0.001 <0.001 0.016 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 6 Day 8 
ACE-056 vs. ACE-000 NS NS 
ACE-028 vs. ACE-000 0.001(0.010) 0.005 (0.017) 
ACE-014 vs. ACE-000 <0.001(0.009) <0.001 (0.010) 
ACE-056 vs. ACE-014 0.006(0.013) <0.001 (0.009) 
ACE-056 vs. ACE-028 NS 0.002 (0.013) 
ACE-028 vs. ACE-014 NS NS 
Statistical significance: Unadjusted P value (critical Level)  NS = Not significant  
 
Table 6.5: Summary results for mean platelet volume - acetate study 
Mean platelet volume (fL) Final 
Concentration 
of Added 
Acetate 
Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 7.9 ± 0.2 7.9 ± 0.2 8.7 ± 0.3 8.8 ± 0.3 9.2 ± 0.2 
14 mmol/L 7.9 ± 0.2 7.9 ± 0.2 8.1 ± 0.2 8.3 ± 0.1 8.7 ± 0.4 
28 mmol/L 8.0 ± 0.2 7.9 ± 0.2 8.1 ± 0.2 8.4 ± 0.0 8.7 ± 0.3 
56 mmol/L 8.1 ± 0.2 8.1 ± 0.2 8.5 ± 0.1 8.8 ± 0.3 9.2 ± 0.3 
Mean ± SD (n=5) 
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Swirling 
Swirling at the end of the storage period was moderate to strong in all test groups. In 
units with no added acetate and 14 mmol/L acetate, swirling was at least moderate 
throughout the storage period. In units with 28 mmol/L and 56 mmol/L acetate, weak 
swirling was seen in some of the units on day 2 but improved over the storage period 
(table 6.6).  
 
Table 6.6: Swirling - acetate study (individual results) 
DAY 2 DAY 3 DAY 6 DAY 8 DAY 10
ACE-000-01 3 2 3 3 3
ACE-000-05 2 3 3 3 3
ACE-000-09 2 2 3 3 3
ACE-000-13 2 2 2 2 2
ACE-000-17 2 3 2 2 2
ACE-014-02 2 2 3 3 3
ACE-014-06 2 3 3 3 3
ACE-014-10 2 2 3 3 3
ACE-014-14 2 2 2 2 2
ACE-014-18 2 2 2 2 2
ACE-028-03 2 2 2 3 3
ACE-028-07 2 2 3 3 3
ACE-028-11 2 2 3 3 3
ACE-028-15 1 2 2 2 2
ACE-028-19 1 1 2 2 2
ACE-056-04 2 2 2 3 3
ACE-056-08 2 2 3 3 3
ACE-056-12 1 1 2 3 3
ACE-056-16 1 2 2 2 2
ACE-056-20 1 1 2 2 2
56 mmol/l
Final Concentration 
of Added Acetate 
(mmol/l) 
TEST NUMBER
Swirling
0 mmol/l
14 mmol/l
28 mmol/l
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Hypotonic Shock Response and Extent of Shape Change 
Statistically significant differences in hypotonic shock responses were observed on day 
2 between all the test groups with the exception of units with no added acetate and units 
with 14 mmol/L acetate (p<0.001). Mean day 2 levels in units with no acetate were 45.4 
± 4.7% compared to 16.5 ± 5.7% in units with 56 mmol/L acetate (p<0.001) (table 6.7). 
HSR in the latter test group remained stable throughout the storage period. The chart 
recordings from such low responses were virtually flat and suggested the limits of this 
assay were being reached. However, the responses in the test group with 28 mmol/L 
acetate were also observed to be fairly stable, reducing from a  mean of 27.7 ± 9.2% on 
day 2 to 23.1 ± 3.2% on day 10 (83% of day 2 values) (table 6.8). By contrast, the 
responses in units with no acetate decreased to 63% of day 2 levels by end of storage 
(45.4 ± 4.7% to 28.4 ± 3.8% by day 10). The pattern suggests a dose-dependent effect 
of acetate on the hypotonic shock response occurred early during the storage period, 
prior to the onset of measurements (figure 6.3).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3: Hypotonic shock 
response (acetate study; mean ± 
SD, n=5; 100% plasma n=3) 
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Table 6.7: Statistical comparison of hypotonic shock response - acetate study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA <0.001 <0.001 <0.001 <0.001 <0.001 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 2 Day 3 Day 6 Day 8 Day 10 
ACE-056 vs. ACE-000 <0.001 (0.009) 
<0.001 
(0.009) 
<0.001 
(0.009) 
<0.001 
(0.009) 
<0.001 
(0.009) 
ACE-028 vs. ACE-000 <0.001 (0.013) 
<0.001 
(0.013) 
0.005 
(0.017) 
0.007 
(0.013) NS 
ACE-014 vs. ACE-000 NS NS NS NS NS 
ACE-056 vs. ACE-014 <0.001 (0.010) 
<0.001 
(0.010) 
<0.001 
(0.010) 
<0.001 
(0.010) 
<0.001 
(0.010) 
ACE-056 vs. ACE-028 0.009 (0.017) 
0.011 
(0.025) 
0.002 
(0.013) NS 
0.005 
(0.013) 
ACE-028 vs. ACE-014 0.023 (0.025) 
0.010 
(0.017) NS 
0.012 
(0.017) NS 
Statistical significance: Unadjusted P value (critical level) NS = Not significant  
 
Table 6.8: Summary results for hypotonic shock response - acetate study 
Hypotonic shock response (%) Final 
Concentration 
of Added 
Acetate 
Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 45.4 ± 4.7 43.7 ± 5.2 36.5 ± 5.5 31.2 ± 2.6 28.4 ± 3.8 
14 mmol/L 37.4 ± 2.3 37.6 ± 6.1 30.8 ± 4.9 30.5 ± 5.0 27.4 ± 3.1 
28 mmol/L 27.7 ± 9.2 27.3 ± 5.9 26.9 ± 5.1 23.3 ± 3.3 23.1 ± 3.2 
56 mmol/L 16.5 ± 5.7 17.0 ± 5.3 15.6 ± 3.1 17.8 ± 4.6 15.5 ± 4.5 
Mean ± SD (n=5) 
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The same general pattern noted for hypotonic shock response was observed with extent 
of shape change (figure 6.4), although statistically significant differences were only 
present on day 3 between units with 56 mmol/L acetate and units with either 14 mmol/L 
acetate or no acetate (p=0.002) (table 6.9). Mean day 3 results in units with no added 
acetate were 19.1 ± 3.1% compared with 10.2 ± 4.7% for units with 56 mmol/L. The 
response decreased by day 10 to a mean of 11.8 ± 1.7% and 8.0 ± 2.5, respectively 
(p=0.041) (table 6.10).  
 
 
Table 6.6: Extent of shape change in acetate study 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4: Extent of shape change 
 (acetate study; mean ± SD, n=5; 
100% plasma n=3) 
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Table 6.9: Statistical comparison for extent of shape change - acetate study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA 0.018 0.002 0.027 0.115 0.041 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 3 
ACE-056 vs. ACE-000 <0.001 (0.009) 
ACE-028 vs. ACE-000 NS 
ACE-014 vs. ACE-000 NS 
ACE-056 vs. ACE-014 0.003 (0.010) 
ACE-056 vs. ACE-028 NS 
ACE-028 vs. ACE-014 NS 
Statistical significance: Unadjusted P value (critical level) NS = Not significant  
 
Table 6.10: Summary results for extent of shape change - acetate study 
Extent of shape change (%) Final 
Concentration 
of Added 
Acetate 
Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 18.6 ± 3.1 19.1 ± 3.1 16.2 ± 2.9 12.5 ± 2.8 11.8 ± 1.7 
14 mmol/L 16.8 ± 3.8 17.3 ± 2.7 13.4 ± 3.1 12.7 ± 2.0 10.6 ± 1.7 
28 mmol/L 15.8 ± 3.1 13.4 ± 2.1 12.7 ± 2.4 11.1 ± 2.2 9.8 ± 1.7 
56 mmol/L 11.3 ± 3.2 10.2 ± 4.7 10.2 ± 2.6 9.5 ± 1.8 8.0 ± 2.5 
Mean ± SD (n=5) 
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Platelet Metabolism 
Extracellular pH (37°C) 
pH(37°C) levels in all test groups were similar on day 2 (p=0.198), with mean levels 
ranging between 7.252 ± 0.011 and 7.275 ± 0.015 in units with 0 mmol/L and 28 
mmol/L acetate, respectively (table 6.12). Levels subsequently decreased with storage 
in all test groups, with the rate of decrease significantly greater in the test group lacking 
acetate (figure 6.5). Statistically significant differences were present between these units 
and units with added acetate on days 3 (p=0.002), 6 and 8 (p<0.001 for both days), with 
pH37°C in units lacking acetate reaching a minimum level of 6.817 ± 0.050 on day 8. 
Figure 6.5 suggests that in units with added acetate, pH37°C decreased more rapidly in 
units with 56 mmol/L acetate compared with the remaining two test groups, with 
statistically significant differences between units with 56 mmol/L and 28 mmol/L 
acetate on day 8 (mean levels of 6.999 ± 0.042 and 7.080 ± 0.026, respectively; 
p<0.001) and between units with 56 mmol/L and 14 mmol/L acetate on day 10 (mean 
levels of 6.902 ± 0.061 and 6.994 ± 0.028, respectively; p=0.001) (table 6.11). The 
increase in pH37°C in units lacking acetate observed after day 8 may be attributable to 
the depletion of glucose stores in these units (figure 6.6).  
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Figure 6.5: pH (37°C) 
 (acetate study; mean ± SD,  
n=5; 100% plasma n=3) 
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Table 6.11: Statistical comparison for pH (37°C) - acetate study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA 0.198 0.002 <0.001 <0.001 0.001 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 3 Day 6 Day 8 Day 10 
ACE-056 vs. ACE-000 0.005 (0.013) <0.001 (0.013) 
<0.001 
(0.013) NS 
ACE-028 vs. ACE-000 <0.001 (0.009) 
<0.001 
(0.009) 
<0.001 
(0.009) 0.005 (0.013) 
ACE-014 vs. ACE-000 0.005 (0.010) <0.001 (0.010) 
<0.001 
(0.010) 
<0.001 
(0.009) 
ACE-056 vs. ACE-014 NS NS NS 0.004 (0.010) 
ACE-056 vs. ACE-028 NS NS 0.010 (0.017) NS 
ACE-028 vs. ACE-014 NS NS NS NS 
Statistical significance: Unadjusted P value (critical level) NS = Not significant  
 
 
Table 6.12: Summary results for pH (37°C) - acetate study 
pH (37°C) Final Concentration 
of Added 
Acetate Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 7.252 ± 0.011 
7.198 ± 
0.023 
6.946 ± 
0.055 
6.817 ± 
0.050 
6.866 ± 
0.045 
14 mmol/L 7.257 ± 0.023 
7.248 ± 
0.033 
7.159 ± 
0.047 
7.060 ± 
0.051 
6.994 ± 
0.028 
28 mmol/L 7.275 ± 0.015 
7.271 ± 
0.019 
7.180 ± 
0.020 
7.080 ± 
0.026 
6.955 ± 
0.034 
56 mmol/L 7.258 ± 0.017 
7.248 ± 
0.020 
7.127 ± 
0.026 
6.999 ± 
0.042 
6.902 ± 
0.061 
Mean ± SD (n=5) 
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Glucose and Lactate Levels 
Glucose levels decreased at approximately the same rate in all units containing acetate, 
with no statistically significant differences between these three test groups at any point 
during storage (table 6.13). Levels on day 2 ranged from 10.5 ± 1.4 mmol/L in units 
with 14 mmol/L acetate to 12.1 ± 0.7 mmol/L in units with 28 mmol/L acetate. By the 
end of storage, glucose stores had been essentially depleted in units with 56 mmol/L 
acetate (0.1 ± 0.3 mmol/L). In units with 14 mmol/L and 28 mmol/L acetate, day 10 
glucose levels were 0.9 ± 1.2 and 1.4 ± 0.8 mmol/L, respectively (table 6.14). In the 
units lacking acetate glucose was metabolised at a faster rate, with stores depleted by 
day 8 and a statistically significant difference between these units and the three test 
groups with added acetate (p<0.001) (table 6.13).   
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Figure 6.6: Glucose levels 
 (acetate study; mean ± SD, n=5; 
100% plasma n=3)) 
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Table 6.13: Statistical comparison for glucose concentration - acetate study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA 0.250 0.155 0.003 <0.001 0.040 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 6 Day 8 
ACE-056 vs. ACE-000 0.008 (0.010) 0.004 (0.013) 
ACE-028 vs. ACE-000 <0.001 (0.009) <0.001 (0.009) 
ACE-014 vs. ACE-000 NS 0.003 (0.010) 
ACE-056 vs. ACE-014 NS NS 
ACE-056 vs. ACE-028 NS NS 
ACE-028 vs. ACE-014 NS NS 
Statistical significance: Unadjusted P value (critical level) NS = Not significant  
 
Table 6.14: Summary results for glucose concentration - acetate study 
Glucose concentration (mmol/L) Final Concentration 
of Added 
Acetate 
Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 11.6 ± 1.4 10.1 ± 1.5 3.6 ± 1.6 0.1 ± 0.2 0.0 ± 0.0 
14 mmol/L 10.5 ± 1.4 9.5 ± 1.5 6.1 ± 1.8 3.1 ± 2.0 0.9 ± 1.2 
28 mmol/L 12.1 ± 0.7 11.4 ± 0.5 7.7 ± 0.6 4.7 ± 0.8 1.4 ± 0.8 
56 mmol/L 11.2 ± 1.3 10.4 ± 1.3 6.4 ± 1.4 3.0 ± 1.7 0.1 ± 0.3 
Mean ± SD (n=5) 
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The pattern of glucose utilisation described above was mirrored in the levels of lactate, 
which increased at a faster rate in the test group lacking acetate. Lactate levels in these 
units reached a maximum of 22 ± 3 mmol/L on day 8, before decreasing marginally 
after the depletion of glucose (figure 6.7). In the three test groups with added acetate, 
lactate levels increased throughout storage, with no statistically significant differences 
at any time point (table 6.15). In contrast, statistically significant differences were 
observed between units with no exogenous acetate and the three test groups with added 
acetate on days 2 to 8 (p<0.001 to 0.001). By day 10 the cessation of lactate production 
in the former due to the depletion of glucose resulted in similar values for lactate 
concentration in all test groups (p=0.541) (table 6.15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7: Lactate levels 
 (acetate study; mean ± SD, 
n=5; 100% plasma n=3) 
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Table 6.15: Statistical comparison for lactate concentration - acetate study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA <0.001 <0.001 <0.001 0.001 0.541 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 2 Day 3 Day 6 Day 8 
ACE-056 vs. ACE-000 <0.001 (0.010) 
<0.001 
(0.010) 
<0.001  
(0.013) 0.003 (0.009) 
ACE-028 vs. ACE-000 0.001 (0.013) <0.001 (0.009) 
<0.001 
(0.010) 
<0.001 
(0.010) 
ACE-014 vs. ACE-000 <0.001 (0.009) 
<0.001  
(0.013) 
<0.001 
(0.009) 
<0.001 
(0.009) 
ACE-056 vs. ACE-014 NS NS NS NS 
ACE-056 vs. ACE-028 NS NS NS NS 
ACE-028 vs. ACE-014 NS NS NS NS 
Statistical significance: Unadjusted P value (critical level) NS = Not significant  
 
Table 6.16: Summary results for lactate concentration - acetate study 
Lactate concentration (mmol/L) Final Concentration 
of Added 
Acetate Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 2.7 ± 0.1 5.4 ± 0.5 16.5 ± 2.1 22 ± 3 21 ± 4 
14 mmol/L 2.2 ± 0.1 4.0 ± 0.2 10.4 ± 0.9 15 ± 2 19 ± 2 
28 mmol/L 2.3 ± 0.2 4.0 ± 0.3 10.4 ± 0.9 15 ± 1 20 ± 3 
56 mmol/L 2.2 ± 0.2 4.0 ± 0.5 11.2 ± 1.4 17 ± 2 21 ± 4 
Mean ± SD (n=5) 
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Glucose consumption and lactate production confirm that glucose stores were depleted 
more rapidly in units lacking acetate (figures 6.8 and 6.9). Rates in these units reached a 
maximum between days 3 to 6 (2.57 ± 0.14 mmol/day/1012plts for glucose 
consumption; 4.39 ± 0.42 mmol/day/1012plts for lactate production) (tables 6.18 and 
6.20). Beyond day 6 rates decreased, with minimal production of lactate between days 8 
and 10 coinciding with the depletion of glucose stores. Statistically significant 
differences in glucose consumption between units lacking acetate and the three test 
groups with added acetate were observed between days 2 to 3, 3 to 6 and between days 
8 to 10 (p<0.001 in all cases) (table 6.17). Similar differences were found in lactate 
production (table 6.21). No significant differences were evident between the three test 
groups containing exogenous acetate.  
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Figure 6.8: Glucose consumption 
 (acetate study; mean ± SD, n=5; 
100% plasma n=3) 
 
Figure 6.9: Lactate production 
 (acetate study; mean ± SD, n=5; 
100% plasma n=3) 
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Table 6.17: Statistical comparison for glucose consumption - acetate study 
Comparison Between Groups 
 Day 2-3 Day 3-6 Day 6-8 Day 8-10 
One Way ANOVA <0.001 <0.001 0.580 <0.001 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 2-3 Day 3-6 Day 8-10 
ACE-056 vs. ACE-000 <0.001 (0.002) <0.001 (0.003) <0.001 (0.002) 
ACE-028 vs. ACE-000 <0.001 (0.002) <0.001 (0.002) <0.001 (0.002) 
ACE-014 vs. ACE-000 NS <0.001 (0.002) NS 
ACE-056 vs. ACE-014 NS NS NS 
ACE-056 vs. ACE-028 NS NS NS 
ACE-028 vs. ACE-014 NS NS NS 
Statistical significance: Unadjusted P value (critical level) NS = Not significant  
 
Table 6.18: Summary results for glucose consumption - acetate study 
Glucose consumption (mmol/day/1012 plts) Final 
Concentration 
of Added 
Acetate 
Day 2-3 Day 3-6 Day 6-8 Day 8-10 
0 mmol/L 1.78 ± 0.16 2.57 ± 0.14 2.12 ± 0.89 0.06 ± 0.14 
14 mmol/L 1.21 ± 0.20 1.40 ± 0.15 1.79 ± 0.21 1.46 ± 0.63 
28 mmol/L 0.92 ± 0.34 1.53 ± 0.13 1.81 ± 0.15 2.11 ± 0.21 
56 mmol/L 1.00 ± 0.39 1.66 ± 0.16 2.09 ± 0.24 1.85 ± 1.03 
Mean ± SD (n=5) 
 
Table 6.19: Statistical comparison for lactate production - acetate study 
Comparison Between Groups 
 Day 2-3 Day 3-6 Day 6-8 Day 8-10 
One Way ANOVA <0.001 <0.001 0.772 <0.001 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 2-3 Day 3-6 Day 8-10 
ACE-056 vs. ACE-000 <0.001 (0.002) <0.001 (0.003) <0.001 (0.002) 
ACE-028 vs. ACE-000 <0.001 (0.002) <0.001 (0.002) <0.001 (0.002) 
ACE-014 vs. ACE-000 <0.001 (0.003) <0.001 (0.002) 0.002 (0.003) 
ACE-056 vs. ACE-014 NS NS NS 
ACE-056 vs. ACE-028 NS NS NS 
ACE-028 vs. ACE-014 NS NS NS 
Statistical significance: Unadjusted P value (critical level) NS = Not significant  
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Table 6.20: Summary results for lactate production – acetate study 
Lactate production (mmol/day/1012 plts) Final 
Concentration 
of Added 
Acetate 
Day 2-3 Day 3-6 Day 6-8 Day 8-10 
0 mmol/L 3.24 ± 0.24 4.39 ± 0.42 3.26 ± 1.59 -0.61 ± 0.29 
14 mmol/L 2.20 ± 0.21 2.57 ± 0.22 2.90 ± 0.34 2.29 ± 0.89 
28 mmol/L 2.07 ± 0.18 2.64 ± 0.18 3.03 ± 0.30 3.11 ± 0.80 
56 mmol/L 2.18 ± 0.38 2.96 ± 0.36 3.44 ± 0.59 2.94 ± 2.01 
Mean ± SD (n=5) 
 
Bicarbonate Levels 
Bicarbonate levels on day 2 ranged from 14.83 ± 1.77 mmol/L in units with 14 mmol/L 
acetate to 16.22 ± 0.38 mmol/L in units with 28 mmol/L acetate (table 6.22), with no 
statistically significant differences between any of the test groups (p=0.315) on days 2 
and 3 (p=0.308). Beyond day 3, bicarbonate levels decreased at a faster rate in units 
with no added acetate, with statistically significant differences between these units and 
the test groups with acetate at all remaining time points (p<0.001 in all cases) (figure 
6.10), reflecting the more acute consumption of glucose in the test group lacking 
acetate. Bicarbonate levels in units with no exogenous acetate reached a minimum on 
day 10 of 2.63 ± 0.24 mmol/L compared to 5.79 ± 0.91 mmol/L in units with 28 
mmol/L acetate (table 6.22). There was a suggestion that bicarbonate was more rapidly 
consumed in units with 56 mmol/L compared with the other two test groups containing 
acetate, with statistically significant differences on day 10 against the test groups with 
14 and 28 mmol/L added acetate (table 6.21).  
Day tested
1 2 3 4 5 6 7 8 9 10 11
Bi
ca
rb
o
n
at
e
 
co
n
ce
n
tra
tio
n
 
(37
o
C)
 
(m
m
o
l/L
) 
0
2
4
6
8
10
12
14
16
18
20
22
ACE-000-nn 
ACE-014-nn 
ACE-028-nn 
ACE-056-nn 
100% PLASMA 
 
Figure 6.10: Bicarbonate 
concentration (37°C) 
 (acetate study; mean ± SD, n=5; 
100% plasma n=3) 
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Table 6.21: Statistical comparison for bicarbonate concentration - acetate study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA 0.315 0.308 <0.001 <0.001 <0.001 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 6 Day 8 Day 10 
ACE-056 vs. ACE-000 <0.001 (0.013) <0.001 (0.013) <0.001 (0.013) 
ACE-028 vs. ACE-000 <0.001 (0.009) <0.001 (0.009) <0.001 (0.009) 
ACE-014 vs. ACE-000 <0.001 (0.010) <0.001 (0.010) <0.001 (0.010) 
ACE-056 vs. ACE-014 NS NS 0.002 (0.025) 
ACE-056 vs. ACE-028 NS 0.007 (0.017) <0.001 (0.017) 
ACE-028 vs. ACE-014 NS NS NS 
Statistical significance: Unadjusted P value (critical level) NS = Not significant  
 
Table 6.22: Summary results for bicarbonate concentration - acetate study 
Bicarbonate concentration (mmol/L) Final 
Concentration 
of Added 
Acetate 
Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 15.99 ± 1.19 14.00 ± 1.12 6.98 ± 0.80 3.59 ± 0.23 2.63 ± 0.24 
14 mmol/L 14.83 ± 1.77 13.72 ± 1.36 10.35 ± 0.87 7.85 ± 0.69 5.56 ± 0.26 
28 mmol/L 16.22 ± 0.38 15.02 ± 0.34 11.46 ± 0.66 8.65 ± 0.79 5.79 ± 0.91 
56 mmol/L 15.34 ± 1.25 14.17 ± 1.25 10.21 ± 0.97 7.23 ± 0.97 4.23 ± 0.53 
Mean ± SD (n=5) 
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Blood Gases 
Partial pressures of oxygen increased steadily in units with added acetate throughout the 
storage period, from day 2 pressures of approximately 13.5 kPa to day 10 pressures 
ranging from 17.5 ± 1.5 kPa in units with 14 mmol/L acetate to 19.3 ± 1.6 kPa in units 
with 56 mmol/L acetate (table 6.24). However, no statistically significant differences 
were evident between any of these three test groups at any time point (table 6.23). Day 2 
pO2 mean values in units lacking acetate were higher than in the test groups containing 
acetate (16.2 ± 1.4 kPa compared with 13.5 kPa), though this did not result in a 
statistically significant difference (p=0.042). Partial pressures continued to increase and 
reached a maximum on day 6 (19.3 ± 1.0 kPa), with statistically significant differences 
evident between units with no added acetate and all three test groups containing acetate 
(p=0.002) (table 6.23, figure 6.11). By the end of storage, no statistically significant 
differences were observed between any of the test groups (p=0.116).  
  
 
 
 
 
 
 
 
 
 
 
 
Figure 6.11: pO2 (37°C) 
(acetate study; mean ± SD , n=5; 
100% plasma n=3) 
 
Day tested
1 2 3 4 5 6 7 8 9 10 11
pO
2 
(37
o
C)
 
(kP
a)
10
12
14
16
18
20
22
ACE-000-nn 
ACE-014-nn 
ACE-028-nn 
ACE-056-nn 
100% PLASMA 
233 
 
 
Table 6.23: Statistical comparison for pO2 - acetate study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA 0.042 0.117 0.002 0.234 0.116 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 6 
ACE-056 vs. ACE-000 0.002 (0.013) 
ACE-028 vs. ACE-000 <0.001 (0.009) 
ACE-014 vs. ACE-000 0.001 (0.010) 
ACE-056 vs. ACE-014 NS 
ACE-056 vs. ACE-028 NS 
ACE-028 vs. ACE-014 NS 
Statistical significance: Unadjusted P value (critical level) NS = Not significant  
 
Table 6.24: Summary results for pO2 (37°C) - acetate study 
pO2 (37°C) (kPa) Final Concentration 
of Added 
Acetate 
Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 16.2 ± 1.4 17.1 ± 1.7 19.3 ± 1.0 18.6 ± 1.6 19.5 ± 1.5 
14 mmol/L 13.3 ± 1.8 14.7 ± 1.6 16.0 ± 1.6 16.8 ± 1.3 17.5 ± 1.5 
28 mmol/L 13.7 ± 2.0 14.7 ± 2.0 15.8 ± 1.4 16.7 ± 1.8 17.9 ± 1.6 
56 mmol/L 13.3 ± 1.6 14.5 ± 1.9 16.3 ± 1.1 17.5 ± 1.5 19.3 ± 1.6 
Mean ± SD (n=5) 
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In units containing added acetate, pCO2 decreased gradually with storage from day 2 
levels between 4.03 ± 0.27 kPa to 4.25 ± 0.13 kPa in units with 14 and 28 mmol/L 
acetate, respectively, to end of storage values between 2.66 ± 0.58 kPa and 3.16 ± 0.35 
kPa in units with 56 and 28 mmol/L acetate, respectively (table 6.26). There were no 
statistically significant differences between any of the groups with acetate at any time 
during storage (table 6.25). Units with no added acetate had starting pCO2 values 
similar to the other three test groups (p=0.115). Beyond day 6, pCO2 decreased faster 
compared to the other test groups, resulting in day 10 values of 1.77 ± 0.18 kPa and 
statistically significant differences compared to units containing acetate (p<0.001) (table 
6.25) (figure 6.12). This decrease in pCO2 coincided with the decrease in pO2 between 
days 6 and 8 and the decrease in the rate of glucose consumption. 
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Figure 6.12: pCO2 (37°C) 
(acetate study; mean ± SD, n=5; 
100% plasma n=3) 
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Table 6.25: Statistical comparison for pCO2  - acetate study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA 0.115 0.007 0.238 0.002 <0.001 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 3 Day 8 Day 10 
ACE-056 vs. ACE-000 0.009 (0.010) <0.001 (0.009) 0.001 (0.013) 
ACE-028 vs. ACE-000 NS <0.001 (0.010) <0.001 (0.009) 
ACE-014 vs. ACE-000 0.001 (0.009) 0.005 (0.013) <0.001 (0.010) 
ACE-056 vs. ACE-014 NS NS NS 
ACE-056 vs. ACE-028 NS NS NS 
ACE-028 vs. ACE-014 NS NS NS 
Statistical significance: Unadjusted P value (critical level) NS = Not significant  
 
 
Table 6.26: Summary results for pCO2 (37°C) - acetate study 
pCO2 (37°C) (kPa) Final Concentration 
of Added 
Acetate 
Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 4.42 ± 0.28 4.38 ± 0.33 3.90 ± 0.39 2.73 ± 0.45 1.77 ± 0.18 
14 mmol/L 4.03 ± 0.27 3.81 ± 0.12 3.54 ± 0.12 3.36 ± 0.10 2.78 ± 0.19 
28 mmol/L 4.25 ± 0.13 3.98 ± 0.15 3.73 ± 0.23 3.54 ± 0.28 3.16 ± 0.35 
56 mmol/L 4.18 ± 0.23 3.95 ± 0.25 3.75 ± 0.24 3.55 ± 0.29 2.66 ± 0.58 
Mean ± SD (n=5) 
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Oxygen consumption correlated with the results for partial pressures of oxygen, with the 
significantly lower rates in the treatment group lacking acetate corresponding to the 
increased retention of oxygen in these units (figure 6.13). Statistically significant 
differences between units lacking acetate and the three test groups with acetate were 
obtained on days 2 (p=0.009) and day 6 (p<0.001), with mean rates at these time points 
of 0.19 ± 0.02 and 0.12 ± 0.02 mmol/min/109plts, respectively, for the test group 
lacking acetate (table 6.28). By day 8, there were no statistically significant differences 
between any of the four test groups (p=0.081) (table 6.27).  
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Figure 6.13: Oxygen consumption 
rate (acetate study; mean ± SD, 
n=5; 100% plasma n=3) 
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Table 6.27: Statistical comparison for oxygen consumption rate
 
- acetate study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA 0.009 0.039 <0.001 0.081 0.032 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 2 Day 6 
ACE-056 vs. ACE-000 <0.001 (0.009) <0.001 (0.013) 
ACE-028 vs. ACE-000 <0.001 (0.013) <0.001 (0.009) 
ACE-014 vs. ACE-000 <0.001 (0.010) <0.001 (0.010) 
ACE-056 vs. ACE-014 NS NS 
ACE-056 vs. ACE-028 NS NS 
ACE-028 vs. ACE-014 NS NS 
Statistical significance: Unadjusted P value (critical level) NS = Not significant  
 
Table 6.28: Summary results for oxygen consumption rate - acetate study 
Oxygen consumption rate (nmol/min/109plts) Final 
Concentration 
of Added 
Acetate 
Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 0.19 ± 0.02 0.17 ± 0.03 0.12 ± 0.02 0.14 ± 0.03 0.13 ± 0.03 
14 mmol/L 0.26 ± 0.03 0.22 ± 0.04 0.20 ± 0.02 0.18 ± 0.02 0.17 ± 0.02 
28 mmol/L 0.25 ± 0.04 0.23 ± 0.04 0.20 ± 0.03 0.19 ± 0.03 0.17 ± 0.03 
56 mmol/L 0.26 ± 0.03 0.24 ± 0.04 0.20 ± 0.02 0.17 ± 0.03 0.13 ± 0.03 
Mean ± SD (n=5) 
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ATP and ADP Levels 
Day 2 levels of ATP ranged from 5.22 ± 0.41 µmol/1011plts in units with 56 mmol/L 
acetate to 5.48 ± 0.65 µmol/1011plts in units lacking exogenous acetate, with no 
statistically significant differences between any of the test groups (p=0.876). In units 
lacking acetate, ATP increased to maximal levels on day 6 of 6.91 ± 0.68 µmol/1011plts, 
with statistically significant differences between these units and the three test groups 
containing acetate (p<0.001) (table 6.29). Levels in this test group subsequently 
declined by day 10 to 5.15 ± 1.54 µmol/1011plts (table 6.30), with a statistically 
significant difference only evident against units with 56 mmol/L acetate (p=0.006). ATP 
levels in units with 56 mmol/L acetate by day 10 had decreased to 2.65 ± 0.94 
µmol/1011plts compared to 4.02 ± 0.3 and 4.00 ± 0.22 µmol/1011plts in units with 28 
and 14 mmol/L acetate, respectively; though this difference was not statistically 
significant due to the relatively large error bars in the test group with 56 mmol/L (figure 
6.14). By the end of storage, mean levels of ATP in units lacking acetate were 94% of 
day 2 levels. By contrast, mean levels in units with 56 mmol/L added acetate were 51% 
of levels on day 2 (table 6.30). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.14: ATP levels 
(acetate study; mean ± 
SD, n=5; 100% plasma 
n=3) 
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Table 6.29: Statistical comparison of ATP levels between test groups - acetate study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA 0.876 0.182 <0.001 0.003 0.006 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 6 Day 8 Day 10 
ACE-056 vs. ACE-000 <0.001 (0.009) <0.001 (0.009) <0.001 (0.009) 
ACE-028 vs. ACE-000 <0.001 (0.010) 0.003 (0.010) NS 
ACE-014 vs. ACE-000 <0.001 (0.013) NS NS 
ACE-056 vs. ACE-014 NS NS NS 
ACE-056 vs. ACE-028 NS NS NS 
ACE-028 vs. ACE-014 NS NS NS 
Statistical significance: Unadjusted P value (critical level) NS = Not significant  
 
 
Table 6.30: Summary results for ATP levels - acetate study 
ATP (µmol/1011plts) Final 
Concentration 
of Added 
Acetate 
Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 5.48 ± 0.65 6.37 ± 0.77 6.91 ± 0.68 6.31 ± 1.45 5.15 ± 1.54 
14 mmol/L 5.32 ± 0.67 5.77 ± 0.93 5.13 ± 0.67 4.78 ± 0.64 4.00 ± 0.22 
28 mmol/L 5.26 ± 0.40 5.44 ± 0.84 4.34 ± 0.32 4.34 ± 0.58 4.02 ± 0.30 
56 mmol/L 5.22 ± 0.41 5.15 ± 0.91 4.25 ± 0.36 3.84 ± 0.49 2.65 ± 0.94 
Mean ± SD (n=5) 
 
240 
 
 
Mean day 2 levels of ADP ranged from 3.43 ± 0.90 to 3.97 ± 0.70 µmol/1011plts in units 
with 14 and 56 mmol/L acetate, respectively. As in the previous studies, ADP decreased 
with storage in all test groups (figure 6.15). The only statistically significant difference 
was found between units with 56 mmol/L and units with no added acetate on day 6 
(p=0.004) (table 6.31). (The subsequent increase in ADP in the former may be due to a 
discrepant set of results for day 8, since ADP would not be expected to increase 
following a decrease.) By day 10, mean levels in units with 56 mmol/L acetate and units 
lacking acetate had decreased to 1.19 ± 0.28 and 1.38 ± 0.55 µmol/1011plts, 
respectively; corresponding to 30% and 40% of day 2 levels.  
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Figure 6.15: ADP levels 
(acetate study; mean ± SD, 
n=5; 100% plasma n=3) 
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Table 6.31: Statistical comparison for ADP levels - acetate study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA 0.612 0.929 0.004 0.049 0.712 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 6 
ACE-056 vs. ACE-000 <0.001 (0.009) 
ACE-028 vs. ACE-000 NS 
ACE-014 vs. ACE-000 NS 
ACE-056 vs. ACE-014 NS 
ACE-056 vs. ACE-028 NS 
ACE-028 vs. ACE-014 NS 
Statistical significance: Unadjusted P value (critical level) NS = Not significant  
 
Table 6.32: Summary results for ADP levels - acetate study 
ADP (µmol/1011plts) Final 
Concentration 
of Added 
Acetate 
Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 3.49 ± 0.42 3.05 ± 1.30 2.92 ± 0.61 2.44 ± 0.25 1.38 ± 0.55 
14 mmol/L 3.43 ± 0.90 3.32 ± 0.64 1.91 ± 0.53 1.86 ± 0.63 1.46 ± 0.50 
28 mmol/L 3.84 ± 0.89 2.92 ± 1.34 1.98 ± 0.48 1.38 ± 0.15 1.48 ± 0.40 
56 mmol/L 3.97 ± 0.70 2.90 ± 1.06 1.37 ± 0.58 2.22 ± 0.91 1.19 ± 0.28 
Mean ± SD (n=5) 
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Platelet Activation 
Surface Expression and Soluble Levels of CD62P 
The expression of CD62P on the platelet surface suggested that platelet activation 
increased with higher concentrations of acetate early during the storage period, though 
on day 2 this did not reach statistical significance (p=0.019) (table 6.33). The 
percentage of positive expression increased in all four groups between days 2 and 3, 
with mean values on day 3 of 74.37 ± 3.34% in units with no added acetate compared to 
87.03 ± 2.46% in units with 56 mmol/L acetate (p<0.001) (table 6.34). The percent 
positive expression in the four test groups after this time point increased only 
marginally to mean day 10 levels of 75.67 ± 4.48 % and 89.68 ± 2.01 % in units with no 
acetate and 56 mmol/L acetate, respectively (p<0.001) (figure 6.16).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.16: Percent positive 
expression of surface CD62P 
(acetate study; mean ± SD, n=5; 
100% plasma n=3) 
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Table 6.33: Statistical comparison of surface CD62P percent positive expression - 
acetate study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA 0.019 <0.001 <0.001 <0.001 <0.001 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 3 Day 6 Day 8 Day 10 
ACE-056 vs. ACE-000 <0.001 (0.009) 
<0.001 
(0.009) 
<.0001 
(0.009) 
<0.001 
(0.009) 
ACE-028 vs. ACE-000 <0.001 (0.010) 
<0.001 
(0.010) 
<0.001 
(0.010) 
<0.001 
(0.010) 
ACE-014 vs. ACE-000 0.004 (0.017) <0.001 (0.013) 
<0.001 
(0.017) 
<0.001 
(0.013) 
ACE-056 vs. ACE-014 <0.001 (0.013) 
<0.001 
(0.017) 
<0.001 
(0.013) 0.004 (0.017) 
ACE-056 vs. ACE-028 NS NS NS NS 
ACE-028 vs. ACE-014 NS NS 0.007 (0.025) NS 
Statistical significance: Unadjusted P value (critical level) NS = Not significant  
 
Table 6.34: Summary results for surface CD62P percent positive expression - acetate 
study 
Surface CD62P expression (% positive) Final 
Concentration 
of Added 
Acetate 
Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 71.30 ± 3.85 74.37 ± 3.34 69.57 ± 5.29 71.71 ± 4.21 75.67 ± 4.48 
14 mmol/L 74.46 ± 2.97 79.86 ± 2.21 81.08 ± 2.43 80.32 ± 2.93  83.33 ± 2.76 
28 mmol/L 79.44 ± 3.36 83.68 ± 2.07 84.79 ± 2.20 85.81 ± 2.03 86.33 ± 1.72 
56 mmol/L 79.39 ± 6.08 87.03 ± 2.46 89.27 ± 1.26 89.38 ± 0.92 89.68 ± 2.01 
Mean ± SD (n=5) 
 
244 
 
 
In units containing acetate, surface CD62P median fluorescence intensity increased 
from days 2 to 6, after which MFI values remained relatively stable or, in the test group 
with 56 mmol/L acetate, declined till the end of storage (figure 6.17). A statistically 
significant difference was observed between units with 56 mmol/L acetate and units 
with 14 mmol/L acetate from days 2 to 6 (p=001 to p< 0.001). By day 10, the decrease 
in MFI in the former resulted in similar mean MFI values of 3.38 ± 0.26 and 3.27 ± 
0.22, respectively (table 6.36). Mean day 2 values in units with no added acetate (1.87 ± 
0.17) were significantly different to values noted in units with 56 mmol/L (2.54 ± 0.18) 
and 28 mmol/L (2.27 ± 0.21) (p<0.001) (table 6.35). In contrast to units with acetate, 
MFI values in units with no acetate were retained at relatively low levels after an initial 
increase between days 2 and 3, with a mean MFI on day 10 of 1.89 ± 0.20 compared 
with a day 2 value of 1.87 ± 0.17 (table 6.36). The pattern seen with these units was 
similar to that observed with units re-suspended in plasma and markedly different to 
that observed in units with added acetate (figure 6.17). 
 
Day tested
1 2 3 4 5 6 7 8 9 10 11
Su
rfa
ce
 
CD
62
P 
(m
ed
ia
n
 
flu
o
re
sc
en
ce
 
in
te
n
si
ty
)
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
ACE-000-nn 
ACE-014-nn 
ACE-028-nn 
ACE-056-nn 
100% PLASMA 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.17: Median fluorescence 
intensity of surface CD62P 
(acetate study; mean ± SD, n=5; 
100% plasma n=3) 
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Table 6.35: Statistical comparison of surface CD62P (median fluorescence intensity) - 
acetate study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA <0.001 <0.001 <0.001 <0.001 <0.001 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 2 Day 3 Day 6 Day 8 Day 10 
ACE-056 vs. ACE-000 <0.001 (0.009) 
<0.001 
(0.009) 
<0.001 
(0.009) 
<0.001 
(0.009) 
<0.001 
(0.010) 
ACE-028 vs. ACE-000 0.002 (0.013) 
<0.001 
(0.010) 
<0.001 
(0.010) 
<0.001 
(0.010) 
<0.001 
(0.009) 
ACE-014 vs. ACE-000 NS <0.001 (0.013) 
<0.001 
(0.013) 
<0.001 
(0.013) 
<0.001 
(0.013) 
ACE-056 vs. ACE-014 <0.001 (0.010) 
0.001 
(0.017) 
<0.001 
(0.017) NS NS 
ACE-056 vs. ACE-028 NS NS NS NS NS 
ACE-028 vs. ACE-014 NS NS 0.004 (0.025) NS NS 
Statistical significance: Unadjusted P value (critical level) NS = Not significant  
 
Table 6.36: Summary results for surface CD62P median fluorescence intensity - 
acetate study 
Surface CD62P expression (median fluorescence intensity) Final 
Concentration 
of Added 
Acetate 
Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 1.87 ± 0.17 2.23 ± 0.20 2.01 ± 0.27 1.85 ± 0.29 1.89 ± 0.20 
14 mmol/L 2.02 ± 0.12 2.72 ± 0.13 3.21 ± 0.13 3.30 ± 0.36 3.27 ± 0.22 
28 mmol/L 2.27 ± 0.21 2.93 ± 0.18 3.65 ± 0.24 3.61 ± 0.36 3.62 ± 0.21 
56 mmol/L 2.54 ± 0.18 3.20 ± 0.21 3.92 ± 0.15 3.86 ± 0.22 3.38 ± 0.26 
Mean ± SD (n=5) 
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Levels of soluble CD62P on days 2 and 3 were similar in all test groups, with no 
statistically significant differences (p=0.997 and 0.534, respectively) (table 6.37). 
Levels were observed to increase with storage in all test groups (figure 6.18). After day 
3, levels were higher in units containing acetate (all concentrations) compared with the 
test group lacking acetate, with statistically significant differences on days 6 and 8 
(p<0.001 in both cases). Although the pattern remained evident on day 10, the results 
were no longer significantly different (p=0.014). Mean levels in units lacking acetate 
increased from 36.62 ± 5.39 ng/mL on day 2 to 88.59 ± 9.34 ng/mL on day 10, an 
increase of 242%. Comparative levels in units with 56 mmol/L acetate were 36.80 ± 
6.74 ng/mL and 113.53 ± 8.05 ng/mL; an increase of 309% (table 6.38). As noted 
previously, the comparatively high concentrations of soluble CD62P in the units re-
suspended in plasma are derived from the relatively higher fraction of this protein 
already present in the suspending medium. 
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Figure 6.18: Soluble CD62P levels 
(acetate study; mean ± SD, n=5; 
100% plasma n=3) 
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Table 6.37: Statistical comparison of soluble CD62P levels - acetate study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA 0.997 0.534 <0.001 <0.001 0.014 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 6 Day 8 
ACE-056 vs. ACE-000 <0.001 (0.009) <0.001 (0.009) 
ACE-028 vs. ACE-000 <0.001 (0.010) <0.001 (0.010) 
ACE-014 vs. ACE-000 <0.001 (0.013) <0.001 (0.013) 
ACE-056 vs. ACE-014 NS 0.007 (0.017) 
ACE-056 vs. ACE-028 NS NS 
ACE-028 vs. ACE-014 NS NS 
Statistical significance: Unadjusted P value (critical level) NS = Not significant  
 
 
Table 6.38: Summary results for soluble CD62P - acetate study 
Soluble CD62P (ng/mL) Final 
Concentration 
of Added 
Acetate 
Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 36.62 ± 5.39 45.57 ± 4.16 54.60 ± 3.18 69.22 ± 4.66 88.59 ± 9.34 
14 mmol/L 36.44 ± 7.27 50.08 ± 8.27 69.61 ± 4.43 87.23 ± 3.98 103.30 ± 12.95 
28 mmol/L 35.92 ± 5.76 48.98 ± 2.33 71.42 ± 4.09 91.87 ± 6.94 99.20 ± 11.04 
56 mmol/L 36.80 ± 6.74 50.13 ± 5.51 76.21 ± 7.55 97.97 ± 5.91 113.53 ± 8.05 
Mean ± SD (n=5) 
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Markers of Cell Death 
Expression of Aminophospholipids 
The percentage of platelets binding annexin V was similar in all four test groups at the 
start of the storage period, with mean values on day 2 between 10.24 ± 0.99 % in units 
with 56 mmol/L acetate and 11.50 ± 4.40 % in units with 28 mmol/L acetate, with no 
statistically significant differences between any of the test groups (p=0.939) (table 
6.39). The percentage positive expression increased modestly with storage in units with 
14 and 28 mmol/L acetate, with mean day 10 levels of 23.95 ± 5.00 and 19.36 ± 5.22 %, 
respectively (figure 6.19). By contrast, annexin V binding increased after day 6 in units 
with no added acetate and after day 8 in units with 56 mmol/L acetate, resulting in a 
statistically significant difference between the latter test group and units with 14 and 28 
mmol/L acetate by day 10 (p=0.001) (table 6.39). Mean day 10 values for units without 
acetate and units with 56 mmol/L acetate were 34.54 ± 6.07 % and 46.89 ± 15.84 %, 
respectively (table 6.40).  
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Figure 6.19: Annexin V binding as 
percent positive expression 
(acetate study; mean ± SD, n=5; 
100% plasma n=3) 
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Table 6.39: Statistical comparison of annexin V binding (% positive) - acetate study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA 0.939 0.456 0.111 0.056 0.001 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 10 
ACE-056 vs. ACE-000 NS 
ACE-028 vs. ACE-000 NS 
ACE-014 vs. ACE-000 NS 
ACE-056 vs. ACE-014 0.001 (0.010) 
ACE-056 vs. ACE-028 <0.001 (0.009) 
ACE-028 vs. ACE-014 NS 
Statistical significance: Unadjusted P value (critical level) NS = Not significant  
 
Table 6.40: Summary results for annexin V binding (% positive) - acetate study 
Annexin V binding (% positive) Final 
Concentration 
of Added 
Acetate 
Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 10.64 ± 3.93 9.97 ± 3.93 11.25 ± 3.67 18.91 ± 5.41 34.54 ± 6.07 
14 mmol/L 10.33 ± 3.70 10.05 ± 3.78 12.69 ± 2.65 13.50 ± 2.02 23.95 ± 5.00 
28 mmol/L 11.50 ± 4.40 10.97 ± 3.36 12.05 ± 3.17 16.17 ± 3.42 19.36 ± 5.22 
56 mmol/L 10.24 ± 0.99 13.37 ± 3.75 16.03 ± 2.64 20.60 ± 4.21 46.89 ± 15.84 
Mean ± SD (n=5) 
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Annexin V binding measured as mean fluorescence intensity remained fairly stable 
throughout the ten days of storage in units lacking acetate and in the test group with 14 
mmol/L acetate (figure 6.20). In units with 28 mmol/L acetate there was a slight rise, 
with day 2 values of 29.7 ± 5.2 increasing to 36.2 ± 3.1 by day 10 (table 6.42). Figure 
6.20 shows mean MFI values in units with 56 mmol/L were higher from day 2 
compared to the other test groups. However, statistically significant differences were 
not evident until day 10 (p<0.001) (table 6.41), with a mean value in this test group of 
47.3 ± 8.7 at the end of storage.  
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Figure 6.20: Annexin V binding as 
mean fluorescence intensity 
(acetate study; mean ± SD, n=5; 
100% plasma n=3) 
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Table 6.41: Statistical comparison of annexin V binding (mean fluorescence intensity) - 
acetate study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA 0.315 0.412 0.151 0.044 <0.001 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 10 
ACE-056 vs. ACE-000 <0.001 ( 0.009) 
ACE-028 vs. ACE-000 NS 
ACE-014 vs. ACE-000 NS 
ACE-056 vs. ACE-014 <0.001 (0.010) 
ACE-056 vs. ACE-028 0.005 (0.013) 
ACE-028 vs. ACE-014 NS 
Statistical significance: Unadjusted P value (critical level) NS = Not significant  
 
Table 6.42: Summary results for annexin V binding (mean fluorescence intensity) - 
acetate study 
Annexin V binding (mean fluorescence intensity) Final 
Concentration 
of Added 
Acetate 
Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 28.9 ± 5.7 30.3 ± 6.1 31.8 ± 4.2 31.9 ± 6.8 27.3 ± 2.7 
14 mmol/L 29.2 ± 5.0 31.2 ± 5.7 34.4 ± 8.1 32.3 ± 8.3 31.1 ± 5.0 
28 mmol/L 29.7 ± 5.2 32.0 ± 5.5 36.9 ± 5.0 34.3 ± 4.2 36.2 ± 3.1 
56 mmol/L 35.3 ± 7.6 36.1 ± 5.3 41.5 ± 7.8 42.3 ± 2.3 47.3 ± 8.7 
Mean ± SD (n=5) 
 
The expression of aminophospholipds as quantified by mass spectrometry is presented 
graphically in figure 6.21 for a representative sample. The four forms of PE as well as 
PS displayed a consistent pattern of relatively low and unvarying expression between 
days 2 and 8. There was increased expression of all forms of PE and PS after day 8 in 
all four test groups. The flow cytometric assay also showed an accelerated increase in 
the percent positive expression of annexin V binding towards the end of storage; though 
this was more marked in units lacking acetate and units with 56 mmol/L acetate (figure 
6.19). There was no clear relationship between the concentration of acetate and the 
expression of either PE or PS measured by mass spectrometry.  
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Figure 6.21: Expression of aminophospholipids on platelet surface measured by mass 
spectrometry, showing an increase in aminophospholipid expression after day 8 
(acetate study; representative sample) 
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Mitochondrial membrane potential decreased steadily throughout the storage period in 
all test groups (figure 6.22). Ratios of red/green JC-1 fluorescence in units with 28 
mmol/L acetate decreased from 8.26 ± 1.20 on day 2 to 4.50 ± 0.56 on day 10; a 
decrease of 46%. Percentage decreases in MMP ratios from days 2 to 10 were 65%, 
57% and 64% in units with no acetate, 14 mmol/L and 56 mmol/L acetate, respectively 
(table 6.44). The decrease noted in the four treatment groups was not as evident in units 
re-constituted in plasma, where day 10 fluorescence ratios were 80% of day 2 values 
(figure 6.22). Statistically significant differences were evident between some of the test 
groups on days 6, 8 and 10 (table 6.43). However, no clear pattern is evident between 
MMP and the starting concentrations of acetate from this data. 
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Figure 6.22: Mitochondrial 
membrane potential measured as 
JC-1 median red/green 
fluorescence  
(acetate study; mean ± SD, n=5; 
100% plasma n=3) 
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Table 6.43: Statistical comparison of mitochondrial membrane potential (JC-1 median 
red/green fluorescence) between test groups - acetate study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA 0.172 0.232 0.001 0.006 0.002 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 6 Day 8 Day 10 
ACE-056 vs. ACE-000 <0.001 (0.009) NS NS 
ACE-028 vs. ACE-000 0.002 ( 0.010) NS 0.004 (0.010) 
ACE-014 vs. ACE-000 NS NS NS 
ACE-056 vs. ACE-014 NS 0.001 (0.009) NS 
ACE-056 vs. ACE-028 NS NS <0.001 (0.009) 
ACE-028 vs. ACE-014 NS NS No 
Statistical significance: Unadjusted P value (critical level) NS = Not significant  
 
Table 6.44: Summary results for mitochondrial membrane potential (median red/green 
JC-1 fluorescence) - acetate study 
Annexin V binding (mean fluorescence intensity) Final 
Concentration 
of Added 
Acetate 
Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 9.43 ± 0.35 9.00 ± 0.48 7.95 ± 0.41 4.84 ± 1.07 3.34 ± 0.20 
14 mmol/L 9.11 ± 0.66 8.39 ± 0.95 7.02 ± 0.27 6.14 ± 0.82 3.90 ± 0.90 
28 mmol/L 8.26 ± 1.20 8.03 ± 0.90 6.10 ± 1.14 4.87 ± 0.63 4.50 ± 0.56 
56 mmol/L 8.29 ± 1.30 8.14 ± 0.66 5.65 ± 0.98 4.04 ± 0.51 2.95 ± 0.16 
Mean ± SD (n=5) 
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Intracellular Free Calcium 
Levels of intracellular free calcium on day 2 were comparable to those observed in units 
re-suspended in plasma, with day 2 ratios between 0.24 ± 0.01 (no added acetate) and 
0.29 ± 0.02 (56 mmol/L acetate) (table 6.46). Statistically significant differences were 
noted at this time point between units without acetate and units with 56 mmol/L and 28 
mmol/L acetate (p=0.002). However, there were no statistically significant differences 
on days 3, 6 and 8 between any of the test groups (table 6.45). In units with 14 mmol/L 
and 28 mmol/L acetate, intracellular free calcium remained stable throughout the 
storage period (figure 6.23). In units with no added acetate, there was marked increase 
in the dye ratio between days 8 and 10, from a mean of 0.31 ± 0.11 to 0.55 ± 0.09. A 
similar increase is apparent in units with 56 mmol/L acetate. However, there is one clear 
outlier in the results from these units on day 10. Without this result the mean ratio 
would be 0.40 ± 0.11 – higher than the mean values in units with 14 mmol/L and 28 
mmol/L acetate but not generating a statistically significant difference. Exclusion of this 
outlier resulted in statistically significant differences on day 10 between units lacking 
acetate and units with either 14 mmol/L and 28 mmol/L acetate (p<0.001) (table 6.45). 
(The flow cytometry histograms from this outlier did not indicate a clear problem with 
this sample; therefore it was decided not to reject the result from the analysis.) 
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Figure 6.23: Intracellular free 
calcium  
(acetate study; mean ± SD , 
n=5; 100% plasma n=3) 
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Table 6.45: Statistical comparison of intracellular free calcium (Fluo-4/FuraRed) - 
acetate study 
Comparison Between Groups 
 Day 2 Day 3 Day 6 Day 8 Day 10 
One Way ANOVA 0.002 0.015 0.167 0.501 0.030 (<0.001) 
Multiple Pairwise Comparison (Holm-Sidak method)  
Comparison Day 2 Day 10 
ACE-056 vs. ACE-000 0.001 (0.002) NS 
ACE-028 vs. ACE-000 0.001 (0.002) <0.001 (0.002) 
ACE-014 vs. ACE-000 NS <0.001 (0.002) 
ACE-056 vs. ACE-014 NS NS 
ACE-056 vs. ACE-028 NS NS 
ACE-028 vs. ACE-014 NS NS 
Statistical significance: Unadjusted P value (critical level)  NS = Not significant  
In red: alternative analysis without outlier from 56 mmol/L acetate test group (day 10) 
 
Table 6.46: Summary results for intracellular free calcium (Fluo-4/FuraRed) - acetate 
study 
Intracellular free calcium (Fluo-4/FuraRed fluorescence) Final Concentration 
of Added 
Acetate Day 2 Day 3 Day 6 Day 8 Day 10 
0 mmol/L 0.24 ± 0.01 0.25 ± 0.03 0.26 ± 0.04 0.31 ± 0.11 0.55 ± 0.09 
14 mmol/L 0.26 ± 0.02 (n=4)# 0.27 ± 0.04 0.27 ± 0.05 0.28 ± 0.05 0.30 ± 0.07 
28 mmol/L 0.29 ± 0.01 0.28 ± 0.04 0.29 ± 0.05 0.28 ± 0.03 0.28 ± 0.03 
56 mmol/L 0.29 ± 0.02 0.34 ± 0.04 0.33 ±0.05 0.34 ± 0.06 0.53 ± 0.30 (0.40 ± 0.11) 
Mean ± SD (n=5)  
In red: result minus outlier from 56 mmol/L acetate test group (day 10) 
#: One outlier removed from analysis – wide Fluo-4 peak; result not accepted 
 
DISCUSSION  
Based on published studies, the addition of acetate to the storage media would be 
expected to increase oxygen consumption, decrease lactate production and delay the 
consumption of glucose (Hornsey et al., 2006). The combined effects would be a 
stabilisation of pH at a higher value than if acetate were absent. This study confirmed 
the above expectations in the test group lacking acetate. The test groups containing 
acetate did not yield the hypothesised direct relationship between an increase in acetate 
concentration and an enhancement of the above effects, with no clear dose-dependency 
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with these parameters. The improved maintenance of ATP levels that would be 
expected with the addition of increasing concentrations of a metabolic substrate such as 
acetate was also absent - an observation suggested by some earlier studies (Holme, 
1992) which may be related to the metabolism of acetate into acetyl coA, a reaction that 
requires the consumption of an ATP molecule (Knowles et al., 1974). 
 
The inclusion of acetate appeared to have an adverse effect on the parameters of the 
hypotonic shock response and the extent of shape change. This may be related to the 
inability to retain ATP levels as effectively in acetate-containing units. Interestingly, the 
difference between the treatment groups are evident from day 2 of storage, which may 
suggest a more immediate impact on platelet function and morphology with the 
presence of acetate. A similar early effect with increasing concentrations of acetate was 
evident with the surface expression of CD62P, implying that acetate at the 
concentrations used in this study had an adverse effect on platelet function and 
activation despite its expected benefit on platelet metabolism. The addition of acetate in 
the storage medium appeared to have a relatively neutral effect on the indicators of cell 
death, although there is a suggestion (not always translating to statistical significance) 
that units with the highest concentrations of acetate experienced a greater degree of cell 
death. The increase in annexin V binding and intracellular free calcium in the units 
lacking acetate after day 8 may be related to the exhaustion of glucose in these units 
rather than a direct consequence of the lack of exogenous acetate. In summary, the 
results from many of the parameters tested were ambiguous and did not reflect a clear 
benefit for the inclusion of acetate beyond the retention of a higher pH. 
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CHAPTER 7.  
INVESTIGATION OF THE ROLE OF TMEM-16F IN PLATELET PHOSPOLIPID 
EXPRESSION UNDER STORAGE CONDITIONS 
 
INTRODUCTION 
Stimulation of platelets by agonists such as thrombin and or collagen leads to a rapid 
increase in intra-cellular calcium and activation of phospholipid scramblase, resulting in 
the translocation of PS to the external leaflet of the platelet membrane (Zwaal et al., 
2005, Bevers et al., 1982). This process is markedly impaired in patients with Scott 
syndrome, a rare bleeding disorder where patients have a deficiency of TMEM-16F 
(Suzuki et al., 2010, Castoldi et al., 2011). In order to establish whether TMEM-16F 
was involved in the expression of PS following in vitro aging of platelets, investigations 
were performed on the platelets from a patient with Scott syndrome. Investigation of the 
Scott platelets is undertaken on a protocol agreed by the South East Wales Ethics 
Committee and not requiring full ethical approval. A similar pattern of annexin V 
binding in Scott syndrome and control platelets would imply that the membrane 
transport processes responsible for the expression of PS during in vitro aging were 
intact in Scott Syndrome platelets and not related to phospholipid scramblase. To 
confirm that apoptotic mechanisms were intact in Scott syndrome and could potentially 
be implicated in the increased annexin V positivity, the effect of activating apoptosis in 
Scott and control platelets was investigated with ABT-737. ABT-737 promotes 
apoptosis indirectly by binding to anti-apoptotic members of the Bcl-2 family, including 
Bcl-2 and Bcl-XL; thus mimicking the action of sensitizing BH3-only proteins 
(Oltersdorf et al., 2005).  
 
A comparative storage study measuring annexin V binding in Scott and control platelets 
over an 8-day storage period was undertaken at the WBS. The University Hospital of 
Wales adopted the annexin V binding assay previously described and expanded on this 
study by investigating the potential for thrombin generation in stored Scott platelet. 
Repeat experiments on the Scott syndrome platelets were not possible because it was 
not possible to take multiple samples from the patient.  
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METHODS 
Sample collection – storage study 
Peripheral whole blood samples (7 × 5 mL coagulation sodium citrate 3.2% vacutainers) 
were obtained from two normal controls and a Scott Syndrome patient. Samples were 
centrifuged at 800 g for 10 minutes at 22°C to obtain PRP. The PRP was transferred by 
syringe and 19G needle into Baxter PL2410 neonatal platelet storage packs. 
Approximately 3 mL of PRP was obtained from each vacutainer, resulting in a total 
volume of approximately 15 mL. Neonatal packs were stored on a horizontal agitator at 
22 ± 2°C, with an additional gentle manual mix provided at irregular intervals 
throughout the storage period. Samples for testing were taken on days 0 (day of 
preparation), 1, 4, 6 and 8 by means of a sterile 19G needle and syringe.  
 
Response of Scott Platelets to ABT-737 BH3 Mimetic - Experimental Design 
Samples from two normal controls and the Scott patient were obtained as above. 
Samples were centrifuged at 140 g for 15 minutes at 22°C to obtain PRP which was 
subsequently adjusted with autologous platelet poor plasma to provide a platelet count 
of 150 × 109/L. Samples were treated as follows: 
• TIME 0 – measurements performed as soon as possible 
• CRP – addition of collagen-related peptide; a strong platelet agonist that mimics 
the structure of collagen (Polanowska-Grabowska, 2003). 
• NO ABT-737 – No reagents added; 4 hour incubation at ambient temperature 
• ABT-737 POS – 20 µM ABT-737 added; 4 hour incubation at ambient 
temperature 
• ABT-737 NEG – 20 µM A-779024.0 added (less active enantiomer of ABT-
737) 4 hour incubation at ambient temperature 
(CRP was provided by the Oxford Haemophilia and Thrombosis Centre. ABT-737 and 
its enantiomer were provided by Abbot Pharmaceuticals). 
 
Thrombin Generation 
Thrombin generation studies were performed in PRP (150 × 109/L) at UHW by 
Calibrated Automated Thrombography (CAT).  Briefly, the use of a slow-reacting 
fluorogenic substrate allows the generation of thrombin to be continuously measured, 
with the thrombin concentration calculated based on the activity of a parallel sample 
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containing a thrombin calibrator (Hemker et al., 2003). Thrombin generation was 
initiated with 0.15 pM tissue factor (diluted innovin). 
 
RESULTS 
Annexin V Binding to the Platelet Surface 
The platelet concentration and mean platelet volume on day 0 (the day of collection and 
unit preparation) are presented in Table 7.1, with comparatively similar values obtained 
from all three samples. 
 
Table 7.1: Platelet Concentration and Mean Platelet Volume 
Platelet Concentration (x109/L) Mean Platelet Volume (fL) 
DAY 
TESTED Scott 
Patient 
CONTROL 
1 
CONTROL 
2 
Scott 
Patient 
CONTROL 
1 
CONTROL 
2 
0 178 193 208 7.4 6.4 7.0 
 
The annexin V binding results are expressed both as percent positive expression and 
mean fluorescence intensity (Table 7.2). Although a statistical comparison is not 
possible, the percent positive expression was similar between the Scott syndrome 
platelets and the normal controls (figure 7.1). Values at the end of the storage period 
were high compared with results from adult-dose PC suspended in plasma at the same 
time point (chapter 3). This is likely to be due to the small sample volume of 
approximately 15 mL being stored in a neonatal pack designed to hold between 40 to 70 
mL, resulting in the platelets being unable to agitate adequately. Marked variation in the 
results for mean fluorescence intensity was present between all three samples and the 
only observation from this data is that all three samples showed an increase in MFI after 
day 2 of storage (figure 7.2).   
 
It was not possible to repeat the experiments on in vitro ageing with Scott platelets in 
our laboratory because of limitations on the amount of blood that could be donated by 
the patient. However, a similar study on the same patient performed in the laboratory of 
Professor Bevers showed that over a three-day period, annexin V positivity increased 
similarly compared to control platelets (data submitted). 
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Table 7.2: Annexin V Binding in Scott patient study 
Annexin V Binding (% Positive) Mean Fluorescence Intensity DAY 
TESTED Scott 
patient  
CONTROL 
1 
CONTROL 
2 
Scott 
patient 
CONTROL 
1 
CONTROL 
2 
0 5.86 6.67 5.72 22.8 28.5 23.2 
1 6.91 17.94 17.43 17.0 28.9 21.5 
4 51.87 50.12 68.74 19.5 36.4 32.3 
6 67.34 72.19 85.15 22.4 45.9 34.4 
8 80.38 85.85 92.48 28.4 50.9 37.2 
 
Figure  7.1: 
Annexin V Binding in Scott 
patient study 
(percent positive expression) 
Figure  7.2: 
Annexin V Binding in Scott 
patient study 
(mean fluorescence intensity) 
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Thrombin Generation in Stored Scott Platelets 
The pattern of annexin V binding in stored Scott platelets described above was 
duplicated by colleagues at UHW (figure 7.3) though the values were lower throughout 
storage in the Scott platelets. 
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Thrombin generation results for the Scott patient and the two controls over the eight-day 
storage period are presented individually in figure 7.4. Rates of thrombin generation on 
the day of collection were comparatively low with the Scott platelets but progressively 
increased with storage. By day 8, levels of thrombin were comparable to those observed 
in the controls, a finding more clearly illustrated in figure 7.5. 
 
Figure  7.3: 
Annexin V Binding in Scott 
patient study (UHW study) 
(percent positive expression) 
(courtesy of B. Kerr) 
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 Figure 7.4: Thrombin generation in Scott and control platelets measured over 
the course of an 8-day storage period (all graphs courtesy of Dr C Jones, 
UHW). 
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Chart showing thrombin generation at day 8 (Trigger 0.15pM)
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Figure 7.5: Thrombin generation on day 0 (day of unit preparation) and day 8 in 
Scott and normal control platelets (all graphs courtesy of Dr C Jones, UHW) 
 
 
 
Response of Scott Platelets to the BH3 Mimetic ABT-737 
At time 0, annexin V binding was virtually absent in both control and Scott platelets 
(figure 7.6). After a 4-hour incubation, the unmanipulated samples showed an 
approximately two to three fold increase in percent positive expression, with a marginal 
increase noted in the Scott platelets (table 7.3). Addition of CRP prompted a marked 
increase in annexin V binding in the controls, with a more modest increase to a value of 
9.74% positive binding observed in Scott platelets. This was similar to the value of 
10.85% positive binding obtained in these platelets after a 4-hour incubation with 20 
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µM ABT-737. Experiments by Prof. Bevers's team at Maastricht confirmed that the 
Scott platelets were annexin V positive after ABT-737 stimulation (data submitted). 
 
Table 7.3: Annexin V binding on Platelets: Response to Incubation with ABT-737 
ANNEXIN V BINDING (% POSITIVE) 
TEST CONDITION 
CONTROL 1 CONTROL 2 SCOTT PATIENT 
TIME 0 1.65 2.11 1.03 
CRP 61.05 80.24 9.74 
NO ABT-737 3.37 5.66 1.25 
ABT-737 POS 14.48 24.74 10.85 
ABT-737 NEG 4.26 5.93 1.61 
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DISCUSSION  
The progressive increase in annexin V binding observed in Scott platelets was similar to 
that seen in control platelets and demonstrates that the expression of negatively charged 
aminophospholipids associated with in vitro aging was not due to TMEM-16F and Ca2+ 
dependent scramblase activity. The cellular mechanisms required for expression of 
negatively charged aminophospholipids through apoptotic pathways, however, appeared 
to be intact as demonstrated by the response to ABT-737. This demonstrates that the in 
vitro aging changes observed in the platelet storage lesion could be mediated, at least in 
part, by apoptotic pathways. These findings have been independently confirmed by a 
second laboratory. 
 
Figure 7.6: Annexin V binding in 
normal control and Scott 
platelets in response to a 4-hour 
incubation with 20µM ABT-737 
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The data presented here also suggest that the increased expression of negatively charged 
aminophospholipids (as demonstrated by annexin V binding) associated with in vitro 
ageing can have functional consequences. The ability of aged platelets to support 
coagulation reactions and the generation of thrombin shows that the annexin V 
positivity equates to expression of functionally active phospholipids.  It is also possible 
that platelets expressing negatively charged aminophospholipids may be cleared from 
the circulation more rapidly (Hirt and Leist, 2003, Fadok et al., 2001). 
  
In normal platelets, increased expression of PS on platelets provides a procoagulant 
surface for the enhanced activity of the prothrombinase complex and the resulting 
generation of thrombin (Monroe et al., 2002). The observed increase in thrombin 
generation with storage in the Scott platelets suggested that the PS expressed on the 
surface of these platelets retained one of its primary functions, though whether this 
functional activity is retained in vivo remains to be ascertained. A further study 
employing the apoptosis-inducing BH3 mimetic ABT-737 resulted in increased annexin 
V binding in Scott platelets. Although annexin V binding was lower compared to the 
normal controls, the results were consistent with the suggestion that at least part of the 
changes observed during the ageing study may be caused by a process of cell death akin 
to apoptosis. It was not possible to repeat the experiments on the Scott platelets because 
of limitations on the amount of blood that can be taken; however, these data were 
replicated by an external laboratory (Professor Bevers' laboratory, Maastricht). 
 
In both the extrinsic and intrinsic pathways of apoptosis, caspases are the cysteine 
proteases associated with the execution of cell death (Kumar, 2007). The addition of a 
pan caspase inhibitor to the suspending medium of a platelet concentrate unit would 
thus be expected to confirm or refute the role of apoptosis in platelet death during 
storage. This would be an area worthy of further investigation. 
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EXPLORATORY INVESTIGATION INTO THE ROLE OF APOPTOSIS IN 
PLATELETS STORED AS CONCENTRATES 
 
INTRODUCTION 
The Bcl-2 family of proteins are key regulators of cell death by apoptosis (Chipuk et al., 
2010, Brunelle and Letai, 2009). If the machinery of apoptosis is viable in platelets 
stored as concentrates in additive solution, the addition of the BH3-only mimetic ABT-
737 should result in enhanced expression of aminophospholipids on the platelet surface. 
Of particular interest in this respect is the role of glucose, in view of the association 
between glucose depletion and increased annexin V binding described in chapter 5. A 
comparative study was undertaken in which samples from identical platelet concentrates 
in SAS, with or without added glucose, were obtained at periodic intervals over a 14-
day storage period and either incubated with ABT-737 or vehicle only. Cell death was 
determined by the expression of aminophospholipids on the platelet surface, as 
measured by annexin V binding.  
 
METHOD 
Unit and sample preparation 
A buffy coat-derived platelet concentrate was centrifuged at 2400 g for 10 minutes at 
22°C to pellet the platelets. As much of the plasma as possible was drained into a waste 
pack, and the pellets re-suspended by gentle manual mixing in 300 mL of SAS. Sodium 
bicarbonate and acetate were added aseptically to final concentrations of 20 mmol/L and 
28 mmol/L, respectively. The unit was subsequently split into two neonatal packs with 
unit volumes of 50 mL. Glucose was aseptically added to one of the packs to a final 
concentration of 30 mmol/L, with an equal volume of diluent added to the remaining 
unit.  
 
Samples were removed from the units on days 2, 5, 8, 10 and 14. The samples were split 
into pairs and diluted in autologous plasma to a platelet concentration of approximately 
200 × 109/L. To one of the samples was added ABT-737 to a final concentration of 10 
µmol/L. An equal volume of DMSO vehicle was added to the second sample. Units 
containing ABT-737 were incubated at ambient temperature for 3 hours before analysis.  
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Assays 
Glucose levels were measured from the units before sample preparation on the days of 
testing. Due to the association observed in the glucose study (chapter 5) between 
annexin V binding, intracellular free calcium and ATP levels, the last two parameters 
were measured in addition to annexin V binding. All assays were performed as 
previously described.  
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RESULTS 
The parent PC was confirmed to be leucoreduced and all four neonatal packs were 
negative for bacterial contamination at end of storage. Glucose levels in the two units 
with exogenous glucose were depleted between days 10 to 14. There was progressive 
disruption of platelets with increasing storage in units with no added glucose, 
determined by a decrease in platelet concentration (table 7.4 and figure 7.7). 
 
Table 7.4: Impact of the BH3-only mimetic ABT-737 on platelet concentration in the 
presence and absence of glucose in an artificial storage medium 
  PLATELET CONCENTRATION (×109/L) 
  No Glucose 30 mmol/L Glucose 
  ABT-737 POS ABT-737 NEG ABT-737 POS ABT-737 NEG 
Day 2 202 202 205 215 
Day 5 172 188 204 179 
Day 8 150 144 215 206 
Day 10 108 128 198 204 
Day 14 70 59 165 178 
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Figure 7.7: Impact of the BH3-only mimetic on platelet concentration in PC stored with 
or without glucose in the suspending medium (results from single experiment). 
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Annexin V Binding 
On day 2, the addition of ABT-737 resulted in increased annexin V binding in samples 
with and without added glucose compared to controls (figure 7.8), indicating that the 
machinery that induces apoptosis was intact at this time. With the exhaustion of glucose 
in the unit, there was a rapid increase in annexin V binding between days 10 to 14. In 
units without glucose, there was a relatively rapid increase in annexin V binding with 
progressive storage, with no clear indication that the addition of ABT-737 caused an 
increase in percent positive expression beyond day 2 (table 7.5). This suggests that the 
machinery that induces apoptosis was not functional at these timepoints.  
 
In the units with added glucose, the addition of ABT-737 resulted in increased annexin 
V binding on days 2 and 5 and possibly day 8, suggesting the apoptosis-inducing 
machinery was functional at these timepoints but was not functional after day 8.   
 
Table 7.5: Impact of the BH3-only mimetic ABT-737 on annexin V binding in PC stored 
in SAS in the presence and absence of glucose 
  ANNEXIN V BINDING (% POSITIVE) 
  No Glucose 30 mmol/L Glucose 
  ABT-737 POS ABT-737 NEG ABT-737 POS ABT-737 NEG 
Day 2 22.6 7.37 24.26 8.25 
Day 5 44.38 37.66 25.42 14.12 
Day 8 67.43 65.31 29.63 22.03 
Day 10 83.14 81.19 24.07 25.66 
Day 14 97.26 97.34 82.09 79.15 
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Figure 7.8: Impact of the BH3-only mimetic on annexin V binding as percent positive 
expression in PC stored with or without glucose in the suspending medium (results 
from single experiment). 
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Intracellular free calcium 
The absence of glucose resulted in a progressive increase in intracellular free calcium 
throughout the storage. Glucose depletion coincided with a marked increase in 
intracellular free calcium after day 10 in units with added glucose (table 7.6 and figure 
7.9). The addition of ABT-737, by contrast, did not result in a clear difference in 
intracellular free calcium compared to the control sample. 
 
Table 7.6: Impact of the BH3-only mimetic ABT-737 on levels of intracellular free 
calcium in PC stored in SAS in the presence and absence of glucose 
  INTRACELLULAR FREE CALCIUM (Fluo-4/FuraRed MFI ratio) 
  No Glucose 30 mmol/L Glucose 
  ABT-737 POS ABT-737 NEG ABT-737 POS ABT-737 NEG 
Day 2 0.31 0.23 0.35 0.22 
Day 5 1.09 0.83 0.43 0.30 
Day 8 2.12 1.77 0.52 0.42 
Day 10 2.75 3.25 0.43 0.89 
Day 14 4.63 3.80 2.87 2.80 
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Figure 7.9: Impact of the BH3-only mimetic on intracellular free calcium levels in PC 
stored with or without glucose in the suspending medium (results from single 
experiment). 
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ATP Levels 
As expected from the glucose study, an absence of glucose in the storage medium 
resulted in a more rapid decline in ATP levels with storage (table 7.7 and figure 7.10). 
As with intracellular free calcium, the addition of ABT-737 did not result in a clear 
difference in ATP levels compared to the control sample.    
 
Table 7.7: Impact of the BH3-only mimetic ABT-737 on ATP levels in PC stored in SAS 
in the presence and absence of glucose 
  ATP (µmol/1011 plts)  
  No Glucose 30 mmol/L Glucose 
  ABT-737 POS ABT-737 NEG ABT-737 POS ABT-737 NEG 
Day 2 5.112 5.488 4.419 4.965 
Day 5 2.88 2.734 3.955 3.697 
Day 8 1.68 1.729 3.416 3.398 
Day 10 0.656 0.571 2.840 3.125 
Day 14 N/A 0.026 0.485 0.408 
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Figure 7.10: Impact of the BH3-only mimetic on ATP levels in PC stored with or without 
glucose in the suspending medium (results from single experiment). 
 
 
DISCUSSION 
On day 2, platelets responded to the addition of the BH3 mimetic ABT-737 with 
increased translocation of aminophospholipids to the platelet surface, a response that 
was still observed (though muted) in the unit with added glucose on day 8. This 
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suggested that mechanisms leading to apoptotic driven expression of 
aminophospholipids were intact and could be contributing to the annexin V positivity 
observed with in vitro ageing. After that time ABT-737 did not increase annexin V 
positivity, implying that mechanisms other than apoptosis would have been required to 
externalise aminophospholipids in old platelets. 
 
In the unit with no added glucose, mechanisms for apoptotic cell death were intact at 
day 2 but not after that time, and other mechanisms would have been required to 
externalise aminophospholipids. ATP levels on day 5 had already declined to 
approximately 50% of day 2 values in the platelets with no added glucose. This may 
have prompted a mechanism of cell death that was more akin to necrosis (Leist et al., 
1997, Skulachev, 2006). This was reflected in the increasing levels of intracellular free 
calcium which would also be compatible with necrosis (Rizzuto et al., 2003, Rasola and 
Bernardi, 2011), resulting in increased mitochondrial dysfunction and ultimately platelet 
disruption, as observed by the decrease in platelet concentration. 
 
Thus, platelets stored as concentrates in additive solution initially have functional 
machinery for a Bcl-2 protein-mediated mechanism of cell death. This may be 
superseded with progressive storage by a mechanism more akin to necrosis as energy 
stores are depleted. This is exacerbated and occurs earlier during storage in media 
lacking glucose, where the maintenance of ATP levels by glycolysis may be aided by 
the maintenance of mitochondrial function via antioxidant mechanisms mediated via the 
pentose phosphate pathway (Brookes et al., 2004). 
 
Following confirmation of the results reported above, the next logical step would be to 
undertake a similar storage study in the presence or absence of a caspase inhibitor. 
Addition of a broad spectrum caspase inhibitor such as Q-VD-OPh (Caserta et al., 2003) 
to the unit would be expected to negate an increase in annexin V binding caused by 
ABT-737 if caspase-dependent apoptosis is indeed a viable mechanism of cell death for 
platelets in storage. 
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8. DISCUSSION 
 
A progressive deterioration of in vitro characteristics associated with platelet function, 
morphology and metabolism are characteristic of the storage of platelets as concentrates 
and collectively referred to as the platelet storage lesion (PSL). Platelet activation, the 
release of potentially harmful bioactive substances from cellular elements, changes in 
morphology and either the inability to maintain or suppress platelet metabolism, have 
all been associated with the phenomenon (Picker et al., 2009, Smyth et al., 2009). The 
suggestion that a programmed mechanism of cell death may be involved in the 
development of the PSL has been more recently considered following studies 
investigating the possibility that platelets are capable of displaying responses typically 
associated with apoptosis in other cell types (Leytin and Freedman, 2003, Rinder and 
Smith, 2003, Kile, 2009). However, it is difficult to assign a causative element to these 
observations, and no comprehensive model of the PSL is currently available. This thesis 
aimed to contribute to the current debate on the origin and mechanism of the PSL, 
proceeding under the hypothesis that a process akin to apoptosis serves as a central 
mechanism to explain the variety of changes associated with the phenomenon. A 
concurrent applied aim for the investigations was to provide insight into the 
manufacturing and storage of platelet concentrates that may enhance the viability and 
efficacy of platelets post-transfusion. 
 
The progressive changes described in the literature in association with the PSL were 
confirmed in the fourteen-day storage study using PC suspended in plasma or a 70% 
SSP+™ additive solution, with the work adding to the currently limted body of data 
available for characteristics of the PSL beyond the storage periods recommended by 
official guidelines. The subsequent investigations suggested that a Bcl-2 protein-
mediated mechanism of cell death was viable in platelets in the presence of adequate 
stores of energy in the form of glucose. Depletion or absence of glucose resulted in 
platelet death by a mechanism associated with decreased ATP levels, accelerated 
aminophospholipid translocation and platelet disruption which was more reminiscent of 
necrosis. 
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The study investigated the PSL in buffy coat-derived platelet concentrates suspended in 
a platelet additive solution containing minimal concentrations of plasma and leucocytes. 
The ability to more comprehensively control the composition of a relatively simple 
artificial medium allowed for comparative studies to be undertaken on the role of 
individual constituents of platelet additive solutions. White cells are known to affect the 
in vitro characteristics of platelets through the release of cytokines and other bioactive 
substances (Mueller et al., 2008), whilst the complex nature of plasma may complicate 
the interpretation of results.  By substantially reducing the influence of these two factors 
it was possible to more directly interpret results as the response of platelets to the 
storage conditions. It has been suggested that the various changes associated with the 
PSL may be assigned to categories describing platelet metabolism, activation, 
morphology and senescence (Rinder and Smith, 2003, Li et al., 2005a). A range of 
assays was adopted to determine the response of platelets across these broadly-defined 
categories. In particular, repeated measures over the storage period may offer an insight 
into the timeline of events, which may in turn suggest avenues for further research into 
the relationship between the different aspects of the PSL. 
 
An initial study was undertaken on buffy coat-derived PC suspended in either 100% 
autologous plasma or a combination of SSP+ additive solution and plasma in an 
approximate 70:30 ratio over an extended storage period of 14 days. Current UK 
guidelines restrict the shelf-life of PC to a maximum of seven days (James, 2005). As a 
result, studies investigating the ability of novel suspension media to maintain platelet 
function and viability in storage have often understandably limited themselves to 
obtaining measurements up to the accepted shelf-life or shortly thereafter. To determine 
whether it is feasible to consider extending the shelf-life of PC beyond the current 
limits, it would be useful to obtain information on the in vitro characteristics of platelets 
over an extended period of storage using present manufacturing processes and storage 
conditions. Such comparative studies extending to storage periods beyond seven days 
are relatively uncommon in the literature (Cardigan et al., 2005), though more recent 
publications have begun to address the issue (Sandgren et al., 2010). In addition, results 
from the subsequent studies in additive solutions using the same assays would be more 
directly comparable than comparisons against published data, since significant 
variability in the values of assays can be found in the published literature for some of 
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the parameters of interest (Girotti et al., 1989, Curvers et al., 2008). A paired study 
design that pooled the requisite number of buffy coats to provide two identical starting 
PCs would have negated any donor variability and increased the power of the 
comparative analysis. However, such an approach would deviate from standard 
manufacturing processes and it was deemed more appropriate for this study to remain 
within the confines of established practice. 
 
Units were sampled on days 1, 2, 3, 6, 8 10 and 14. Regular sampling at the beginning 
of the storage period was important to characterise early changes in the in vitro 
characteristics of platelets stored in additive solutions in subsequent studies, as the 
storage conditions and processing methods were expected to be harsher than standard 
methods and thus possibly lead to accelerated expression of the PSL. In addition, it is 
possible that changes in parameters associated with the PSL early in the storage period 
may be evident in standard units and may offer insight into the subsequent development 
of the PSL. Published studies tend to omit measurements early in the storage period, as 
their generally stated aim is to determine the suitability of PCs for transfusion at the end 
of shelf-life. This study thus offered the opportunity to investigate this often neglected 
early period of storage. However, such an extensive series of measurements inevitably 
results in a marked volume loss. It is unclear whether such a change in the ratio of unit 
volume to pack surface area would artificially affect the in vitro characteristics towards 
the end of storage, or whether any impact would prove significant; thus limiting the 
study to a comparative investigation. Further work in which similarly processed units 
were only sampled on days 1 and 14 would help to address this question, but could not 
be undertaken at the time due to time and processing restrictions.  
 
For clarity, the following discussion is separated into sections. The first section 
examines the results obtained in the study comparing the in vitro storage characteristics 
of platelets suspended in a 70:30 SSP+ and plasma medium against platelets 
suspended in 100% autologous plasma. The second section discusses the results from 
the series of studies using variously-modified standard additive solution as a suspension 
medium. (However, the studies cannot be regarded in total isolation and the discussion 
will reflect this where appropriate.) The subsequent series of experiments undertaken in 
collaboration with the University Hospital of Wales to more directly explore the 
mechanisms for annexin V binding in platelet ageing by investigating the characteristics 
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of platelets from a Scott Syndrome patient, as well as the role of a Bcl-2 protein family-
mediated initiation of cell death in platelets during storage are discussed next. These 
sections serve as the foundation for suggested models of platelet death in the storage 
conditions evaluated in the thesis and determine whether they support the hypothesis 
that apoptosis is a central player in the PSL. The limitations of the thesis are also 
evaluated as are suggestions for future potential studies that would build on the many 
questions generated from this work. 
IN VITRO STORAGE CHARACTERISTICS OF PLATELET CONCENTRATES 
STORED IN 100% AUTOLOGOUS PLASMA VERSUS A MEDIUM 
COMPRISED OF 70% SSP
+
 AND 30% PLASMA 
The expected decrease in extracellular pH with storage was evident after day 6 in PCs 
suspended in plasma. This is generally attributed to the consumption of bicarbonate 
which acts as the principal buffer in plasma by taking up H+ ions produced by 
glycolysis and converting them to H2O and CO2 via carbonic acid. Carbon dioxide is 
able to escape through the gas-permeable plastic of the storage pack, thus maintaining 
pH levels (Wallvik and Akerblom, 1990, de Wildt-Eggen et al., 1998) (figure 8.1).  
 
 
Figure 8.1: Reactions associated with the buffering capacity of bicarbonate in plasma 
(Cordat and Casey, 2009) (Reproduction permitted with accreditation, Portland Press, 
©The Biochemical Society) 
 
There is sufficient bicarbonate present in plasma to buffer the platelet concentrates until 
lactate levels reach approximately 20 mmol/L, after which pH levels have been shown 
to decrease at an accelerated rate (Murphy, 1999). It may be difficult to entirely attribute 
the decrease in pH after day 6 to exhaustion of bicarbonate in the plasma, since previous 
studies have shown bicarbonate levels in buffy coat-derived PCs remain relatively 
constant for up to seven days of storage (Sandgren et al., 2008, Gulliksson, 2001). The 
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increase in pH observed in plasma units during the first three days of storage has been 
previously reported, both in pooled units and in PCs collected by apheresis technologies 
(Krailadsiri et al., 2001, Goodrich et al., 2006). This may be related to the rapid 
decrease in pCO2 levels noted in these units between days 1 and 3, suggesting 
accumulated CO2 was being rapidly lost through the storage pack. The more alkaline 
conditions would also reduce the solubility of CO2 – a further potential factor 
contributing to the marked decrease in pCO2 in these units (Zhang et al., 2008b). In 
contrast to the plasma units, pH values in all SSP+ units remained above 7.0 
throughout the storage period, with pH increasing markedly after day 10 due to the 
stalled lactate production following the depletion of glucose. In common with all 
commercially available additive solutions, SSP+ does not contain glucose. The only 
glucose available to these units would have originated from the reduced volume of 
autologous plasma, and this was effectively depleted by day 10. 
  
The relatively reduced partial pressure of carbon dioxide in the SSP+ units throughout 
the storage period reflects the reduced lactate production in this group. The difference in 
pCO2 between plasma and SSP+ units was most significant at the start of the storage 
period, suggesting the preparation of the units had an impact on this parameter. The 
only major difference in the preparation was the use of additive solution instead of 
plasma. The excess CO2 in the plasma is most likely to have originated from glycolytic 
red cell activity in the whole blood unit and remained in the impermeable plasma pack 
ready to be transferred to the platelet concentrate. However, once in the gas-permeable 
PC storage packs, CO2 was allowed to escape to the atmosphere resulting in a rapid 
decline of pCO2 at the start of the storage period. It remains to be determined if the 
platelets are adversely affected by this transiently high level of CO2. Levels of pO2 and 
rates of oxygen consumption were similar in both groups of PCs. The steady increase in 
pO2 in both groups over the storage period reflects the high gas permeability of the 
current generation of storage packs, since oxygen consumption was relatively stable 
throughout storage. 
 
The stable rates of oxygen consumption coincided with the maintenance of ATP for the 
first ten days of storage in both plasma and SSP+ units, with day 10 levels remaining 
over 85% of starting values. The increase in ATP concentration over the first few days 
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of storage, particularly evident in plasma units, was somewhat surprising and was 
instrumental in maintaining ATP levels in both groups. However, a recent study in BC-
PC has also reported increases in ATP levels that did not reduce below starting levels 
until after 7 days of storage (Sandgren et al., 2010). Absolute levels of ATP quoted in 
the literature vary considerably. A review of ATP levels in human platelets from whole 
blood samples found levels varied between 3.78 ± 0.68 to 7.5 ± 1.7 µmol/1011plts. A 
major variable is the use of different assay methodologies, with methods ranging from 
high-pressure liquid chromatography (HPLC) to bioluminescence and 
spectrophotometric assays. However, even with methods employing the same general 
principles, considerable variation has been reported (Girotti et al., 1989). Similar 
variability is still evident in relatively recent storage studies, with levels in plasma units 
on day 1 varying between 4.7 ± 0.3 µmol/1011plts (Gulliksson et al., 2000) to 8.28 ± 
0.40 µmol/1011plts (Sandgren et al., 2008). 
 
On activation platelets release the contents of their storage granules, including the 
platelet agonists ADP and serotonin from the dense granules. ADP levels have not been 
commonly reported in the transfusion literature. An early study by Rao et al obtained 
mean levels of 3.5 ± 0.2 µmol/1011plts in fresh PRP-PC; substantially lower than the 
mean levels obtained in the current study (Rao et al., 1981). Levels in the Rao study 
decreased by approximately 40% in 72 hours - a similar decrease was evident after day 
8 of storage in the present study. A more recent study reported that levels in buffy coat-
derived PC were maintained in the first four days of storage, but declined thereafter 
(Botchway et al., 2000). Both papers observe that the progressive decline in ADP with 
storage could be interpreted as an acquired storage pool defect, with Botchway et.al 
suggesting the effect may not be reversible even after transfusion, with implications for 
the efficacy of platelet transfusions. The δ-storage pool diseases are characterised by 
defective platelet dense granules, with mild to severe bleeding as one of the clinical 
manifestations (Simon et al., 2008, Sandrock and Zieger, 2010). An acquired defect of 
similar nature in stored platelets may be of clinical relevance and may account for some 
of the variation in the efficacy of PC transfusions to control bleeding (Apelseth et al., 
2010). Particularly relevant scenarios include the transfusion of patients treated with 
anti-platelet agents such as clopidogrel which inhibit the ADP receptor P2Y12 
(Cattaneo, 2011) - such patients may benefit from the transfusion of fresh platelets to 
combat haemorrhage. The variable patient response to treatment with such anti-platelet 
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agents may be compounded by individual variability in the response to ADP by the 
transfusion recipient, possibly due to variation in the structure or density of the ADP 
receptors on the platelet surface (Michelson, 2004, Michelson et al., 2007, Fontana et 
al., 2003). ADP elicits its role in platelet aggregation by binding to neighbouring 
platelets via two G-protein coupled P2 receptors (Kunapuli et al., 2003). Binding to the 
P2Y12 receptor releases the Gi protein subunits αGi and βγ. The former inhibits adenylyl 
cyclase (AC) which in turn decreases levels of cyclic adenosine monophosphate 
(cAMP) resulting in reduced phosphorylation of vasodilator-stimulated phosphoprotein 
(VASP); a process which would otherwise inhibit the activation of the GPIIb/IIIa 
receptor. The βγ fragment activates phosphatidylinositol 3-kinase (PI3K), which 
promotes further granule secretion in a positive feedback loop (Woulfe et al., 2001, 
Johnston-Cox et al., 2011, Nguyen et al., 2005) (figure 8.2). 
 
Figure 8.2: The relationship between ADP and platelet P2 receptors and their role in platelet 
aggregation, including the inhibitory effect of the anti-platelet drug clopidogrel which 
irreversibly binds to the P2Y12 receptor (Nguyen et al., 2005) (Reproduced with permission; © 
American College of Cardiology Foundation) 
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A limitation of the study in this context was the lack of platelet aggregation assays 
which would have provided more direct information on platelet function. Nevertheless, 
the ADP results point to a different mechanism being associated with this aspect of the 
storage lesion that appears unrelated to the energy stores of the platelets. 
 
Platelet activation as a consequence of processing and storage of PC has been 
commonly measured in recent years by the flow cytometric estimation of CD62P on the 
platelet surface. CD62P is constitutively expressed on the membrane of α-granules. As 
part of the secretory response following platelet activation, the membrane of the α-
granules fuses with the plasma membrane, resulting in an increased expression of the 
CD62P glycoprotein on the platelet surface (Berman et al., 1986, Jurk and Kehrel, 
2005). With increasing platelet activation expected during storage as the environment in 
which the platelets are suspended degrades, an increase in the percentage of platelets 
expressing CD62P would be expected. Interestingly, the percentage positive expression 
of CD62P decreased during the initial period of storage, only increasing after day 3 in 
plasma units and day 6 in SSP+ units; a similar, though more subtle decrease, was also 
evident with the median fluorescence intensity. A survey of the literature resulted in a 
recent study by Zhang et al that also reported a decrease between days 1 and 2 of 
storage in BC-PC suspended in various media (Zhang et al., 2008b). Such a decrease 
would suggest that CD62P is either being re-internalised or shed from the surface. Re-
internalisation of CD62P would potentially allow the protein to be re-expressed on 
subsequent platelet activation. However, studies measuring the response of stored 
platelets to physiological agonists have concluded that an increased concentration of 
thrombin is required to elicit 50% positive expression of CD62P in platelets from 7 day-
old PCs compared with platelets from PCs stored for 3 days (Cardigan and Williamson, 
2003). This depressed response may be indicative of a reduced store of CD62P in α-
granules that is not being replenished by the re-uptake of previously expressed CD62P 
(Jilma-Stohlawetz et al., 2008). Studies using a CD62P-deficient murine model 
described the presence of a soluble form of CD62P in the plasma of these animals 
within 15 minutes of the transfusion of activated wild-type platelets and identified it as 
a 100-kDa fragment by Western blotting (Berger et al., 1998). The same study affirmed 
the hypothesis that expressed CD62P was cleaved from the platelet surface by re-
infusing thrombin-activated biotinylated platelets into mice. The re-infused platelets 
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were found to lose their surface CD62P expression and were not found to re-acquire it 
after exposure to thrombin or the calcium ionophore A23187. 
  
CD62P is a member of the selectin family of adhesion molecules. Initial interest in the 
introduction of an assay to measure surface-expressed CD62P on platelets was based on 
the observation that its ligand, PSGL-1, was present on leucocytes (Larsen et al., 1989). 
This led to the suggestion that binding of platelets expressing CD62P to leucocytes, 
particularly neutrophils and monocytes (Gutensohn et al., 2002), could lead to 
accelerated clearance of these platelets from the circulation and thus explain the 
decrease in recovery and survival of platelets after transfusion, especially following the 
transfusion of older PCs with increased expression of the protein. Two studies often 
discussed in relation with this hypothesis reported inverse correlations between the 
degree of platelet activation, as determined by the surface expression of CD62P, and 
platelet recovery up to one hour post-transfusion in either normal volunteers or 
thrombocytopenic patients (Rinder et al., 1991, Triulzi et al., 1992).  Subsequent studies 
with animal models, however, have found that thrombin-activated, degranulated 
platelets are able to circulate and function after shedding the expressed CD62P (Berger 
et al., 1998, Michelson et al., 1996). It is possible that the two seemingly contradictory 
results reflect a time-course of events, with CD62P expression involved in an initial 
clearance of a proportion of the transfused platelet population. A time limit would be 
imposed by the shedding of CD62P from the surface. Indeed, studies have demonstrated 
that 50% of CD62P is lost from the platelet surface during the first 5.5 hours after 
transfusion (Leytin et al., 2004). Loss of CD62P from the platelet surface in vivo may 
render platelets less adhesive to leucocytes expressing the PSGL-1 receptor and thus 
prevent excessive leucocyte recruitment to the site of injury, which could otherwise lead 
to damaging levels of inflammation (Li et al., 2011). 
  
If the decrease in the percentage positive expression was due to the proteolytic cleavage 
of surface-expressed CD62P, an increase in the soluble fraction of CD62P (sCD62P) 
would be expected. Increases in sCD62P are indeed evident throughout the storage 
period, but the rate of increase is relatively stable and does not reflect the variation in 
surface expression of the molecule. A tentative explanation would involve a proportion 
of the initially activated population of platelets shedding the majority of the surface-
expressed CD62P into the medium, accounting for the initial increase in sCD62P and 
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apparent recovery from activation measured by flow cytometry (also see (Zhang et al., 
2008b). Subsequent rates of CD62P externalisation and cleavage may occur in a more 
measured manner as conditions during storage change more gradually or simply as a 
result of progressive ageing of the platelet population, resulting in a more direct 
relationship between surface expression and shedding of CD62P. A clearer quantitative 
association between the surface expression of CD62P and the concentration of the 
soluble fraction would be necessary to explore this further. The increase in median 
fluorescence intensity (MFI), particularly evident in plasma units after day 10 of 
storage, suggests that externalisation of CD62P on individual platelets is not an all-or-
nothing response. The possibility of a graded response is also evident from a study by 
Rinder et al which demonstrated a four-fold higher CD62P expression per platelet 
following activation with thrombin compared to activation by a combination of 
epinephrine and ADP (despite similar percent positive expression) (Rinder et al., 1991). 
If an increase in MFI is related to a stronger stimulus, the rise noted in this parameter 
after day 10 may suggest a deterioration of the storage environment. For plasma units, 
this may be related to the decrease in extracellular pH22°C to median levels of 6.6. 
 
Two further observations related to the externalisation and shedding of CD62P require 
discussion. Firstly, the levels of sCD62P in SSP+ units at the start of the storage 
period and secondly, the relatively high levels of percent positive expression of CD62P 
in comparison to the published literature. Median levels of sCD62P in plasma units 
were 89.7 ng/mL at the start of the storage period. This reflects levels in normal human 
plasma ranging between 36 – 250 ng/mL (Ushiyama et al., 1993, Katayama et al., 1992, 
Dunlop et al., 1992). Considering that only about 30% of plasma was carried over into 
the SSP+ units, the expected median concentration of sCD62P in SSP+ units would 
be 26.9 ng/mL. Measured levels were approximately twice this value (median of 52.0 
ng/mL). Similar proportional levels were reported in a recent study comparing various 
in vitro characteristics in PC suspended in plasma or two different platelet additive 
solutions in a 70:30 PAS to plasma ratio (Cardigan et al., 2008). A possible explanation 
would be an increase in platelet activation caused by the processing of the two groups of 
PCs. However, the only difference in the processing of the two groups was the 
replacement of 70% of plasma with SSP+. In addition, other in vitro parameters were 
similar in both study groups on day 1; in particular, both measures of the surface 
expression of CD62P. It is possible that the source of the plasma carried over into the 
284 
 
SSP+ units is the source of the high sCD62P levels. This plasma remnant is obtained 
from the residual plasma bathing the buffy coats, which are held overnight prior to 
processing. Berger et al reported that infusion of platelets incubated in whole blood led 
to a significant decrease in CD62P expression after re-infusion into mice compared with 
platelets incubated in either platelet-poor-plasma or a buffer solution, suggesting 
increased shedding of CD62P from platelets in the presence of other cellular elements 
(Berger et al., 1998). If the overnight storage of platelets in a buffy coat promoted the 
externalisation and shedding of CD62P into the residual plasma, these proportionately 
high levels of sCD62P would have been retained in the SSP+ units and reflected in the 
day 1 values. Measuring the concentrations of soluble CD62P in buffy coat-derived 
plasma as well as in the plasma units retained separately for the preparation of BC-PC 
in 100% plasma would help to determine if this explanation accounts for the measured 
levels of sCD62P. 
 
A number of storage studies have reported percent positive values for surface CD62P 
ranging between 12.6% and 36.6% on day 1 (with units in either 100% plasma or a 
PAS-IIIM formulation) (Keuren et al., 2006, Dijkstra-Tiekstra et al., 2004, Cardigan et 
al., 2008, Wagner et al., 2008, Wagner et al., 2002, Hornsey et al., 2006). These 
published values compare with median levels of 53.5% in the plasma group and 55.7% 
in SSP+ units on day 1. As the units were processed by standard procedures, it seems 
unlikely that the relatively high values in this study reflect greater platelet activation 
compared to other studies. It is more likely that the relatively high values are due to 
assay methodology. In the studies referenced above in which details of the methodology 
were provided, the samples were fixed either before or after staining. The assay used in 
these studies omitted fixing the samples in preference of immediate analysis after 
staining. In addition, the assay combined the measurement of CD62P with annexin V 
binding. Binding of CD62P occurred initially with a 15-minute incubation, with the 
annexin-V-FITC probe requiring a second incubation in the same sample tube. Without 
fixation, it is possible that platelet activation could continue in the sample tube during 
the second incubation, resulting in higher surface expression of CD62P.  However, the 
combined incubation of 30 minutes with anti-CD62P is not excessive compared to 
published methodologies. A further variable which may be of significance is the use of 
phycoerythrin (PE)-conjugated anti-CD62P instead of a FITC-conjugated antibody, as 
PE is an inherently brighter fluorescent stain than FITC (Shapiro, 2003) (though both 
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stains are referred to in the literature). Further variables posited as having an impact on 
CD62P surface expression include the instrument used, the choice of antibody clone and 
the definition of the gating for the isotypic control; that is, the percentage of negative 
events included in the gate used to define CD62P positivity (Curvers et al., 2008). The 
adopted method used a Beckman Coulter FC500 and Immunotech clones (Beckman 
Coulter, Milton Keynes, UK) for both the anti-CD62P stain and the isotypic control. 
The CD62P gate was set on one percent of negative events, following common practice 
(Ormerod, 2000). Additional investigations to determine whether particular aspects of 
the assay methodology are responsible for the relatively high percentage positive 
expression should initially centre on the role of fixation. The study by Curvers et al 
described a statistically significant reduction in CD62P staining when cells were fixed, 
though the gross differences did not appear sufficient to account entirely for the 
variation in results between the adopted assay and the referenced literature. The 
approach of combining the anti-CD62P and annexin V binding and its possible role may 
also be worth re-visiting, though the initial development of the assay did not suggest an 
impact on results. 
  
The possible involvement of programmed cell death in the platelet storage lesion was 
investigated through the increased expression of aminophospholipids on the outer 
leaflet of the plasma membrane and the disruption of the mitochondrial membrane 
potential (∆Ψm). The former was measured by the binding of fluorescently-conjugated 
annexin V to aminophospholipids on the platelet surface, whilst disruption of the 
membrane potential was measured by changes in the mitochondrial uptake of the 
cationic dye JC-1. As described in the introduction, the loss of phospholipid asymmetry 
that leads to a proportionate increase in aminophospholipids on the outer leaflet of the 
plasma membrane of activated platelets is important for normal coagulation. The 
increased expression of phosphatidylserine on the outer leaflet, as demonstrated by 
annexin V positivity, is also commonly seen in cells undergoing apoptosis and is 
generally regarded as an early indication of a cell entering a process of programmed cell 
death (Martin et al., 1995, Schlegel and Williamson, 2001, Leventis and Grinstein, 
2010). (However, it should be stressed that increased phosphatidylserine expression is 
not confined to an apoptotic mechanism of cell death and has been also been reported in 
various examples of cell death by necrosis (Krysko et al., 2004, Galluzzi et al., 2009, 
Jackson and Schoenwaelder, 2010, Hirt and Leist, 2003, Poon et al., 2009)).  The higher 
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levels of percent positive expression in units suspended in 100% plasma compared with 
SSP+ contrasted with relatively lower mean fluorescence intensities in the same units; 
the latter indicating a lower expression of aminophospholipids per platelet in units 
suspended in plasma. The kinetics of annexin V binding per platelet in the two groups 
throughout the storage period was similar. MFI levels generally decreased in both 
groups between days 1 and 10. One possible interpretation is that externalisation of 
aminophospholipids was transiently increased during processing, with the normal 
phospholipid asymmetric distribution gradually re-established in the more controlled 
conditions of standard storage. The relatively higher MFI levels in SSP+ suggests the 
initial phospholipid disruption was more marked in these units (and may have continued 
in the initial period of storage, as suggested by the increase in levels between days 1 and 
2 in these units). The similar rate of decrease in MFI levels between the two study 
groups over time suggests a standard rate of activity for the ATP-dependent translocase 
associated with the inward movement of aminophospholipids. 
  
The higher percent positive expression during most of the storage period in platelets 
suspended in plasma suggests that although more platelets were expressing detectable 
levels of aminophospholipids, the concentration of these phospholipids was lower per 
platelet than for platelets in SSP+ units. The processing-related increase in annexin V 
binding per platelet in both study groups is limited to a small subpopulation of platelets, 
as less than 5% of platelets exhibit annexin V binding at the start of storage. Similar 
starting values have been reported in the literature for PCs prepared by various 
processes and suspended in a variety of media (Perez-Pujol et al., 2004, Shapira et al., 
2000, Sweeney et al., 2006). Levels on day 8 were similar to those published by 
Cardigan et al for plasma-suspended BC-PC stored in ELX packs at comparable time 
periods (days 7 - 9) (Cardigan et al., 2008). Despite the accelerated increase in positive 
percentage expression after day 8 in both groups, day 14 values of approximately 30% 
suggested a relatively large pool of platelets remained viable, although their in vivo 
survival and ability to support coagulation reactions remains to be conclusively 
determined. A loss of aminophospholipids on the surface of platelets could be related to 
increased formation and shedding of microparticles in plasma units (Heijnen et al., 
1999, Perez-Pujol et al., 2005), although microparticles were not quantified in this 
study. 
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The progressive decline in the red to green (R/G) fluorescence ratio of the JC-1 cationic 
dye used to investigate the effect of storage on the mitochondrial membrane potential 
indicates a relative reduction of J-aggregates in the mitochondria with respect to green-
fluorescing monomers restricted to the cytosol; a change attributed to the depolarisation 
of the inner mitochondrial membrane with PC storage. There is limited data on the 
impact that processing and subsequent storage of platelet concentrates has on 
mitochondrial membrane potential. Some studies have found little difference over the 
first seven days of storage (Perrotta et al., 2003); others have described an initial 
increase in the fluorescence ratio over the first few days of storage followed by a 
decrease (Verhoeven et al., 2005), whilst still others have shown steady decreases in the 
ratio with storage (Li et al., 2005b). A number of groups have reported results in terms 
of percentage of cells expressing red (polarised) and/or green (depolarised) 
fluorescence (Perrotta et al., 2003, Li et al., 2004). Interestingly, the limited number of 
studies that have reported results using both approaches have found disparate patterns 
between the two methods over the storage period. The study by Li et al reported limited 
decrease in the percentage of polarised cells over 7 days of storage, but an approximate 
50% decrease in the red/green fluorescence ratio (Li et al., 2005b). Similarly, a recent 
study by Albanyan et al reported significant decreases in the red/green fluorescence 
ratio in both apheresis and buffy coat-derived PCs, but failed to detect a significant 
increase in the percentage of depolarised platelets in the BC-PC units (though marked 
increases were noted in the apheresis-derived PCs) (Albanyan et al., 2009). The last 
study suggested that the two approaches for reporting ∆Ψm reflect different aspects of 
mitochondrial membrane depolarisation, with the R/G fluorescence ratio indicating a 
platelet population displaying partial as well as full depolarisation of mitochondrial 
membranes whilst percentage of depolarised platelets indicates solely complete 
depolarisation. The decrease in the R/G ratio in the first half of the storage period may 
thus reflect partial as well as complete depolarisation of the mitochondrial membrane. 
Depolarisation was evident from the beginning of the storage period, without the delay 
evident for the externalisation of aminophospholipids; thus agreeing with observations 
that suggest changes to the ∆Ψm are an early indication of programmed cell death 
(Mignotte and Vayssiere, 1998, Castedo et al., 1996, Newmeyer and Ferguson-Miller, 
2003). In addition, the platelets in both study groups were able to adequately 
compensate for any disruption to oxidative phosphorylation, since ATP production 
during the first half of the storage period was well-maintained.  
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In summary, platelets suspended as concentrates in a storage medium comprising a 
ratio of 70:30 SSP+ and plasma performed at least as well as platelets suspended in 
100% autologous plasma for up to 10 days of storage. Beyond this time-point, an 
accelerated deterioration was observed, possibly related to the depletion of glucose in 
these units, which was not reflected by the routine quality parameters of pH and 
swirling. The increase in the percentage positive expression of annexin V binding and 
decrease in ∆Ψm suggest an apoptosis-like process may be involved in the platelet 
storage lesion, with mitochondrial changes preceding an increase in the percentage of 
platelets expressing annexin V. However, subsequent studies suggested that whilst this 
may have played a role in the first few days of storage, this was not the case at later 
timepoints. The subsequent studies targeting constituents of an artificial additive 
solution and the response to the BH3 mimetic ABT-737 were undertaken to further 
investigate this hypothesis. Although the assessment of platelet in vitro characteristics 
is a logical starting point for the investigation of platelet viability beyond 7 days of 
storage, the questions of haemostatic function as well as platelet recovery and survival 
following transfusion would need to be addressed prior to any consideration of 
extending the storage period of PCs beyond seven days. 
 
INVESTIGATION INTO THE ROLE OF ALBUMIN, GLUCOSE AND ACETATE 
ON THE IN VITRO STORAGE CHARACTERISTICS OF PLATELETS STORED AS 
CONCENTRATES IN AN ARTIFICIAL ADDITIVE SOLUTION WITH MINIMAL 
PLASMA CARRY-OVER 
 
Albumin Study 
Human albumin is the most abundant protein in plasma, comprising 50 – 60% of the 
total serum protein, with a normal concentration of 40 – 50 g/L (Farrugia, 2010). It is a 
65 kDa glycoprotein with a flexible molecular structure, a negative surface charge and a 
large number of disulphide bridges (He and Carter, 1992) - all attributes of the molecule 
which relate to its varied functions. Albumin is the most significant contributor to 
normal colloid osmotic pressure due to a combination of its molecular weight and high 
plasma concentration as well as its negative surface charge (Nicholson et al., 2000). The 
flexible nature of the molecule allows it to bind to a wide variety of molecules and serve 
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as a carrier for free fatty acids which may be incorporated in the metabolism of other 
lipids (Okuma et al., 1971). Other suggested roles for albumin include an ability to act 
as a buffer (McAuliffe et al., 1986) and as an antioxidant. The latter may be due to the 
large number of sulfhydryl groups which serve to remove oxygen free radicals and other 
oxidising agents (Nicholson et al., 2000). In addition, studies on cultured endothelial 
cells have identified albumin as an inhibitor of apoptosis (Zoellner et al., 1996). The 
suggested role of albumin in fatty acid transport, plasma buffering, the scavenging of 
oxidants and inhibition of apoptosis suggest a potential beneficial effect on in vitro 
platelet viability, and suggested albumin may be partly responsible for the requirement 
to retain a significant proportion of plasma in the suspending medium. The presence of 
albumin in the suspending medium was thus hypothesised to aid in maintaining platelet 
viability in storage. 
 
The principal observation from the three replicate experiments which incorporated a 
20% human albumin solution (Zenalb®20, BioProducts Laboratory, Elstree, UK) to the 
standard additive solution was the rapid deterioration of the platelets after day 3. This 
was evident across all the parameters measured. For a significant proportion of the 
platelet population disruption was total, as evidenced by the marked decrease in platelet 
concentration, suggestive of platelet lysis. The results suggested the disruption was 
directly related to the addition of the albumin solution, as a dosage-dependent response 
was clearly evident. The loss of swirling in albumin-containing units was also 
indicative of gross morphological changes. The possibility that differences in osmotic 
balance were responsible appeared remote since the concentrations of albumin in the 
media were not expected to result in a hyperosmotic environment. For confirmation, the 
osmolality of a sample from a unit re-suspended with SAS containing the highest 
concentration of albumin (120 ml of Zenalb®20) was measured with an Osmomat 030 
cryoscopic osmometer (Gonotec GmBH; Berlin, Germany). The result of 292 
mOsm/kg was comparable to normal levels in extracellular fluid of approximately 300 
mOsm/kg (Bourque, 2008). 
 
Glucose was consumed at an accelerated rate in the presence of albumin, leading 
directly to the cessation of lactate production by day 6. This was reflected by the pH 
levels which failed to decrease beyond day 6; reinforcing the observation made in the 
comparative study of plasma and SSP+ units that extracellular pH is highly dependent 
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on the presence of glucose in the suspending medium. It also highlights the limits of 
employing pH in isolation as an indicator of platelet viability in routine quality control 
for PC components with limited glucose stores, since pH values remained stable despite 
obvious deterioration of the components. As well as the collapse of glycolysis by day 6, 
the partial pressures of oxygen and carbon dioxide indicated oxidative metabolism was 
also compromised. The relatively high pO2 levels on day 2 in the presence of albumin 
suggest oxygen diffusing into the pack was not being utilised, even at this early stage in 
the storage period, and may indicate early damage to the mitochondria. The loss of both 
mechanisms of ATP synthesis in the albumin-containing units was reflected in the 
absence of ATP by day 6. ATP levels on days 2 and 3 were similar to units suspended 
in SAS in the absence of albumin, suggesting that the increased rate of glycolysis in the 
albumin-containing PC early during the storage period was compensating for any 
disruption of oxidative metabolism. 
  
Starting levels of surface-expressed CD62P with all four groups in this study were high 
compared to BC-PC processed by standard methods; a finding which was not 
unexpected considering the stress imposed on the platelets during processing by the 
hard spin required to pellet the platelets and remove the majority of the plasma. 
Interestingly, though, similarly-processed PC re-suspended in 100% plasma showed 
markedly lower percentage positive expression of CD62P at the start of storage, 
suggesting that a component in plasma not characterised by the albumin in solution 
reduced platelet activation to levels more comparable to standard BC-PCs. The 
progressive decrease in percent positive expression with storage suggested that 
shedding of the CD62P occurred preferentially with higher concentrations of albumin. 
This finding appeared to be corroborated by the higher concentrations of soluble 
CD62P in albumin-containing units compared with the group lacking albumin as the 
storage period increased. However, the clear dosage-dependent effect of albumin noted 
with percent positive expression was not matched by higher concentrations of soluble 
CD62P in units with higher concentrations of albumin. It is possible that lysis of the 
platelets resulted in CD62P-bearing fragments that were not quantified by the flow 
cytometer protocol employed, since this was aimed towards the counting of intact 
platelets. The increased platelet lysis associated with higher albumin concentrations 
may thus account for the more pronounced decrease in the percentage of platelets 
expressing CD62P, as well as the decrease in CD62P expression per platelet. As the 
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CD62P on these fragments would remain membrane-associated, it may also be 
“hidden” from the ELISA assay adopted to measure concentrations of the soluble 100 
kDa fragment of the molecule. 
 
The parameters selected to investigate apoptosis provided a comprehensive pattern that 
confirmed the conclusion derived from the metabolic and morphological markers that 
the platelets suspended in albumin-containing SAS had experienced a catastrophic 
disruption of function and viability. Mitochondrial membrane potential decreased 
rapidly in these units from the beginning of the storage period, which may be related to 
the impaired oxidative phosphorylation implied by the increase in pO2 from day 2. By 
comparison, the comparative delay in the increase in annexin V binding and 
intracellular free calcium, with levels only increasing after day 3, suggest that 
aminophospholipid externalisation and release of calcium into the cytosol occur 
subsequent to mitochondrial disruption during platelet storage. The loss of phospholipid 
asymmetry is expected to result in an increase of both PE and PS on the outer leaflet of 
the platelet membrane. The nature of the aminophospholipids expressed on the platelet 
surface was further characterised by mass spectrometry on a representative sample. As 
expected, both PE and PS increased with storage in albumin-containing units. However, 
expression of all four isoforms of PE in non-albumin containing units remained stable 
throughout storage, suggesting that the relatively minor increase in the percentage of 
annexinV-binding platelets during storage was principally due to the increase in PS 
expression observed by mass spectrometry. Mass spectrometric measurements were 
performed on a representative sample, and further replicates would be required to 
confirm whether this observation is reproducible.  
 
The addition of human albumin to the additive solution resulted in a clear degradation 
of platelet function and viability in excess of changes associated with the platelet 
storage lesion in more conventional media. This comprised an early increase in both 
aerobic and anaerobic metabolism, with total consumption of exogenous glucose by day 
6 coinciding with the depletion of ATP stores. This in turn was associated with results 
from the cell death and platelet morphology parameters indicative of irreversible 
platelet degradation. The human albumin solution used was a 20% solution of 
commercially available human albumin (Zenalb® 20, Bio Products Laboratory, Elstree, 
UK). Different batches of Zenalb®20 were used for the three replicate experiments; a 
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possible artefact caused by a manufacturing anomaly of a single batch was thus 
excluded as a possible explanation. 
 
Further experiments were undertaken with a different commercially available albumin 
solution (Baxter Healthcare, Norfolk, UK) as well as with fatty acid-free lyophilised 
albumin from human serum (Sigma-Aldrich, Dorset, UK) to determine whether the 
formulation of the albumin solution selected was responsible for the observed results. 
Both experiments strongly suggested that the rapid deterioration in platelet 
characteristics noted with Zenalb®20 was caused by the formulation of the albumin 
solution, though Zenalb® solutions are well-established in the clinical setting, with no 
reported effects on platelets. Therefore, the observed changes appear to be limited to in 
vitro phenomena. Details of the composition of the human albumin solutions (as 
determined from the publicly available package inserts) suggest the two products are 
similar, with both manufacturers adopting sodium octanoate as a stabilizer against the 
relatively high temperatures of the pasteurisation steps during manufacture and the 
Baxter formulation additionally employing sodium n-acetyltryptophanate to reduce 
oxidation (Yu and Finlayson, 1984, Anraku et al., 2004) (table 8.1). 
 
Table 8.1: Composition of commercial human albumin solutions as provided by the 
manufacturers in their publicly available literature. (Sodium n-octanoate and sodium 
caprylate are synonyms) 
 
Zenalb®20 Baxter 20% human albumin 
Sodium 50-120 mmol/L Sodium chloride 3.0 g/L 
Potassium Sodium caprylate 2.7 g/L 
Chloride Sodium n-
acetyltryptophanate 
Citrate  
Sodium n-octanoate  
<200 µg/l of aluminium  
 
Differences in the methods employed for the manufacture of the two commercial 
albumin solutions may provide an alternative explanation for the varying platelet 
response to the two solutions. BPL has introduced diafiltration to remove excess water 
and ethanol after the initial fractionation steps and a chromatographic step to further 
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remove contaminating proteins (Matejtschuk et al., 2000). Baxter has retained the Cohn 
cold fractionation method for the manufacture of plasma products, although it is 
difficult to determine from the published literature whether significant alterations to the 
original method have been adopted. 
 
Questions over the safety of albumin were raised by the publication of a meta-analysis 
of 30 randomised controlled trials which concluded there was a 6% increase in the risk 
of death in patients treated with albumin (Berger, 1998). Subsequent studies have failed 
to confirm these conclusions (Wilkes and Navickis, 2001, Vincent et al., 2004, Dubois 
et al., 2006). In light of the markedly different impact on platelet characteristics 
resulting from the inclusion of albumin solution from two different manufacturers to the 
storage media, the question arose as to whether the use of albumin solutions from 
different manufacturers could explain the heterogeneity of results regarding the safety 
and efficacy of albumin in the clinical literature. A review of the publications used in 
the meta-analyses referenced above failed to yield any further insight due to the failure 
in a large proportion of the studies to identify the albumin manufacturer as well as the 
wide variety of manufacturers used in the various studies where the albumin source was 
quoted. However, different albumin preparations have been reported to demonstrate 
variable upregulation of endothelial cell adhesion molecules, even between batches 
from the same manufacturer (Nohe et al., 1999). Variable responses in blood pressure 
have also been reported on infusion of different batches of 5% human serum albumin 
(Heringlake et al., 2000). Thus, although it is not possible at this stage to definitively 
identify the causative factor behind the disparate effect on platelets in storage of the 
BPL and Baxter albumin solutions, it is clear that despite advances in the manufacture 
of human albumin solutions, there remains significant variability in the in vitro 
characteristics of different albumin solutions. 
  
The inclusion of human albumin in the storage medium was hypothesized to aid in the 
maintenance of platelet viability in vitro. In this regard, the experiments with the Baxter 
formulation and powdered human serum albumin failed to demonstrate improved 
platelet storage characteristics, though care is required in deriving a conclusion from a 
single data point. 
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Glucose Study 
The studies on platelet metabolism by Kilkson et al led to the conclusion that glucose 
was not an important substrate for aerobic metabolism, and called into question the 
relevance of glucose as a component of the storage medium (Kilkson et al., 1984). The 
possibility that it may even be harmful was suggested due to the promotion of 
glycolysis by glucose with a resultant decrease in pH. The consensus from more recent 
work on PC storage has increasingly converged on the notion that glucose is required 
throughout the storage period (Gulliksson, 2000, Gulliksson, 2003). However, the 
mechanism of action remains elusive and a consensus on its role remains to be reached 
(Gyongyossy-Issa, 2011).  
 
Glucose was utilised by the platelets from the beginning of the storage period. The rate 
of decline was independent of the initial concentration of glucose and correlated closely 
with the rate of lactate production, suggesting glucose was being consumed via 
glycolysis from the beginning of the storage period. This was despite unrestricted access 
to oxygen through the gas-permeable packs and the presence of oxidisable fuels, as 
noted in early studies on platelet metabolism during storage (Holme et al., 1987). A 
precedent for the continued generation of lactate from glucose via the glycolytic 
pathway in environments with abundant oxygen was first described by Warburg in 
relation to the metabolism of proliferating cancer cells (Warburg, 1956) and has since 
been recognised as a feature in healthy dividing cells (Lunt and Vander Heiden, 2011). 
A posited explanation is that aerobic glycolysis, though inefficient in terms of the 
overall number of ATP molecules generated per glucose molecule compared to the 
oxidative phosphorylation pathway, is able to produce ATP at a faster rate (Pfeiffer et 
al., 2001). In rapidly proliferating cells which may be competing for limited resources, a 
faster rate of ATP may thus be more desirable (Vander Heiden et al., 2009, Lunt and 
Vander Heiden, 2011). It is unclear at this time, however, how this could translate to the 
physiology of platelets stored as concentrates. The rate of glucose consumption 
increased over the storage period. It is possible that the platelets are preferentially using 
the exogenous acetate as the principal fuel to maintain energy levels and progressively 
converting to glucose as a metabolite as the acetate is consumed (Murphy, 2002, 
Vetlesen et al., 2007, Ringwald et al., 2006). 
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Results from other metabolic parameters suggest that the role of glucose in platelet 
metabolism is not restricted to glycolysis. The absence of glucose in the medium 
resulted in a decrease in pCO2 – in isolation, this may be indicative of reduced CO2 
generation as a result of impaired oxidative phosphorylation. However, as already 
discussed, various studies investigating the contribution of glucose to oxidative 
pathways of metabolism have concluded that it plays a minor role (Guppy et al., 1990, 
Murphy, 1995). A possible alternative explanation could relate the reduction in CO2 
generation to reduced activity of the bicarbonate buffering system as lactate levels cease 
to rise with the exhaustion of glucose. Loss of glucose was also associated with a 
reduced oxygen consumption rate and a decrease in ATP concentration; indeed, ATP 
levels were markedly lower from the start of the storage period in units lacking 
exogenous glucose. Mean ATP levels on day 2 in the units lacking glucose were 78% of 
mean levels in the group containing the highest concentration of glucose. It is possible 
that this difference simply reflects the proportion of ATP that would otherwise be 
supplied by glycolysis, estimated to be approximately 15-25% of total ATP production 
(Guppy et al., 1997, Bertolini et al., 1992). ATP levels in units lacking glucose declined 
steadily with storage, suggesting the exogenous acetate and endogenous fuels were 
unable to compensate for glucose in the production of ATP, unlike the results observed 
with units that retained reserves of glucose to the end of storage.  
 
The glucose study showed that early changes in mitochondrial membrane polarisation 
were followed by increases in cytosolic Ca2+ and surface expression of 
aminophospholipids which were linked to a decrease in ATP levels coincident with the 
exhaustion of glucose in the media and ultimately resulted in platelet degradation 
indicated by decreased platelet concentration. The depletion of glucose may have 
provided a trigger for these events. Though some of the observations seemed to concur 
with the proposal that a process akin to apoptosis was a central component of the 
platelet storage lesion, the loss of ATP and cellular disruption coincident with the 
exhaustion of glucose stores are not consistent with the classical description of 
apoptosis since this is an energy dependent process (Kung et al., 2011). Regardless of 
the mechanism of cell death, the implication remains that glucose is required for the 
maintenance of platelets stored as concentrates and would be a beneficial component of 
artificial additive solutions, particularly if the aim is to reduce patient exposure to 
donor plasma by minimising plasma load in PC units.  
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Acetate Study 
The addition of acetate to the SAS resulted in reduced glucose consumption (with the 
concomitant decrease in lactate production), a more reduced drop in pH and an 
increased oxygen consumption rate. Similar results have been reported in the literature 
(Gulliksson, 2000, Murphy, 2005) and are likely related to the preferred use of acetate 
as an oxidisable fuel by platelets as well as to its buffering capacity. However, although 
the decrease in pH and glucose during the first half of the storage period was not as 
marked, levels were not found to be stabilised by the inclusion of acetate. In addition, 
also in accordance with the published literature, the addition of acetate failed to 
maintain ATP levels and resulted in a concentration-dependent depression of the 
response in the HSR and ESC assays (Holme, 1992). The seemingly paradoxical 
decrease in ATP levels may be related to the metabolism of acetate into acetyl coA, a 
reaction that requires the consumption of an ATP molecule and results in the formation 
of AMP and a pyrophosphate (Liang and Lowenstein, 1978, Knowles et al., 1974). 
Studies associated with the use of acetate in haemodialysis have noted that a rapid ATP-
consuming process occurred at high concentrations of acetate in cardiac myocytes, 
actually reducing the concentration of ATP and increasing AMP levels. Mitochondria 
are incapable of rephosphorylating AMP, instead forming two ADP molecules with the 
additional use of ATP by the adenylate kinase reaction (Vinay et al., 1987). Animal 
studies have also noted a decrease in ATP/ADP ratios and an increase in AMP levels 
following the infusion of acetate into heart or skeletal muscle (Liang and Lowenstein, 
1978, Spydevold et al., 1976). 
 
The reduced responses in HSR and ESC assays evident at the start of the storage period 
were accompanied with enhanced platelet activation and platelet lysis, as inferred from 
lower platelet concentrations. Subsequent measurements of these parameters during the 
storage period tended to occur at similar rates, suggesting the initial exposure to acetate 
was the principal stressor rather than progressive changes imposed over the storage 
period. Also evident was a direct relationship between the concentration of exogenous 
acetate and the level of the adverse response. Although it was not possible to infer a 
mechanism to explain these findings from this study, the possibility that acetate may 
have adverse effects has been suggested by clinical observations of the use of acetate 
and whole-body studies on animals. Acetate has been employed as a buffer in various 
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clinical solutions but been found to be associated with vasodilation effects, impaired 
contraction of cardiac myocytes and in some cases hypotension (Olinger et al., 1979, 
Jacob et al., 1997, Vinay et al., 1987). The impact of added acetate on the markers of 
apoptosis was less clear, with only a suggestion that the highest concentrations of 
acetate may be enhancing cell death. The marked increase in anionic phospholipid 
externalisation observed after day 8 may be related to the exhaustion of glucose stores 
rather than a storage-related effect of acetate in the medium. 
  
The inclusion of acetate in artificial storage media has been principally based on its 
buffering action and associated ability to maintain pH at relatively higher levels. 
However, its addition to SAS in this study resulted in lower levels of ATP as well as 
decreased performance in assays related to platelet function (HSR/ESC). Further 
studies on the impact of exogenous acetate on platelet function, morphology, activation 
and apoptosis would help to clarify its role in the progression of the PSL. If the adverse 
effects suggested by this study were confirmed, the possibility remains that with 
adequate levels of sodium bicarbonate in the storage medium, acetate may not be 
required for the maintenance of platelets as concentrates. 
  
 
INVESTIGATION INTO THE MECHANISM OF AMINOPHOSPHOLIPID 
TRANSLOCATION AND THE ROLE OF BCL-2 FAMILY INITIATION OF 
PLATELET DEATH IN RELATION TO THE PSL 
 
Efforts to determine the optimal conditions for the storage of platelets as concentrates 
initially centred on the metabolic characteristics of platelets in vitro. Application of this 
work led to the adoption of gas-permeable plastics and storage under constant agitation 
at 22°C, with clear practical benefits evident in the maintenance of pH levels and 
platelet survival in the circulation post-transfusion (Murphy et al., 1982, Holme et al., 
1978, van der Meer and Korte, 2011). However, current guidelines for PC storage 
continue to result in changes that adversely affect the survival and function of platelets 
in storage. Interest in the possibility that a controlled process of cell death may play a 
significant role in this phenomenon has been increasing, with the applied aim that a 
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better understanding of the phenomenon may allow the manipulation of the storage 
conditions to reduce the adverse effects of the PSL. The opportunity arose to investigate 
the mechanism of platelet death in storage more directly by examining the translocation 
of aminophospholipids in platelets from a Scott syndrome patient stored for up to ten 
days alongside platelets from normal volunteers. Specifically, this would determine 
whether the increase in aminophospholipid expression on the platelet surface with 
storage was due to platelet ageing or activation. 
  
Scott syndrome is a rare platelet coagulation disorder characterised by an inability to 
express PS on the platelet surface following activation (Rosing et al., 1985). A recent 
study showed that transmembrane protein 16F (TMEM16F) is a required component of 
Ca2+-dependent phospholipid scrambling, with a point mutation on the TMEM16F gene 
of a Scott syndrome patient resulting in premature termination of the protein at the third 
transmembrane region (Suzuki et al., 2010). Two further mutations have since been 
identified in this gene in peripheral blood leucocytes of a second Scott patient (the 
patient investigated in this study), confirming the role of this protein on Ca2+-dependent 
PS expression (Castoldi et al., 2011). First recognised in lymphocytes, surface 
expression of PS is also associated with cells entering apoptosis and is believed to act as 
a recognition signal for cell clearance by phagocytes (Fadok et al., 1992, Bevers and 
Williamson, 2010). A study on B lymphocytes from a Scott patient detected normal PS 
exposure in cells stimulated to undergo apoptosis but failed to detect a similar change in 
cells exposed to a calcium ionophore, suggesting that two distinct pathways of PS 
exposure may be operating in haemopoietic cells (Williamson et al., 2001, Zwaal et al., 
2004). A recent study investigated this concept in platelets using mice with variable 
expression of the pro-apoptotic Bcl-2 family members Bak and Bax. Bak-/-Bax-/- 
platelets exposed to the apoptosis-inducing BH3 mimetic ABT-737 failed to express PS 
on the surface, whereas exposure to either a calcium ionophore or CRP/thrombin 
resulted in normal levels of PS exposure. These results confirmed the hypothesis that 
expression of PS on the platelet surface follows at least two distinct pathways 
depending on whether the platelets are subjected to a physiologic agonist, an apoptotic 
process (Schoenwaelder et al., 2009) or another mechanism. They also indicate that the 
scramblase remains unaffected by the Scott gene mutation and serves as a juncture for 
the convergence of the two pathways (Bevers and Williamson, 2010) (figure 8.3). 
Recent work on platelets from the Scott patient investigated in this study further 
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suggests that PS translocation occurs by at least two pathways. One pathway observed 
in both Scott and normal platelets is independent of functional TMEM16F and exhibits 
a relatively slow response to incubation with ABT-737. The second pathway is 
TMEM16F-dependent, absent from Scott platelets, and associated with high 
intracellular Ca2+ and rapid scrambling (van Kruchten; revised manuscript submitted).  
 
 
Figure 8.3: Two distinct pathways leading to PS exposure in platelets. Exposure of PS following 
Ca2+ ionophore or agonist stimulation is blocked in Scott syndrome patients. The alternative 
pathway, initiated by the Bcl-2 family of proteins, is unaffected by the Scott defect and is able to 
lead to PS translocation via regulation of mitochondrial changes (SOCE – store-operated 
calcium entry) (Bevers and Williamson, 2010) (Reproduced with permission, © Elsevier B.V.) 
 
 
If scramblase independent mechanisms were associated with the expression of 
aminophospholipids during platelet storage, the platelets from a Scott patient would be 
expected to increasingly express PS on their surface over the course of the storage 
period, similar to platelets from normal individuals. Results from the current study 
confirmed this, with similar levels of annexin V binding on platelets from a Scott 
patient and two normal volunteers over the course of 9 days of storage. Subsequent 
experiments at the University Hospital of Wales (UHW) and by Professor Bevers’ team 
at Maastricht confirmed these findings. The team at UHW subsequently investigated the 
relationship between this increased expression of aminophospholipids in Scott platelets 
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and their ability to support thrombin generation. An increased expression of PS in 
activated platelets from normal individuals serves to spatially concentrate the activities 
of the tenase and prothrombinase complexes and thus promote thrombin generation 
(Heemskerk et al., 2002). If the PS progressively expressed on the surface of stored 
Scott platelets retains this function, an increase in thrombin generation would be 
observed with increased storage. The results were consistent with this, with levels of 
thrombin generation in Scott platelets similar to control platelets by day 8 of storage. 
The question remains as to whether aged Scott platelets retain this functional capacity in 
vivo. The studies thus confirmed that the increase in annexin V binding observed with 
storage was not due to activation mediated by scramblase. A further experiment was 
undertaken to determine whether an increase in aminophospholipid translocation could 
be observed in platelets stored in additive solution on addition of a promoter of a 
controlled mechanism of cell death. 
 
The central role played in the apoptosis of nucleated cells by the Bcl-2 family of 
proteins has been confirmed in numerous studies (for recent reviews see (Danial, 2007, 
Chipuk et al., 2010, Brunelle and Letai, 2009, Dewson, 2010)). Following exposure to 
an apoptotic stressor, the conformational change and oligomerisation of pro-apoptotic 
members Bax and/or Bak on the outer mitochondrial membrane is thought to form pores 
allowing for the release into the cytosol of intermembrane space proteins such as 
cytochrome c and Smac/DIABLO which proceed to initiate or enhance caspase 
activation leading to apoptosis (Youle and Strasser, 2008, Westphal et al., 2011). Two 
major models have been postulated to explain the regulation of apoptosis by Bcl-2 
family proteins; both involving the interaction of BH3-only proteins as facilitators of 
apoptosis. The indirect activation model suggests the role of the anti-apoptotic Bcl-2 
and Bcl-XL proteins is to inhibit pro-apoptotic Bax and Bak. BH3-only proteins in this 
model sequester the anti-apoptotic Bcl-2 proteins is response to apoptosis-inducing 
signals, thus releasing Bax and Bak and allowing them to oligomerize (Willis et al., 
2005, Fletcher and Huang, 2008). The direct activation model further classifies the 
BH3-only proteins into sensitizers and activators. Activators such as Bim and tBid 
directly bind and promote the oligomerization of Bax and Bak. The role of anti-
apoptotic Bcl-2 proteins in this model is to bind and inhibit the activators. BH3-only 
sensitizers such as Bad are able to promote apoptosis by binding to anti-apoptotic Bcl-2 
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and/or Bcl-XL and thus release the activators (Kim et al., 2006). A further model 
referred to as “embedding together”, which incorporates aspects of both the direct and 
indirect activation models, has also been proposed that emphasises the vital role played 
by the mitochondrial membrane in the initiation of apoptosis by the Bcl-2 protein family 
(Leber et al., 2007, Bogner et al., 2010). A common theme of these models is that the 
interaction between pro- and anti-apoptotic members of the Bcl-2 family acts to regulate 
the process of cell death (Leytin and Freedman, 2003, Brown et al., 2000) (figure 8.4).  
 
Figure 8.4: Direct and indirect activation models of Bax and Bak activation. A). In the 
direct model, proapoptotic Bax and Bak require activator BH3-only proteins to 
function. These are preferentially bound to antiapoptotic Bcl-2s in viable cells. Bax and 
Bak are able to oligomerise and form pores in the mitochondrial outer membrane 
function when the concentration of activator proteins exceeds the capacity of the 
antiapoptotic proteins to sequester them. Sensitizer BH3-only proteins (e.g. Bad, Noxa) 
facilitate the process by binding to the antiapoptotic proteins and promoting the release 
of activators. B). In the indirect or diaplacement model, antiapoptotic Bcl-2 members 
bind to Bax and Bak, inhibiting their ability to oligomerise. BH3-only proteins bind to 
antiapoptotic Bcl-2s, thus releasing the proapototic proteins. C). Anti-apoptotic Bcl-2 
proteins mobilised to the mitochondrial outer membrane bind to and inhibit both 
activator BH3-only proteins such as tBid and pro-apoptotic Bax and Bak. Sensitiser 
BH3-only proteins (e.g. Bad) may displace the activators, freeing them to bind to pro-
apoptotic proteins and initiate mitochondrial outer membrane permeabilisation 
(Shamas-Din et al., 2011) (Reproduced with permission, © Elsevier B.V.). 
 
ABT-737 binds avidly to the hydrophobic groove of Bcl-XL, mimicking the action of 
the Bad BH3-only protein (figure 8.5) (Dewson, 2010). An increase in annexin V 
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binding in response to the addition of ABT-737 would thus indicate that 
aminophospholipid translocation in platelets stored in additive solution was able to 
proceed through a process of cell death regulated by the Bcl-2 family of proteins.  
 
 
 
Figure 8.5: Interaction of the BH3-only protein Bad with the hydrophobic groove of the 
antiapoptotic Bcl-XL and the corresponding activity of the BH3 mimetic ABT-737 
(Dewson, 2010) (Open access, ©Dove Medical Press Ltd) 
 
In the unit with added glucose in the storage medium, the addition of ABT-737 
increased annexin V binding early in the storage period compared to control samples, 
with the effect gradually decreasing over time. The reduced response to ABT-737 was 
temporally related to falling levels of glucose and ATP. The depletion of glucose was 
also temporally related to a marked increase in annexin V binding, but with no 
additional increase observed in samples with ABT-737 compared with the control. This 
suggests that after glucose and ATP levels fall, the platelets are no longer able to 
express aminophospholipids through an apoptotic mechanism and another mechanism 
needs to be postulated.  
 
In the unit with no added glucose, ABT-737 resulted in an increase in annexin V 
binding compared to controls only on day 2. Beyond this time-point, annexin V binding 
increased rapidly with storage but with no additional expression caused by ABT-737. 
The results indicated that early during the storage period, a mechanism regulated by 
Bcl-2 proteins was present that could increase aminophospholipid translocation in 
platelets. In addition, the depletion or absence of glucose in the storage medium 
markedly increased aminophospholipid translocation without the involvement of this 
ABT-737 
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Bcl-2 protein-regulated mechanism, by a process coincident with a marked decrease in 
ATP levels, an increase in intracellular free calcium and progressive platelet disruption. 
 
SUGGESTED MODEL FOR THE MECHANISM OF PLATELET DEATH IN 
PLATELETS STORED AS CONCENTRATES 
 
The increase in annexin V binding following the addition of ABT-737 suggested a 
pathway of cell death mediated by the Bcl-2 family of proteins could be initiated in 
platelets at the start of storage and prevailed for up to eight days in the presence of 
energy stores able to maintain ATP levels. This is consistent with apoptosis being an 
energy-dependent process (Nicotera and Melino, 2004). Recent studies have confirmed 
the release of cytochrome c and activation of caspase 3 in stored platelets in response to 
the BH3 mimetic ABT-737 (Dasgupta et al., 2010), showing that apoptosis via a Bcl-2 
family-mediated mitochondrial pathway is a credible mechanism for platelet death in 
storage. A Bcl-2 protein-mediated cell death mechanism may have been present in PC 
stored for 14 days in autologous plasma, where an increase in annexin V binding was 
observed after day 8, despite glucose still being available in the medium and ATP levels 
retained close to day 1 values.  These results are consistent with the concept of an 
internal clock limiting platelet lifespan, as suggested by Mason et al in their study with 
Bak knockout mice in which they proposed that levels of anti-apoptotic Bcl-XL 
inherited from the parent megakaryocyte degrade more rapidly than those of pro-
apoptotic Bak. Once free from the inhibitory activity of Bcl-XL, the remaining Bak is 
able to initiate platelet death via apoptosis (Mason et al., 2007, Qi and Hardwick, 2007). 
Various lines of evidence have suggested a role for the Bcl-2 protein family in platelet 
death. In mature platelets, levels of pro-apoptotic Bax and Bak have been found to 
increase with platelet storage (Brown et al., 2000). Anti-apoptotic members of the 
family are predominantly represented by Bcl-XL, with minimal levels of Bcl-2 having 
been detected by Western blot (Sanz et al., 2001, Zhang et al., 2007). Bcl-XL levels 
have been reported to decline after 7 days in platelets stored as concentrates in standard 
storage conditions, with the rate of decline accelerated markedly with an increase in 
storage temperature to 37°C (Bertino et al., 2003). An additional factor is the 
progressive mitochondrial dysfunction suggested by the gradual loss of mitochondrial 
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membrane potential observed with storage, which may lead to increased strain on the 
antioxidant defences of the platelets and facilitate Bcl-2 protein mediated cell death 
(Voehringer, 1999, Howard et al., 2009). Thus, a TMEM16F-independent mechanism 
of controlled cell death - mediated by the Bcl-2 family of proteins and dependent on the 
retention of adequate levels of ATP - is suggested to be a plausible mechanism of cell 
death for platelets stored as concentrates. The viability of this mechanism may be 
limited by the “shelf-life” of internal stores of anti-apoptotic Bcl-XL and may be 
exacerbated by a gradual loss of mitochondrial function. 
 
In the absence of glucose in the storage medium, the translocation of 
aminophospholipids was markedly accelerated in the absence of a Bcl-2 family-
mediated mechanism, as evidenced by the lack of any additional annexin V binding on 
addition of ABT-737. An alternative mechanism is thus required to explain platelet 
death in a glucose-depleted environment. 
 
A consistent observation in this study has been that the absence or depletion of glucose 
in the storage medium resulted in an increased expression of the markers associated 
with cell death that coincided with a decline in the levels of ATP. It seems likely that 
the ability of glucose to generate ATP via glycolysis at least partly compensated for a 
decrease in ATP generation via oxidative phosphorylation and helped to maintain ATP 
levels during storage. In addition to its ability to regenerate ATP via glycolysis, the 
question arose as to whether the absence of glucose may be having an adverse effect on 
platelet biology with indirect consequences on the ability of platelets to maintain or 
regenerate ATP. A clue may lie in the markedly greater disruption in the mitochondrial 
membrane potential evident from the start of storage in units lacking glucose. 
 
Loss of mitochondrial membrane potential was evident before marked changes in other 
markers of cell death, suggesting an early and progressive mitochondrial dysfunction 
with storage. Synthesis of ATP via the electron transport chain is a critical role of 
mitochondria and is mediated by four complexes associated with the inner membrane of 
the mitochondria. The transfer of electrons between complexes I to IV is coupled to the 
extrusion of H+ ions from the mitochondrial matrix to the intermembrane space via 
complexes I, III and IV, resulting in an electrochemical gradient across the inner 
mitochondrial membrane of approximately 180 mV (negative on the matrix side of the 
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membrane). The flow of protons back into the mitochondrial matrix through the fifth 
complex (ATP synthase) subsequently drives the synthesis of ATP from ADP (Nicholls, 
2002, Bayir and Kagan, 2008) (figure 8.6). Disruption of the proton-motive force would 
result in depolarisation of the membrane potential and reduction in the rate of ATP 
synthesis. 
 
Figure 8.6: Synthesis of ATP via the mitochondrial electron transport chain (Bayir and 
Kagan, 2008) (Open Access, © BioMed Central Ltd) 
 
 
Deviation of electrons from the orderly progression through the mitochondrial transport 
chain can lead to their sequestration by oxygen and result in the generation of 
superoxide (O2•-) (Adam-Vizi and Chinopoulos, 2006, Murphy, 2009). Platelets were 
first reported to generate O2•- by Marcus et.al (Marcus et al., 1977). Reactive oxygen 
species have been reported to promote platelet activation, platelet aggregation and 
platelet sequestration and recruitment to developing thrombi (Iuliano et al., 1997, Krotz 
et al., 2004). Various lines of evidence further support the concept that reactive oxygen 
species can participate in cell death (Kroemer et al., 1995, Zhao et al., 2003), with the 
possibility that the levels of ROS in the cell may help to decide its ultimate fate 
(Mignotte and Vayssiere, 1998). A possible link between platelet death in storage and 
the lack of glucose may involve a reduction in the ability of the platelets to combat 
oxidative stress due to reduced activity of the pentose phosphate pathway. Glycolysis 
and the pentose phosphate pathway both require glucose as a starting substrate, linked 
via glucose-6-phosphate (figure 8.7). 
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Figure 8.7: The role of glucose as a substrate in both glycolysis and the pentose 
phosphate pathway (Grant, 2008) (Open Access, © BioMed Central Ltd) 
 
The pentose phosphate pathway generates NADPH which is able to reduce oxidised 
glutathione. Reduced glutathione acts as the substrate for a peroxidase-catalysed 
conversion of peroxides such as H2O2 to water, helping to limit damage from these 
highly reactive molecules (Grant, 2008). High levels of intracellular glutathione levels 
have been previously reported to prevent apoptotic methods triggered by ROS such as 
H2O2 (Pierce et al., 1991, Simon et al., 2000). Although ROS and glutathione 
metabolism were not investigated in the thesis, and discussion of their role in the 
observed results must remain speculative, it is possible that a similar antioxidant 
mechanism was compromised from the start of storage by the total absence of glucose, 
leading to disruption of the respiratory chain and enhanced depolarisation of the inner 
mitochondrial membrane. 
 
Also associated with ATP metabolism is the concentration of mitochondrial and 
intracellular calcium. Three of the dehydrogenases involved in the TCA cycle are 
known to be activated by increases in Ca2+ concentrations (Duchen, 1999, Denton, 
2009), with a primary function of Ca2+ in the mitochondria being the stimulation of 
oxidative phosphorylation (Balaban, 2002, Hansford and Zorov, 1998). Oscillations in 
the cytosolic Ca2+ concentration ([Ca2+]c) can cause similar spiking in the mitochondrial 
Ca2+ concentrations ([Ca2+]m) which result in a relatively prolonged increase in NADH 
in the stimulated cell which can enhance the proton-motive force and increase ATP 
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levels (Rizzuto et al., 2000, Pozzan and Rizzuto, 2000). Indeed, a direct relationship 
between [Ca2+]m and ATP levels has been established in cultured cells (Jouaville et al., 
1999). It has been suggested that this mechanism offers an attractive method of 
targeting ATP supply to demand, since increases in cytosolic calcium are associated 
with a large number of cellular functions (Duchen, 2000, Pozzan and Rizzuto, 2000). It 
may also help explain the increase in ATP levels observed during the first few days of 
storage in PC suspended in plasma or SSP+™, though some authors remain cautious and 
cite that evidence in intact systems is limited (Szabadkai and Duchen, 2008). 
 
One of the principal calcium stores in platelets is located in the dense tubular system, 
comprised of residual smooth endoplasmic reticulum (Jurk and Kehrel, 2005). A close 
physical association between ER membranes and mitochondria has been identified 
which allows for the rapid and highly localised uptake of Ca2+ by mitochondria (Rizzuto 
and Pozzan, 2006). This has suggested a role for mitochondria as a buffer against the 
general propagation of calcium into the cytosol, with the potential for recycling of Ca2+ 
back into the DTS via ATP-dependent SERCA pumps (Wang and El-Deiry, 2004). 
Cytochrome c may also act as a signalling molecule and induce a moderate release of 
calcium ions from the intracellular stores of the dense tubular system. Cytochrome c is 
able to interact with the InsP3 receptors on the membrane of the DTS, promoting 
calcium release from the intracellular stores (Boehning et al., 2003). This may be 
reflected in the results, which showed minimal increases in cytosolic calcium 
concentrations whilst glucose was still available, despite a moderate reduction in 
mitochondrial membrane potential. This essentially physiological role for Ca2+ may be 
subsequently overwhelmed by the pathological changes comprising the PSL (Rasola 
and Bernardi, 2011). 
 
Progressive depletion of the DTS calcium pool may amplify the process of 
mitochondrial dysfunction, as suggested by the two-hit hypothesis in which calcium’s 
nominally benign physiological role is altered on exposure to a pathological stimulus 
such as ROS. Calcium itself may exacerbate this process, as Ca2+-induced 
permeabilisation of the outer mitochondrial membrane has been observed to lead to loss 
of mitochondrial GSH and reduced antioxidant capacity (Brookes et al., 2004). Thus, 
the changes in mitochondrial membrane potential that preceded the increase in cytosolic 
calcium in the additive solution studies may reflect an early change in mitochondrial 
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function at least partly driven by an increase in Ca2+ levels within the mitochondrial 
matrix. A measured increase in cytosolic Ca2+ was only evident following the 
exhaustion of glucose and is suggested to be a consequence of the increased 
mitochondrial dysfunction possibly caused by the accumulation of ROS; a sequence of 
events previously suggested in other cell systems (Tan et al., 1998, Macho et al., 1997) 
and emphasising the close relationship between mitochondrial function and the 
dynamics of intracellular calcium. Extracellular calcium was minimally available to the 
platelets in the additive solution studies, since the SAS did not contain any Ca2+-
containing compounds. Thus, the principal source for the increase in cytosolic Ca2+ 
would be the intracellular stores, which appeared adequate to maintain calcium’s 
physiological functions until mitochondrial dysfunction triggered adverse changes to the 
mechanisms for Ca2+ homeostasis. The associated loss of ATP, phospholipid asymmetry 
and continued mitochondrial membrane depolarisation were also able to proceed in the 
absence of extracellular calcium (see also (Lopez et al., 2007)). 
 
The results and above discussion suggest a complex interaction between mitochondrial 
function, ATP generation, intracellular Ca2+ and the redox state of the platelet was 
possibly initiated and likely exacerbated by the depletion of glucose in the storage 
medium.  The absence of glucose in the medium would have resulted in a loss of 
glycolytic ATP generation, compounding any decline in ATP regeneration by oxidative 
phosphorylation due to depolarisation of the mitochondrial membrane potential.   
Mitochondrial calcium levels may have increased in an attempt to promote ATP 
generation. With continually decreasing energy stores, however, Ca2+
 
re-uptake by the 
DTS via the ATP-dependent SERCA pump may have been compromised, leading to 
excessive levels of Ca2+ in the mitochondrial matrix.  The lack of glucose may also have 
led to a reduced antioxidant capacity in the platelets due to decreased GSH levels. The 
combination of increased ROS, [Ca2+]m overload and ATP depletion resulted in 
permanent opening of the mitochondrial permeability transition pore (Zong and 
Thompson, 2006), leading to further ROS production and mitochondrial disruption 
(Baines, 2010). Persistent opening of the pore allows for the unselected entry of small 
molecules into the mitochondrial matrix. Due to the high protein concentration in the 
matrix this will include an influx of water, leading to mitochondrial swelling which may 
terminate in rupture of the organelle due to the higher surface area of the highly 
convoluted inner membrane relative to the outer mitochondrial membrane (Desagher 
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and Martinou, 2000). Organelle and plasma membranes may be disrupted by the 
increased cytosolic Ca2+ concentrations, exacerbated by the lipid peroxidation activity 
of ROS. Cellular lysis would be the inevitable outcome. Disruption of the normal 
phospholipid asymmetry would also be expected as a consequence of the increased 
levels of cytosolic Ca2+ and reduced ATP. The general scenario is of a necrotic pathway 
to cell death (Golstein and Kroemer, 2007) (figure 8.8). 
 
 
Figure 8.8: Mechanisms associated with necrosis, including a reduction in 
mitochondrial membrane potential (∆Ψm), decreased ATP production, increased ROS 
generation and enhanced opening of the mitochondrial permeability transition pore 
(mPTP) (Jackson and Schoenwaelder, 2010) (Reproduced with permission, © The 
American Society of Hematology). 
 
 
Taken as a whole, the results suggest a Bcl-2 mediated mechanism of cell death was 
present in platelets stored with adequate energy stores which may be initiated under 
normal storage conditions by the interplay between pre-existing concentrations of the 
Bcl-2 family proteins. Further studies involving the manipulation of caspases would 
help to confirm whether this is in fact an apoptotic process. A further consideration is 
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the suggestion that apoptosis and necrosis may not be processes to be viewed strictly in 
isolation, but may form part of a graduated response to cellular insult. In this context, 
the cell’s response to ATP depletion may involve a critical threshold beyond which the 
energy-dependent process of apoptosis is superseded by necrosis (Chen, 2009, Kim et 
al., 2003). Of particular relevance to the artificial environment of platelet storage is the 
phenomenon of secondary necrosis, whereby apoptosis culminates in a necrotic 
outcome following the failure of apoptotic cells to be removed by scavenging 
phagocytes (Lauber et al., 2004, Zong and Thompson, 2006). By contrast, the lack of a 
critical component such as glucose in an artificial additive solution led to a primary 
necrotic mechanism being imposed on platelets due to a critical depletion of energy 
stores. Further insight into the PSL may be gained by extending investigations into the 
role of both necrosis and apoptosis on platelet death, with particular emphasis on the 
central part played by mitochondria in the control of both processes. 
 
SUGGESTIONS FOR FUTURE INVESTIGATIONS 
 
− A more comprehensive investigation of the ∆Ψm during prolonged platelet storage 
would be beneficial in describing the role of mitochondria in the PSL. In addition to 
further work with JC-1, other fluoroprobes sensitive to changes to membrane 
potential such as tetramethylrhodamine methyl ester (TMRM) could be used in 
concert for confirmation of the results (Castedo et al., 2002, Galluzzi et al., 2007). 
− To differentiate between inner and outer mitochondrial membrane permeabilisation, 
it may be possible to adopt the calcein quenching method. Calcein in the form of an 
acetoxymethyl ester is able to diffuse into mitochondria whereas cobalt ions, which 
are able to quench the fluorescence signal from calcein, are excluded unless the IM 
has been compromised (figure 8.9) (Petronilli et al., 1999, Poncet et al., 2003). 
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Figure 8.9: HeLa cells stained with calcein and its quencher Co2+. Cells either  left 
untreated or treated for 24 hours with the calcium ionophore A23187(Galluzzi et 
al., 2007) (Reproduced with permission, ©Springer Science)  
 
− Disruption of the plasma membrane typical of necrotic cells has been previously 
studied with vital dyes such as trypan blue and the release of intracellular contents 
such as lactate dehydrogenase (LDH). However, some authors have suggested 
caution in the use of trypan blue with platelets (Brown et al., 2000), whilst 
measuring the loss of proteins such as LDH may not be sufficient to discriminate 
between cell death pathways (Galluzzi et al., 2009). Since morphological changes 
continue to provide some of the more definitive indicators differentiating between 
apoptosis and necrosis, direct observation of platelet morphology by electron 
microscopy may help to elucidate which mechanism is involved in platelet death 
during storage (Martinez et al., 2010) (figure 8.10). However, the approach is 
limited in that only a few cells can be imaged, making it difficult to interpret results 
in relation to the population dynamics whereby various sub-groups of platelets may 
be experiencing different stages of cell death at the same time point.  
 
Figure 8.10: Scanning electron micrographs showing morphological changes in 
platelets incubated for the annotated periods of time with ABT-737 (Schoenwaelder 
et al., 2011) (Reproduced with permission, © The American Society of Hematology). 
 
− Measurement of extracellular Ca2+ in addition to intracellular levels would improve 
the picture on Ca2+ movements (Sandgren 2010 found no increase in PCs with 
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storage) (Sandgren et al., 2010). Quantitation of intracellular calcium levels may be 
possible by the use of standard lines derived from commercially available buffers 
with known concentrations of Ca2+ (Dustin, 2000). 
 
− The temporal correlation between the exhaustion of glucose and increasing activity 
in the markers suggestive of platelet death evident in this study led to the suggestion 
that ROS generation promoted by the loss of glutathione-mediated antioxidant 
capacity was an initiator of platelet death in storage. Further studies that directly 
measure ROS and glutathione levels, preferably in relation to mitochondrial 
function, would be necessary to test this hypothesis (Cossarizza et al., 2009). 
Possible methods include the use of fluorescent dyes such as 2ʹ-7ʹ-
dichlorodihydrofluoroscein diacetate (DCFH-DA) for determining the redox state of 
the cell as well as dyes which may localise reactive species to specific organelles 
(Curtin et al., 2002). Various techniques for the measurement of H2O2 and O2•- have 
been described, though caution is required in their application to reduce the 
influence of confounding factors in the interpretation of results (Degli Esposti, 2002, 
Halliwell, 2007). 
− Measurement of levels of Bcl-2 family members in platelets (Leytin et al., 2006) 
stored as concentrates, with emphasis on Bax, Bak and Bcl-XL, may serve to 
complement published studies on knockout mouse models postulating that the 
decline of Bcl-XL levels is a principal controller of platelet death (Mason et al., 
2007).  
− The pivotal role played by cytochrome c in the formation of the apoptosome and the 
subsequent activation of caspases during apoptosis makes the protein an attractive 
target to help determine the role of apoptosis in the PSL. Isolation of the 
mitochondria from the cytosol and progressive measurements of cytochrome c in the 
two fractions over the course of the storage period would help to show the time 
course of cytochrome c release. Its relation to other parameters such as ATP loss 
may help determine the nature of the cell death pathway in platelets during storage. 
The rate of caspase 3 activation would be an interesting parallel measure suggestive 
of the initiation of caspase-dependent apoptosis (Dasgupta et al., 2010, Martinez et 
al., 2010). 
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− Experiments employing inhibitors to initiators or regulators of cell death processes 
such as specific caspases or inhibitors of Bcl-2 family members may provide a 
systematic approach to aid in the identification of the cell death pathways involved 
in the PSL. Studies into the role of cyclophilin D, which plays a central role in 
promoting MPTP opening, have suggested a function as a regulator of necrotic 
death with little or no impact on events associated with apoptosis (Kung et al., 
2011). Addition of the cyclophilin D inhibitor, cyclosporine A, to PC may provide 
further insight into platelet death in storage as well as the procoagulant activity of 
aged platelets (Jobe et al., 2008, Jackson and Schoenwaelder, 2010). A barrier with 
all these investigations in the context of a large-volume system such as platelet 
concentrate storage is the cost. Thus, the development of a small-volume model of 
PC in storage may be required before they can be practically considered.  
− The partial pressure of oxygen in arterial blood ranges between 10.6 to 13.3 kPa and 
is lower still in capillaries (6.0 – 8.0 kPa) (Kumar and Clark, 2009, Halliwell and 
Gutteridge, 2007). Thus, platelets in vivo are seldom exposed to the levels of oxygen 
that were observed in the storage packs even at the start of the storage period. The 
hypothesis that ROS generation by platelets during storage is at least partly 
causative of the changes comprising the PSL would suggest that storage of platelet 
concentrates in a limited oxygen environment in gas-permeable packs that allow for 
the loss of CO2 may help to limit some of these changes. A storage study using a 
paired design would help to answer this question.  
− It would be interesting to investigate platelet death in storage against methods 
developed to measure platelet function. Such methods could include classical 
aggregation studies due to the long history of published work and continued 
relevance in the clinical setting. More recent technologies aim to mimic platelet 
function in vivo somewhat more faithfully. They include the measurement of platelet 
aggregation under conditions of high shear in response to agonists (PFA-100 
analyer: Dade-Behring, Marburg, Germany) (Tanaka, 2006), and platelet adhesion 
and aggregation to a matrix expressing various glycoproteins associated with the 
platelet surface (Impact R: DiaMed, Switzerland) (Harrison, 2005). Both 
technologies were designed for use with whole blood but can be modified to study 
PCs by reconstituting the units with leucodepleted whole blood or leucodepleted red 
cells plus plasma (Morrison et al., 2007, Cardigan et al., 2005). A recent study has 
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reported that treatment of mice with the BH3-mimetics ABT-737 or ABT-263 led to 
the shedding of GP1bα vWF receptor and the collagen receptor GPVI, with 
defective adhesion to thrombogenic surfaces (Schoenwaelder et al., 2011). 
Combining platelet function studies with flow cytometric measurements of platelet 
surface glycoproteins as well as measurements of Bcl-2 family proteins may help to 
determine whether Bcl-2 proteins commonly associated with cell death can also help 
regulate the function of stored platelets post-transfusion. 
− Finally, an increasingly detailed understanding of the mechanisms behind the PSL 
must be related to the practical clinical setting, with in vivo studies to determine 
platelet function post-transfusion as well as patient morbidity in addition to the more 
traditional measures of platelet survivability. 
 
LIMITATIONS OF THE STUDY 
− Experience with the methods adopted and developed as part of the study identified 
some limitations that, if addressed, could improve their robustness and applicability 
for the study of the platelet storage lesion. The relatively high levels of surface 
CD62P expression in comparison with some of the published literature have already 
been discussed in depth. Published results on mitochondrial membrane potential 
measured flow cytometrically with cationic dies such as JC-1 have resulted in 
differing interpretations regarding the role of changes in mitochondrial functional 
integrity in the progression of the storage lesion. It would be advantageous to use a 
second technique to investigate the role of ∆Ψm in platelet death during storage and 
confirm the timeframe of mitochondrial changes in relation to the other markers 
indicative of platelet death. Additionally, although ATP levels were measured 
against a standard line, a reliable ATP control could not be sourced in a timely 
manner. Such a control would increase confidence in any direct comparison of the 
numerical results with the published literature.  
 
− Relatively low levels for the HSR and ESC assays were evident in all PCs 
suspended solely in additive solution when compared with levels obtained for PC in 
plasma or a standard 70:30 ratio of additive solution and plasma. The harsher 
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processing method used to generate the former units could only account for a small 
proportion of this disparity, as units similarly manufactured but re-suspended in 
plasma showed a relatively small decrease in HSR and ESC responses. Existing 
recommendations based on PC suspended in plasma suggest that HSR values below 
60% correspond to platelet recovery levels below 50% following transfusion 
(Diedrich et al., 2008). It would be difficult to apply such limits to PC in 100% 
additive solution if the results from this study are confirmed. It has also been 
suggested that platelet recoveries below 50% are observed when HSR values fall 
below 70-75% of levels in fresh platelets (Cardigan et al., 2005). Such a self-
contained comparison appears more applicable to the results from the additive 
solution studies. Similarly, using limits based on percentage decrease of starting 
levels would be more applicable for ESC, with platelet recovery below 50% 
corresponding with ESC values below 60% of day 1 levels (Holme et al., 1998). An 
additional consideration is that the autologous plasma used as the sample diluent 
was stored at ambient temperature. A comparison of HSR and ESC results 
subsequent to the work for this thesis did not confirm that the storage temperature of 
the plasma was a significant factor. Buffering of the plasma was not undertaken 
until the day of testing – a further variable that would be worth investigating. 
 
− Logistical considerations limited the number of replicates to five for the studies 
investigating the role of albumin, glucose and acetate. However, results from the 
preliminary study - which measured the storage characteristics of platelets stored in 
either autologous plasma or a medium of SSP+ plus plasma over an extended 
storage period - provided confidence in the reproducibility of the assays adopted.  
 
CONCLUDING REMARKS 
The platelet storage lesion is a term used to encompass the varied changes observed in 
platelets stored as concentrates. The study employed a wide range of methodologies to 
provide a relatively comprehensive picture of the nature of the PSL in a variety of both 
standard and manipulated storage media. The aim was to provide a better understanding 
of the phenomenon in the context of the hypothesis that apoptosis plays a central role in 
platelet death in storage. 
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Results suggested that in storage media with adequate energy stores in the form of 
glucose, a Bcl-2 protein-mediated mechanism of cell death was viable, though possibly 
storage-time dependent and limited by the pre-existing levels of anti-apoptotic Bcl-2 
proteins in the platelets.  Further studies would be required to determine if this 
mechanism is akin to caspase-dependent apoptosis. In media lacking glucose, a 
mechanism more reminiscent of necrosis was observed, associated with decreased ATP 
levels, accelerated mitochondrial dysfunction, elevated intracellular free calcium and 
culminating in platelet disruption.  
 
The thesis has certainly raised far more questions than it has answered, illustrating the 
complexity of the processes involved and the need for a more fundamental approach to 
the understanding of platelet senescence, with the ultimate aim of enhancing the 
efficacy of platelet transfusions and improving patient care. 
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